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ABSTRACT 
 
 Diabetes is a world-wide epidemic; 90-95% of diabetes cases are type 2 in nature.  
Albuminuria and hypertension are risk factors of diabetes complications, specifically 
nephropathy and cardiovascular disease.  Angiotensin-converting enzyme inhibitors 
(ACEIs) or angiotensin receptor blockers (ARBs) are recommended as monotherapy to 
reduce albuminuria and hypertension.  Because of this, we sought to compare patients 
with type 2 diabetes (P2DM) who received neither therapy to those who received either 
monotherapy for end-stage renal disease (ESRD), cardio- and cerebro- vascular disease, 
and all-cause mortality.  Additionally, because there are very limited data on comparisons 
between ACEI and ARB therapies, none of which compare occurrence of incident cardio- 
or cerebro- vascular disease or mortality, these monotherapies were compared.  
Moreover, because diabetes incidence is expected to increase, healthcare utilization was 
also analyzed.  This longitudinal study followed P2DM maximally for five years.  
Comparisons between patients receiving neither therapy and either monotherapy were 
  
 
xi
performed with multivariate logistic or negative binomial regression, while comparisons 
between ACEI and ARB patients were performed with propensity score weighted logistic 
or negative binomial regression.  Compared to neither therapy, ACEI patients were 
associated with lower odds of ESRD, higher odds of incident cardio- or cerebro- vascular 
disease events, lower odds of mortality, and higher incidence rates of healthcare 
utilization.  Treatment selection existed between ACEI and ARB monotherapies in 
P2DM, necessitating propensity score analysis (PSA).  Fortunately, the PSA balanced 
between group characteristics and had substantial overlap in propensity scores between 
groups, allowing for precise estimates of causal interpretation.  No differences were 
found between ACEI and ARB monotherapies for all endpoints studied.  Since only 
associations can be found between comparisons of ACEI and ARB patients with neither 
patients and because ACEIs or ARBs are recommended in guidelines, significance is 
focused on comparisons between ACEI and ARB patients.  This is the second study 
lasting more than a year comparing outcomes of ACEI and ARB monotherapies for 
nephropathy and the first study comparing ACEI and ARB monotherapies for other 
endpoints.  This study confirms that ACEIs and ARBs have no significant difference in 
effects for two years mean follow-up.  Until this study, similar effects have only been 
assumed. 
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CHAPTER 1:  INTRODUCTION 
 
 
 Type 2 diabetes is a public health concern; its prevalence is expected to increase 
substantially.  The disease causes a plethora of complications, including morbidity due to 
macro- and micro- vascular outcomes, and mortality.  ACEI or ARB monotherapy is 
recommended in clinical practice guidelines for prevention of progressive nephropathy in 
patients with type 2 diabetes (P2DM) by reducing albuminuria levels and by reducing 
blood pressure.  Albuminuria and hypertension are risk factors for cardio- and cerebro- 
vascular disease events and all-cause mortality.  There have been few well-controlled 
head-to-head comparisons of ACEI and ARB monotherapy for end-stage renal disease 
(ESRD) and no head-to-head comparisons of ACEI and ARB monotherapy for cardio- 
and cerebro- vascular disease events or all-cause mortality in P2DM.  These clinical 
outcomes are the most relevant long-term outcomes for this comparison in this 
population.  Also important from a public health perspective is the comparison of 
outpatient visits, emergency department (ED) visits, and hospitalizations as healthcare 
resources are already strained.  With an expected increase of people afflicted with type 2 
diabetes, answers to these questions are of utmost importance  Lastly, because of the few 
studies of ACEI or ARB monotherapy compared to placebo yielding disputed findings 
for cardio- and cerebro- vascular disease and all-cause mortality, the current study 
extends knowledge about these outcomes in P2DM receiving ACEI or ARB monotherapy 
or neither therapy. 
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Type 2 Diabetes Burden 
 
Type 2 diabetes is already heralded as a national epidemic,1 it is currently the 
sixth leading cause of death nationally.2  Approximately 20.8 million Americans had 
diabetes in 2005;3 of which, 90%-95% of had type 2 diabetes.3  The prevalence of 
diabetes has increased by 80% in the last ten years,4 and between the years 2000 and 
2050, projections estimate its prevalence to increase by more than 2.5 fold.5  If current 
trends concerning diabetes continue, 33% of Americans born in the year 2000 will 
develop diabetes in their lifetime.6 
 The escalating prevalence and incidence of type 2 diabetes are due to an aging 
population, a more ethnically diverse population, consumption of many foods with high 
sugar and fat content, a sedentary lifestyle, and overeating.  For instance, 23.8% of 
people at least 60 years of age have diabetes7 and as baby boomers continue to age, the 
number of elders will increase;8 thus the absolute number of American elders with 
diabetes will also increase.  The number of people at least 65 years of age has already 
increased 2.3 fold between the years 1970 and 2006.9  In addition to an increasingly aged 
population, genetics place Hispanics, American Indians, and African Americans at higher 
risk than non-Hispanic whites.10  Specifically, Hispanics, American Indians/Alaska 
Natives, and African Americans have a 1.7, 2.2, and 1.9 times higher prevalence rate, 
respectively, compared to non-Hispanic whites.11  Obesity is also strongly associated 
with diabetes, yet, in terms of prevention, only 23% eat 5 servings of fruits and 
vegetables daily and 22% of Americans exercise regularly.12  These habits are evident 
based on the increasing prevalence of people who are overweight or obese.13  The 
National Health and Nutrition Examination Survey found a 55.9% prevalence rate of 
  3
people who were overweight in 1988-1994 versus 64.5% in 1999-2000 and a 22.9% 
prevalence rate of people who were obese versus 30.5% in the same time periods, 
respectively.13 
             Diabetes is progressive and its complications result in high morbidity and 
mortality.14  Diabetes-related complications are attributed to more than 200,000 deaths 
annually.3  In the United States (U.S), if a man is diagnosed with diabetes at age 40, he 
will lose 11.6 years of life after having diabetes for 28.0 years.6  Corresponding numbers 
for a woman are 14.3 years of lost life after having diabetes for 38.4 years.6 
Complications 
 
 The incidence and severity of end-stage renal disease (ESRD) in patients with 
diabetes is also expected to increase as the U.S. population becomes more diverse.  For 
instance, Hispanics and African Americans with diabetes have a much higher risk of 
acquiring ESRD compared to non-Hispanic whites with diabetes.15  At least in the 
Southwest U.S., lower extremity amputation from diabetes has been found to be 3.5-fold 
higher in Native Americans compared to non-Hispanic whites.16  Evidence also exists 
that African Americans with diabetes have a 27% higher mortality rate compared to non-
Hispanic whites.17 
Following natural history of the disease, one to two in every five 
microalbuminuric (2-20mg/dL or 30-300mg/g) patients with type 2 diabetes (P2DM) 
become macroalbuminuric (>20mg/dL or >300mg/g) without intervention; approximately 
one in five macroalbuminuric P2DM will develop ESRD.18  Since the majority of deaths 
in patients with diabetes are currently attributed to cardiovascular disease (CVD) events, 
prevention of CVD events may place more people in ESRD.18  Diabetes is the leading 
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health condition contributing to incident ESRD cases according to the U.S. Renal Data 
System (USRDS); 45% of ESRD patients have type 2 diabetes.19  Dialysis patients with 
diabetes have a 27.2% and 23.3% five-year survival rate for hemodialysis and peritoneal 
dialysis, respectively.19     
In addition to nephropathy events, CVD complications are important in this 
disease.  People who are afflicted with diabetes have two times the risk of developing 
CVD compared to the general population20 and patients with diabetes and a history of 
CVD have more than double the risk of subsequent CVD events.20  Patients with diabetes 
also have a 2-4 times higher risk of stroke compared to patients without diabetes.3  
Approximately 65% of deaths in patients with diabetes result from heart disease and 
stroke in the U.S.3   
Hypertension, a risk factor for complications, has a 73% prevalence rate in the 
American diabetes population.3  Compared to normotensive patients, hypertensive 
patients have a 22 times higher risk of developing ESRD.21  Patients with type 2 diabetes 
mellitus (P2DM) and hypertension are at higher risk for diabetic nephropathy and 
CVD.22,23  In P2DM and nephropathy, patients with lower blood pressure have slower 
progression of renal dysfunction.24  Blood pressure reduction and antihypertensives have 
been shown to decrease microvascular and macrovascular complications in type 2 
diabetes.25-27    
Cost Implications 
 
 Complications are also more costly than ever, and with the increasing prevalence 
of diabetes, are continuing to rise.  At the individual level, development of ESRD can 
cause costs to increase by 771% while suffering a CVD event can cause costs to increase 
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by 360%.28  Additionally, healthcare expenditures have been increasing at a rate higher 
than inflation for several years,29-32 and healthcare organizations have been tightening 
their budgets.33 
The Department of Veterans Affairs (VA) and Diabetes 
 
In the U.S., the VA healthcare system is the largest provider of healthcare 
services.34  About 20% of veteran patients have been diagnosed with diabetes, which is 
considerably higher than 5.8% of the general U.S. population with diabetes diagnosis.7  
Patients with diabetes in the VA or in the general U.S. population, compared to patients 
without diabetes, have twice the mortality rate.3,35  Mirroring racial disparities observed 
in the general U.S. population, African American veteran patients were found to be more 
likely to have renal disease.36  Higher prevalence makes diabetes a large burden for the 
VA while the similar patterns of mortality rates and racial disparities give credence that 
the VA population may not be that different from health maintenance organization 
populations, apart from being overwhelmingly male.   
 
Theoretical Framework 
 
 In normal physiological functioning, people should be normoalbuminuric 
(<2mg/dL of albumin in their urine or < 30mg/g of albumin to creatinine (also known as 
the albumin-to-creatinine ratio)).  Albuminuria is progressive in diabetes.  Although a 
continuous measure of nephropathy, in the diabetes literature, it has been categorized into 
normoalbuminuria, microalbuminuria (2-20mg/dL or 30-300mg/g), and 
macroalbuminuria (> 20mg/dL or > 300mg/g).  Thus, ESRD is not defined by an amount 
of albumin in urine.  Instead, ESRD is an administrative term signaling dialysis initiation, 
  6
which is characterized by a reduction in glomerular filtration and the quantity and 
duration of albuminuria. 
 More than one-fourth of type 2 diabetes patients have microalbuminuria or 
macroalbuminuria upon diagnosis.37  All P2DM are prone to increasing levels of 
albuminuria as a result of progressive loss of beta cell functioning, which deteriorates 
with duration of diabetes.38  Worsening beta cell function leads to poorer blood glucose 
control, which, in turn, contributes to progressive nephropathy,39 ultimately leading to 
ESRD. 
 There is a gradient effect between level of albuminuria and cardiorenal risk, 
starting at the upper end of the normal albumin excretion rate,40 which is associated with 
a 1.83 times higher likelihood of major CVD events.40  Albuminuria is a continuous 
independent predictor for CVD events, congestive heart failure (CHF), and all-cause 
mortality.40  It is associated with hospitalization, left ventricular dysfunction, stroke, and 
myocardial infarction (MI).41 
 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) effectively reduce albuminuria.  At the molecular level, ACEIs and 
ARBs work by inhibiting angiotensin II from stimulating angiotensin II type 1 (AT1) 
receptors.  ACEIs prevent conversion of angiotensin I to angiotensin II while ARBs 
compete with angiotensin II for AT1 receptor sites.42,43  When followed downstream, 
AT1 receptor stimulation increases urinary albumin excretion through vasoconstriction, 
which increases intraglomerular pressure.44  Vasoconstriction also leads to increased 
systemic pressure, causing increased blood pressure.  As monotherapy, ACEIs and ARBs 
have shown attenuation in the progression of albuminuria throughout the disease 
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process.45-49  Additionally, studies have shown ACEIs or ARBs negate disease 
progression by causing P2DM to revert to the previous albuminuric state.45,50,51   
 
Overall Hypothesis 
 
Diabetes increases patients’ risk of vascular disease, including cardiovascular 
disease (CVD), i.e., left ventricular dysfunction and MI, and cerebrovascular disease, i.e., 
ischemic stroke. Diabetes also increases patients’ risk of kidney damage via increased 
albumin excretion, which is characteristic of ESRD. Additionally, many P2DM have 
hypertension, a risk factor for ESRD, cardio- and cerebro- vascular disease, and 
mortality.   
P2DM are prescribed ACEIs and ARBs for two reasons:  to reduce blood pressure 
and to reduce albuminuria.  Albuminuria, the amount of albumin in urine, has been found 
to be the strongest predictor of ESRD.52  Albuminuria expressed as mg/g creatinine 
adjusts for hydration while mg/dL does not, so the creatinine ratio is preferred as it is 
more accurate (Personal communication, G. Murata, March 11, 2009).  Since there is 
preliminary evidence of a larger reduction in albuminuria exhibited with ACEI 
monotherapy compared to ARB monotherapy, ACEI monotherapy may lead to decreased 
incidence of ESRD, cardio- and cerebro- vascular disease events, and mortality.  
Avoiding clinical outcomes with ACEI monotherapy may lead to decreased resource 
utilization.  
Few randomized controlled trials have established the efficacy of ACEIs or ARBs 
in reducing albuminuria; including development of ESRD; in P2DM.46,49,53  Further, there 
are no studies comparing cardio- and cerebro- vascular disease events, all-cause 
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mortality, outpatient visits, emergency department (ED) visits, or hospitalizations in 
P2DM.  Comparing these event rates between therapeutic classes will provide meaningful 
answers for ensuring optimal care of P2DM. This naturally extends to gaining knowledge 
about preventing complications, including deaths, in the diabetes population.  However, 
there is scant evidence on long-term effectiveness, and little data on head-to head 
comparisons between ACEIs and ARBs as monotherapy.  
This study will fill this gap by studying clinical outcomes in veteran P2DM who 
have received ACEIs or ARBs for development of ESRD; reduction of albuminuria; 
incident vascular disease events (IVDE), incorporating cardio- and cerebro- vascular 
disease outcomes MI, LVH, and stroke; and all-cause mortality over a maximum of 5 
years. Resource utilization will also be assessed in this sample over the time period via 
number of outpatient visits, ED visits, and hospitalizations. 
 
 
Specific Aims 
 
Specific Aim 1:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing the incidence of ESRD. 
H01:  There will be no difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing the incidence of ESRD in P2DM. 
 
Specific Aim 2a:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing albuminuria. 
H02a:  There will be no difference in effectiveness between ACEIs or 
ARBs and neither therapy in reducing albuminuria in P2DM. 
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Specific Aim 2b:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing albuminuria in those with baseline 
microalbuminuria. 
H02b:  There will be no difference in effectiveness between ACEIs or 
ARBs and neither therapy in reducing albuminuria in P2DM with 
microalbuminuria at baseline. 
 
Specific Aim 2c:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing albuminuria in those with baseline 
macroalbuminuria. 
H02c:  There will be no difference in effectiveness between ACEIs or 
ARBs and neither therapy in reducing albuminuria in P2DM with 
macroalbuminuria at baseline. 
 
Specific Aim 3:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing the incidence of vascular disease events 
(IVDEs):  left ventricular hypertrophy, MI, and stroke. 
H03:  There will be no difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing the incidence of IVDEs in P2DM. 
 
Specific Aim 4:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing all-cause mortality. 
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H04:  There will be no difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing all-cause mortality in P2DM. 
 
Specific Aim 5:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing outpatient visits. 
H05:  There will be no difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing outpatient visits in P2DM. 
 
Specific Aim 6:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing emergency department (ED) visits. 
H06:  There will be no difference in effectiveness between ACEIs or ARBs 
and neither therapy for reducing ED visits in P2DM. 
 
Specific Aim 7:  To determine the difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing hospital admissions. 
H07:  There will be no difference in effectiveness between ACEIs or ARBs 
and neither therapy in reducing hospital admissions in P2DM. 
 
Specific Aim 8:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing the incidence of ESRD. 
H08:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing the incidence of ESRD in P2DM. 
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Specific Aim 9a:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing albuminuria. 
H09a:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing albuminuria in P2DM. 
 
Specific Aim 9b:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing albuminuria for those with baseline microalbuminuria. 
H09b: There will be no difference in effectiveness between ACEIs and 
ARBs in reducing albuminuria in P2DM with microalbuminuria at 
baseline. 
 
Specific Aim 9c:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing albuminuria for those with baseline macroalbuminuria. 
H09c: There will be no difference in effectiveness between ACEIs and 
ARBs in reducing albuminuria in P2DM with microalbuminuria at 
baseline. 
 
Specific Aim 10:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing the IVDEs. 
 H010:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing the IVDEs in P2DM. 
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Specific Aim 11:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing all-cause mortality. 
 H011:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing all-cause mortality in P2DM. 
 
Specific Aim 12:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing outpatient visits. 
 H012:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing outpatient visits in P2DM. 
 
Specific Aim 13:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing ED visits. 
 H013:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing ED visits in P2DM. 
 
Specific Aim 14:  To determine the difference in effectiveness between ACEIs and ARBs 
in reducing hospital admissions. 
H014:  There will be no difference in effectiveness between ACEIs and 
ARBs for reducing hospital admissions in P2DM. 
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Significance 
 
Choice Between ACEIs and ARBs   
 
 The results of this study are important for the prevention and treatment of 
albuminuria in U.S. P2DM.  In patients with microalbuminuria or macroalbuminuria, the 
American Diabetes Association (ADA) guidelines recommend monotherapy with ACEIs 
or ARBs as interventional strategies against progressive nephropathy.54  Unfortunately, 
there is hardly any available information about which treatment strategy is better in 
reducing albuminuria and no information about which is better in slowing progression to 
ESRD, preventing IVDEs, or reducing all-cause mortality.  ACEIs may be associated 
with a persistent, dry cough (1-10% prevalence),55 if bothersome enough, individuals 
switch medications within the therapeutic class or replace them with ARBs.56  ARBs do 
not typically produce a cough.57  In addition to cough, ACEIs have a higher incidence of 
angioedema58 and hyperkalemia56 (>5.0mEq/L serum potassium) than ARBs.  Formulary 
status also comes into play when deciding between ACEIs and ARBs; in this study, both 
therapeutic classes have been available on the VA national formulary throughout the 
study period. 59  Although on the national formulary, Veterans Integrated Service 
Network (VISN) formularies and institution formularies are allowed to deviate.  During 
this study period, patent expiration occurred sooner with ACEIs than ARBs, perhaps 
making prescription cost a local formulary consideration. 
High Complication Rate among P2DM 
 
Almost half of ESRD cases occur in P2DM.19  The U.S. has the highest incidence 
and second-highest prevalence of ESRD compared to 11 other developed countries.60  
Over the last 10 years, incidence of ESRD in the U.S. has doubled,61 a reflection of 
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diabetes prevalence increasing by 80% in the same time period.4  Patients with ESRD 
have a low quality of life leaving few ESRD patients with the ability to work.62  
Preventing P2DM from progressing to ESRD will reduce the burden of ESRD, especially 
since projections estimate diabetes prevalence to increase by 2.5 times between the years 
2000 and 2050.5  Dialysis patients who have diabetes have a 25% and 23%, 5-year 
survival rate, for hemodialysis and peritoneal dialysis, respectively.63  Additionally, 
diabetes patients with ESRD have a worse prognosis than patients with ESRD due to 
other conditions, both in terms of vascular disease events and mortality.64,65  Furthermore, 
two-thirds of P2DM die from vascular disease.3  Clearly, cardio- and cerebro- vascular 
disease is currently placing a larger burden on healthcare resources as many P2DM die 
from cardio- and cerebro- vascular disease before ESRD has time to develop.  At the 
patient level, development of ESRD can cause costs to increase almost 8-fold while 
suffering a CVD event can cause costs to increase 3.5 fold.28  In 2006, diabetes was the 
seventh leading cause of death in the U.S.7  Even more interesting to this statistic, 
diabetes is underreported on death certificates 60% to 65% of the time.7    
Significance in Terms of Public Policy 
 
The results of this study also have potential implications on health policy relating 
to P2DM.  Healthy People 2010, priorities for health as determined by the U.S. 
Department of Health and Human Services, acknowledges the need for reducing 
nephropathy and CVD in patients with diabetes.10  To decrease the onset of ESRD, 
Healthy People 2010 proposes two objectives.  The first objective relevant to Healthy 
People, 4-7, is to reduce the number of patients with incident cases of ESRD by 31%. In 
1996, there were 113 incident cases of ESRD per million diabetes patients.  Objective 4-8 
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is an extension of Objective 4-7, which stipulates the need for increasing the proportion 
of patients with diabetes and proteinuria who receive medical treatment to attenuate 
progression to chronic renal insufficiency.10  In addition to these objectives, Healthy 
People 2010 seeks a 10% reduction in CVD-related deaths, an 11% reduction in diabetes-
related mortality, and a 43% reduction in all-cause mortality in P2DM.  It is evident from 
this public policy document that more clinical and research efforts should be directed 
toward the prevention of these complications in patients with diabetes.  This study, by 
seeking to determine the therapy that has the largest reduction in albuminuria, will 
provide information on which treatment is effective at preventing cases of ESRD, IVDE, 
and all-cause mortality.  For instance, patients with diabetes and microalbuminuria, 
compared to normoalbuminuria, have a 1.97 times; 2.15 times; and 3.70 times increased 
likelihood of MI, stroke, or death due to CVD; all-cause mortality; and hospitalization 
associated with congestive heart failure, respectively.40   
Significance to the VA 
 
In the U.S., the VA healthcare system is the largest provider of healthcare 
services.34  Annually, an average of 4.1 million veterans use the VA to access healthcare.  
Since prevalence of diabetes in the VA is higher than the national average, examination 
of clinical outcomes provides valuable information in this setting.   
Direct VA costs attributed to diabetes is in the billions. Based on our sample size 
calculations, potential identification of cost savings of minimally $29.6 million in the 
study sample just by identifying the best strategy for a significant reduction in ESRD is 
of importance to the VA. Based on the 20% prevalence of diabetes in the VA 
population35 and knowledge that 90-95% of patients with diabetes have type 2,3 if we 
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extrapolate the sample to the VA population of roughly 1 million P2DM, we could 
potentially prevent upwards of 10,323 patients from reaching ESRD. Using costs 
associated with ESRD in 2005 from the USRDS, this equates to $2.8 billion due to ESRD 
over 4.25 years.66  Similarly, finding a significant reduction in IVDE in our sample could 
lead to identification of an absolute risk reduction of up to 5.5%, which could lead to a 
cost savings due to prevented events of another $2.3 million in the study sample.  If we 
extrapolate the sample to the VA population, we could prevent upwards of 55,000 
IVDEs.  Using 2005 costs from a pharmacoeconomic analysis of newly-diagnosed P2DM 
using ACEIs, $2.1 billion could be saved due to prevented costs within in one year of 
IVDEs.67  Assuming 12.4 times more CVD events than strokes,34 this would lead to 
prevention of up to 33,082 CVD-related deaths in the VA.  Finally, studying veteran 
patients will provide insight into the effects of long duration of therapy, as this study will 
document patients who were prescribed ACEIs or ARBs for maximally 5 years.   
Significance to the Literature 
 
 The additional significance of this study is its uniqueness in duration of therapy 
for treatments that attenuate renal disease progression, the country of study, and the 
effectiveness data it will yield.  In particular, information about hard outcomes, rather 
than surrogate markers, will be extremely valuable.  As recently publicized in a 
population of type 2 diabetes, analysis of hard outcomes may yield unexpected results 
compared to previously-examined short-term surrogate outcomes which formed 
previously- and widely- held expert opinion.68  Additionally, this study will have the 
benefit of determining effectiveness without exclusion of patients with common 
comorbidities.  By examining patients longitudinally and without them receiving 
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additional attention by investigators, we can also see the effect of the medications when 
used in patients’ daily routines:  true effectiveness data.  This will be the first population 
study comparing effectiveness of ACEI and ARB monotherapy.  It will also be the first 
study conducted in the U.S.
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CHAPTER 2:  REVIEW OF THE LITERATURE 
 
 
Introduction 
 
This chapter presents a detailed literature review. I begin by providing a brief 
review of diabetes.  Then, a review of diabetes in the Department of Veterans Affairs is 
presented.  Next, drug treatment in diabetes is discussed.  This is followed by a more in-
depth look at the natural history of diabetes and complications of interest. 
Together, these topics lead into the importance of using ACEIs and ARBs for 
reduction of ESRD, albuminuria, IVDE, and mortality.  As there are no effectiveness 
studies, the review of studies that have examined the impact of ACEIs and ARBs on 
health is presented as follows. First, studies establishing the efficacy of ACEIs or ARBs 
compared to placebo are discussed.  Second, studies comparing ACEIs or ARBs to active 
controls are examined.  From here, head-to-head studies of ACEI and ARB monotherapy 
are presented.  Next, studies comparing combination therapy to monotherapy with these 
agents are reviewed.  Although the primary analysis is comparing ACEI and ARB 
monotherapies, it is important to contextualize the combination versus mono- therapy 
studies since this is the most recent direction that studies in this field seem to be headed. 
  
Diabetes Classification and Etiology 
 
 To put type 2 diabetes in context, it is first important to differentiate it from 
normal physiologic functioning and from the other types of diabetes.  Diabetes mellitus is 
a multi-factoral disease. Diabetes results from an insulin abnormality, leading to 
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hyperglycemia. There are three major types of diabetes: type 1, type 2, and gestational.7  
Type 1; formerly known as Insulin Dependent Diabetes Mellitus (IDDM), childhood-
onset diabetes, or juvenile diabetes; is caused by pancreatic beta cell damage.  This 
damage leads to the body’s inability to produce insulin, leaving high amounts of glucose 
in the blood as it is unable to be transported to cells.  Type 1 diabetes is unavoidable 
while type 2 diabetes is preventable. Type 2 diabetes, formerly known as Non-Insulin 
Dependent Diabetes Mellitus (NIDDM) or adult-onset diabetes, reflects a reduction in 
insulin release from pancreatic beta cells, increased insulin resistance, and/or increased 
hepatic glucose output.69  Women who are diagnosed with gestational diabetes, meaning 
diagnosed during pregnancy, are more likely to develop type 2 diabetes during their 
lifetime.3   
Approximately 90%-95% of patients with diabetes have type 2.3  Approximately 
23.6 million (7.8%) Americans had diabetes in 2007.7  Of these, an estimated 5.7 million 
were undiagnosed.  People with type 2 diabetes usually do not become diagnosed until 
they become symptomatic or suffer complications.54  This explains why a higher 
proportion of patients newly-diagnosed with type 2 diabetes, compared to type 1 diabetes, 
have microalbuminuria or macroalbuminuria.18   
Diabetes Diagnosis 
 
 A person can be diagnosed with diabetes through three different methods.54  The 
first method uses a threshold of plasma glucose level of ≥ 200mg/dL.  Diagnosis is made 
at this level regardless of meal timing when symptoms of unexplained weight loss, 
frequent urination (polyuria), and frequent drinking (polydipsia) are present.  The second 
method, the oral glucose tolerance test, is performed by measuring a patient’s blood 
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glucose 2 hours after fasting and consuming a high-glucose drink.  If the person has a 
blood glucose level of ≥ 200mg/dL at that time, diabetes is confirmed.  Third, a person 
can be diagnosed with the fasting plasma glucose test with a blood glucose level of 
≥120mg/dL.  The American Diabetes Association recommends the last test due to its 
ease, timeliness, and cost.54 
Microvascular and Macrovascular Complications 
 
 Complications of diabetes are microvascular and macrovascular in nature.  
Microvascular complications include retinopathy (an eye complication), neuropathy 
(nerve complications), and nephropathy (kidney complications).  Macrovascular 
complications include CVD, cerebrovascular disease, and peripheral vascular/artery 
disease.   
Standards of Practice for Diabetes Care 
 
 A person with diabetes has higher risk of cardiovascular and renal disease 
compared to people without diabetes54 due to elevated HbA1c, hypertension, increased 
albumin excretion, and poorer lipid profile.   
HbA1c is a long-term indicator of blood glucose control.  It is recommended that 
HbA1c is tested at a frequency of every 6 months in patients meeting goals with stable 
glycemia and every 3 months in patients who are not.39  Whereas a healthy individual has 
an HbA1c of 4%-6%, it is rarely this level in a person with diabetes.  The target is < 7% 
in diabetes patients.   
People with diabetes have a high prevalence of hypertension (75%),7 which 
contributes to poor HbA1c and increased albumin excretion.  The Seventh Report of the 
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Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC-7 report) recommends a hypertension goal of < 130/80mm Hg.70   
Normal albumin excretion is < 2mg/dL or < 30mg/g; if a test is positive for 
microalbuminuria, 2 of 3 tests over 6 months need to be positive before microalbuminuria 
is diagnosed.  Annual testing of albumin excretion should be performed.  Focusing on 
macrovascular complications in diabetes patients, LDL and triglyceride tests should be 
performed annually in most adults, with goals of < 100mg/dL and < 150mg/dL, 
respectively.54 
 
Diabetes and ESRD 
 
Type 2 diabetes is the leading condition contributing to incident ESRD cases in 
the U.S.19  More than one-fourth of P2DM have microalbuminuria or macroalbuminuria 
upon diagnosis.37  Over one’s lifetime, 20% to 40% of P2DM with microalbuminuria 
progress to macroalbuminuria without intervention; about 20% of these people will 
develop ESRD.18  In a randomized controlled trial of P2DM with microalbuminuria, 
17.5% of subjects randomized to placebo progressed to macroalbuminuria in 2 years.45  
In a separate randomized trial of type 2 diabetes patients of mostly non-Hispanic white 
ancestry, an annual rate of 2.0% was seen for progression from normoalbuminuria to 
microalbuminuria, an annual rate of 2.8% was seen for microalbuminuria to 
macroalbuminuria, and an annual rate of 2.3% was seen from macroalbuminuria to 
ESRD.71  Also noteworthy for this study was a 0.1% annual progression from 
normoalbuminuria to macroalbuminuria and a 0.3% annual progression from 
microalbuminuria to ESRD.  Furthermore, in a cohort study of 1,832 mostly non-
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Hispanic Whites in Minnesota, researchers found P2DM progress from start of 
macroalbuminuria to ESRD in a mean interval of 7 years (range: 2 months-22 years).72   
It is well-documented that minority groups with diabetes tend to develop renal 
complications more frequently and more severely.  American Pima Indians with diabetes 
have been extensively studied for their relatively short progression to ESRD,73-81 and as 
of 1993, incidence of ESRD among Pima Indians was 23-fold higher than the general 
U.S. population.82  P2DM who are Native American, Hispanic, and African-American 
have a much higher risk of acquiring ESRD compared to Caucasians.83  Specifically, 
Native Americans, Hispanics, African Americans, and Asians had 1.9, 1.4, 1.9, and 1.8 
higher odds of developing ESRD, respectively, compared to non-Hispanic whites.84  
Additionally, Native Americans and African Americans had 1.5 and 1.3 higher odds of 
developing early diabetic nephropathy, respectively, compared to non-Hispanic whites.84   
All P2DM are prone to increasing levels of albuminuria as a result of progressive 
loss of beta cell functioning, which deteriorates with duration of diabetes.38  Increasing 
beta cell dysfunction leads to worsening blood glucose control, which, in turn, 
contributes to progressive nephropathy states (microalbuminuria and 
macroalbuminuria),39 ultimately leading to ESRD.  More specifically, hyperglycemia 
leads to glycosylated proteins, which at first, are reversible.85  However, when advanced 
glycosylation end products are formed via irreversible covalent bonding, the proteins pass 
through the glomerular basement membrane despite the membrane previously repelling 
the protein.86  This cycle progresses, resulting in glomerular basement membrane 
thickening, allowing for more proteins to pass into the urine.86  Angiotensin II stimulation 
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of AT1 receptors also increases albuminuria excretion through vasoconstriction, which 
increases intraglomerular pressure.44,85   
Based on this mechanism, controlling hyperglycemia, blood pressure, and 
albuminuria will aid in slowing the decline of progressive nephropathy.  Other risk 
factors include genetic predisposition, smoking, and dyslipidemia; dietary consumption 
of protein may also be a risk factor.87  According to a meta-analysis of randomized 
controlled trials of subjects with type 1 or 2 diabetes eating a low protein diet 
significantly reduced albuminuria.  However, the reduction, compared to a normal diet, 
was only seen in two of the eight trials and results of this meta-analysis contradict 
findings of three other meta-analyses.88  The VA and Department of Defense cite further 
evidence to back this comment, stating that there is lack of support because the trials 
were not blinded and were “not optimally designed to test this hypothesis.”89 
In a study of 75 VA and non-VA patients on dialysis, patients were categorized 
by condition leading to dialysis and followed for mortality.64  The group that had 
hypertension (10 of 45) or diabetes (35 of 45) had a worse mortality rate at 2 and 3 years 
(41% and 63%, respectively) then those who suffered from primary nephropathy (11% 
and 19%, respectively).  This finding that diabetes patients with ESRD have higher 
mortality has been corroborated by another study.65  In that study, non-VA patients with 
ESRD were followed for survival.  No one with diabetes survived after 7 years, 27% of 
people who had ESRD as a result of hypertension survived 12 years, and 40% of patients 
with ESRD due to other causes survived 12 years.65     
More recently, a randomized controlled trial of VA patients with advanced 
chronic kidney disease or ESRD undergoing hemodialysis or peritoneal dialysis followed 
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patients for all-cause mortality.90  Fifty-five percent of patients had diabetes.  Among 
those who had ESRD, 42% died within 4.5 years.  (There was no breakout of diabetes 
patients in this group.)  Collectively, these 3 studies demonstrate the importance of 
preventing ESRD among veteran patients with diabetes. 
 
Diabetes and Cardio- and Cerebro- Vascular Disease 
 
The Framingham Study, a longitudinal U.S. population-based study, revealed 
diabetes doubles the risk of CVD in men and triples the risk in women.91  It is also 
widely-known that patients with diabetes are 2-4 times more likely to have a stroke 
compared to those without diabetes.3  P2DM have higher levels of albuminuria compared 
to other patients.  Like hypertension, albuminuria is also a predictor for cardio- and 
cerebro- vascular disease events.40  As albuminuria increases, there is an increase in the 
number of cardio- and cerebro- vascular disease events.  Higher levels of albuminuria 
have been shown to be associated with hospitalization, left ventricular dysfunction, MI, 
and stroke.41  In addition, there is a gradient effect between level of albuminuria and 
cardiorenal risk, starting at the upper end of the normal albumin excretion rate,40 which is 
associated with a 1.83 times higher likelihood of major CVD events.40  Cardiac 
remodeling (i.e., left ventricular hypertrophy) is at least partly attributed to angiotensin II 
stimulating AT1 receptors.42,92   
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Diabetes and Mortality 
 
 Compared to the general population in the U.S., patients with diabetes have a 2-
fold higher mortality rate.3  Albuminuria is a predictor for all-cause mortality.40  There is 
an increase in mortality rates with increasing albuminuria.  This is based on the HOPE 
trial, a 4.5 year study with a sample consisting of high-risk patients with diabetes, of 
whom 32.00% had microalbuminuria and 68.00% had normoalbuminuria at baseline.  
Investigators found those with microalbuminuria were twice as likely to die from all-
causes compared to those who were normoalbuminuric.40  A U.S. study found that, 
compared to those with normoalbuminuria, P2DM with microalbuminuria and 
macroalbuminuria were 1.68-1.97 and 2.47-3.28 times as likely to die from all causes, 
were 2.20-2.45 and 2.33-3.05 times as likely to die from stroke, and were 1.96-2.39 and 
2.73-3.85 times as likely to die from coronary heart disease, respectively.93 
 
 
 
Risk and Preventive Factors for ESRD, IVDEs, and Mortality 
 
Differences in age, gender, and race/ethnicity are generally documented to be 
associated with poorer health outcomes across disease states.  Similarly, patients with 
lower income tend to have poorer health while those living in rural areas are more likely 
to have access to care issues, leading to poorer health outcomes.  Smoking, hypertension, 
and obesity are health conditions predisposing patients to poorer health outcomes while 
higher levels of HbA1c, LDL cholesterol, and triglycerides are risk factors for ESRD in 
P2DM.  Compliance with ACEIs and ARBs need to be controlled to obtain a realistic 
picture of benefit of these therapies, and thus, differences between these therapies. 
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Duration of therapy with NSAIDs is a risk factor:  NSAIDs inhibit vasodilator 
prostaglandins, leading to decreased renal perfusion in P2DM.94  
For IVDEs and all-cause mortality, risk factors are age, gender, obesity, 
race/ethnicity, income, rural versus urban/suburban living, history of MI/stroke, family 
history of CVD, smoking, hypertension, compliance of ACEIs or ARBs, HbA1c, LDL 
cholesterol, and triglycerides.  HbA1c, LDL cholesterol, and triglycerides are also risk 
factors for cardio- and cerebro- vascular disease and all-cause mortality in P2DM.  
Diabetes in the Department of Veterans Affairs (VA) 
 
 As the population of this study comprises of VA patients with type 2 diabetes, the 
following section is devoted to the VA Health Care System. 
History 
 
Since 1974, the VA has been making strides towards caring for its diabetes 
patients.95  In that year, Congress mandated the VA and 22 other federal organizations to 
coordinate activities involving research, education, and public service.95  Fourteen years 
later, the VA became the first federal organization to have ADA accreditation for its 
education program.95   
Process and Outcome Measures 
 
In a random sample of diabetes patients from every VA facility, between October 
1, 2004 and September 30, 2005, 85% of patients had yearly HbA1c tests with results of 
≤9%, 77% had LDL and triglyceride levels performed biennially with an LDL < 
120mg/dL, and 75% had blood pressure ≤140/90mmHg.96  In a cohort study of patients 
receiving VA or commercial managed care health services from 6 states, researchers 
compared processes of care between the two healthcare entities.  After adjusting for 
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covariates, compared to patients in commercial managed care, a higher percentage of VA 
patients received annual HbA1c tests (93% and 83%, respectively, p=0.006), received 
annual proteinuria screening (92% and 81%, respectively, p=0.005), received annual lipid 
screenings (79% and 63%, respectively, p=0.02), had better LDL levels (< 100mg/dL for 
52% and 36%, respectively, p=0.003), and had better HbA1c levels (< 8.5% for 83% and 
65%, respectively, p=0.009). The two groups had similar blood pressure control 
(<130/85mmHg for 29% and 29%, respectively, p>0.2).97  These data confirm the VA 
commitment to diabetes care. 
Between 1999 and 2000, prevalence of diagnosed diabetes in the general 
population was estimated to be 5.9%.98  Between 1998 and 2000, prevalence of 
diagnosed diabetes was 3.4 times higher in the VA population, at about 20% indicating 
the importance of studying diabetes in this population.3,35  A substantial amount of VA 
resources are spent on diabetes patients.  Approximately 19% of all VA hospitalizations 
are associated with diabetes.34  In one study, 10.7% of veterans diagnosed with diabetes 
were found to have macroalbuminuria or ESRD in 1998.36  One-year mortality for this 
group was approximately 3.7 times higher compared to those without these conditions 
(10.7% versus 2.9%, respectively).36  Paralleling racial disparities observed in the general 
U.S. population, African Americans were found to be more likely to have renal disease.36   
 
Drug Treatment in Diabetes 
 
 People with diabetes have a high prevalence of hypertension and hyperlipidemia. 
It is typical for patients with diabetes to be prescribed several medications as multiple 
risk factors for complications need to be controlled. Accordingly, oral hypoglycemics and 
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insulin are commonly prescribed agents.  In addition, patients may be prescribed 
antihypertensives and antihyperlipidemics.  Table 1 lists FDA approved medications 
commonly used among P2DM.  Monotherapy with ACEIs or ARBs are recommended as 
first-line antihypertensive agents among P2DM with microalbuminuria or 
macroalbuminuria.  Table 2 provides a list of FDA approved ACEIs and ARBs.
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Table 1:  Common Therapeutic Classes Used in Diabetes Patients 
 
Therapeutic class 
     Subclass (if applicable) 
Generic medication names 
Oral hypoglycemics 
  
Sulfonylureas Acetohexamide, chlorpropamide, 
tolazamide, tolbutamide, glipizide, 
glyburide, glimiperide 
Short-acting insulin secretagogues Nateglinide, repaglinide 
Biguanides Metformin  
Thiazolidinediones Pioglitazone, rosiglitazone 
Alpha-glucosidase inhibitors Acarbose, miglitol 
Dipeptidyl peptidase-IV inhibitors Sitagliptin  
 
Insulin 
  
Rapid-acting Insulin lispro, insulin aspart, insulin 
glulisine, inhaled human insulin 
Short-acting Regular  
Intermediate-acting Neutral Protamine Hagadern 
Long-acting Insulin glargine, insulin detemir 
 
Antihypertensives 
  
ACEIs Benazepril, captopril, enalapril, fosinopril, 
lisinopril, moexipril, perindopril, 
quinapril, ramipril, trandolapril 
ARBs Eprosartan, irbesartan, losartan, 
olmesartan, telmisartan, valsartan 
Direct rennin inhibitor Aliskiren 
Diuretics  
     Thiazides Chlorthalidone, hydrochlorothiazide, 
indapamide, metolazone 
     Loop Bumetanide, furosemide, torsemide 
     Potassium sparing Amiloride, triamterene 
     Aldosterone antagonist Eplerenone, spironolactone 
Beta-blockers  
      Cardioselective Atenolol, betaxolol, bisoprolol, 
metoprolol 
      Nonselective Nadolol, propranolol, timolol 
     Intrinsic sympathomimetic activity Acebutolol, carteolol, penbutolol, pindolol 
     Mixed alpha- and beta- blockers Carvedilol, labetalol 
Calcium channel blockers  
     Dihydropyridines Amlodipine, felodipine, isradipine, 
nicardipine, nisoldipine 
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Table 1 (cont.) 
 
Therapeutic class 
     Subclass (if applicable)
Generic medication names 
     Nondihydropyridines Diltiazem, verapamil 
Alpha-blockers Doxazosin, prazosin, terazosin 
Central alpha2 agonists Clonidine, methyldopa 
Peripheral adrenergic antagonist Reserpine  
Direct arterial vasodilators Minoxidil, hydralazine 
 
Antihyperlipidemics 
  
Bile acid resins Cholestyramine, colestipol, colesevelam 
Fibrates Clofibrate, fenofibrate, gemfibrozil 
HMG-CoA reductase inhibitors 
(“Statins”) 
Lovastatin, pravastatin, simvastatin, 
atorvastatin, rosuvastatin 
Niemann-Pick C1-Like 1 inhibitor Ezetimibe 
Niacin Niacin 
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Table 2: List of Food and Drug Administration (FDA)-approved ACEIs and ARBs 
 
ACEIs ARBs 
Generic Name Trade Name(s) Generic Name Trade Name(s) 
Benazepril, 
Benazepril + 
hydrochlorothiazide 
(HCTZ), 
Benazepril + 
amlodipine 
Lotensin,  
Lotensin HCT,  
 
 
Lotrel 
Candesartan, 
Candesartan + 
HCTZ 
Atacand, 
Atacand HCT 
    
Captopril,  
Captopril + HCTZ 
Capoten,  
Capozide 
Eprosartan, 
Eprosartan + HCTZ 
Teveten, 
Teveten HCT 
    
Enalapril, 
Enalapril + 
Felodipine 
Vasotec, 
Lexxel 
Irbesartan, 
Irbesartan + HCTZ 
Avapro, 
Avalide 
    
Fosinopril, 
Fosinopril + HCTZ 
Monopril, 
Monopril HCT 
Losartan, 
Losartan + HCTZ 
Lozaar, 
Hyzaar 
    
Lisinopril, 
Lisinopril + HCTZ 
Prinivil; Zestril,  
Prinzide; Zestoretic 
Olmesartan, 
Olmesartan + 
HCTZ 
Benicar, 
Benicar HCT 
    
Moexipril Univasc Telmisartan, 
Telmisartan + 
HCTZ 
Micardis, 
Micardis HCT 
    
Perindopril Aceon Valsartan, 
Valsartan + HCTZ,  
Valsartan + 
amlodipine 
Diovan, 
Diovan HCT, 
Exforge 
Quinapril Accupril   
    
Ramipril Altace   
    
Trandolapril, 
Trandolapril + 
Verapamil 
Mavik, 
Tarka 
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In a study that examined a cohort of 22,954 patients in the VA who were 
diagnosed with type 2 diabetes and hypertension, 22,477 patients (97.92%) were 
prescribed ACEIs while 1,542 patients (6.85%) were prescribed ARBs in the year 2000.99  
Of the 22,954 patients, 28.3%, 7.1%, and 11.2% were also receiving oral hypoglycemics, 
insulin, and antihyperlipidemics, respectively.99  Other prescribed antihypertensive 
therapies in P2DM in the year 2000 included beta-blockers, calcium channel blockers, 
diuretics, and alpha-blockers.99   
 
Mechanism of Action of ACEIs and ARBs 
 
 In patients with microalbuminuria or macroalbuminuria, the ADA guidelines 
recommend monotherapy with ACEIs or ARBs as interventional strategies against 
progressive nephropathy and hypertension.54  ACEIs may be associated with a persistent, 
dry cough; if bothersome enough, patients may replace them with ARBs.56  The cough 
attributed to ACEIs is a result of blocking bradykinin breakdown, which causes blood 
pressure lowering and regression of cardiac hypertrophy.57  ARBs, on the other hand, do 
not block bradykinin catabolism and do not produce a cough.57  Although ARBs do not 
reap the benefits of bradykinin afforded to ACEIs, through specific blockade of 
angiotensin II type 1 (AT1) receptors, they may lead to increased systemic levels of 
angiotensin II, which, in turn, could lead to enhanced stimulation of angiotensin II type 2 
(AT2) receptors56 (Figure 1). This may be beneficial, leading to augmented vasodilation 
and enhanced tissue repair.57  In addition to cough, ACEIs have a higher incidence of 
angioedema58 and hyperkalemia56 (>5.0mEq/L serum potassium) than ARBs.   
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In practice, patients usually have initial therapy with ACEIs100 although there are 
no conclusive data establishing efficacy or effectiveness of ACEIs over ARBs for 
P2DM.101  Due to the higher incidence of cough with ACEIs, clinicians may be more 
likely to prescribe ARBs to patients who are more likely to cough (Personal 
communication, G. Murata, August 25, 2008).  For instance, those who smoke (Personal 
communication, G. Murata, August 25, 2008),102 have asthma, allergic rhinitis, 
gastroesophageal reflux disease, chronic obstructive pulmonary disease, chronic 
bronchitis, postnasal drip,103 and are initiated on therapy during winter months are more 
likely to be prescribed ARBs (Personal communication, G. Murata, August 25, 2008). 
Lastly, clinician choice is dependent on the availability of ACEIs and ARBs on a 
formulary. In the VA population, both therapeutic classes have been available on the 
national formulary throughout the study period.59 
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Figure 1:  Effects of ACEI and ARB Blockade. 
The top pathway depicts the effects of ACE blockade with an ACEI.  The bottom 
pathway depicts the effects of an ARB 
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ACEIs and ARBs work by inhibiting angiotensin II from stimulating AT1 
receptors.  ACEIs prevent conversion of angiotensin I to angiotensin II while ARBs 
compete with angiotensin II for AT1 receptor sites (blockade).42,43  AT1 receptors are 
located in the blood vessels, heart, kidney, adrenal gland, and nerves.43  When stimulated 
by angiotensin II, AT1 receptors lead to vasoconstriction, sodium retention, cardiac 
fibrosis, sympathetic nervous system stimulation, arrhythmia induction, plasminogen 
activator inhibitor 1 stimulation, and renal perfusion alteration through systemic 
resistance (i.e., vasoconstriction) and afferent and efferent arteriole resistance.42,43,92   
 Intuitively, ARBs more effectively block the deleterious effects of the renin-
angiotensin-aldosterone system since angiotensin II is made by ACE-dependent and 
ACE-independent pathways.42,92  It has been estimated that about one-third of angiotensin 
II is generated through ACE-independent pathways.104  ARBs, through blockade of the 
AT1 receptor, inhibit the negative effects of angiotensin II, regardless of the pathway 
used in its formation105 (Figure 2).  Inhibition of angiotensin II with ACEIs or ARBs has 
been shown to be both cardioprotective92 and renoprotective.42,92  The slight difference in 
mechanisms of action between the two classes, however, may lead to different levels of 
albuminuria. 
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Figure 2:  Differences in Mechanisms of Action between ACEI and ARB Monotherapies 
Depiction of ACE-dependent (top) and ACE-independent (bottom) pathways. An ACEI 
can only reduce angiotensin II in an ACE-dependent pathway while an ARB 
competitively blocks angiotensin II from stimulating the AT1 receptor in both types of 
pathways. 
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Dose response of these therapeutic classes has been based on antihypertensive 
results in patients without diabetes rather than antiproteinuric effects in patients with 
diabetes, which indicates the possibility of underdosing for renoprotective effects.106,107  
In fact, in one study, researchers compared the urinary albumin excretion rates of the 
optimal dosage for blood pressure control of an ARB, irbesartan 300mg daily, with 
irbesartan 900mg daily; they found the 900mg dosage decreased urinary albumin 
excretion 15% more than the 300mg dosage.108 
 
ACEIs, ARBs and Development of ESRD, Cardio- and Cerebro- Vascular Disease, 
and All-cause Mortality  
 
ACEIs or ARBs Compared to Placebo 
 
Effect on Albuminuria 
 
 Several clinical trials have indicated that ACEIs and ARBs in monotherapy are 
efficacious in reducing the progression of albuminuria throughout the disease process.45-
49  This is evidenced by a reduction in risk of progression to macroalbuminuria from 
normoalbuminuria or microalbuminuria by 1.9% (6.5% versus 8.4%) over 4.5 years for 
ramipril 10mg daily (ACEI) compared to placebo.46  This is further shown by a reduction 
in risk of progression from microalbuminuria to macroalbuminuria by 5.2% (14.9% 
versus 9.7%) and 9.7% (14.9% versus 5.2%) over 2 years for irbesartan 150mg and 
irbesartan 300mg daily (ARB) compared to placebo.45  Similarly, losartan 50-100mg 
daily (ARB) when compared to placebo during a 4 year period reduced the risk of 
progression from macroalbuminuria to ESRD by 5.9% (25.5% versus 19.6%).49  
Additionally, one study has shown ACEIs or ARBs negate disease progression by 
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causing P2DM to revert to the previous albuminuric state.45  Three other studies found 
similar results.47,48,53 
Effect on Cardio- and Cerebro- Vascular Disease and Mortality 
 
 Cardio- and cerebro- vascular disease and mortality were examined in 3 articles 
representing 2 studies.46,53,109  In the first study, HOPE, ramipril 10mg daily (ACEI) was 
found to reduce risk of developing the composite endpoint of MI, stroke, or 
cardiovascular death by 4.5% at 4.5 years (15.3% versus 19.8%).46  Analysis of the 
components found ramipril conferred a reduced risk in each of them compared to 
placebo.  The trial also found ramipril reduced the risk of all-cause mortality at 4.5 years 
by 3.2% (10.8% versus 14.0%).46 In IDNT, the researchers found a nonsignificant 
difference between irbesartan 300mg daily (ARB) and placebo for the composite 
endpoint of death from cardiovascular disease, nonfatal MI, hospitalization for heart 
failure, permanent neurological defect from a cerebrovascular event, or lower limb 
amputation above the ankle.53  Similarly, the trial did not demonstrate irbesartan to be 
more effective at reducing the risk of death than placebo.  In a separate article discussing 
the results of IDNT, an analysis of each component of the composite endpoint revealed 
that irbesartan was only more effective than placebo at reducing the risk of developing 
CHF (13.8% versus 19.9%).109  
In summary, the use of ACEIs or ARBs has been associated with better renal 
outcomes;45-49,53 however, there has been fewer and less consistent data regarding cardio- 
and cerebro- vascular disease and mortality in P2DM.46,53,109  Please see Appendix B for 
more information about study results.   
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ACEIs or ARBs Compared to Active Controls 
 
Effect on Albuminuria 
 
Therapeutic agents such as beta-blockers (BBs) and calcium channel blockers 
(CCBs) are called active controls as studies have used these medications as comparison 
therapies with some theoretical basis that the medications will work for the outcome of 
interest.  BBs and CCBs have had conflicting information regarding renal protection 
when compared with ACEIs or ARBs.  For example, in the United Kingdom Prospective 
Diabetes Study (UKPDS), P2DM and hypertension had similar incidence of 
microvascular complications when given atenolol 50-100mg daily (BB) or captopril 25 to 
50mg twice daily (ACEI).110  In a randomized double-blind trial of P2DM, hypertension, 
and either normoalbuminuria or microalbuminuria, cilazapril 2.5mg daily (ACEI) and 
amlodipine 5mg daily (CCB) had similar blood pressure effects and similar decreases in 
albumin excretion rate.111  In a randomized trial of P2DM, hypertension, 
microalbuminuria, and diabetic glomerulopathy, the investigators found a significant 
reduction in urinary albumin excretion in patients receiving enalapril 5 to 20mg daily 
(ACEI) compared to nitrendipine 10-40mg daily (CCB) despite similar blood pressure 
reduction at 98 days.112  Interestingly, at 1 year after these first 98 days, urinary albumin 
excretion was similar between groups.112  In the same vein, investigators of a blinded 
randomized parallel study of P2DM, hypertension, and nephropathy showed similar 
renoprotection with atenolol 50 to100mg daily (BB) or lisinopril 10 to 20mg daily 
(ACEI).113  In a randomized study with 6 year follow-up of P2DM, hypertension, 
retinopathy, and proteinuria, the researchers found significantly better decreases in 
albumin excretion with lisinopril (ACEI) or diltiazem/verapamil (nondihydropyridine 
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CCB group) compared with atenolol (BB) (dosages not reported).114  There are two 
important issues to note.  No published study was identified in which a protective benefit 
was observed in BBs or CCBs when compared to ACEIs, and a similar or protective 
benefit was observed for BBs or CCBs when compared to ARBs.  
Effect on Cardio- and Cerebro- Vascular Disease and Mortality 
 
 Despite the previous studies showing similar promise for renal protection with 
BBs and CCBs compared to ACEIs, the following studies show a cardiorenal advantage 
for ACEIs or ARBs compared to BBs or CCBs.  In a randomized study, although 
nitrendipine 20mg daily (CCB) and ramipril 5mg daily (ACEI) similarly lowered blood 
pressure, ramipril decreased urinary albumin excretion at an earlier point in time and to a 
greater extent.115  In another randomized clinical trial, P2DM and microalbuminuria had a 
significant decrease in urinary albumin excretion in the enalapril 10mg daily (ACEI) 
group compared to the nifedipine 20mg twice daily (CCB) group.116  The same study 
found attenuation of renal function decline in macroalbuminuric patients randomized to 
enalapril compared to nifedipine.116  In the Microalbuminuria Reduction with Valsartan 
(MARVAL) study, yet another randomized clinical trial, despite similar blood pressure 
reduction in valsartan 80mg daily (ARB) and amlodipine 5mg daily (CCB) groups, a 
renoprotective effect was seen in normotensives and hypertensives in the valsartan group 
compared to the amlodipine group.117  Again, these studies lack a hard endpoint 
measuring renal effects. 
In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) 
study, a randomized clinical trial of patients with diabetes, hypertension, and left 
ventricular hypertrophy, losartan 50 to 100mg daily (ARB), compared to atenolol 50 to 
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100mg daily (BB), reported hazard ratios of 0.63, 0.59, and 0.61 for CVD mortality, 
hospitalizations for heart failure, and all-cause mortality, respectively.50  This trial also 
found losartan conferred an absolute risk reduction of 14.4% of the composite outcome of 
CVD mortality, MI, or stroke compared to those taking atenolol over 4.7 years (incidence 
of 39.2% and 53.6%, respectively).  In the Appropriate Blood Pressure Control in 
Diabetics (ABCD) trial, the enalapril 40mg daily group (ACEI) had significantly fewer 
MIs than nisoldipine 60mg daily (CCB) group.118  In the Fosinopril versus Amlodipine 
Cardiovascular Events Randomized Trial (FACET), an open-label randomized clinical 
trial of hypertensive P2DM with normoalbuminuria, although subjects in the amlodipine 
10mg daily (CCB) group achieved a larger reduction in systolic blood pressure, patients 
in the fosinopril 20mg daily (ACEI) group were less likely to develop a CVD event.119  
Specifically, fosinopril achieved an absolute risk reduction of the composite outcome of 
MI, stroke, or hospitalized angina of 6.7% compared to patients receiving amlodipine 
over 3.5 years (incidence of 7.4% and 14.1%, respectively).119  This body of literature 
points to the need for controlling for beta-blocker and CCB use in determining the effects 
of monotherapy with ACEIs and ARBs. 
In addition to cardiorenal protection, a double-blind trial of hypertensive diabetic 
patients with left ventricular hypertrophy comparing losartan 50-100mg daily (ARB) to 
atenolol 50-100mg daily (BB) over 4.7 years, losartan achieved a reduction in risk of 
mortality of 14.7% (22.5% versus 37.2%).50    
In summary, ACEIs were consistently better at reducing the progression of 
albuminuria compared to BBs despite conflicting evidence between ACEIs and CCBs for 
this outcome.110-116,118-120  None of the studies comparing ACEIs and BBs assessed 
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cardio- or cerebro- vascular endpoints or mortality.  Two of the studies comparing ACEIs 
and CCBs examined cardio- and cerebro- vascular endpoints and both indicated ACEIs 
were better at reducing risk of vascular endpoints, but none of the endpoints were the 
same across studies.118,119  Even though the researchers of the ABCD trial found ACEIs 
were better at preventing nonfatal MI or nonfatal and fatal MI, they found ACEIs was no 
better at preventing CVAs, CHF, CVD death, or all-cause mortality.118  This is the only 
study of active controls compared to ACEI or ARB monotherapy where all-cause 
mortality was assessed as an outcome.   
We have been unable to identify a head-to-head comparison of ARBs and BBs to 
be able to say anything about this outcome, cardio- or cerebro- vascular disease, or 
mortality.  For the two studies comparing ARBs to CCBs, both found ARBs reduced the 
risk of albuminuria progression; only one of these studies analyzed vascular events or 
mortality, which showed no difference between the two therapeutic strategies.53,109,117  
Please see Appendix C for more details about the studies comparing active controls to 
ACEI or ARB monotherapy. 
ACEI Monotherapy Compared to ARB Monotherapy 
 
We were able to identify sixteen studies that examined the efficacy or 
effectiveness of ACEIs compared to ARBs in P2DM in attenuating albuminuria.  None 
statistically examined the effect on cardio- or cerebro- vascular outcomes or mortality.  
Appendix D provides a description of these studies.   
Effect on Albuminuria 
 
 Sixteen studies compared ACEI and ARB monotherapy in attenuating 
albuminuria.  These studies were randomized, mostly consisting of double-blind trials or 
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crossover studies with sample sizes ranging from 20 to 250 subjects.  The results from 
these studies indicated that few had controlled for baseline albuminuria.  Next, we 
expand on the three studies controlling for baseline albuminuria. 
The study by Barnett et al. (2004) was a double-blind randomized controlled trial 
of 250 subjects who had microalbuminuria or macroalbuminuria at baseline.  The sample 
consisted of 98.4% non-Hispanic whites.  Median baseline urinary albumin excretion 
rates were 60.0 and 46.2µg/min for enalapril (ACEI) and telmisartan (ARB), 
respectively.  The study had 5 years of duration.  Researchers found enalapril reduced 
albuminuria by 4.0% (enalapril reduced albuminuria by 3.0% while telmisartan increased 
it by 1.0%) (p-value not reported).  The study had a drop-out rate of 30.4% and 33.6% for 
telmisartan 40mg daily and enalapril 10mg daily, respectively.121  Numbers reflecting 
albuminuria levels at baseline or study end were not reported.   
The study by Mogensen et al. (2000), compared lisinopril 20mg daily (ACEI) to 
candesartan 16mg daily (ARB) in 197 subjects who were microalbuminuric at 
baseline.122  This was a double-blind randomized controlled trial.  Mean baseline 
albumin-to-creatinine ratios were 5.9 and 6.6mg/mmol for candesartan and lisinopril, 
respectively.  Compared to baseline, there were significant reductions in albuminuria of 
30% and 46% for candesartan and lisinopril monotherapy, respectively, at week 12 
(p<0.001 each).  This equates to a 30% difference between lisinopril and candesartan at 
week 12 (p=0.058) after controlling for baseline value, site, weight, and change in 
diastolic blood pressure.122  At week 24, these reductions remained significant (p<0.001 
for lisinopril, p=0.05 for candesartan).  
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The third study was a randomized, open-label, crossover study of 219 subjects 
who were microalbuminuric at baseline by Sengul.123  The study compared lisinopril 
20mg (ACEI) with telmisartan 80mg (ARB) in subjects with mean urinary albumin 
excretion rates of 264 and 256mg/d for lisinopril and telmisartan, respectively.  
Investigators reported an 18% relative reduction in albuminuria with lisinopril 20mg 
compared to telmisartan at week 24 (p=0.12).  For this study, subjects were advised to 
limit ingestion of sodium and maintain ingestion of protein at 1.2g/kg.  Due to the 
relatively short duration of the study and the more intensive following compared to 
clinical practice, the diet specifications in themselves may not make this generalizable to 
practice.  While it suffers external invalidity because of this fact, it also suffers more 
internal invalidity compared to double-blind clinical trials.   
Studies by Rosei et al. (2005) and Lim et al. (2007) did not control for baseline 
albuminuria.  Their results showed ARBs led to a statistically significantly reduction in 
albuminuria compared to ACEIs.124,125  Rosei et al. did not mention albuminuria as an 
endpoint, leaving one to assume it was a post hoc analysis.124  The researchers of this 
randomized double-blind trial found, among 118 microalbuminuric patients, candesartan 
led to an additional 80.2mg/g reduction in albuminuria at 24 weeks compared to 
enalapril.  At baseline, the mean albuminuria of the ARB group was 82mg/g higher.  The 
researchers in the second study enrolled 41 patients at microalbuminuria or 
macroalbuminuria for 4 weeks in a randomized single-blind crossover study.125  The 
authors mention losartan conferred an additional 44mg/g reduction in albuminuria 
compared to quinapril.  At baseline, the mean albuminuria of the ACEI group was 
79mg/g higher than the ARB group. 
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The 4 studies that were reviewed by the Agency for Healthcare Research and 
Quality (AHRQ) were only found to be of “fair” quality.126  As AHRQ is the Federal 
agency in charge of improving the effectiveness, quality, efficiency, and safety, the fact 
that the studies reviewed were of only “fair” quality is important to note.  Only three 
studies described above controlled for baseline differences in albuminuria between 
ACEIs and ARBs.  Controlling for such differences at baseline is important in these 
studies when the outcome is reduction in albuminuria.  In particular, a group that has a 
larger albuminuria value at baseline may have more of a potential to have a larger 
reduction in albuminuria.  Alternatively, it may be indicative of a group that is further 
along in nephropathy progression, perhaps making it less likely for that group to have a 
similar reduction in albuminuria.  This is an especially important consideration as many 
of the studies had substantial differences in baseline albuminuria.  In each of these 
studies, ACEIs demonstrated greater reduction in albuminuria compared to ARBs, but the 
difference was statistically insignificant.121-123  For ACEIs, the relative reduction in 
albuminuria ranged from 4%-30% compared to ARBs.   
Conversely, two of the 13 studies not controlling for baseline albuminuria found 
ARBs significantly lowered albuminuria compared to ACEIs.  What is particularly 
intriguing about this fact is that the mean baseline between group difference in 
albuminuria was approximately 80mg/g, but with one study having the ACEI group with 
higher albuminuria and the other study having the ARB group with higher albuminuria.   
To the best of our knowledge, these 16 small studies are the only published data 
comparing ACEIs to ARBs: all only statistically compare the surrogate endpoint of 
reduction in albuminuria.  In these trials, all measured albuminuria continuously.  None 
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of these studies enrolled patients from the U.S.  As is the case in most clinical trials, 
subjects were healthier than the general population.  For instance, of the studies reporting 
exclusion criteria, 80% excluded patients with severe hypertension or enrolled patients 
who had a mean systolic blood pressure <140mmHg, 60% excluded patients with recent 
CVD events or strokes, and 60% excluded patients with cancer.51,121-123,125,127-133  
Moreover, as there is evidence for discrepancies in effects of angiotensin blockade across 
race/ethnic groups in left ventricular hypertrophy or hypertension,134,135  there is a gap in 
the studies analyzing effects across race/ethnic groups, especially in light of the fact that 
individuals in minority groups are among those who are most likely to develop 
progressive albuminuria.  As a result, data are not available to inform us which treatment 
is more effective in preventing nephropathy progression, or development of ESRD, in 
U.S. clinical practice.  
Effect on Cardio- and Cerebro- Vascular Disease and Mortality 
 
There are no published studies making statistical comparisons of ACEIs to ARBs 
in terms of cardio- or cerebro- vascular disease outcomes.  One study, a 5 year double-
blind randomized controlled trial conducted by Barnett and colleagues,121 combined 
stroke; nonfatal MI; and death from stroke, MI, or cardiac insufficiency to evaluate safety 
profiles of enalapril 10mg daily and telmisartan 40mg daily.  Investigators found a 15.0% 
incidence in the telmisartan group and a 10.8% incidence in the enalapril group.  
Similarly, there was a 7.5% and 5.4% incidence of congestive heart failure in the 
telmisartan and enalapril groups, respectively.  This study suggests a relative risk 
reduction of each adverse event of 39% with ACEIs compared to ARBs. 
  47
 Finally, no studies were identified comparing all-cause mortality or healthcare 
utilization. 
 
ACEI and ARB Combination versus Mono-therapy 
 
 There were 11 studies that compared ACEI and ARB combination to mono- 
therapy in P2DM.  All were conducted outside the U.S., had small sample sizes, and 
followed patients for a short time.  Two studies had patients on one year of therapy, but 
most studies only had patients on therapy for a maximum of four months.  The majority 
of these studies did not control for baseline albuminuria between groups.  Appendix E 
provides more information about these studies. 
 Four studies controlled for baseline differences in albuminuria.  Two of these 
studies also compared ACEI and ARB in monotherapy and were mentioned previously.  
The study by Mogensen et al. (2000)122 was a double-blind randomized controlled trial 
comparing lisinopril 20mg plus candesartan 16mg to each as a monotherapy for 12 
weeks.  The results indicated that combination therapy reduced albuminuria significantly 
by 34% (95% confidence interval: 3%-55%) when compared to candesartan (p=0.04).  
However, the combination therapy was less effective when compared to lisinopril.  
Although it reduced albuminuria by 18% (95% confidence interval: -20% to 44%), the 
results were nonsignificant (p>0.20).   
 Sengul et al. (2006)123 was an open-label randomized crossover study of 219 
microalbuminuric subjects with hypertension.  Treatment with lisinopril 20mg plus 
telmisartan 80mg or each monotherapy continued for 28 weeks.  The investigators of this 
study reported a significant reduction in albuminuria between the combination therapy 
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and each monotherapy (p=0.04).  No details regarding magnitude of reduction were 
reported. 
 The third study was an open-label before-and-after study of 27 microalbuminuric 
and macroalbuminuric patients with hypertension conducted by Fujisawa.136  In that 
study, investigators switched monotherapy for combination therapy at half-doses.  If a 
subject received 8mg candesartan at the beginning of the study, the patient would receive 
combination therapy of 4mg candesartan and 5mg imidapril.  The same holds true of a 
patient initially on 10mg imidapril.  The monotherapies were pooled for analysis.  
Combination therapy led to a 34% reduction in albuminuria (14%-49%) compared to the 
monotherapies (p<0.01).  The researchers were able to determine combination therapy 
reduced albuminuria independent of individual albuminuria or blood pressure at baseline.   
 The last study, conducted by Song,137 was a double-blind randomized crossover 
study of 18 macroalbuminuric patients without hypertension.  Combination therapy with 
candesartan 4-8mg plus ramipril at a dosage over 5mg led to a 0.8% reduction in 
albuminuria over 16 weeks compared to taking ramipril alone (p>0.05).  The researchers 
concluded there was no difference while controlling for blood pressure reduction. 
 Of the studies not controlling for baseline albuminuria, there was also a mixture 
of positive and negative findings.  Two studies found nonsignificant differences between 
combination and monotherapies, two studies found significant differences between 
combination therapy and ACEI monotherapy, and three studies found significant 
differences between combination therapy with each monotherapy. 
 From what was identified in our exhaustive literature review of studies comparing 
combination therapy to monotherapy, these 11 studies are the only data available on the 
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subject.  All of these studies examined the surrogate endpoint of reduction in 
albuminuria.  Every study measured albuminuria continuously rather than looking at 
progression or reversion from one albuminuric state to another.  All studies had small 
sample sizes and short treatment durations, with the sample sizes ranging from 17-219 
subjects and treatment durations lasting 2-12 months.  No studies were conducted in the 
U.S.  As to be expected, subjects in these studies were healthier than the general 
population.  Specifically, 67% excluded patients with severe hypertension or enrolled 
patients with a mean systolic blood pressure <140mmHg; 60% excluded patients with 
uncontrolled diabetes, severe diabetes complications, or who used insulin; 50% excluded 
patients with recent CVD or stroke; and 50% excluded patients with cancer.51,122,123,130-
132,136-140  Additionally, no study assessed the treatment strategies across race/ethnic 
groups.  These limitations do not permit prescribers to know if combination therapy is 
superior, equal, or inferior to each monotherapy in preventing nephropathy progression in 
U.S. clinical practice. 
To the best of our knowledge no studies examined the impact of these therapies 
on ESRD, cardio- or cerebro- vascular disease, all-cause mortality, or healthcare 
utilization.  
 
 
Summary  
 
There is undisputed evidence that type 2 diabetes has already reached epidemic 
proportions, with incidence expected to continue to rise for the next four decades. The 
disease is more prevalent and more severe in minority populations.  The VA has a diverse 
population and has been a forerunner in combating this disease state over the last four 
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decades.  With a diabetes incidence 4-times higher than the general population, it is 
essential to study type 2 diabetes among this population.  Process and outcome measures 
demonstrate VA patients are tested more frequently for HbA1c, proteinuria, and lipids; 
and have better LDL and HbA1c levels compared to managed care patients.  Despite this, 
complications remain high among veterans, straining available resources.  As the 
argument can be made that VA patients receive better care, one can speculate if a 
difference is seen between treatments in this population, that a larger difference would be 
seen in managed care patients.  
Overwhelming evidence exists about the seriousness of complications arising 
from type 2 diabetes.  Duration since diabetes diagnosis has a positive relationship with 
diabetes complications as a result of increasing likelihood of hypertension, which leads to 
worsening HbA1c and albuminuria.  ACEIs and ARBs have proven to be effective at 
reducing blood pressure and albuminuria, although there is no consensus of whether the 
albuminuria effects are independent or dependent of blood pressure lowering.  A possible 
reason for this is that doses regularly given to P2DM are based on the FDA-approved 
indication for hypertension.   
Literature Review Summary 
 This literature review provides a historical record of the literature relating to 
ACEI and ARB therapy.  First, efficacy was demonstrated in ACEI or ARB monotherapy 
in studies using placebo and active controls.  From there, researchers and clinicians 
started comparing the two monotherapies to each other.  Recently, interest has sparked in 
comparing each monotherapy to combination therapy. 
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In terms of monotherapy comparisons, more valid conclusions can be made with 
the studies controlling for baseline albuminuria.  Of these 3 studies, although no 
significant differences were found, a 4%-30% relative reduction in albuminuria was seen 
with ACEIs versus ARBs.  The only study lasting over 6 months assessed reduction in 
albuminuria as a secondary outcome.  Interestingly, of the 13 studies not controlling for 
baseline albuminuria, the 2 studies that showed a significant difference between groups 
had a treatment effect favoring ARBs.  None of the 16 studies have analyzed the clinical 
outcomes ESRD, cardio- or cerebro- vascular disease, or all-cause mortality to know if 
ACEI or ARB monotherapy provides clinically significant differences in patient 
outcomes.  Simply no evidence exists for comparisons of monotherapies with these 
important events, making research into these outcomes critical. 
Among the studies comparing combination with mono- therapy, there is also lack 
of consensus.  Only 4 of these 11 studies controlled for baseline albuminuria, which again 
places more weight on findings from these 4 studies.    The 2 open-label studies found 
combination therapy to be better than both monotherapy while the 2 double-blind 
randomized studies found no difference between combination therapy and ACEI 
monotherapy.  Only 1 of the 2 double-blind studies compared combination therapy to 
ARB monotherapy, which found ARB monotherapy to be significantly less effective at 
reducing albuminuria.  The 7 studies that did not control for albuminuria differences at 
baseline yielded a similar picture of mixed results.  None of the 11 studies analyzed 
ESRD, vascular disease, or all-cause mortality to know if combination therapy is 
clinically different than either monotherapy. 
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Whittling down the studies to only those controlling for albuminuria at baseline, 
we need to collectively analyze the findings from the 3 monotherapy comparison studies 
and the 4 combination versus mono- therapy studies. By doing this, we can say that there 
is evidence that ACEI monotherapy may work better at reducing albuminuria than ARB 
monotherapy, despite lack of statistically significant differences.  The first part of this 
picture is that relative reductions of 4%-30% for attenuation of albuminuria are seen for 
ACEI monotherapy compared to ARB monotherapy.  The second is that the 2 double-
blind randomized studies comparing combination and mono- therapy show no significant 
difference between ACEI monotherapy and combination therapy.  As these conclusions 
do not rely on a particularly large number of studies, further research into reduction in 
albuminuria is essential.
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CHAPTER 3:  METHODS 
 
 
 The beginning of this chapter talks about human subjects and VA approval and 
the pilot study. The research design, data sources, and data storage follow this.  Next, 
inclusion and exclusion criteria, sample size, and the pilot study are described.  Lastly, 
data management, data cleaning, data coding, and statistical analyses are discussed.   
 
Human Subjects Approval 
 
 We submitted for two departmental reviews, one through the University of New 
Mexico College of Pharmacy and one through the VA Research and Development (R&D) 
Committee on March 14, 2008.  After obtaining each of their approvals, we applied for 
expedited review through the University of New Mexico Health Sciences Center Human 
Research Review Committee (HRRC), which occurred on March 21, 2008.  The HRRC 
approved the study on April 4, 2008 (see Appendix A for HRRC approval letter).  We 
requested an informed consent waiver and a Health Insurance Portability and 
Accountability Act (HIPAA) waiver as we felt the research would be more harmful to 
patients if we actually obtained their consent:  we would need their social security 
number to do so, which would cause a larger risk to confidentiality. 
 
VA Approval 
 
 After obtaining HRRC approval, we submitted our proposal to National Data 
Systems division of Information Assurance, Veterans Health Administration (VHA) 
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Office of Information and Decision Support Office, the division in charge of Decision 
Support Systems.  From this point, National Data Systems forwarded our proposal to 
VHA Office of Research Oversight and VHA Office of Research and Development.  All 
approvals were given in October 2008, which had to be obtained before any data were 
provided.   
 
Research Design 
 
This was a quasi-experimental retrospective longitudinal secondary database 
analysis.  The aim of this study was to compare the effectiveness of two treatments 
(ACEIs and ARBs) used in P2DM.  As mentioned earlier, the VA is an ideal setting for 
this comparison; we used national VA data for our analysis.  The study period for 
observing outcomes at any Department of Veterans Affairs (VA) healthcare facilities is 
October 1, 2002-September 30, 2007.  A patient would only be counted as newly-
diagnosed between fy2003 and fy2006 if there was no mention of type 2 diabetes the year 
before.  A main reason we picked this time frame is because provider ID (for the intended 
instrumental variables analysis) was not available until October 1, 2002.  This means 
recorded patient data was potentially used from October 1, 2001 to define patients as 
newly-diagnosed, new users of ACEIs or ARBs, and having comorbidities.  Similarly, 
because we wanted minimally one year of follow-up for each patient the last day 
someone could have his first date of healthcare utilization documenting type 2 diabetes 
was September 30, 2006.  The analysis plan is described later. 
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Data Sources 
 
The data provide information on outpatient visits, emergency department (ED) 
visits, and hospitalizations for services provided by the VA, including prescription 
utilization and lab results.  The datasets are available in different files. Scrambled social 
security number, date of service, and date of birth linked patients across these files unless 
otherwise noted.   
In particular, we used the following datasets available at the VA Corporate 
Franchise Data Center. National Data Systems provided the VHA Medical SAS 
Outpatient files, the VHA Medical Inpatient files, and the death files.  The Decision 
Support Office provided the VHA Decision Support System National Data Extract files. 
Table 3 summarizes the data sets and the variables used in the analysis.  We briefly list 
these files below by type of information extracted: 
Outpatient Care and Emergency Department (ED) Visits at the VA 
 
a) The VHA Medical SAS Outpatient Event dataset: This dataset contains 
information pertaining to outpatient encounters in the VA.  Specifically, it has 
ICD-9 codes, CPT-4 codes, date of outpatient encounter, and provider 
identification number (ID). 
b) The VHA Medical SAS Outpatient Visit dataset: This dataset contains 
information pertaining to outpatient encounters in the VA and demographic 
variables such as age, race, and detailed income information. 
 
 
  56
Inpatient Care at the VA 
 
c) The VHA Medical Inpatient Main dataset: This dataset contains information on 
diagnostic codes, admission and discharge dates, length of stay, demographic 
information, and date of death. 
d) The VHA Medical Inpatient Procedure dataset: This dataset contains ICD-9 codes 
and dates pertaining to procedures. 
e) The VHA Medical Inpatient Surgery dataset: This dataset contains ICD-9 codes 
and dates pertaining to surgeries. 
Laboratory Results at the VA 
 
f) The VHA Decision Support System National Data Extract Clinical Laboratory 
Results (VHA DSS NDE LAR) dataset: This dataset contains information on 
laboratory results and includes information about lab name, date, lab result, date 
of lab procedure, and date lab procedure was ordered for inpatient and outpatient 
laboratory procedures. 
Pharmacy Utilization at the VA 
 
g) The VHA Decision Support System National Data Extract Clinical Pharmacy 
(VHA DSS NDE PHA) dataset: This dataset contains information about 
medication name, dose, quantity, and days supply for inpatient and outpatient 
prescriptions.  Information was requested from October 1, 2002-September 30, 
2007. 
h) The Pharmacy Benefits Management (PBM) dataset: This dataset was requested 
from the PBM/Strategic Health Group (SHG).  The Group regularly extracts data 
requested by researchers, with a usual turnaround time of 6 months.  Information 
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was requested from October 1, 1998 to October 1, 2002.  This is because data are 
unavailable in the VHA DSS NDE PHA dataset before October 1, 2002. Looking 
before the index date allows us to distinguish between new users and longer-term 
users of ACEIs or ARBs.  There are 3 separate PBM extracts, but only one is 
given to researchers141. This is the prescription extract, PBM PRE EXT, which 
refers to outpatient prescriptions only.   
Deaths 
 
j) The Beneficiary Identification Records Locator Subsystem (BIRLS) Death File, 
Social Security Administration (SSA) Death Master File, and the VHA Medical 
Inpatient Main datasets: These datasets were requested from National Data 
Systems at the VA Corporate Data Franchise Center.  These files were used for 
date of death. 
k) The VA-Medicare Vital Status file: This file contains dates of death and was 
requested from the VA Corporate Data Franchise Center. 
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Table 3: Name of Datasets and Variables to Extract 
 
Dataset Variable 
VHA Medical SAS Outpatient Event Outpatient data:  Dates of office visits, Diagnosis (ICD-9) 
and Procedure (CPT-4) codes 
Demographic and patient characteristics:  Gender, Zip code 
of patient’s residence, Race/ethnicity, Income, Provider  
  
VHA Medical SAS Outpatient Visit Demographic and patient characteristic: Income 
  
VHA Medical SAS Inpatient Main Inpatient data:  Admission and discharge dates, length of 
stay, ICD-9 codes, Diagnosis related groups (DRGs) 
Demographic and patient characteristics: Gender, 
Race/ethnicity, Income, Zip code of patient’s residence, 
Dates of birth and death 
  
VHA Medical SAS Inpatient Bedsection, Medical 
Surgery 
Inpatient data:  Admission and discharge dates, Admission 
and discharges dates for bedsection 
  
VHA Medical SAS Inpatient Bedsection, Non-medical 
Surgery 
Inpatient data:  Admission and discharge dates, Admission 
and discharges dates for bedsection 
  
VHA Medical SAS Inpatient Procedure Inpatient data:  Admission and discharge dates, ICD-9 
codes relating to procedures, Procedure dates 
  
VHA Medical SAS Inpatient Surgery Inpatient data:  Admission and discharge dates, ICD-9 
codes  relating to surgeries, Surgery dates 
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 Table 3 (cont.) 
 
Dataset Variable 
VHA DSS NDE LAR Visit data:  Admission and discharge dates (if inpatient), 
Date of outpatient visit 
Test data:  Test name, Test results, Units of results, Date 
lab procedure was performed, Date lab procedure was 
ordered 
  
VHA DSS NDE PHA Visit data:  Admission and discharge dates (if inpatient), 
Date of outpatient visit 
Pharmacy data:  Medication name, Dose, Days supply, 
Quantity, Dispensing date, Provider 
  
PBM PRE EXT Pharmacy data:  Medication name, Dose, Days supply, 
Quantity, Dispensing date, Provider 
  
VA-Medicare Vital Status File Demographic and patient characteristics:  Race/ethnicity, 
Dates of birth and death 
  
BIRLS Death File Demographic and patient characteristics:  Dates of death 
  
SSA Death Master File Demographic and patient characteristics:  Dates of death 
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Data Storage, Patient Confidentiality 
 
Scrambled social security numbers (SCRSSNs) are generated by the National 
Data Systems at the VA.   All SCRSSNs are based on an algorithm used throughout the 
datasets to ensure appropriate linkages across datasets without use of true social security 
numbers.   The investigators neither had access to true social security numbers nor to the 
crosswalk that provides the conversion from SCRSSNs to true social security numbers.   
Further, it is part of the Information Technology security guidelines at the VA 
Cooperative Studies Program Clinical Research Pharmacy Coordinating Center for no 
investigator to ever have true social security numbers.    
In terms of maintaining confidentiality of subjects, all compact discs (CDs) that 
contained patient-level data were stored in a locked CD cabinet in a locked office at the 
VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center.   To 
comply with VA guidelines, all analyses were conducted at this VA facility, which is a 
limited access facility.   Before data could be collected from the CDs, the researcher 
needed a password from the programmer extracting the data at the National Data 
Systems.   This password was relayed via telephone to the researcher; email was not 
acceptable as it is not considered a secure means of communication.   After data had been 
extracted from the CD and the data had been placed on the network for management and 
analysis, the data were stored on a restricted access network drive behind a VA firewall.   
This network drive is only accessible by the researchers of this study.  
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Study Population and Sample Size Estimation 
 
The sample was restricted to VA beneficiaries continuously receiving VA care 
who have type 2 diabetes. P2DM were identified through ICD-9-CM codes 250.X0 or 
250.X2.  
Although consistent information exists in the literature for ACEI or ARB 
monotherapy comparisons to placebo for effect on albuminuria, which has led to 
guidelines recommending ACEI or ARB monotherapy for P2DM, there has been less 
information about cardio- and cerebro- vascular disease and all-cause mortality.  
Therefore, it is also of importance to compare those who have not received therapy to 
those who have received either monotherapy.  We planned to study patients who did not 
receive ACEIs or ARBs through the VA in an effort to describe the proportion of patients 
who fit this description. Since the guidelines advocate their use in diabetes patients with 
hypertension, heart failure, or at least microalbuminuria, all patients should be receiving 
therapy.54,89,142-146  
Inclusion and Exclusion Criteria 
 
It was identified a priori that it would be better to have an analysis of only new 
users of ACEIs or ARBs who were newly-diagnosed with type 2 diabetes.  This was done 
to limit bias associated with differences in duration of therapy, and secondarily, any 
unobserved bias related to duration since diabetes diagnosis.  Additionally, each P2DM 
must have had baseline microalbuminuria or macroalbuminuria for two reasons:  1.  
patients with normoalbuminuria were not expected to have many events compared to 
those with microalbuminuria and macroalbuminuria and 2.  patients with ESRD could not 
be followed since ESRD is an endpoint.  To increase generalizability to the VA 
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population and maintain data integrity, patients younger than 30 years of age were 
excluded as individuals are usually not diagnosed with type 2 diabetes until at least 30 
years of age.147  Patients also must not have had renal insufficiency/failure due to a 
nondiabetic cause to rule out confounding of ESRD development.  These include patients 
with documented ICD-9-CM codes of 593.89, 599.6, 599.60, 599.69 (urinary 
obstruction), 600.01, 600.11, 600.21, 600.31, 600.41, 600.51, 600.61, 600.61, 600.71, 
600.81, 600.91 (urinary obstruction due to hyperplasia of prostate), 592.0, 592.1, 592.9 
(kidney or ureter stone) were excluded from analysis as these diagnostic codes reflect 
nondiabetic causes of renal insufficiency/failure.  Finally, patients who did not have at 
least one test result for albuminuria, HbA1c, LDL, and triglycerides were inherently 
excluded from analysis as individuals with missing information are dropped from 
statistical analysis.  Since albuminuria was the emphasis of this study, all patients had to 
have albuminuria at baseline to be included.  See Figure 3.   
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Figure 3:  Inclusion/exclusion Criteria 
 
Inclusion Criteria:  patients documented as having newly-diagnosed type 2 diabetes             
during the study timeframe 
 
Exclusion Criteria:  
1. prevalent use of ACEIs or ARBs 
2. patients with normoalbuminuria at baseline 
3. age <30 years 
4. female gender 
5. patients with ESRD at baseline 
6. diagnosis of renal failure/insufficiency due to a nondiabetic cause 
7. combination therapy 
8. 0 test results for albuminuria, HbA1c, LDL, or triglycerides  
9. missing baseline albuminuria value 
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Sample Size Calculation  
  
The sample size calculation is based on the difference in the primary dependent 
variable, onset of ESRD. 
Hsieh et al. recommend using the formula n<4P(1-P)(Z1-/2 + Z1-)2/(P1-P2)2  for 
logistic regression.148 
Where P = probability of occurrence of the dependent variable,  
Z1-/2 = the standard normal deviate for 1-/2 (i.e., 1.96 for =0.05),  
Z1- = the standard normal deviate for 1- (i.e., 0.84 for 80% power, 1.28 for 90% 
power),  
P1 = event rate for ARB monotherapy, and  
P2 = event rate for ACEI monotherapy.  
Previous studies of combination therapy compared to monotherapy have 
documented 11% to 26% reduction in albuminuria in the combination therapy 
regimen.122,136-140  Since these were determined to be significant in combination versus 
mono- therapy studies and since there are no studies demonstrating significance in ACEI 
versus ARB monotherapy for reduction in albuminuria with comparable baseline 
albuminuria,51,121-123,125,127-133 the significance criteria for combination versus mono- 
therapy comparisons were used for calculating significance associated with difference in 
onset of ESRD associated with ACEI or ARB monotherapy. 
Table 4 below displays the sample size calculations based on the aforementioned 
combination therapy versus monotherapy studies as applied to this study.  All of the 
calculations assume an annual incidence of onset of ESRD of 0.06 for monotherapy 
patients who are macroalbuminuric at baseline and an annual incidence of onset of ESRD 
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of 0.00 for monotherapy patients who are microalbuminuric at baseline.  This is a 
conservative estimate as 1)  RENAAL, a randomized clinical trial, showed monotherapy 
can lead to a 0.068 annual incidence of ESRD in those who are microalbuminuric at 
baseline49 and 2)  those who are microalbuminuric at baseline are expected to have 
progressively worsening albuminuria.  If the independent variable (treatment) is 
correlated with covariates, the sample size needs to be multiplied by 1/(1- ρ2) where ρ is 
the multiple correlation coefficient between the independent variable and the covariates.  
This is done to account for variance inflation that would occur in this circumstance.148  
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Table 4: Sample Size Calculations for ESRD 
 
Power Relative 
risk 
reduction 
Absolute 
risk 
reduction 
Sample 
size,  
ρ = 0.0 
Sample  
size, 
ρ = 0.1 
Sample 
size,  
ρ = 0.2 
Sample 
size,  
ρ = 0.3 
80% 13% 1.59% 10,516 10,623 10,955 11,557 
       
80% 17% 2.46% 6,150 6,213 6,407 6,759 
       
80% 21% 3.03% 4,030 4,071 4,198 4,429 
       
90% 13% 1.59% 14,080 14,223 14,667 15,473 
       
90% 17% 2.46% 8,234 8,318 8,578 9,049 
       
90% 21% 3.03% 5,396 5,451 5,621 5,930 
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IVDEs are important to study in this population as well.  Therefore, following the 
same sample size formula and, this time, estimating treatment effect based on studies 
demonstrating significance between ACEIs or ARBs and controls,46,49,109,118 we verify 
that we will have adequate power to detect a statistically significant difference in IVDEs 
(Table 5). 
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Table 5: Sample Size Calculations for IVDEs 
 
Power Relative 
risk 
reduction 
Absolute 
risk 
reduction 
Sample 
size,  
ρ = 0.0 
Sample  
size, 
ρ = 0.1 
Sample 
size,  
ρ = 0.2 
Sample 
size,  
ρ = 0.3 
80% 17% 2.40% 1,078 1,089 1,123 1,185 
       
80% 21% 2.55% 708 716 738 779 
       
80% 37% 5.50% 322 326 336 354 
       
90% 17% 2.40% 2,709 2,737 2,822 2,977 
       
90% 21% 2.55% 1,777 1,795 1,852 1,953 
       
90% 37% 5.50% 430 435 448 473 
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In the absence of available data we believed we would have adequate sample size 
based on the study by Wang (2006)99 and our pilot study.  The former study was focused 
on P2DM who were new users of antihypertensive therapy in 2000.  The study identified 
695,586 patients between October 1, 1998 and September 30, 2004.  Among those who 
were new users of antihypertensive drugs (44,534), 22,477 were either prescribed an 
ACEI while 1,542 were prescribed an ARB in 2000.  Assuming a similar number are on 
ACEIs and ARBs in other years, our estimated sample size is 72,057 for similar patients 
started on an ACEI or ARB between October 1, 2000 and October 1, 2003.  Note we did 
not restrict analysis to new users of antihypertensive agents. 
 
Pilot Study 
 
 We conducted a pilot study using local VA data to further assess patients fitting 
our inclusion and exclusion criteria.  The point of this study was to determine the 
numbers and proportions of patients receiving ACEI monotherapy, ARB monotherapy, 
both therapies, and neither therapy in later years of the study’s follow-up period.  The 
researcher had a de-identified set of data and conducted a descriptive analysis.  
At the Raymond G. Murphy VA Medical Center in Albuquerque, 7,648 patients 
with type 2 diabetes (newly diagnosed and those who have had it for years) were 
identified.  Among these individuals, 47.72% of patients were on ACEI monotherapy in 
2006, which increased to 51.16% in 2007.  Whereas only 8.64% received ARB 
monotherapy in 2006, in 2007 11.07% were on ARB monotherapy.  The percentage of 
patients receiving neither therapy decreased from 38.93% in 2006 to 32.06% in 2007.  (In 
this circumstance patients receiving neither therapy received absolutely zero prescriptions 
  70
for ACEI or ARB monotherapy.)  Only 2.35% received combination therapy in 2006, 
which increased to 2.85% in 2007.  The pilot study gives us confidence that we would 
have a large enough sample size when extending the study to all VA facilities.  A concern 
that we had was the amount of patients receiving combination therapy as that was the 
emerging trend in the literature among P2DM. 
 
Data Management and Cleaning 
 
Data Management 
 
 The VA datasets each consisted of hundreds of thousands to millions of records 
for each requested year for P2DM.  The reason for this is a record is created for each 
outpatient visit, each ED visit, day of hospitalization, inpatient procedure, inpatient 
surgery, transfer between bedsections, prescription fill, and laboratory result.  Therefore, 
to make this data easier to work with, a programmer placed each dataset on a VA server 
to create a summary of each patient’s care, diagnoses, and outcomes for each year of 
patient data.  This lead to the creation of person-time observations.   
 Speed of query results is dependent upon the number of columns and the number 
of rows.  The first two steps reduced the number of columns while the next two steps 
reduced the number of rows.  Data were optimized, meaning one field was created from 
the 10 ICD-9 code fields among the variables that relied on documentation of an ICD-9 
code in any of the fields.  Next, variables that were not needed specifically for this 
analysis were deleted to make the queries run faster.  After this, because the population of 
type 2 diabetes patients has a majority who is normoalbuminuric, these patients were 
deleted.  Following this, records not having ICD-9, CPT-4, or DRG codes of interest 
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were dropped.  The last step was not involved with directly reducing the number of rows 
or columns.  Rather, normalizing data indirectly reduces the number of rows the 
computer processor has to analyze.  Normalizing data basically orders words 
alphabetically and numbers from smallest to largest.   A flag signifies the start of another 
letter or number.  When the processor finds the record of interest is in between two tabs, 
it starts at the earlier of the two tabs, bypassing the previous records.   
Data Cleaning 
 
 After completion of the processes involved to make queries run faster, data 
cleaning began.  Instances of more than one date of birth, gender, or race/ethnicity for a 
subject were treated similarly.  For a subject with more than one date of birth, the 
decision was made to use the date of birth appearing most frequently for that patient, 
making the assumption that data entry error would occur with the less frequent date of 
birth.  For the five patients with more than one date of birth that appeared with equal 
frequencies, the decision was made to take the midpoint of the two dates of birth as long 
as the two dates of birth did not exceed twenty years of separation.  In that case, the age 
was coded as missing.  For a patient with more than one value for gender or 
race/ethnicity documented across visits, the patient was labeled with the most frequently 
occurring value.  If more than one value was documented with equal frequency, the 
respective variable was coded as missing.  Additionally for race/ethnicity, values of 
“unknown” were coded as missing. 
 Albuminuria and albumin:creatinine ratio results were extracted from the datasets.  
These values were character/string rather than numeric.  A value with the letter “O” was 
transformed to number “0”.  A values such as “<4” was transformed to the closest integer 
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(“3” in this example).  A value with a range was transformed to the number in the middle 
of the range (for instance, “30-300” would become “135”).  Values with words that could 
not be easily translated were deleted.  From here, because the albumin:creatinine ratio is 
more exact than albuminuria, we used albumin:creatinine ratio preferentially at baseline 
and in each year of observation for each patient.  When there was no value for the ratio, 
we used the albuminuria values rather than considering it missing data.  If neither value 
was present for a patient in a year, it became a missing value.  If more than one test was 
performed in a given year the mean of the values was recorded for study purposes. 
HbA1c, LDL, and triglyceride test results were obtained similarly as albuminuria 
and albumin:creatinine ratios, meaning that the data were directly lifted from the datasets, 
so similar translations occurred.  Also similar to albuminuria and albumin:creatinine 
ratio, if, within a test, more than one test was run in a given year of observation, the mean 
of the values was taken.  Rarely did this happen.  For more details about coding 
Elixhauser comorbidities, covariates, variables used to control selection bias, and 
dependent variables, please see Appendix F, Tables 1, 2, 3, and 4, respectively.
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Empirical Analysis 
 
Introduction 
 
 In this section we first present the advantages of propensity score analysis 
compared to OLS.  Then, we discuss propensity score analysis; including regression, 
stratification, and matching; comparing and contrasting these techniques.  Then we talk 
about sensitivity analysis of propensity score analysis results.  From this topic we explain 
how we incorporated propensity score analysis into logistic regression as well as 
regressions specific to count variables.  In the context of regression models for count 
variables we explain the advantages of count regression models over OLS, then we 
recount the controversy in the different models, and discuss different model fit 
diagnostics.  Next we talk about how we dealt with non-independence of observation, 
how we followed patients, and how we accounted for multiple comparisons in assessing 
significance.  Since there were univariate comparisons in our analysis, but these are much 
more common techniques, a short overview is included.  From here, we talk about 
construction of independent and dependent variables and covariates.  Lastly, we 
summarize all the techniques as applied to this study and report a timeline of activities. 
Theory suggests that choice of treatment is associated with patient characteristics. 
Treatment selection reflects clinical practice; expert opinion exists for preferential 
selection of ARBs based upon patient propensity for cough due to the much higher rate of 
cough witnessed with ACEIs. We expect differences between groups in patient 
characteristics as confounding by indication naturally exists in clinical practice: those 
who are expected to receive the most benefit from a treatment are more likely to receive 
that treatment. In an observational design, treatment selection can produce biased 
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estimates. Use of longitudinal data and quasi-experimental design helps us to control for 
this selection bias. Specifically, we used one method to control for selection bias: 
propensity scores analysis (Figure 4).   
Propensity score analysis controls observable variables that could lead to selection 
bias.  Observable patient characteristics can potentially be confounders. In order for this 
to happen, a characteristic must be correlated with both the independent and dependent 
variables while not being an intermediate step in the path. If there is no evidence of 
selection bias, ordinary least squares (OLS) with robust standard errors is more efficient, 
so would be preferred.   
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Figure 4: Conceptual Framework.  
The top diagram acknowledges selection bias and how we will control for selection bias.  
Basically, controlling for selection bias through propensity scores analysis should make 
therapy groups similar.  From here, we will be able to assess how ACEIs and ARBs 
influence albuminuria and the other outcomes of interest.   
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Propensity Scores Analysis 
 
 Propensity scores analysis (PSA) has been used to control for selection bias 
associated with treatment assignment by adjusting for the propensity score, defined as 
“the conditional probability a patient will be treated based on observed covariates.”149  
The limitation with propensity scores analysis is that it only controls for observed 
variables, unlike other approaches such as instrumental variables analysis.150  That being 
said, the theory behind PSA is that if all observed covariates are included in the model 
predicting odds of treatment selection, this reduces the association between treatment 
assignment and prognosis.149  Further, if people between groups are similar on observed 
variables, they should be similar on unobserved variables as well.  Therefore, PSA may 
lead to more precise estimates than OLS regression, which may underestimate treatment 
effect.  The last ideal of PSA is that matching patients on propensity scores leads to 
exclusion of patients that are at tails of the distribution.  This leads to identification of 
patients who have a low or high probability of one treatment or another based on their 
covariates, meaning there is no clinical equipoise for these patients. Thus, it could be 
postulated that these patients should not be included in the analysis.151  In fact, there is 
evidence that using PSA to account for treatment selection provides similar treatment 
effect estimates obtained from randomized clinical trials.152 
In the propensity scores method, a logistic regression is first run to determine the 
odds of receiving each treatment strategy, the propensity score, for each patient based on 
observed covariates.153  More technically: 
P (Tr|X, Yobs, Ymis) = P(Tr|X) for all Ymis, Yobs is the probability an individual 
assigned a particular treatment is only related to observed variables X.154  Since Yobs is 
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the outcome observed for a patient given his/her assigned treatment and Ymis is the 
outcome observed in a patient with the same propensity score assigned the alternate 
treatment (i.e., the counterfactual outcome), the equation explicitly states treatment 
assignment is not dependent on recorded outcomes of treatment assigned nor is it 
dependent on unrecorded outcomes of treatments not assigned. Extending this to each 
patient: pi=P(Tri|Xi, Yobs) is the propensity score.154 
Accordingly, enough overlap in the propensity scores between the groups needs to 
be present to provide valid estimates of the treatment effect.149   PSA, in an attempt to 
make groups equal, extracts the variation in therapy not related to, at least, observed 
characteristics.  In STATA, this is accomplished by including only those patients 
identified as having common support equal to one, which restricts analyses to any 
combination of observables that can be observed in both treatment groups.155  In other 
words, analysis is restricted to matched patients.  Said yet another way, if people are 
matched on similar propensity scores, since these patients had similar probability of 
treatment, as far as we can tell from comparable baseline observable characteristics, a 
coin was flipped to determine treatment assignment.156  
A model explaining treatment assignment is necessary for causal inference.154  
This points to the usual regression assumptions that if model misspecification is present 
or if covariates are measured with error, the treatment effect estimates are biased; the 
same holds true for PSA.153  Additionally, bias from between group differences in 
baseline observed covariates is inherent in regression without propensity score 
adjustment.157  For PSA, it is believed to be better to include a weak confounder, thus 
allowing for some inefficiency, than to omit it and create bias.158  The first stage of the 
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PSA should include all variables believed to be associated with the outcome regardless of 
their association to treatment.159,160  If the model predicting treatment selection is 
correctly specified, it will result in a consistent estimator.161  The benefit of collapsing all 
potential observed covariates into a single predictor variable is improved efficiency149 as 
possible multicollinearity from inclusion of many observed covariates will make the 
standard error larger than if just incorporating one predictor into the next step of the 
analysis.   
Regression adjustment with propensity score can be accomplished by using a 
large set of baseline observable covariates to estimate the propensity score, and then 
using a subset of the covariates with the propensity score in the second stage 
regression.162  In the second stage, the regression can be weighted by the inverse of the 
propensity score for each patient.160  Weighting by the inverse of the propensity score 
removes the imbalance of observed covariates between the treatment groups as well as 
the associated bias.163  This approach provides a relatively simple way to incorporate 
propensity scores into longitudinal data.160  Weighting may also allow for more patients 
to be included in the second stage PSA, providing for more generalizability.152   
In this study, we reweighted the second stage regression model by using a logit 
regression of drug therapy to estimate the conditional probability, pi, of being in the 
ACEI monotherapy group, with weight of pi/(1- pi).164  This implies we only applied this 
weight to patients receiving ARB monotherapy in order to make the outcomes that 
occurred in the ARB monotherapy group represent the counterfactual outcomes of the 
ACEI monotherapy group “by making the two groups similar with respect to observable 
characteristics.”165  “A weighted regression of outcome on treatment is thus a comparison 
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of means across treatment and control groups, but the control group is reweighted to 
represent the average outcome that the treatment group would have exhibited in the 
absence of treatment.  That is, every control group observation is contributing to an 
estimate of the mean counterfactual outcome for all treated observations (rather than 
specific observations being matched).”165  Reweighting with this method provided the 
average treatment effect on the treated (ATT of ACEI monotherapy), which allows for 
direct comparison to the other techniques used to derive ATT.164  These techniques, 
stratification and matching, are described below. 
The creators of PSA, Rosenbaum and Rubin, recommend to balance the 
nonequivalent groups using stratification (5 strata) or matching,166 which is the original 
intent of the technique.150  Stratifying or matching across treatment groups allows the 
treatment effect to be estimated as observed covariates are similar between the groups.  
Stratification is different than regression as it obtains propensity scores through iterative 
testing to see if there is balance between groups on the propensity score; if not, the 
stratum is halved to see if the propensity score is then balanced between groups.165  Once 
equal, if the F ratios of any variables are large, interactions with these variables need to 
be added and/or squares of these variables need to be added and the process repeated 
until variables are balanced.167  Obtaining this balance in propensity scores effectively 
creates a 90-95%  reduction in bias.167  An alternate strategy that can be employed as a 
next step is to use propensity scores generated in the first stage as part of the second stage 
PSA.160  Matching on propensity score is usually less efficient than weighting, meaning 
fewer observations are generally included with the former method.157  Additionally, 
matching can make it complicated to make confidence intervals incorporating the 
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propensity score obtained in the first stage.157  We compared the PSA methods of 
stratification, nearest-neighbor matching, and two stage regression in this study. 
Using a weighted second stage regression does not guarantee the distributions of 
propensity scores are identical between the two treatment groups, for those who are on 
common support, but it does balance the majority of the propensity score data across the 
groups.165  Another thing to touch on is the lack of confidence in attaining standard errors 
(SEs) in nearest-neighbor matching while they are known (and not controversial) in 
stratification.  Since the t-statistic is derived from dividing the mean difference between 
groups by the SE, a different SE (for instance, obtained through bootstrapping) may have 
yielded significant results.  Nearest-neighbor matching yields SEs that do not take 
propensity score into account.  Based on the limited information about this that I can find, 
this causes SEs to be biased downward, leading to larger t-statistics, which would 
overestimate significance.168  Although this seems to be the case and an alternative is to 
bootstrap to find the SE, there is literature saying that bootstrapping will lead to 
miscalculation of the SE as well.169  The ATT derived through stratification is based on a 
weighted average of treatment effect of each of the strata170 while the ATT derived 
through nearest-neighbor matching is calculated by comparing an ACEI patient’s 
outcome to the ARB patient’s outcome with the closest propensity score.  Given this 
information the reader may ask why we want to assess outcomes with nearest-neighbor 
matching.  The reason is because nearest-neighbor matching permits the researcher to 
conduct sensitivity analyses.  As can be inferred, there is some underlying controversy in 
the techniques, and because different techniques have the potential to yield different 
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results, we sought to compare ATT obtained from each second stage PSA technique:  
regression, stratification, and matching. 
Validity of PSA Approach 
 
To assess the stability of the propensity score we used sensitivity analyses in case 
unknown unobserved heterogeneity (hidden bias) was present.  According to Rosenbaum 
(2002), presence of unobserved variables that affect treatment assignment and dependent 
variable may result in a hidden bias.171  Rosenbaum bounds calculates the difference in 
treatment effect of the dependent variable (i.e., outpatient visits) between the two 
treatment groups if various levels of hidden bias did exist, meaning this technique 
indicates the robustness of PSA results.171,172  It is important to point out that it is 
impossible to test that unobserved variables are truly not confounders, which is a PSA 
assumption.167,171   
Specifically: 
Pi = P(xi, µi) = F(ßxi+γµi) where Pi is the probability of the outcome, xi are the 
observed variables for the individual, µi is the unobserved variable, and γ is the effect of 
µi on the outcome.172  If unobserved heterogeneity is absent, γ will be zero, meaning the 
outcome is determined by xi only.172  Conversely, if unobserved heterogeneity is present, 
two people with the same observed variables have different chances of assignment to a 
treatment group by a factor γ, meaning γ does not equal zero.172  Since patients are 
matched on propensity score, xi drops out of this equation.  Converting this into a logistic 
regression for individuals with the same observed variables gives the following:172 
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_Pi_
1-Pi = Pi(1-Pj) = exp[γ(µi-µj)]
_Pj_     Pj(1-Pi)
1-Pj
 
From this thought, Rosenbaum (2002) places bounds on the odds ratio that two matched 
individuals from PSA will be assigned the same treatment: 
where eγ only is one when matched individuals will have the 
same outcome.171,172  (If = 1.5 it means that individuals with the same observed variables 
could have up to a factor 1.5 difference in treatment assignment.)172 
This technique provides the Wilcoxon signrank tests that give upper and lower 
bound estimates of significance levels at given levels of unobserved heterogeneity at 
different levels of γ (γ =1 means no heterogeneity).173  It also calculates Hodges-
Lehmann point estimates and confidence intervals for the ATT.173   
A similar sensitivity analysis was developed for dichotomous variables:  Mantel-
Haenszel bounds.172  This technique uses the Mantel and Haenszel test statistic, QMH, to 
compare the actual, versus expected, number of successful patients in the treatment 
group, for treatment effect equal to zero.172  Since QMH can be bounded by two known 
distributions we use the bounds of no unobserved heterogeneity and some unobserved 
heterogeneity and run several scenarios with increasing levels of unobserved 
heterogeneity.172  A positive QMH is the test statistic assuming overestimation of 
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treatment effect; conversely, a negative QMH is the test statistic assuming underestimation 
of treatment effect.172 
 
Other Statistical Considerations 
 
 We have mentioned the techniques used to most accurately depict effect of 
therapy on outcome.  Next, we need to mention how we incorporated these previous 
techniques in analysis of the dependent variables.  The latter techniques in this section are 
independent of the previous of these techniques. 
Type of Dependent Variables: Dichotomous Variables 
 
We performed logistic regression for the clinical outcomes ESRD, IVDEs, and 
all-cause mortality.  Exponentiating the coefficient (β) provides the odds ratio that the 
outcome will occur for the independent variable conditional on covariates.  The equation 
is:  
 
 Y =    eA + BX__ 
       1 + eA + BX 
 
Where Y is the outcome (ESRD, IVDEs, or all-cause mortality), A is the intercept 
and B is the estimate of effect for each variable in a vector of predictors, X.   
Type of Dependent Variables:  Count Variables 
 
 Although OLS is sometimes used to model count data when there are more zero 
values than other values in the data, power is decreased as OLS assumptions are violated, 
while at the same time, using the central limit theorem as a justification to use OLS may 
lead to incorrectly rejecting the null hypothesis.174  One could also transform dependent 
variables to achieve a normal distribution, but these transformed variables generally are 
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not interpretable (i.e., what is the inverse of a hospitalization or the natural logarithm of 
ED visits?).174  Additionally, “there is a very real danger that the log scale results may 
provide a very misleading, incomplete, and biased estimate of the impact of covariates on 
the untransformed scale, which is usually the scale of interest.”175  Another important 
consideration is there is no transformation that can “spread out a stack of zeroes”.174  
“Transforming the outcome fundamentally alters the structure of residuals, and it is 
possible to transform the residuals to normality while concurrently violating a different 
assumption, such as unequal variances”.174  Lastly, OLS or OLS with transformed 
dependent variables can be biased and inefficient with count data.176  Manning (1998) 
and Mullahy (1998) add that OLS methods can lead to biased estimates in the presence of 
heteroskedasticity if not retransformed appropriately.175,177  Manning (2001) also 
mentions that generalized linear models (GLM) may have more precise estimates than 
OLS when heteroskedasticity is absent.178 
 Instead, a family of different models are recommended for analysis of count 
variables.  The Poisson distribution is referred to as a log-linear model since the natural 
logarithm of the conditional mean is linear in the parameters, ln E[yi|xi]=xi’ß.  It is a 
generalized linear model with a natural logarithm link function and Poisson distribution 
(in contrast, logistic regression has a logit link and binomial distribution).174  It is a better 
choice than the normal distribution for count data.  For example, while count data are 
necessarily positive, the normal distribution extends from negative infinity to positive 
infinity.174  For Poisson regression, correct specification of the conditional mean is 
required to obtain consistent estimates.179  Alternatively, consistent estimates are 
independent of Poisson distribution of the dependent variables.179  Although statistical 
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inference is still valid in the presence of data that are not equidispersed with correct 
specification of the conditional mean, Poisson regression will result in less efficient 
estimators than other distributions.179  In particular, the standard errors will be biased 
downward, giving large z-values, which will overestimate significance.180  Poisson’s 
equidispersion property (i.e., mean = variance) is akin to the homoskedastacity 
assumption in OLS.  As already alluded to, count variables often have overdispersion 
(i.e., variance > mean).  One cause of overdispersion is not taking heterogeneity of mean 
rate across individuals into account.181  Although observed heterogeneity is indicated 
with μ in Poisson regression, the negative binomial regression allows for unobserved 
heterogeneity through introduction of the dispersion parameter, α.181  It is this larger 
variance that makes the negative binomial distribution have more low counts, one of 
which would be zero values.181 
 In this circumstance, there are alternative methods to pursue.  The first is to 
conduct a Poisson regression, but with adjustment to the standard errors with a robust 
sandwich estimator (a.k.a. Huber-White estimator), called Poisson-pseudo maximum 
likelihood estimate.179  This takes overdispersion into account.   
 The second alternative is to use the negative binomial distribution, of which the 
Poisson distribution is a special case.179  The negative binomial distribution inherently 
assumes the data are overdispersed since the variance is a multiple of the mean.  This 
model is the standard parametric model to account for overdispersion.179  Specifically, 
while the Poisson distribution assumes variance=μ=exp(xi’ß), the conditional variance of 
Yi given xi, ωi=μi+αip where p is specified.  The NB1 function holds p at 1, making 
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ωi=(1+α) while the NB2 function holds p at 2, making ωi=μi+αμi2.  In either case, α needs 
to be estimated.  If α=0 then the negative binomial distribution reduces to the Poisson.179   
 Overdispersion can be detected by comparing the variance and mean, which was 
done before running each regression so we knew what to anticipate before running any 
formal tests of overdispersion.  The likelihood ratio test statistic is a more formal test of 
overdispersion.  Since the Poisson model is nested in the negative binomial, “the test 
statistic is twice the difference in log-likelihoods between the two models, which is 
distributed as a χ2 random variable with degrees of freedom equal to the difference in 
number of parameters between the two models.”174  This test assesses if there is a 
difference between the two models; if there is not a difference, the test will have a 
nonsignificant p-value indicating lack of overdispersion.  When the dependent variable is 
overdispersed the negative binomial model’s standard errors will be larger and more 
appropriate; said a different way, using Poisson regression in these circumstances would 
result in lower p-values and narrower confidence intervals than should be.174 
Zero-inflated Models 
 
 Zero-inflated models introduce two more methods to our repertoire to depict 
count variables; however, their use is more controversial.  For instance, Manning (2001) 
says parsimony may be more advantageous than achieving a better fit.178   The rationale 
behind using zero-inflated models is that patients use healthcare through two distinct 
processes:  some patients will not use healthcare resources while others clearly will, but 
the amount of care used among those using it needs to be estimated differently from 
whether or not patients are using healthcare resources.177  Since we do not know who 
tried to access care and did not versus who did not try to access care, modeling this way, 
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by forming two different groups, accounts for this unobserved heterogeneity.181  The 
overall probability of zeroes is formed from the probability of zeroes in each group 
weighted by the probability of each individual being in that group.181  The first part uses 
all count values to estimate the mean with a Poisson distribution, then the second part 
uses individual characteristics, ψ, to estimate zeroes with a logit or probit model.177,181  
Zero-inflated Poisson and zero-inflated negative binomial models lower the expected 
count by μψ, which also changes the conditional variance.181  The zero-inflated Poisson 
model has conditional variance= μi(1- ψ i)(1+ μiψ i) while the zero-inflated negative 
binomial model has conditional variance = μi(1- ψ i)[1+ μi(ψ i+α)].181  If ψ =0 for the 
zero-inflated Poisson, the model reduces to a Poisson regression and if ψ =0 for the zero-
inflated negative binomial, the model reduces to a negative binomial regression.181 The 
Vuong test can be used to assess which model is favored (zero-inflated Poisson versus 
Poisson or zero-inflated negative binomial versus negative binomial),181 but cannot be 
used with clustered robust standard errors, as we have used in this study.   
 At least in the non-robust standard error situation, standard errors should be larger 
for the negative binomial than the Poisson and for the zero-inflated negative binomial 
than the zero-inflated Poisson.174,182  Similarly, for non-robust standard errors, standard 
errors for zero-inflated Poisson tend to be larger than for Poisson.183 
 The same overdispersion test that compared Poisson and negative binomial 
models can be used to compare zero-inflated Poisson and zero-inflated negative 
binomial.174 
Model Fit Diagnostic Tests 
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 Just as there is controversy with use or non-use of zero-inflated models due to 
their lack of parsimony and difficulty in interpretation, there is controversy in what 
diagnostic tests should be used to determine the count model with the best fit of the data. 
Kibria (2006) says the model with the lowest Akaike’s information criterion (AIC) 
should be selected.184  AIC=-2L+2k where L is the log likelihood and k is the number of 
parameters in the model.  In contrast, Basu et al (2004) used the Hosmer and Lemeshow 
goodness-of-fit test, Pregibon’s Link Test, and Pearson’s correlation for the predicted and 
residual on the raw scale to determine the best model fit for the dependent variables 
length of stay and inpatient expenditure.185  In contrast, the Statistical Consulting Group 
at University of California, Los Angeles says if we’re between a negative binomial and 
zero-inflated negative binomial to look at the log likelihoods and the Bayesian 
information criterion (BIC); if similar, they advise to go with the negative binomial 
model because it has fewer degrees of freedom.186   
 Since the Vuong test cannot be used in this study to determine best model choice 
of each count variable and because controversy surrounds zero-inflated models due to 
their lack of parsimony and difficult interpretation, we report negative binomial 
regression in Results.  The researchers performed Poisson, negative binomial, zero-
inflated Poisson, and zero-inflated negative binomial regression analyses for each count 
variable and provide summary tables of model fit diagnostics of each model in Appendix 
F. 
Non-independence of Observations  
 
Incorporating time-varying covariates means we have multiple observations per 
person, a violation of OLS regression. To account for this we used the Huber-White 
  89
Sandwich Estimator and clustered by patient to account for non-independence of 
observation.187  This is because we expect heteroskedasticity between groups since 
variance in variables changes across treatments.187  Heteroskedasticity is a violation of 
OLS, biasing variance, which means we cannot correctly test for significance with OLS 
procedures.187  Although the Huber-White Sandwich Estimator does not fix the 
heteroskedasticity problem, it is robust to its implications.187   
 
 
 
Intention-to-Treat Analysis 
 
 We performed an intention-to-treat analysis to maintain balance achieved at 
baseline through PSA between monotherapy groups, meaning if a patient switched from 
an ACEI to an ARB, this analysis counted that patient as receiving an ACEI.  This type 
of analysis evaluates the decision to assign the patient to one therapy or the other.  
Intention-to-treat is a conservative estimate of effect due to treatment crossovers. 
Multiple Comparisons 
 
 It is well-described in the literature that using the same sample to answer multiple 
questions results in inflation of alpha.188 Thus, in the researchers’ eyes variables were 
only significant at p<0.017 (p=0.05/3) for analyses involving three group comparisons 
and p<0.05 for comparisons limited to ACEI and ARB monotherapies, which follows 
advice of having a conservative value of α in the context of multiple comparisons.189  
There are several techniques that can be used to adjust for multiple comparisons and we 
acknowledge the controversy around Bonferroni adjustment.  ANOVAs used Tukey 
Honestly Significant Difference pairwise comparisons because it is the most conservative 
approach of the other pairwise comparisons.188  Pairwise comparisons using this method 
  90
are significant when the studentized range critical value is less than the observed value.188  
Kruskal-Wallis tests used Bonferroni adjustment for control of family-wise error 
associated with pairwise comparisons.190 
Univariate Comparisons 
 
Analysis of Variance (ANOVA) and Kruskal-Wallis Test 
 
 ANOVA was performed for between group comparisons of continuous and count 
variables.  If the Levene test showed homogeneity of variance, the results were retained.  
However, if the Levene test detected heterogeneity of variance, the Kruskal-Wallis test 
was conducted to detect between group differences as there are more relaxed assumptions 
about the distribution in this non-parametric test as compared to the parametric 
ANOVA.191 
Chi-square Test 
 
 Chi-square tests were performed for between group comparisons of categorical 
variables to assess differences in proportions of baseline characteristics.192 
Construction of Variables 
 
Independent Variable 
 
 Drug therapy is a mutually exclusive and exhaustive categorical variable in our 
sample.  ACEI, ARB, neither, and combination therapy status was defined by looking at 
the original prescription and subsequent refill pharmacy records, thus compliance is 
inherently embedded in this.  Specifically, the days supply in each year that each patient 
received an ACEI or ARB was first calculated.  (Note this is the medication possession 
ratio.193)  Then, looking across each day of the observation period, if any overlap in ACEI 
or ARB prescription days supply existed, these patients were considered to be taking 
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combination therapy during that time.  If patients received less than enough medication to 
last one-half of the year, those patients were considered to be on neither therapy.  Patients 
receiving neither therapy in any year were excluded from subgroup analysis.  Alternately, 
if a patient had at least enough of a days supply of an ACEI (excluding any combination 
therapy with concomitant days supply of an ARB), to cover one-half of the year, that 
person was considered to have received ACEI monotherapy.  In a similar vein, ARB 
monotherapy was calculated.  If patients had overlapping ACEI and ARB prescriptions 
that covered at least one-half of any year of observation, those patients were excluded 
from analysis as they were considered taking combination therapy. 
Dependent Variables 
 
Development of ESRD is a mutually exclusive and exhaustive categorical variable 
in our sample.  This is dichotomous in nature: people who developed ESRD were coded 
as “1”s while people who did not develop ESRD were coded as “0”s. Patients with ICD-
9-CM codes of 585.6(, V45.1, or V56 or CPT codes 36800, 36810, 36815, 90935, 90937, 
or 90947, 90989, 90993; 50300, 50340, 50360, 50365; 90920, 90921, 90924, 90925, 
90945, 90997, 90999) were classified as having ESRD (dialysis; kidney transplant; 
ESRD-related services, respectively). Those identified as having ESRD at baseline were 
excluded.   
Change in albuminuria is a categorical variable reflecting the change in 
albuminuria during the observation period. 
IVDE is a mutually exclusive and exhaustive categorical variable in our sample.  
This is dichotomous in nature: people who suffered an IVDE were coded as “1”s while 
people who did not will be coded as “0”s. Patients with MI or ischemic stroke were 
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identified with ICD-9 codes 410.00-.02, 410.10-.12,410.30-.32, 410.40-.42, 410.50-.52, 
410.60-.62, 410.70-.72, 410.80-.82, 410.90-.92 or ICD-9 codes 433, 433.0, 433.1, 433.2, 
433.3, 434, 434.0, 434.1, 434.9, 434.91.  Patients with LVH were identified with ICD-9-
CM code 429.3.  If a patient had one or more MIs in the same year that patient was 
documented as having an MI in that year and subsequent years.  Ischemic stroke had the 
same logic as MI.  Since once a patient has LVH the person has it the rest of his life, 
LVH was documented in the year it occurred as well as subsequent years of observation. 
If ICD-9 codes 438 or V12.59 were coded with ICD-9-CM code 434.91 (or, if before 
occurrence of another stroke, if coded by themselves), these patients were classified as 
having a history of stroke.  Similarly, if ICD 9(-CM) codes 412 or 429.7 were found, 
these patients were classified as having a history of MI.  Individuals with a family history 
of CVD were identified with ICD-9 codes V17.1, V17.3, and V17.4.  These people were 
included; history of CVD will be a covariate. 
All-cause mortality is a mutually exclusive and exhaustive categorical variable in 
our sample.  This is dichotomous in nature: people who died were coded as “1”s while 
people who did not were coded as “0”s. 
 Number of outpatient visits is the number of times a patient was seen by a 
provider during an outpatient visit.  Determined by unique visit date, it is the subset of 
unique outpatient visits that do not have a CPT-4 code denoting an ED visit.  Range can 
be 0 to 365 in each year. 
 Number of ED visits is the number of times a patient was admitted to the 
emergency department.  Determined by unique visit date, it is the subset of unique 
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outpatient visits that have a CPT-4 code denoting an ED visit (CPT-4 codes 99281-8). 
Range can be 0 to 365 in each year. 
Number of hospitalizations is the number of hospitalizations a patient 
encountered.  After the initial admission date, every additional admission date signifies 
another hospitalization.  Range can be 0 to 365 in each year. 
Other Variables 
 
 The majority of other variables were created based upon presence of ICD-9-CM, 
DRG, and/or CPT-4 codes (see Tables 6-8).  The following variables, however, were not 
as straightforward.   
 New user is a dichotomous variable of ACEI or ARB monotherapy patients.  A 
patient received a “1” if there was no documented prescription of an ACEI or ARB in the 
six months before the index date.  If a prescription for an ACEI or ARB was found in this 
time period, the variable was coded as “0”. 
 Newly-diagnosed is a dichotomous variable.  A patient received a “1” if there was 
no documentation of type 2 diabetes in the year previous to the first date of healthcare 
utilization for type 2 diabetes in the study period.  If there was such documentation, the 
patient received a “0”. 
 Cohort is a mutually exclusive and exhaustive categorical variable.  The cohort in 
which a person belongs is based on the fiscal year within the study period in which the 
first date of healthcare utilization for type 2 diabetes occurred.  A patient was classified 
into cohort 2003, 2004, 2005, or 2006. 
 Time is a mutually exclusive and exhaustive categorical variable.  For each 
patient, it corresponds to each year for which information on healthcare utilization was 
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available after the first date of healthcare utilization for type 2 diabetes.  Time t 
corresponds to year 1, time (t+1) to year 2, time (t+2) to year 3, time (t+3) to year 4, and 
time (t+4) to year 5.  (The maximum amount of follow-up a patient can have is dependent 
upon the cohort to which he belongs since patients were not followed after September 30, 
2007). 
 Urban/suburban versus rural living is dichotomous variable determined from zip 
codes based on census tract information.194  Rural Urban Commuting Area Codes 
(RUCA) for 2006 were used.  Specifically, RUCA2 codes with zip codes were used to 
differentiate between urban/suburban and rural status.  Zip codes were retained in the 
dataset as well. 
 Treatment initiated in winter is a dichotomous variable of ACEI or ARB 
monotherapy patients.  A patient received a “1” if he received his first prescription for an 
ACEI or ARB between December 1 and February 28 (or 29 if a leap year) of the year.  If 
he did not, this variable was coded as “0”. 
 
Covariates Used in Regression Analyses 
 
For ESRD, covariates were compliance of ACEIs or ARBs; time; age; income 
(<$6,000, $6,000-17,999, $18,000-34,999, ≥$35,000, missing); rural versus 
urban/suburban living; smoking (current versus former versus never smoker); HbA1c; 
LDL cholesterol; triglycerides; Elixhauser comorbidities, including hypertension and 
obesity; cohort; and metropolitan area/county.  Compliance with ACEIs and ARBs needs 
to be controlled to obtain a realistic picture of benefit of these therapies, and thus, 
differences between these therapies.  Time was taken into account as that is the strength 
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longitudinal studies have over cross-sectional.  Differences in age are generally 
documented to be associated with poorer health outcomes across disease states.  
Similarly, patients with lower income tend to have poorer health while those living in 
rural areas are more likely to have access to care issues, leading to poorer health 
outcomes.  Smoking, hypertension, and obesity are health conditions along with the other 
Elixhauser comorbidities predisposing patients to poorer health outcomes.  Higher levels 
of HbA1c, LDL cholesterol, and triglycerides are risk factors for ESRD in P2DM.  
Cohort was controlled in case there was a difference in health status based on year of type 
2 diabetes diagnosis.  To account for between group differences in local formulary status 
metropolitan area/county were entered into the first-stage PSA. 
For IVDE, all-cause mortality, number of outpatient visits, number of ED visits, 
and number of hospitalizations, covariates were compliance of ACEIs or ARBs, time, 
age, income (<$6,000, $6,000-17,999, $18,000-34,999, ≥$35,000, missing), rural versus 
urban/suburban living, history of MI, history of stroke, family history of CVD, smoking 
(current versus former versus never smoker), HbA1c, LDL cholesterol, triglycerides, 
Elixhauser comorbidities (including hypertension and obesity), cohort, and metropolitan 
area/county.  The reasons for inclusion of these covariates for IVDE and all-cause 
mortality are similar to those for ESRD.  HbA1c, LDL cholesterol, triglycerides, history 
of MI, history of stroke, and family history of CVD are also risk factors for cardio- and 
cerebro- vascular disease and all-cause mortality in P2DM.  Since they are risk factors for 
these dependent variables, referring to Figure 4, we would want to control for these for 
number of outpatient visits, number of ED visits, and number of hospitalizations.  
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Smoking status was determined with ICD-9-CM codes of 305.1, 989.84, 491.0, 
and V15.82, which identify current tobacco dependence, toxic effect of tobacco, 
smoker’s cough, and history of tobacco use, respectively.  Patients with hypertension 
were identified with ICD-9 code 401 while obese patients were identified with ICD-9 
code 278.   
 
Elixhauser Case-Mix Index 
 
In all specifications, to help control health status among different treatment 
strategies that might be associated with treatment selection, we constructed an Elixhauser 
index of comorbidities, which identifies 30 different conditions.195  There are many 
severity of illness indices; none have been identified for predicting ESRD or cardio- or 
cerebro- vascular disease.  The advantages to using the Elixhauser case-mix index 
include its development based upon about 1.8 million patients from 439 hospitals, its 
ability to assess effects of each comorbidity (which would otherwise be missed in a single 
index that combines all comorbidities into one measure), and its increased model power.  
For instance, a comparison of the Charlson comorbidity index to Elixhauser found 
Elixhauser to be better due to the aforementioned differences as well as the fact that 
Elixhauser accounts for a greater number of comorbidities.196,197 
The Charlson comorbidity index includes conditions that occurred in <600 
patients in 1 hospital in 1 month.197  It also adds weights for comorbidities from relative 
weights in Cox regression despite relative weights not being additive. The Nursing 
Severity Index is similar to the Charlson comorbidity index in creating one number from 
patient comorbidities198 and has less published literature supporting its use.  RxRisk, 
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formerly known as the Chronic Disease Score, was found to be less consistent than the 
diagnosis-based models to which it was compared.199 
Since diabetes is one of the 30 conditions identified in Elixhauser and the purpose 
of its use is to identify comorbidities rather than complications or the disease of interest, 
we did not include diabetes-related complications occurring after the index date or 
diabetes as comorbidities.  Specifically, complications of interest were captured as 
outcomes and diabetes at baseline was excluded as a comorbidity.  However, history of 
CVD or any other conditions potentially identifiable as complications at baseline were 
considered as comorbidities.  Comorbidities were captured when codes documenting 
each comorbidity were found in the three months before the first date of healthcare 
utilization documenting type 2 diabetes. 
Figure 5 provides a summary of data collection and patient follow-up. Table 6 
shows the statistical techniques used in each analysis.  Table 7 depicts the time allocated 
to each study activity.   
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Figure 5: Summary of Data Collection, Patient Follow-up 
 
 
 
 
 
 
 
  
 
October 1, 2001 
 Determined eligibility criteria for veteran P2DM. 
o New diagnosis of type 2 diabetes: looked back one year from 
first date of healthcare utilization in which type 2 diabetes was 
documented during time period 
o New user of ACEI or ARB:  looked back 6 months from first 
date of healthcare utilization in which type 2 diabetes was 
documented during time period  
 Characterized included patients. 
o Comorbidities:  looked back 3 months from first date of 
healthcare utilization in which type 2 diabetes was 
documented during time period  
 Followed patients for outcomes, healthcare utilization October 1, 
2002-September 30, 2007 
September 30, 2007 
cohort 
2003 
cohort 
2006 
cohort 
2004 
cohort 
2005 
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Table 6:  Summary of Study Hypotheses and Statistical Techniques 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
ACEI Monotherapy or ARB Monotherapy versus neither  
1.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing the 
incidence of 
ESRD in P2DM. 
Development of 
ESRD (categorical) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, smoking status 
HbA1c, LDL cholesterol 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
Multivariate logistic 
regression with robust 
SEs clustered by patient 
     
2a.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing 
albuminuria in 
P2DM. 
Change in 
albuminuria over 
study time period 
(categorical) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
 Univariate comparison 
     
 
 
 
 
 
  100
 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
2b.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing 
progression 
albuminuria for 
those with 
baseline 
microalbuminuria 
in P2DM. 
Change in 
albuminuria over 
study time period 
(categorical) 
Drug therapy 
(ACEIs,  ARBs, 
or neither) 
 Univariate comparison 
     
2c.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing 
progression 
albuminuria for 
those with 
baseline 
macroalbuminuria 
in P2DM. 
Change in 
albuminuria over 
study time period 
(categorical) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
 Univariate comparison 
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 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
3.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing 
incident vascular 
disease events 
(IVDEs) in 
P2DM. 
IVDEs: LVH, MI, 
ischemic stroke 
(categorical) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
Multivariate logistic 
regression with robust 
SEs clustered by patient 
     
4.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing all-
cause mortality in 
P2DM.   
All-cause mortality 
(categorical) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
Multivariate logistic 
regression with robust 
SEs clustered by patient 
     
 
  102
 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
5.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing 
outpatient visits 
in P2DM. 
Number of 
outpatient visits 
(count) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
All count models with 
robust SEs clustered by 
patient (Poisson, negative 
binomial, zero-inflated 
Poisson, zero-inflated 
negative binomial 
     
6.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing ED 
visits in P2DM. 
Number of ED visits 
(count) 
Drug therapy 
(ACEIs, ARBs, 
or neither) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
All count models with 
robust SEs clustered by 
patient (Poisson, negative 
binomial, zero-inflated 
Poisson, zero-inflated 
negative binomial 
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 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
7.  There will be 
no difference in 
effectiveness in 
ACEIs or ARBs 
compared to 
neither therapy 
for reducing 
hospital 
admissions in 
P2DM. 
Number of 
outpatient visits 
(count) 
Drug therapy 
(ACEIs, ARBs, 
or neither 
therapy) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
All count models with 
robust SEs clustered by 
patient (Poisson, negative 
binomial, zero-inflated 
Poisson, zero-inflated 
negative binomial) 
 
ACEI Monotherapy versus ARB Monotherapy 
8. There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing the 
incidence of 
ESRD in P2DM. 
Development of 
ESRD (categorical) 
Drug therapy 
(ACEIs or 
ARBs) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, smoking status 
HbA1c, LDL cholesterol 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
Multivariate logistic 
regression with robust 
SEs clustered by patient; 
propensity scores 
analyses; intention-to-
treat analysis 
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 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
9a.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing 
albuminuria in 
P2DM. 
Change in 
albuminuria over 
study time period 
(categorical) 
Therapy (ACEIs 
or ARBs) 
 Univariate comparison 
     
9b.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing 
progression 
albuminuria for 
those with 
baseline 
microalbuminuria 
in P2DM. 
Change in 
albuminuria over 
study time period 
(categorical) 
Therapy (ACEIs 
or ARBs) 
 Univariate comparison 
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 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
9c.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing 
progression 
albuminuria for 
those with 
baseline 
macroalbuminuria 
in P2DM. 
Change in 
albuminuria over 
study time period 
(categorical) 
Drug therapy 
(ACEIs or 
ARBs) 
 Univariate comparison 
     
10.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing IVDEs 
in P2DM. 
Development of 
IVDEs during study 
time period 
(categorical) 
Drug therapy 
(ACEIs or 
ARBs) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
Multivariate logistic 
regression with robust 
SEs clustered by patient; 
propensity scores 
analyses; intention-to-
treat analysis 
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 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
11.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing all-cause 
mortality in 
P2DM.   
All-cause mortality 
(categorical) 
Drug therapy 
(ACEIs or 
ARBs) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
Multivariate logistic 
regression with robust 
SEs clustered by patient; 
propensity scores 
analyses; intention-to-
treat analysis 
     
12.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing 
outpatient visits 
in P2DM. 
Number of 
hospitalizations 
(count) 
Drug therapy 
(ACEIs or 
ARBs) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
All count models with 
robust SEs clustered by 
patient (Poisson, negative 
binomial, zero-inflated 
Poisson, zero-inflated 
negative binomial); 
propensity scores 
analyses; intention-to-
treat analysis 
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 Table 6 (cont.) 
 
Null hypothesis Dependent variable Independent 
variable 
Covariates Statistical technique(s) 
13.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing ED 
visits in P2DM. 
Number of ED visits 
(count) 
Drug therapy 
(ACEIs or 
ARBs) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
All count models with 
robust SEs clustered by 
patient (Poisson, negative 
binomial, zero-inflated 
Poisson, zero-inflated 
negative binomial); 
propensity scores 
analyses; intention-to-
treat analysis 
     
14.  There will be 
no difference in 
effectiveness 
between ACEIs 
and ARBs for 
reducing hospital 
admissions in 
P2DM. 
Number of 
outpatient visits 
(count) 
Drug therapy 
(ACEIs or 
ARBs) 
Compliance of ACEIs or 
ARBs, time, age, income, 
rural versus urban/suburban 
living, history of MI, history 
of stroke, family history of 
CVD, smoking status, 
HbA1c, LDL cholesterol, 
triglycerides, Elixhauser 
comorbidities (including 
hypertension and obesity), 
cohort, and metropolitan 
area/county 
All count models with 
robust SEs clustered by 
patient (Poisson, negative 
binomial, zero-inflated 
Poisson, zero-inflated 
negative binomial); 
propensity scores 
analyses; intention-to-
treat analysis 
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Table 7:  Timeline of Study Activities 
 
Activity Date(s) 
VA R&D Application 03/14/2008 
VA R&D Conditional Approval 03/20/2008 
UNM HRRC Application 03/21/2008 
UNM HRRC Approval 04/04/2008 
National VA Data Application 04/07/2008 
VA R&D Full Approval 06/2008 
National VA Data Approvals 10/2008 
Data Extraction 10/2008-12/2008 
Data Management, Cleaning, and Coding 12/15/2008-05/31/2010 
Data Analysis 03/02/2009-01/18/2011 
UNM Continuing Approval Applications 02/09/2009, 03/08/2010 
UNM Continuing Approvals 04/14/2009, 04/14/2010 
VA R&D Committee Annual Reviews 11/19/2009 
VA Research Compliance Officer Audit 02/26/2010-03/05/2010 
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CHAPTER 4: RESULTS 
Sample Selection and Size 
 
We identified 1,719,387 P2DM who received care at a VA facility between 
fy2000 and fy2007.  As the data were too large for our SQL server (programmer) and/or 
our desktop (researcher) to handle without “crashing” we started with fy2003 (i.e., 
October 1, 2002) patients and accrued annual cohorts of patients through fy2006, which 
yielded 671,411 patients.  Patients were followed through fy2007 (i.e., September 30, 
2007).  Of newly-diagnosed type 2 diabetes patients, there were 145,078 (21.61%) 
incident users and 526,333 (78.39%) prevalent users.  To avoid confounding associated 
with duration of ACEI or ARB treatment, we included only incident users.  Our final 
sample size, after exclusion criteria were applied, was a total of 124,296 person-year 
observations corresponding to 40,669 patients in our sample.  Figure 6 shows patient 
flow and respective number of person-year observations through the study.  Of the 
124,296 person-years, 40,669 (32.72%) occurred in the first year of follow-up, 40,133 
(32.29%) occurred in the second, 27,021 (21.74%) occurred in the third, 14,342 (11.54%) 
occurred in the fourth, and 2,124 (1.71%) occurred in the fifth.  (Please see Table 8.)  
Table 9 presents this information by cohort. 
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Figure 6: Patient Flow through Study for Patients with Documented Newly-diagnosed 
Type 2 Diabetes, Fy2003-06  
 
 671,411 patients (2,426,246 person-years) 
526,333 prevalent users of ACEIs, ARBs 
(909,952 person-years) 
Age<30 years: 99 patients (34 person-
years) 
Female: 1,593 patients (4,205 person-
years) 
Baseline ESRD:  54 patients (137 person-
years) 
Renal dysfunction due to nondiabetic 
causes:  5,340 patients (10,041 person-
years) 
Combination therapy:  2,462 patients 
(8,282 person-years) 
40,669 patients on ACEI, ARB, or Neither 
therapy at baseline included (124,296 
person-years) for follow-up through FY2007 
Baseline normoalbuminuria: 94,861 
patients (1,369,029 person-years) 
18,947 patients on 
ACEI at baseline 
19,793 patients on 
neither at baseline 
1,929 patients on 
ARB at baseline 
Exclusion criteria 
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Table 8:  Person-year Observations by Time Since Identification 
 
Year Frequency Percent 
Year 1 40,669  32.72 
   
Year 2 40,133  32.29 
   
Year 3 27,021  21.74 
   
Year 4 14,349  11.54 
   
Year 5 2,124  1.71 
   
Total Person-years 124,296  100.00 
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Table 9:  Number of Observations by Cohort 
 
Cohorta Frequency Percentage 
2003 11,331 9.12 
   
2004 51,192 41.19 
   
2005 37,427 30.11 
   
2006 24,346 19.59 
   
Total 124,296 100.00 
 
aCohort defined by fiscal year patients were first identified as having type 2 diabetes
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 Tables 10 and 11 illustrate percentage of patients on each drug therapy.  Overall,  
ACEI monotherapy was present in 38.24% of person-years, ARB monotherapy in 4.10%, 
and neither therapy in 57.66%.  Table 11 shows that 84.13% of patients receiving ACEI 
monotherapy in one year of follow-up are also on ACEI in the second; corresponding 
numbers for ARB and neither groups are 75.99% and 65.03%, respectively.  We verify 
that all subsequent years of each patient are compared to his first year as the total number 
of patient-years shown in Table 11, 83,627, when subtracted by the total number of 
patient-years in the study sample, 124,296, yields 40,669 person-years.  (Note this also 
relates to Table 10 because multiplying the percentages that appear within a drug therapy 
at each year of follow-up by the respective sample size in each year of follow-up for all 
years except year 1 yields the column total of the drug therapy in Table 11.  Also note the 
reason for what appears as a possible discrepancy between Tables 10 and 11 is due to the 
fact that if someone died, they would appear to have received neither therapy in Table 
10.) 
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Table 10: Drug Therapy Percentages, by Time Since Identification 
 Sample 
Overall 
Year 1 Year 2 Year 3 Year 4 Year 5 
ACEI 38.24 46.59 39.34 34.76 23.21 3.44 
       
ARB 4.10 4.74 4.23 3.94 2.80 0.28 
       
Neither 57.66 48.79 56.43 61.30 73.98 96.28 
       
Sample Size 124,296 40,669 40,133 27,021 14,349 2,124 
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Table 11: Mean Drug Therapy Switch over Time (Two Subsequent Years at a Time) 
 
 ACEI, Year 2 
Frequency, (%) 
ARB, Year 2 
Frequency, 
(%) 
Neither, Year 2 
Frequency, (%) 
Total  
ACEI, Year 1 24,049 (84.13) 167 (5.27) 16,326 (31.47) 40,542 
     
ARB, Year 1 72 (0.25) 2,408 (75.99) 1,813 (3.50) 4,293 
     
Neither, Year 1 4,465 (15.62) 594 (18.74) 33,733 (65.03) 38,792 
     
Sample Size 28,586 3,169  51,872 83,627 
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 Table 12 depicts the mean and standard deviation of days supply of medication 
that patients had on-hand in each year within each drug therapy.  It also shows 81.42% of 
patients classified as neither patients received less than a 30 days supply of ACEI or ARB 
monotherapy (mean±standard deviation=22.03±42.07 days) while more ACEI and ARB 
patients received 270-360 days supply of monotherapy compared with 180-270 days 
(mean±standard deviation=298.13±49.17 and 291.68±51.66 days, respectively).
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Table 12: Description of Patient Days Supply/Medication Possession Ratio 
Days Supply ACEI Patients ARB Patients Neither Patients 
<30  0 0 81.40% 
    
30-60 0 0 1.99% 
    
61-90 0 0 1.57% 
    
91-121 0 0 6.50% 
    
122-151 0 0 2.22% 
    
152-181 0 0 6.32% 
    
182-212 6.41% 8.24% 0 
    
213-242 7.83% 9.28% 0 
    
243-272 14.68% 14.98% 0 
    
273-303 17.19% 17.73% 0 
    
304-333 19.91% 21.00% 0 
    
334-365 33.98% 28.77% 0 
    
Mean±standard deviation 298.13±49.17 298.68±51.66 22.03±42.07 
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Descriptive Characteristics 
 
The sample was 63.78 ± 11.17 years of age and reported an annual income of 
$35,082.20 ± $67,166.40. At baseline 78.03% had microalbuminuria, 21.97% had 
macroalbuminuria, 70.96% were hypertensive, 13.67% suffered from diabetes 
complications, and 16.53% were obese according to VA records (Table 14).  In terms of 
clinical parameters, mean ± standard deviation baseline HbA1c, LDL, and triglycerides 
were 7.29 ± 1.84%, 97.82 ± 33.63 mg/dL, and 195.50 ± 175.00 mg/dL, respectively.   
Univariate comparisons of baseline characteristics revealed several between group 
differences (Tables 13 and 14). As expected, there were fewer between group differences 
for ACEI and ARB than either monotherapy compared to neither therapy.  In more detail, 
ARB patients were the oldest, followed by neither patients, followed by ACEI patients 
(p<0.0083 each); ACEI patients had higher HbA1c values at baseline than the other 
groups (p<0.001 each); and all groups were significantly different from each other for 
LDL values (p<0.001 each).  In this circumstance, patients in the neither group had the 
highest LDL values, followed by ACEI, followed by ARB. 
As Table 14 shows, the ACEI group had more patients with macroalbuminuria 
compared to the neither group (23.37% versus 20.57%, p<0.001).  Also noteworthy, 
patients in the ARB group had the highest percentage of never smokers (81.18%), 
followed by neither (79.30%), followed by ACEI (76.40%) (p<0.001 each).  More 
patients in the ACEI group had a history of stroke or MI versus neither patients (1.44% 
versus 1.06% and 2.83% versus 2.21%, p<0.001 each).  The ARB group had the highest 
amount of patients with peripheral vascular disorders at baseline:  7.52% compared to 
6.02% of ACEI patients and 5.80% of neither patients (p<0.01 each).  An extremely 
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interesting finding is significantly fewer patients receiving neither therapy were 
hypertensive compared to ACEI or ARB monotherapy (60.30% versus 80.80% and 
83.51%, p<0.001 each). 
A post hoc analysis comparing number of comorbidities by drug therapy with 
Kruskal-Wallis test found similar numbers of comorbidities between ACEI and ARB 
patients, both of whom have significantly higher comorbidities than neither patients 
(p<0.0083).  Another item to note is each of the conditions that may lead to propensity to 
cough, (i.e., smoking, allergic rhinitis, GERD, treatment initiated in winter, and chronic 
pulmonary disease) were not present at a significantly higher rate for ARB patients 
compared to ACEI patients (Table 14).  We expected clinicians would preferentially 
prescribe ARBs to patients presenting with these conditions since ACEIs have higher 
rates of cough than ARBs. 
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Table 13:  Differences in Baseline Characteristics by Drug Therapy, Continuous 
Variables  
 
Variable All patients 
(n=40,669) 
Mean (SD)  
ACEI 
(n=18,947) 
Mean (SD) 
ARB 
(n=1,929) 
Mean (SD) 
Neither 
(n=19,793) 
Mean (SD) 
Age*** 63.78 (11.17) 63.42 (10.65) 65.82 (10.27) 64.16 (11.78) 
     
HbA1c††† 7.30 (3.19) 7.32 (1.82) 7.21 (3.24) 7.27 (1.66) 
     
LDL‡‡‡ 94.56 (33.45) 96.19 (32.64) 91.66 (30.32) 100.20 (34.79) 
     
Triglycerides║ 189.96 (177.86) 197.70 (169.70) 198.00 (182.50) 193.00 (179.50) 
 
***p<0.001, drug therapy group comparisons for Kruskal-Wallis test.  Pairwise 
comparisons finds three differences in rank means. Rank Mean difference = 2,610.60, 
critical value = 671.72, finds a significant difference between ACEI and ARB groups 
(rank mean = 19,810.26 and 22,420.87, respectively, p<0.0083 (adjusted p-value)).  Rank 
Mean difference = 1,786.84, critical value = 670.39, finds a significant difference 
between ARB and neither groups (rank mean = 22,420.87 and 20,634.02, respectively, 
p<0.0083 (adjusted p-value)).  Rank Mean difference = 823.76, critical value = 285.66, 
finds a significant difference between ACEI and neither groups (rank mean = 19,810.26 
and 20,634.02, respectively, p<0.0083 (adjusted p-value)). 
†††p<0.001, drug therapy group comparisons for Kruskal-Wallis test. Pairwise 
comparisons find two differences in rank means.  Rank Mean difference = 1,265.91, 
critical value = 649.98, finds a significant difference between ACEI and ARB groups 
(rank mean = 19,256.85 and 17,990.94, respectively, p<0.00083 (adjusted p-value)).  
Rank Mean difference = 887.25, critical value = 274.29, finds a significant difference 
between ACEI and neither groups (rank mean = 19,256.85 and 18,369.60, respectively, 
p<0.00083 (adjusted p-value)).  
‡‡‡ p<0.001, drug therapy group comparisons for ANOVA.  Pairwise comparisons find 
three differences in rank means.  Rank Mean difference = 1,469.30, critical value = 
602.72, finds a significant difference between ACEI and ARB groups (rank mean = 
16,507.80 and 15,038.49, respectively, p<0.00083 (adjusted p-value)).  Rank Mean 
difference = 2,549.73, critical value = 604.37, finds a significant difference between ARB 
and neither groups (rank mean = 15,038.49 and 17,588.22, respectively, p<0.00083 
(adjusted p-value)). Rank mean difference = 1,080.42, critical value = 260.95, finds a 
significant difference between ACEI and neither groups (rank mean = 16,507.80 and 
17,588.22, respectively, p<0.00083 (adjusted p-value)). 
║p<0.05, drug therapy group comparisons for ANOVA.  Tukey’s Honestly Significant 
Difference finds no difference between the three comparisons as the studentized range 
critical value (.05, 3, 36793) = 3.315. Of the four variables in the table, this is the only 
one that did not fail the Levene Test, so ANOVA was retained. 
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Table 14:  Differences in Baseline Characteristics by Drug Therapy, Categorical Variables  
 
Variable All patients 
(n=40,669)  
Frequency (%) 
ACEI 
(n=18,947) 
Frequency (%) 
ARB 
(n=1,929) 
Frequency (%) 
Neither 
(n=19,793) 
Frequency (%) 
Albuminuria Stage     
    Microalbuminuria 31,734 (78.03) 14,520 (76.63) 1,493 (77.40)a 15,721 (79.43)b 
    Macroalbuminuria 8,935 (21.97) 4,427 (23.37) 436 (22.60) 4,072 (20.57) 
     
Smoking Status     
     Never 31,727 (78.01) 14,476 (76.40)c 1,566 (81.18) d 15,696 (79.30) e 
     Ever 1,146 (2.83) 574 (3.00) 68 (3.53) 505 (2.50) 
     Current 7,796 (19.17) 3,903 (20.60) 295 (15.29) 3,602 (18.20) 
     
Family History of CVD  267 (0.66) 140 (0.74)f 28 (1.45) g 99 (0.50) h 
     
History of Stroke 497 (1.22) 273 (1.44)i 15 (0.78) 210 (1.06) j 
     
History of MI 1,018 (2.50) 536 (2.83) 44 (2.28) 437 (2.21) k 
     
NSAID user* 3,160 (36.22) 1,727 (38.59) 156 (37.30) l 1,276 (33.31) m 
     
Annual Household 
Income 
    
     < $6000 9,555 (23.49) 4,085 (21.56)n 470 (24.36) o 5,000 (25.26) p 
     $6,000-17,999 9,696 (23.84) 4,730 (24.96) 398 (20.63) 4,568 (23.08) 
     $18,000-34,999 10,200 (25.08) 4,847 (25.58) 462 (23.95) 4,891 (24.71) 
     ≥$35,000 9,894 (24.33) 4,674 (24.67) 537 (27.84) 4,683 (23.66) 
     Income missing 1,324 (3.26) 611 (3.22) 62 (3.21) 651 (3.29) 
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Table 14 (cont.) 
 
Variable All patients 
(n=40,669)  
Frequency (%) 
ACEI 
(n=18,947) 
Frequency (%) 
ARB 
(n=1,929) 
Frequency (%) 
Neither 
(n=19,793) 
Frequency (%) 
Urban/suburban 28,935 (71.15) 13,282 (70.10) 1,391 (72.11) 14,271 (72.10) q 
     
CHF 2,096 (5.15) 1,040 (5.49)r 163 (8.45) s 893 (4.51) t 
     
Cardiac Arrhythmias 2,084 (5.12) 999 (5.27)u 131 (6.79) v 954 (4.82) w 
     
Valvular Disease 278 (0.68) 125 (0.66) 21 (1.09)  132 (0.67) 
     
Pulmonary Circulation 
Disorders 
73 (0.18) 33 (0.17) 4 (0.21) 36 (0.18) 
     
Peripheral Vascular 
Disorders 
2,434 (5.98) 1,141 (6.02)x 145 (7.52) y 1,148 (5.80) 
     
Hypertension 28,857 (70.96) 15,309 (80.80)z 1,611 (83.51) aa 11,935 (60.30) bb 
     
Paralysis 138 (0.34) 50 (0.26) 3 (0.16) 85 (0.43) cc 
     
Other Neurological 
Disorders 
368 (0.90) 147 (0.78) 15 (0.78) 206 (1.04) dd 
     
Chronic Pulmonary 
Disease 
4,151 (10.21) 1,849 (9.76)ee 216 (11.20) 2,078 (10.50) ff 
     
Hypothyroidism 1,951 (4.80) 866 (4.57) 99 (5.13) 986 (4.98) 
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Table 14 (cont.) 
 
Variable All patients 
(n=40,669)  
Frequency (%) 
ACEI 
(n=18,947) 
Frequency (%) 
ARB 
(n=1,929) 
Frequency (%) 
Neither 
(n=19,793) 
Frequency (%) 
Diabetes Complicated 5,560 (13.67) 2,785 (14.70) 264 (13.69) 2,514 (12.70) gg 
     
Liver Disease 612 (1.50) 252 (1.33) 24 (1.24) 336 (1.70) hh 
     
Peptic Ulcer Disease 378 (0.93) 167 (0.88) 26 (1.35) 185 (0.93) 
     
AIDS 72 (0.18) 23 (0.12) 0 (0.00) ii 49 (0.25) jj 
     
Lymphoma 165 (0.41) 58 (0.31) 6 (0.31) 101 (0.51) kk 
     
Metastatic Cancer 74 (0.18) 24 (0.13) 2 (0.10) 48 (0.24) ll 
     
Solid Tumor Without 
Metastasis 
2,883 (7.09) 1,237 (6.53) 141 (7.31) 1,504 (7.60) mm 
     
Rheumatoid 
Arthritis/Collagen 
Vascular Diseases 
331 (0.81) 133 (0.70) 14 (0.73) 184 (0.93) nn 
     
Coagulopathy 449 (1.10) 193 (1.02) 28 (1.45) 228 (1.15) 
     
Obesity 6,722 (16.53) 3,543 (18.70) 334 (17.31) oo 2,850 (14.40) pp 
     
Weight Loss 40 (0.10) 11 (0.06) 0 (0.00) 29 (0.15) qq 
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Table 14 (cont.) 
 
Variable All patients 
(n=40,669)  
Frequency (%) 
ACEI 
(n=18,947) 
Frequency (%) 
ARB 
(n=1,929) 
Frequency (%) 
Neither 
(n=19,793) 
Frequency (%) 
Fluid and Electrolyte 
Disorders 
765 (1.88) 341 (1.80) 33 (1.71) 392 (1.98) 
     
Blood Loss Anemia 30 (0.07) 14 (0.07) 3 (0.16) 13 (0.07) 
     
Deficiency Anemias 1,386 (3.41) 591 (3.12) 69 (3.58) 724 (3.66) rr 
     
Alcohol Abuse 1,268 (3.12) 563 (2.97) 50 (2.59) 655 (3.31) 
     
Drug Abuse 566 (1.39) 237 (1.25)ss 11 (0.57) tt 319 (1.61) uu 
     
Psychoses 1,809 (4.45) 807 (4.26)vv 58 (3.01) ww 942 (4.76) xx 
     
Depression 3,847 (9.46) 1,825 (9.63) 178 (9.23) 1,845 (9.32) 
     
Other Considerations 
for Propensity to 
Cough (Used Only in 
PSA) 
    
     
Allergic Rhinitis 162 (0.40) 96 (0.51) 14 (0.73) yy 52 (0.26) zz 
     
Gastroesophageal 
Reflux Disease 
2,699 (6.64) 1,618 (8.54) 158 (8.19) aaa 932 (4.71) bbb 
     
Postnasal Drip 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 
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Table 14 (cont.) 
 
Variable All patients 
(n=40,669)  
Frequency (%) 
ACEI 
(n=18,947) 
Frequency (%) 
ARB 
(n=1,929) 
Frequency (%) 
Neither 
(n=19,793) 
Frequency (%) 
ACEI/ARB Started in 
Winter 
7,877 (19.37) 4,680 (24.70) 475 (24.62) ccc 2,731 (13.80) ddd 
*NSAID user had 8,724 observations: 4,475 observations for ACEI, 418 observations for ARB, and 3,831 observations for neither.  
NSAID user was defined as having received enough medication to cover ≥ 50% of the days in the first year. 
 
a p<0.05, ARB versus neither for chi-square test. χ²(1) = 4.402. 
b p<0.001, ACEI versus neither for chi-square test. χ²(1) = 44.071. 
c p<0.001, ACEI versus ARB for chi-square test. χ²(1) = 31.246. 
d p<0.001, ARB versus neither for chi-square test. χ²(1) = 15.333. 
e p<0.001, ACEI versus neither for chi-square test. χ²(1) = 48.250. 
f p<0.01, ACEI versus ARB for chi-square test. χ²(1) = 11.138. 
g p<0.001, ARB versus neither for chi-square test. χ²(1) = 27.370. 
h p<0.01, ACEI versus neither for chi-square test. χ²(1) = 8.998. 
i p<0.05, ACEI versus ARB for chi-square test. χ²(1) = 5.661. 
j p<0.01, ACEI versus neither for chi-square test. χ²(1) = 11.674. 
k p<0.001, ACEI versus neither for chi-square test. χ²(1) = 15.496. 
l p<0.01, ARB versus neither for chi-square test. χ²(1) = 6.992. 
m p<0.001, ACEI versus neither for chi-square test. χ²(1) = 76.094. 
n p<0.001, ACEI versus ARB for chi-square test. χ²(4) = 28.566. 
o p<0.01, ARB versus neither for chi-square test. χ²(4) = 18.375. 
p p<0.001, ACEI versus neither for chi-square test. χ²(4) = 78.015. 
q p<0.001, ACEI versus neither for chi-square test. χ²(1) = 19.040. 
r p<0.001, ACEI versus ARB for chi-square test. χ²(1) = 28.143. 
s p<0.001, ARB versus neither for chi-square test. χ²(1) = 59.148. 
t p<0.001, ACEI versus neither for chi-square test. χ²(1) = 19.918. 
u p<0.01, ACEI versus ARB for chi-square test. χ²(1) = 7.885. 
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v p<0.001, ARB versus neither for chi-square test. χ²(1) = 14.392. 
w p<0.05, ACEI versus neither for chi-square test. χ²(1) = 4.145. 
x p<0.01, ACEI versus ARB for chi-square test. χ²(1) = 6.767. 
y p<0.01, ARB versus neither for chi-square test. χ²(1) = 9.254. 
z p<0.01, ACEI versus ARB for chi-square test. χ²(1) = 8.283. 
aa p<0.001, ARB versus neither for chi-square test. χ²(1) = 403.915. 
bb p<0.001, ACEI versus neither for chi-square test. χ²(1) = 2.00 X 10³. 
cc p<0.01, ACEI versus neither for chi-square test. χ²(1) = 7.640. 
dd p<0.01, ACEI versus neither for chi-square test. χ²(1) = 7.525. 
ee p<0.05, ACEI versus ARB for chi-square test. χ²(1) = 4.034. 
ff p<0.05, ACEI versus neither for chi-square test. χ²(1) = 6.289. 
gg p<0.001, ACEI versus neither for chi-square test. χ²(1) = 30.552. 
hh p<0.01, ACEI versus neither for chi-square test. χ²(1) = 8.749. 
ii p<0.05, ARB versus neither for chi-square test. χ²(1) = 4.786. 
jj p<0.01, ACEI versus neither for chi-square test. χ²(1) = 8.307. 
kk p<0.01, ACEI versus neither for chi-square test. χ²(1) = 9.872. 
ll p<0.01, ACEI versus neither for chi-square test. χ²(1) = 7.003. 
mm p<0.001, ACEI versus neither for chi-square test. χ²(1) = 16.683. 
nn p<0.05, ACEI versus neither for chi-square test. χ²(1) = 6.182. 
oo p<0.01, ARB versus neither for chi-square test. χ²(1) = 11.835. 
pp p<0.001, ACEI versus neither for chi-square test. χ²(1) = 133.110. 
qq p<0.01, ACEI versus neither for chi-square test. χ²(1) = 7.344. 
rr p<0.01, ACEI versus neither for chi-square test. χ²(1) = 8.545. 
ss p<0.01, ACEI versus ARB for chi-square test. χ²(1) = 6.829. 
tt p<0.001, ARB versus neither for chi-square test. χ²(1) = 12.742. 
uu p<0.01, ACEI versus neither for chi-square test. χ²(1) = 9.188. 
vv p<0.01, ACEI versus ARB for chi-square test. χ²(1) = 6.966. 
ww p<0.001, ARB versus neither for chi-square test. χ²(1) = 12.352. 
xx p<0.05, ACEI versus neither for chi-square test. χ²(1) = 5.603. 
yy p<0.001, ARB versus neither for chi-square test. χ²(1) = 12.441. 
zz p<0.001, ACEI versus neither for chi-square test. χ²(1) = 15.138. 
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aaa p<0.001, ARB versus neither for chi-square test. χ²(1) = 44.546. 
bbb p<0.001, ACEI versus neither for chi-square test. χ²(1) = 230.895. 
ccc p<0.001, ARB versus neither for chi-square test. χ²(1) = 163.401. 
ddd p<0.001, ACEI versus neither for chi-square test. χ²(1) = 747.111. 
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To provide insight into albuminuria progression over time, within the first year of 
follow-up, 4.91 ± 0.11% of our sample regressed to normoalbuminuria (data not shown).  
At years 2, 3, 4, and 5 of follow-up, 26.34 ± 0.35%, 27.89 ± 0.46%, 29.90 ± 0.72%, and 
24.31 ± 2.53% had normoalbuminuria, respectively (data not shown).  The next two 
tables reveal categories of albuminuria (i.e., normoalbuminuria, microalbuminuria, 
macroalbuminuria) within each drug therapy at each year of follow-up.  Table 15 
compares drug therapy within each year of follow-up while Table 16 compares changes 
over time in albuminuria within each drug therapy.  Table 15 presents data indicating that 
albuminuria was only significantly different between therapies at year 1. ACEI or ARB 
patients each have a wider spectrum of albuminuria than neither patients; ACEI and ARB 
patients had comparable albuminuria levels.  Table 16 shows, within each drug therapy, 
there are significant differences between the first year of follow-up and each subsequent 
year of follow-up.  In particular, because baseline normoalbuminuria was an exclusion 
criterion for study entry, we see a small proportion of patients with normoalbuminuria 
within each drug therapy at first year of follow-up, with attenuation of albuminuria across 
follow-up. For more detail about changes in clinical parameters across time, please see 
Appendix F Tables 5-10.   
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Table 15: Albuminuria by Drug Therapy and Time Since Identification, Comparisons by 
Drug Therapy 
 
Variable  Time t  Time 
(t+1)c
Time 
(t+2)c
Time 
(t+3)c
Time 
(t+4)c 
Total  
ACEI       
Normoalbuminuria  0.05a  0.27 0.29 0.32 0.16  0.15 
Microalbuminuria  0.72   0.53   0.51 0.46  0.59  0.63 
 
Macroalbuminuria  0.23  0.20  0.21  0.22  0.25  0.22 
ARB       
Normoalbuminuria  0.06b  0.25 0.31  0.30  0.50  0.16 
Microalbuminuria  0.71  0.56 0.48  0.50  0.25  0.63 
Macroalbuminuria  0.23  0.19  0.21  0.21  0.25  0.22 
Neither       
Normoalbuminuria  0.04  0.26 0.27  0.29  0.25  0.14 
Microalbuminuria  0.75  0.54 0.52  0.51  0.56  0.66 
Macroalbuminuria  0.21  0.19 0.22  0.21  0.19  0.21 
Notes:  values represent proportions 
 
a p<0.001, albuminuria, ACEI versus neither, within time t for chi-square test. χ²(2) = 
49.99. 
b p<0.01, albuminuria, ARB versus neither, within time t for chi-square test. χ²(2) = 
13.61. 
c p=nonsignificant for albuminuria within time period across drug therapies
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Table 16: Albuminuria by Drug Therapy and Time Since Identification, Comparisons by 
Time 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
Normoalbuminuria  0.05a,b,c,d 0.27e,f 0.29g 0.32 0.16  0.15 
Microalbuminuria  0.72   0.53   0.51 0.46  0.59  0.63 
Macroalbuminuria  0.23   0.20  0.21  0.22  0.25  0.22 
ARB       
Normoalbuminuria  0.06h,i,j,k 0.25l 0.31  0.30  0.50  0.16 
Microalbuminuria  0.71  0.56 0.48  0.50  0.25  0.63 
Macroalbuminuria  0.23  0.19  0.21  0.21  0.25  0.22 
Neither       
Normoalbuminuria  0.04m,n,o,p 0.26q,r 0.27  0.29  0.25  0.14 
Microalbuminuria  0.75  0.54 0.52  0.51  0.56  0.66 
Macroalbuminuria  0.21  0.19 0.22  0.21  0.19  0.21 
Notes:  values represent proportions 
 
a p<0.001, albuminuria, time t and time (t+1), within ACEI for chi-square test. χ²(2) = 
2.40 X 10³. 
b p<0.001, albuminuria, time t and time (t+2), within ACEI for chi-square test. χ²(2) = 
2.30 X 10³. 
c p<0.001, albuminuria, time t and time (t+3), within ACEI for chi-square test. χ²(2) = 
1.60 X 10³. 
d p<0.05, albuminuria, time t and time (t+4), within ACEI for chi-square test. χ²(2) = 
7.03. 
e p<0.01, albuminuria, time t and time (t+2), within ACEI for chi-square test. χ²(2) = 
10.12. 
f p<0.001, albuminuria, time t (t+1) and time (t+4), within ACEI for chi-square test. χ²(2) 
= 30.31. 
g p<0.01, albuminuria, time t (t+2) and time (t+3), within ACEI for chi-square test. χ²(2) 
= 9.79. 
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h p<0.001, albuminuria, time t and time (t+1), within ARB for chi-square test. χ²(2) = 
210.28. 
i p<0.001, albuminuria, time t and time (t+2), within ARB for chi-square test. χ²(2) = 
263.65. 
j p<0.001, albuminuria, time t and time (t+3), within ARB for chi-square test. χ²(2) = 
137.17. 
k p<0.01, albuminuria, time t and time (t+4), within ARB for chi-square test. χ²(2) = 
14.89. 
l p<0.05, albuminuria, time t (t+1) and time (t+2), within ARB for chi-square test. χ²(2) = 
8.94. 
m p<0.001, albuminuria, time t and time (t+1), within neither for chi-square test. χ²(2) = 
2.70 X 10³. 
n p<0.001, albuminuria, time t and time (t+2), within neither for chi-square test. χ²(2) = 
2.30 X 10³. 
o p<0.001, albuminuria, time t and time (t+3), within neither for chi-square test. χ²(2) = 
1.80 X 10³. 
p p<0.01, albuminuria, time t and time (t+4), within neither for chi-square test. χ²(2) = 
236.88. 
q p<0.01, albuminuria, time t (t+1) and time (t+2), within neither for chi-square test. χ²(2) 
= 10.13. 
r p<0.05, albuminuria, time t (t+1) and time (t+4), within neither for chi-square test. χ²(2) 
= 8.08. 
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Outcomes of Interest 
 
The next set of tables describes the outcomes of interest to the study.  As Table 17 
depicts, 0.79% of our patients developed ESRD, 7.54% suffered an IVDE, and 9.06% 
died over follow-up.  ACEI patients had the lowest proportion of patients who developed 
ESRD over follow-up.  ACEI and ARB patients had higher rates of development of LVH 
and stroke than neither patients (p<0.001 each).  When each of the components of IVDE 
(i.e., MI, LVH, stroke) were incorporated into the composite endpoint, the same pattern 
was observed.  Despite ACEI and ARB patients having comparable mortality rates, 
neither patients were dying at an approximately 12 times higher rate than ACEI or ARB 
patients (p<0.001 each). 
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Table 17: Descriptive Statistics by Drug Therapy, Categorical Outcomes  
 
Variable All patients 
(n=124,296 person- 
years; n=40,669 
patients)  
Frequency, (%) 
ACEI 
(n=47,533 person- 
years; n=18,947 
patients) 
Frequency, (%) 
ARB 
(n=5,098 person-
years; n=1,929 
patients) 
Frequency, (%) 
Neither 
(n=71,665 person-
years; n=19,793 
patients) 
Frequency, (%) 
ESRD 320 (0.79) 80 (0.42) a 17 (0.88) 223 (1.13) b 
     
MI 433 (1.07) 236 (1.25) 21 (1.09) c 176 (0.89) d 
     
LVH 1,240 (3.05) 523 (2.76) e 74 (3.84) f 643 (3.25) g 
     
Stroke 1,490 (3.66) 823 (4.34) 84 (4.36) h 583 (2.95) i 
     
IVDE* 3,065 (7.54) 1,529 (8.07) 169 (8.76) j  1,367 (6.91) k 
     
Mortality 3,685 (9.06) 192 (1.01) 20 (1.04) l 3,473 (17.55) m 
 
*Although IVDE is a composite of MI, LVH, and Stroke, IVDE does not equal the sum of these components.  For instance, if a person 
had an MI in year 2 and a Stroke in year 3, that person was documented as having a IVDE event in year 2.  Also note once a patient 
had IVDE he is documented as having IVDE in subsequent years. 
 
a p<0.01, drug therapy comparison of ACEI versus ARB for chi-square test. χ²(1) = 6.83. 
b p<0.001, drug therapy comparison of ACEI versus neither for chi-square test. χ²(1) =  23.01. 
c p<0.05, drug therapy comparison of ARB versus neither for chi-square test. χ²(1) =  5.15. 
d p<0.001, drug therapy comparison of ACEI versus neither for chi-square test. χ²(1) =  52.23. 
e p<0.05, drug therapy comparison of ACEI versus ARB for chi-square test. χ²(1) = 5.07. 
f p<0.001, drug therapy comparison of ARB versus neither for chi-square test. χ²(1) =  15.81. 
g p<0.001, drug therapy comparison of ACEI versus neither for chi-square test. χ²(1) =  12.17. 
h p<0.001, drug therapy comparison of ARB versus neither for chi-square test. χ²(1) =  38.45. 
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i p<0.001, drug therapy comparison of ACEI versus neither for chi-square test. χ²(1) =  206.58. 
j p<0.001, drug therapy comparison of ARB versus neither for chi-square test. χ²(1) =  48.09. 
k p<0.001, drug therapy comparison of ACEI versus neither for chi-square test. χ²(1) =  206.64. 
l p<0.001, drug therapy comparison of ARB versus neither for chi-square test. χ²(1) =  217.37. 
m p<0.001, drug therapy comparison of ACEI versus neither for chi-square test. χ²(1) =  1.90 X 103. 
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Tables 18 and 19 depict changes in rates of outcomes across time and drug 
therapy.  Table 18 shows the only difference between ACEI and ARB patients was for 
ESRD at year 4, when ACEI patients had a lower rate of acquiring ESRD than ARB 
patients (p<0.001).  For cardio- and cerebro- vascular events, ACEI patients had a higher 
rate of MI at years 1, 2, and 3 than neither patients.  The first four years of observation 
showed more ACEI patients suffered strokes compared to neither patients; this was also 
true for ARB patients at years 2 and 3.  Since we saw a similar pattern for acquiring 
LVH, but only for the first three years for ACEI patients and only for year 3 for ARB 
patients; ACEI and ARB patients had a higher proportion develop IVDE compared to 
neither patients in the first four years.  This analysis gives us a clearer picture of what we 
saw earlier in terms of between group comparisons for all-cause mortality:  neither 
patients are dying at about ten times the rate of ACEI or ARB patients for each year of 
years 1 through 4. 
Table 19 portrays these same dependent variables across time.  Among ACEI 
patients ESRD increased progressively through years 1 and 3 of follow-up.  Rates of 
LVH increased progressively the first four years of follow-up; year 5 was comparable to 
year 1.  All-cause mortality increased progressively through year 4.  ARB patients were 
more stable across follow-up.  The only difference seen was an increase in acquiring 
ESRD from year 1 to year 2.  Patients receiving neither therapy experienced a rise in the 
rate of acquiring ESRD from years 1 through 4.  Development of LVH progressively 
increased across time.  Lastly, all-cause mortality significantly increased from first 
through fourth years of follow-up.   
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Table 18:  Categorical Outcomes by Drug Therapy and Time Since Identification, 
Comparisons by Drug Therapy 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI   
ESRD  0.001  0.002 0.003 0.002a 0.00  0.002 
  (0.03)  (0.04) (0.06) (0.04) (0.00)  (0.04)
       
MI  0.006  0.004 0.005 0.003 0.00  0.005 
  (0.08)  (0.06) (0.07) (0.06) (0.00)  (0.07)
       
LVH  0.008  0.01 0.01 0.02 0.01  0.01 
  (0.09)  (0.10) (0.12) (0.13) (0.12)  (0.10)
       
Stroke  0.02  0.02 0.02 0.01 0.00  0.02 
  (0.14)  (0.13) (0.13) (0.11) (0.00)  (0.13)
       
IVDE 0.03 0.03 0.04 0.03 0.01 0.03 
 (0.18) (0.17) (0.18) (0.18) (0.12) (0.18) 
       
Mortality 0.003 0.004 0.004 0.01 0.03 0.004 
 (0.05) (0.07) (0.07) (0.08) (0.16) (0.06) 
ARB       
ESRD  0.001  0.004 0.003 0.01b 0.00  0.003 
  (0.03)  (0.06) (0.05) (0.11) (0.00)  (0.06)
       
MI  0.01c  0.002 0.003 0.002 0.00  0.004 
  (0.08)  (0.05) (0.05) (0.05) (0.00)  (0.06)
       
LVH  0.01d  0.01e 0.02f 0.03 0.00  0.02 
  (0.10)  (0.12) (0.14) (0.16) (0.00)  (0.12)
       
Stroke  0.02g  0.02h 0.02i 0.01 0.00  0.02 
  (0.12)  (0.13) (0.13) (0.11) (0.00)  (0.13)
       
IVDE 0.03j 0.03k 0.04l 0.04m 0.00 0.03 
 (0.17) (0.18) (0.19) (0.20) (0.00) (0.18) 
       
Mortality 0.003n 0.004o 0.005p 0.005q 0.00 0.004 
 (0.06) (0.06) (0.07) (0.07) (0.00) (0.06) 
Neither       
ESRD  0.002r  0.003 0.005 0.004s 0.002  0.003
  (0.04)  (0.05) (0.07) (0.06) (0.05)  (0.06)
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Table 18 (cont.) 
 
Variable Time t Time 
(t+1) 
Time 
(t+2) 
Time 
(t+3) 
Time 
(t+4) 
Total  
MI  0.004t  0.003u 0.002v 0.002 0.00  0.002
  (0.06)  (0.05) (0.04) (0.04) (0.00)  (0.05)
       
LVH  0.006w  0.01x 0.01y 0.01 0.02  0.01 
  (0.08)  (0.09) (0.10) (0.12) (0.13)  (0.10)
       
Stroke  0.01z  0.01aa 0.01bb 0.005cc 0.003  0.01 
  (0.10)  (0.09) (0.09) (0.07) (0.06)  (0.09)
        
IVDE 0.02dd 0.02ee 0.02ff 0.02gg 0.01 0.02 
 (0.14) (0.14) (0.14) (0.14) (0.12) (0.14) 
       
Mortality 0.02hh 0.06ii 0.06jj 0.06kk 0.04 0.05 
 (0.15) (0.23) (0.24) (0.23) (0.19) (0.22) 
 
a p<0.001, ACEI versus ARB for chi-square test. χ²(1) = 16.06. 
b p<0.05, ARB versus neither for chi-square test. χ²(1) = 6.56. 
c p<0.05, ARB versus neither for chi-square test. χ²(1) = 4.74. 
d p<0.05, ARB versus neither for chi-square test. χ²(1) = 6.46. 
e p<0.05, ARB versus neither for chi-square test. χ²(1) = 6.62. 
f p<0.01, ARB versus neither for chi-square test. χ²(1) = 6.83. 
g p<0.05, ARB versus neither for chi-square test. χ²(1) = 4.03. 
h p<0.001, ARB versus neither for chi-square test. χ²(1) = 17.83. 
i p<0.01, ARB versus neither for chi-square test. χ²(1) = 11.58. 
j p<0.01, ARB versus neither for chi-square test. χ²(1) = 8.32. 
k p<0.001, ARB versus neither for chi-square test. χ²(1) = 18.89. 
l p<0.001, ARB versus neither for chi-square test. χ²(1) = 17.81. 
m p<0.01, ARB versus neither for chi-square test. χ²(1) = 7.52. 
n p<0.001, ARB versus neither for chi-square test. χ²(1) = 35.32 
o p<0.001, ARB versus neither for chi-square test. χ²(1) = 89.03. 
p p<0.001, ARB versus neither for chi-square test. χ²(1) = 58.21. 
q p<0.001, ARB versus neither for chi-square test. χ²(1) = 20.17. 
r p<0.01, ACEI versus neither for chi-square test. χ²(1) = 6.86. 
s p<0.05, ACEI versus neither for chi-square test. χ²(1) = 4.55. 
t p<0.001, ACEI versus neither for chi-square test. χ²(1) = 12.60. 
u p<0.01, ACEI versus neither for chi-square test. χ²(1) = 7.06. 
v p<0.001, ACEI versus neither for chi-square test. χ²(1) = 18.64. 
w p<0.01, ACEI versus neither for chi-square test. χ²(1) = 9.69. 
x p<0.01, ACEI versus neither for chi-square test. χ²(1) = 7.84. 
y p<0.01, ACEI versus neither for chi-square test. χ²(1) = 8.72. 
z p<0.001, ACEI versus neither for chi-square test. χ²(1) = 46.64. 
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aa p<0.001, ACEI versus neither for chi-square test. χ²(1) = 56.00. 
bb p<0.001, ACEI versus neither for chi-square test. χ²(1) = 52.14. 
cc p<0.001, ACEI versus neither for chi-square test. χ²(1) = 19.55. 
dd p<0.001, ACEI versus neither for chi-square test. χ²(1) = 63.95. 
ee p<0.001, ACEI versus neither for chi-square test. χ²(1) = 59.83. 
ff p<0.001, ACEI versus neither for chi-square test. χ²(1) = 65.41. 
gg p<0.001, ACEI versus neither for chi-square test. χ²(1) = 15.23. 
hh p<0.001, ACEI versus neither for chi-square test. χ²(1) = 316.14. 
ii p<0.001, ACEI versus neither for chi-square test. χ²(1) = 766.70. 
jj p<0.001, ACEI versus neither for chi-square test. χ²(1) = 493.23. 
kk p<0.001, ACEI versus neither for chi-square test. χ²(1) = 148.24. 
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Table 19:  Categorical Outcomes by Drug Therapy and Time Since Identification, 
Comparisons by Time  
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
ESRD***  0.001a,b 
(0.03) 
0.002 
(0.04)
0.003 
(0.06)
0.002 
(0.04)
0.00 
(0.00) 
0.002 
(0.04)
       
MI  0.006 
(0.08) 
0.004 
(0.06) 
0.005 
(0.07) 
0.003 
(0.06) 
0.00 
(0.00) 
0.005 
(0.07) 
       
LVH†††  0.01c,d,e 
(0.09) 
0.01f,g
(0.10) 
0.01 
(0.12) 
0.02 
(0.13) 
0.01 
(0.12) 
0.01 
(0.10) 
       
Stroke  0.02 
(0.14) 
0.02 
(0.13)
0.02 
(0.13)
0.01 
(0.11)
0.00 
(0.00) 
0.02 
(0.13)
       
IVDE 0.03 0.03 0.04 0.03 0.01 0.03 
 (0.18) (0.17) (0.18) (0.18) (0.18) (0.18) 
       
Mortality‡‡‡  0.003h,i,j 
(0.05) 
0.004 
(0.07)
0.004 
(0.07)
0.007 
(0.08)
0.03 
(0.16) 
0.004 
(0.06)
       
ARB       
ESRD║║  0.001k 
(0.03) 
0.004 
(0.06) 
0.003 
(0.05) 
0.01 
(0.11) 
0.00 
(0.00) 
0.003 
(0.06) 
       
MI  0.007 
(0.08) 
0.002 
(0.05)
0.003 
(0.05)
0.002 
(0.05)
0.00 
(0.00) 
0.004 
(0.06)
       
LVH  0.01 
(0.10) 
0.01 
(0.12)
0.02 
(0.14)
0.03 
(0.16)
0.00 
(0.00) 
0.02 
(0.12)
       
Stroke  0.02 
(0.12) 
0.02 
(0.13) 
0.02 
(0.13) 
0.01 
(0.11) 
0.00 
(0.00) 
0.02 
(0.13) 
       
IVDE 0.03 0.03 0.04 0.04 0.00 0.03 
 (0.17) (0.18) (0.19) (0.20) (0.00) (0.18) 
       
Mortality  0.003 
(0.06) 
0.004 
(0.06) 
0.005 
(0.07) 
0.005 
(0.07) 
0.00 
(0.00) 
0.004 
(0.06) 
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Table 19 (cont.) 
 
Variable Time t Time 
(t+1) 
Time 
(t+2) 
Time 
(t+3) 
Time 
(t+4) 
Total  
Neither       
ESRD§§§  0.002l,m 
(0.04) 
0.003 
(0.05)
0.005 
(0.07)
0.004 
(0.06)
0.002 
(0.05) 
0.003 
(0.06)
       
MI¶¶¶  0.004n,o,p 
(0.06) 
0.003q 
(0.05) 
0.002r
(0.04) 
0.002 
(0.04) 
0.00 
(0.00) 
0.002 
(0.05) 
       
LVH$$$  0.006s,t,u,v 
(0.08) 
0.008w,x,y
(0.09)
0.01z,aa
(0.10)
0.013 
(0.12)
0.02 
(0.13) 
0.01 
(0.09)
       
Stroke πππ  0.011bb,cc,dd,
ee 
(0.10) 
0.008ff,gg
(0.09) 
0.007hh
(0.09) 
0.005 
(0.07) 
0.003 
(0.06) 
0.008 
(0.09) 
        
IVDE 0.02 0.02 0.02 0.02 0.02 0.02 
  (0.02) (0.14) (0.14) (0.14) (0.14) (0.14) 
        
Mortality 
ΔΔΔ 
0.02ii,jj,kk 
(0.15) 
0.06 
(0.23)
0.06 
(0.24)
0.06 
(0.23)
0.04 
(0.19) 
0.05 
(0.22)
Notes:  mean (standard deviation) 
 
***p<0.001, time comparisons for chi-square test. χ2 (4) = 19.02. 
††† p<0.001, time comparisons for chi-square test. χ2 (4) = 34.13. 
‡‡‡ p<0.001, time comparisons for chi-square test. χ2 (4) = 23.09. 
║║p<0.01, time comparisons for chi-square test. χ2 (4) = 13.51. 
§§§ p<0.001, time comparisons for chi-square test. χ2 (4) = 68.01. 
¶¶¶ p<0.001, time comparisons for chi-square test. χ2 (4) = 20.33. 
$$$ p<0.001, time comparisons for chi-square test. χ2 (4) = 65.82. 
πππ p<0.001, time comparisons for chi-square test. χ2 (4) = 30.69. 
ΔΔΔ p<0.001, time comparisons for chi-square test. χ2 (4) = 379.62. 
a p<0.05, time comparison of first and second years of observation for chi-square test. χ² 
(1) = 3.85. 
b p<0.001, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 18.70. 
c p<0.05, time comparison of first and second years of observation for chi-square test. χ² 
(1) = 6.53. 
d p<0.001, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 22.81. 
e p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 23.20. 
f p<0.05, time comparison of second and third years of observation for chi-square test. χ² 
(1) = 5.69. 
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g p<0.01, time comparison of second and fourth years of observation for chi-square test. 
χ² (1) = 8.77. 
h p<0.05, time comparison of first and second years of observation for chi-square test. χ² 
(1) = 5.20. 
i p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 12.50. 
j p<0.001, time comparison of first and fifth years of observation for chi-square test. χ² (1) 
= 14.29. 
k p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 14.44. 
l p<0.001, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 20.34. 
m p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 10.26. 
n  p<0.01, time comparison of first and third years of observation for chi-square test. χ² (1) 
= 8.30. 
o p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 10.09. 
p p<0.01, time comparison of first and fifth years of observation for chi-square test. χ² (1) 
= 7.26. 
q p<0.05, time comparison of second and fifth years of observation for chi-square test. χ² 
(1) = 5.25. 
r p<0.05, time comparison of third and fifth years of observation for chi-square test. χ² (1) 
= 3.96. 
s p<0.01, time comparison of first and second years of observation for chi-square test. χ² 
(1) = 9.58. 
t p<0.001, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 24.84. 
u p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 49.69. 
v p<0.001, time comparison of first and fifth years of observation for chi-square test. χ² 
(1) = 33.57. 
w p<0.05, time comparison of second and third years of observation for chi-square test. χ² 
(1) = 4.68. 
x p<0.001, time comparison of second and fourth years of observation for chi-square test. 
χ² (1) = 20.13. 
y p<0.001, time comparison of second and fifth years of observation for chi-square test. χ² 
(1) = 15.26. 
z p<0.05, time comparison of third and fourth years of observation for chi-square test. χ² 
(1) = 5.53. 
aa p<0.01, time comparison of third and fifth years of observation for chi-square test. χ² 
(1) = 6.80. 
bb p<0.05, time comparison of first and second years of observation for chi-square test. χ² 
(1) = 6.06. 
cc p<0.01, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 10.20. 
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dd p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 20.62. 
ee p<0.01, time comparison of first and fifth years of observation for chi-square test. χ² (1) 
= 9.64. 
ff p<0.01, time comparison of second and fourth years of observation for chi-square test. 
χ² (1) = 7.72. 
gg p<0.05, time comparison of second and fifth years of observation for chi-square test. χ² 
(1) = 5.62. 
hh p<0.05, time comparison of third and fifth years of observation for chi-square test. χ² 
(1) = 4.11. 
ii p<0.001, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 314.14. 
jj p<0.001, time comparison of first and third years of observation for chi-square test. χ² 
(1) = 221.49. 
kk p<0.001, time comparison of first and fourth years of observation for chi-square test. χ² 
(1) = 12.25. 
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In terms of healthcare utilization, veterans had 10.52 ± 13.37 outpatient visits, 
0.18 ± 0.71 ED visits, and 0.13 ± 0.55 hospitalizations per year (Table 20). (Note the 
percentages for outpatient visits are not limited to the conventional range of 0% to 100% 
because, on average, patients have more than one outpatient visit in a given year.)   
Comparisons by drug therapy show ACEI patients had the highest amount of 
outpatient visits of the three therapy groups; ARB patients had a higher amount of 
outpatient visits than neither patients (p<0.001 each). In terms of ED visits, patients on 
neither therapy had significantly fewer ED visits than those on ACEI or ARB therapy 
(p<0.001 each).  ACEI patients had a significantly higher rate of hospitalization than 
neither patients (p<0.001), but they were comparable to ARB patients.  
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Table 20: Descriptive Statistics by Drug Therapy, Count Outcomes  
 
Variable All patients  
(n=124,296 person-
years; n=40,669 
patients)  
Frequency, [mean 
(SD)]/person-year 
ACEI 
(n=47,533 person-
years; n=18,947 
patients) 
Frequency, [mean 
(SD)]/person-year 
ARB 
(n=5,098 person- 
years; n=1,929 
patients) 
Frequency,[mean 
(SD)]/person-year 
Neither 
(n=71,665 person-
years; n=19,793 
patients) 
Frequency, [mean 
(SD)]/person-year 
Outpatient visits***,a 1,307,141 
[10.52 (13.37)] 
661,523  
[13.92 (13.93)] 
70,691  
[13.87 (15.00)] 
574,927  
[(8.02 (12.27)] 
     
ED visits††† 21,737 
[0.18 (0.71)] 
10,356  
[0.22 (0.79)] 
945  
[0.19 (0.68)] 
9,536  
[0.15 (0.64)] 
     
Hospitalizations‡‡‡ 15,503 
[0.13 (0.55)] 
7,364  
[0.16 (0.60)] 
637  
[0.13 (0.51)] 
7,402  
[0.11 (0.52)] 
 
aOutpatient visits look very different from Hospitalizations and ED visits.  Remember, although we do not expect every patient to 
have a hospitalization or ED visit every year, that every patient has to have at least one outpatient visit every year or we would not 
have a medical record available for them for this year unless he received an ACEI or ARB at least 50% of the year. 
***p<0.001, drug therapy comparisons, for Kruskal-Wallis test.  Pairwise comparisons found three significant differences in rank 
means.  Rank Mean difference = 1,611.60, critical value = 1,302.48, found a significant difference between ACEI and ARB groups 
(rank mean = 80,950.33 and 79,338.73, respectively, p<0.0083 (adjusted p-value)).  Rank Mean difference = 27,149.58, critical value 
= 1,279.08, found a significant difference between ARB and neither groups (rank means = 79,338.73 and 52,189.15, respectively, 
p<0.0083 (adjusted p-value)).  Rank Mean difference = 28,761.18, critical value = 517.85, found a significant difference between 
ACEI and neither groups (rank mean = 80,950.33 and 52,189.15, respectively, p<0.0083, (adjusted p-value)). 
†††p<0.001, drug therapy comparisons, for Kruskal-Wallis test. Pairwise comparisons found two significant differences in rank means.  
Rank Mean difference = 1,640.44, critical value = 1,279.08, found a significant difference between ARB and neither groups (rank 
mean = 64,513.30 and 62,872.86, respectively, p<0.0083 (adjusted p-value)).  Rank Mean difference = 2,770.06, critical value = 
517.85, found a significant difference between ACEI and neither groups (rank mean = 65,642.92 and 62,872.86, respectively, 
p<0.0083 (adjusted p-value)). 
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‡‡‡p<0.001, drug therapy comparisons, for Kruskal-Wallis test.  Pairwise comparisons found one significant difference in rank means.  
Rank Mean difference = 2,295.86, critical value = 517.85, finds a significant difference between ACEI and neither groups (rank mean 
= 65,360.46 and 63,064.62, respectively, p<0.0083 (adjusted p-value)).  
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 The following two tables compare hospitalization, ED visit, and outpatient visit 
rates across time and drug therapy for each year of follow-up.  At year 1, ACEI patients 
had more hospitalizations, ED visits, and outpatient visits than those on neither therapy 
(Table 21).  The only difference involving ARB patients at this time point is that they 
also had more outpatient visits than those receiving neither therapy.  During the second 
year of follow-up we see a similar pattern:  ACEI patients had more hospitalizations, ED 
visits, and outpatient visits than neither patients, again with ARB patients having more 
outpatient visits than neither patients.  Neither patients had about one-half the outpatient 
visits as those in the ACEI or neither groups.  Similar patterns were revealed in the third 
and fourth years of follow-up.  In the last year of follow-up the only difference found is 
ACEI patients had more outpatient visits than neither patients. 
Table 22 shows among ACEI patients there is a progressive decrease in the rate of 
hospitalization and ED visits across follow-up as evidenced by year 1 having a 
significantly higher rate than years 2, 3, and 4.  There is even more evidence for a 
continuous decline in hospitalizations across follow-up for ACEI patients as each year of 
follow-up is significantly different from another.  It should be noted that the number of 
outpatient visits in year 5 is approximately one-third of those in year 1.  ARB patients 
only had one significant difference in rates across follow-up:  there were fewer outpatient 
visits in year 5 than year 1.  Patients receiving neither therapy had decreasing rates of 
hospitalization, ED visits, and outpatient visits across the follow-up period. 
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Table 21:  Count Outcomes by Drug Therapy and Time Since Identification, 
Comparisons by Drug Therapy  
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI  
Hospitalization  0.18a 
(0.64) 
0.15b
(0.60)
0.14c 
(0.58)
0.11d 
(0.50)
0.03 
(0.23) 
0.16 
(0.60) 
       
ED visits  0.25e 
(0.84) 
0.20f 
(0.79) 
0.19g
(0.72) 
0.18h 
(0.71) 
0.11i 
(0.39) 
0.22 
(0.79) 
       
Outpatient Visits  15.96j 
(13.88) 
12.87k
(13.88) 
12.53l
(13.88) 
11.32m 
(13.18) 
5.671n 
(5.58) 
13.92 
(13.93) 
       
ARB       
Hospitalization  0.16 
(0.58) 
0.12 
(0.51)
0.10 
(0.42)
0.09 
(0.42)
0.00 
(0.00) 
0.13 
(0.51) 
       
ED visits  0.22 
(0.72) 
0.17 
(0.68) 
0.17 
(0.67) 
0.15 
(0.54) 
0.00 
(0.00) 
0.19 
(0.68) 
       
Outpatient Visits  16.08 
(14.75) 
12.70 
(13.19)
12.71 
(17.89)
11.37 
(13.71)
4.67 
(4.32) 
13.87 
(15.00)
Neither       
Hospitalization  0.16 
(0.64) 
0.10 
(0.51) 
0.09 
(0.47) 
0.06 
(0.37) 
0.02 
(0.20) 
0.11 
(0.52) 
       
ED visits  0.22 
(0.82) 
0.13 
(0.61)
0.11 
(0.54)
0.09 
(0.49)
0.05 
(0.35) 
0.15 
(0.64) 
       
Outpatient Visits  12.93 
(13.99) 
7.20 
(11.90) 
6.17 
(11.23) 
4.66 
(8.89) 
2.07 
(4.11) 
8.02 
(12.27) 
Notes: mean (standard deviation) 
 
a p<0.01, drug therapy comparisons within time t for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Means difference = 
404.46, critical value = 285.66, found a significant difference between ACEI and neither 
(rank mean = 20,546.88 and 20,142.42, respectively, p<0.0083 (adjusted p-value)). 
b p<0.01, drug therapy comparisons within time (t+1) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means. Rank Means difference = 
598.12, critical value = 287.56, found one significant difference between ACEI and 
neither (rank mean = 20,418.68 and 19,820.57, respectively, p<0.0083 (adjusted p-
value)). 
c p<0.001, drug therapy comparisons within time (t+2) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Mean difference = 
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419.44, critical value = 241.20, found a significant difference between ACEI and neither 
groups (rank mean = 13,775.91 and 13,356.46, respectively, p<0.0083 (adjusted p-
value)). 
d p<0.001, drug therapy comparisons within time (t+3) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Mean difference = 
225.96, critical value = 196.94, found one significant difference between ACEI and 
neither groups (rank mean = 7,344.56 and 7,118.59, respectively, p<0.0083 (adjusted p-
value)). 
e p<0.001, drug therapy comparisons within time t for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Mean difference = 
386.28, critical value = 285.66, found a significant difference between ACEI and neither 
groups (rank mean = 20,541.91 and 20,155.63, respectively, p<0.0083 (adjusted p-
value)). 
f p<0.001, drug therapy comparisons within time (t+1) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Mean difference = 
660.14, critical value = 287.56, found a significant difference between ACEI and neither 
groups (rank mean = 20,453.96 and 19,793.82, respectively, p<0.0083 (adjusted p-
value)). 
g p<0.001, drug therapy comparisons within time (t+2) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Mean difference = 
595.62, critical value = 241.20, found a significant difference between ACEI and neither 
groups (rank mean = 13,884.96 and 13,289.34, respectively, p<0.0083 (adjusted p-
value)). 
h p<0.001, drug therapy comparisons within time (t+3) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means. Rank Mean difference = 
342.42, critical value = 196.94, found a difference between ACEI and neither groups 
(rank mean = 7,429.24 and 7,086.82, respectively, p<0.0083 (adjusted p-value)). 
i p<0.05, drug therapy comparisons within time (t+4) for Kruskal-Wallis test.  Pairwise 
comparisons found no significant difference in rank means. 
j p<0.001, drug therapy comparisons within time t for Kruskal-Wallis test.  Pairwise 
comparisons found two significant differences in rank means.  Rank Mean difference = 
3,917.54, critical value = 670.39, found a significant difference between ARB and neither 
groups (rank mean = 22,054.75 and 18,137.21, respectively, p<0.0083 (adjusted p-
value)).  Rank Mean difference = 4,318.63, critical value = 285.66, found a significant 
difference between ACEI and neither groups (rank mean = 22,455.84 and 18,137.21, 
respectively, p<0.0083 (adjusted p-value)). 
k p<0.001, drug therapy comparisons within time (t+1) for Kruskal-Wallis test.  Pairwise 
comparisons found two significant differences in rank means.  Rank Mean difference = 
8,236.89, critical value = 698.05, found a significant difference between ARB and neither 
groups (rank mean = 24,554.68 and 16,317.79, respectively, p<0.0083 (adjusted p-
value)).  Rank Mean difference = 8,644.57, critical value =  287.56, found a significant 
difference between ACEI and neither groups (rank mean = 24,962.36 and 16,317.17, 
respectively, p<0.0083 (adjusted p-value)). 
l p<0.001, drug therapy comparisons within time (t+2) for Kruskal-Wallis test.  Pairwise 
comparisons found two significant differences in rank means.  Rank Mean difference = 
6,345.98, critical value = 590.59, found a significant difference between ARB and neither 
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groups (rank mean = 17,262.87 and 10,916.88, respectively, p<0.0083 (adjusted p-
value)).  Rank Mean difference = 6,743.69, critical value = 241.20, found a significant 
difference between ACEI and neither groups (rank mean = 17,660.57 and 10,916.88, 
respectively, p<0.0083 (adjusted p-value)). 
m p<0.001, drug therapy comparisons within time (t+3) for Kruskal-Wallis test.  Pairwise 
comparisons found two significant differences in rank means.  Rank Mean difference = 
3,836.26, critical value = 503.88, found a significant difference between ARB and neither 
groups (rank mean = 9,977.09 and 6,140.83, respectively, p<0.0083 (adjusted p-value)).  
Rank Mean difference = 3,991.95, critical value = 196.94, found a significant difference 
between ACEI and neither groups (rank mean = 10,132.78 and 6,140.83, respectively, 
p<0.0083 (adjusted p-value)). 
n p<0.001, drug therapy comparisons within time (t+4) for Kruskal-Wallis test.  Pairwise 
comparisons found one significant difference in rank means.  Rank Mean difference = 
580.14, critical value = 174.88, found a significant difference between ACEI and neither 
groups (rank mean = 1,621.17 and 1,041.03, respectively, p<0.0083 (adjusted p-value)). 
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Table 22:  Count Outcomes by Drug Therapy and Time Since Identification, 
Comparisons by Time  
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
Hospitalization***  0.18 
(0.64) 
0.15 
(0.60)
0.14 
(0.58)
0.11 
(0.50)
0.03 
(0.23) 
0.16 
(0.60) 
       
ED visits†††  0.25 
(0.84) 
0.20 
(0.79) 
0.19 
(0.72) 
0.18 
(0.71) 
0.11 
(0.39) 
0.22 
(0.79) 
       
Outpatient 
Visits‡‡‡ 
15.96 
(13.88) 
12.87 
(13.88) 
12.53 
(13.88) 
11.32 
(13.18) 
5.671 
(5.575) 
13.92 
(13.93) 
       
ARB       
Hospitalization║  0.16 
(0.58) 
0.12 
(0.51)
0.10 
(0.42)
0.09 
(0.42)
0.00 
(0.00) 
0.13 
(0.51) 
       
ED visits  0.22 
(0.72) 
0.17 
(0.68) 
0.17 
(0.67) 
0.15 
(0.54) 
0.00 
(0.00) 
0.19 
(0.68) 
       
Outpatient 
Visits§§§ 
16.08 
(14.75) 
12.70 
(13.19)
12.71 
(17.89)
11.37 
(13.71)
4.67 
(4.32) 
13.87 
(15.00)
Neither       
Hospitalization¶¶¶  0.16 
(0.64) 
0.10 
(0.51) 
0.09 
(0.47) 
0.06 
(0.37) 
0.02 
(0.20) 
0.11 
(0.52) 
       
ED visits$$$  0.22 
(0.82) 
0.13 
(0.61)
0.11 
(0.54)
0.09 
(0.49)
0.05 
(0.35) 
0.15 
(0.64) 
       
Outpatient 
Visitsπππ 
12.93 
(13.99) 
7.20 
(11.90) 
6.17 
(11.23) 
4.66 
(8.89) 
2.07 
(4.11) 
8.02 
(12.27) 
Notes:  mean (standard deviation) 
 
*** p<0.001, time comparisons within ACEI for Kruskal-Wallis test.  Pairwise 
comparisons found three significant differences in rank means.  Rank Mean difference = 
472.45, critical value = 415.05, found a difference between the first and second years of 
follow-up (rank mean = 24,116.92 and 23,644.47, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 620.17, critical value = 486.05, found a difference 
between the first and third years of follow-up (rank mean = 24,116.92 and 23,496.76, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 955.86, critical 
value = 723.66, found a difference between the first and fourth years of follow-up (rank 
mean = 24,116.92 and 23,161.06, respectively, p<0.0025 (adjusted p-value)).   
††† p<0.001, time comparisons within ACEI for Kruskal-Wallis test.  Pairwise 
comparisons found three significant differences in rank means.  Rank Mean difference = 
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686.05, critical value = 415.05, found a significant difference between the first and 
second years of follow-up (rank mean = 24,194.69 and 23,508.64, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 700.37, critical value = 486.05, found a 
significant difference in the first and third years of follow-up (rank mean = 24,194.69 and 
23,494.33, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 845.02, 
critical value = 723.66, found a significant difference in the first and fourth years of 
follow-up (rank mean = 24,194.69 and 23,349.67, respectively, p<0.0025 (adjusted p-
value)).   
‡‡‡ p<0.001, time comparisons within ACEI for Kruskal-Wallis test.  Pairwise 
comparisons found ten significant differences in rank means.  Rank Mean difference = 
5,223.30, critical value = 415.05, found a significant difference in the first and second 
years of follow-up (rank mean = 27,197.06 and 21,973.76, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 5,789.55, critical value = 486.05, found a 
significant difference in the first and third years of follow-up (rank mean = 27,197.06 and 
21,407.51, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 7,510.41, 
critical value = 723.66, found a significant difference in the first and fourth years of 
follow-up (rank mean = 27,197.06 and 19,686.65, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 16,052.63, critical value = 4,516.80, found a significant 
difference between the first and fifth years of follow-up (rank mean = 27,197.06 and 
11,144.43, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 566.25, 
critical value = 501.91, found a significant difference in the second and third years of 
follow-up (rank mean = 21,973.76 and 21,407.51, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 2,287.11, critical value = 734.41, found a significant 
difference between the second and fourth years of follow-up (rank mean = 21,973.76 and 
19,686.65, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 
10,829.33, critical value = 4,518.53, found a significant difference between the second 
and fifth years of follow-up (rank mean = 21,973.76 and 11,144.43, respectively, 
p<0.0025 (adjusted p-value)).  Rank Mean difference = 1,720.86, critical value = 776.75, 
found a significant difference in the third and fourth years of follow-up (rank mean = 
21,407.51 and 19,686.65, respectively, p<0.0025 (adjusted p-value)).  Rank Mean 
difference = 10,263.08, critical value = 4,525.60, found a significant difference in the 
third and fifth years of follow-up (rank mean = 21,407.51 and 11,144.43, respectively, 
p<0.0025 (adjusted p-value)).  Rank Mean difference = 8,542.22, critical value = 
4,557.25, found a significant difference in the fourth and fifth years of follow-up (rank 
mean = 19,686.65 and 11,144.43, respectively, p<0.0025 (adjusted p-value)). 
║ p<0.05, time comparisons within ARB for Kruskal-Wallis test.  Pairwise comparisons 
found no differences. 
§§§ p<0.001, time comparisons for ANOVA.  Tukey’s Honestly Significant Difference 
finds one comparison is greater than the studentized range critical value (.05, 5, 5093) = 
3.859. Among ARB users, the first year of observation had more outpatient visits than the 
fifth year (HSD test statistic = 4.140). 
¶¶¶ p<0.001, time comparisons within neither for Kruskal-Wallis test.  Pairwise 
comparisons found six significant differences in rank means.  Rank Mean difference = 
1,058.26, critical value = 565.06, found a significant difference in the first and second 
years of follow-up (rank mean = 36,821.22 and 35,762.95, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 1,323.35, critical value = 611.54, found a 
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significant difference in the first and third years of follow-up (rank mean = 36,821.22 and 
35,497.86, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 1,839.39, 
critical value = 698.61, found a significant difference between the first and fourth years 
of follow-up (rank mean = 36,821.22 and 34,981.82, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 2,644.00, critical value = 1,348.87, found a significant 
difference in the first and fifth years of follow-up (rank mean = 36,821.22 and 34,177.21, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 781.13, critical 
value = 683.07, found a significant difference between the second and fourth years of 
follow-up (rank mean = 35,762.95 and 34,981.82, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 1,585.74, critical value = 1,340.89, found a significant 
difference in the second and fifth years of follow-up (rank mean = 35,762.95 and 
34,177.21, respectively, p<0.0025 (adjusted p-value)). 
$$$ p<0.001, time comparisons within neither for Kruskal-Wallis test.  Pairwise 
comparisons found seven significant differences in rank means.  Rank Mean difference = 
1,528.16, critical value = 565.06, found a significant difference in the first and second 
years of follow-up (rank mean = 37,200.27 and 35,672.12, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 1,949.72, critical value = 611.54, found a 
significant difference in the first and third years of follow-up (rank mean = 37,200.27 and 
35,250.55, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 2,287.79, 
critical value = 698.61, found a significant difference in the first and fourth years of 
follow-up (rank mean = 37,200.27 and 34,912.49, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 3,322.81, critical value = 1,348.87, found a significant 
difference in the first and fifth years of follow-up (rank mean = 37,200.27 and 33,877.46, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 759.63, critical 
value = 683.07, found a significant difference in the second and fourth years of follow-up 
(rank mean = 35,672.12 and 34,912.49, respectively, p<0.0025 (adjusted p-value)).  Rank 
Mean difference = 1,794.66, critical value = 1,340.89, found a significant difference in 
the second and fifth years of follow-up (rank mean = 35,672.12 and 33,877.46, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 1,373.09, critical 
value = 1,361.13, found a significant difference in the third and fifth years of follow-up 
(rank mean = 35,250.55 and 33,877.46, respectively, p<0.0025 (adjusted p-value)). 
πππ p<0.001, time comparisons within neither for Kruskal-Wallis test.  Pairwise 
comparisons found ten significant differences in rank means.  Rank Mean difference = 
15,585.01, critical value = 565.06, found a significant difference in the first and second 
years of follow-up (rank mean = 49,337.50 and 33,752.49, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 18,990.24, critical value = 611.54, found a 
significant difference in the first and third years of follow-up (rank mean = 49,337.50 and 
30,347.26, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 
22,507.56, critical value = 698.61, found a significant difference in the first and fourth 
years of follow-up (rank mean = 49,337.50 and 26,829.94, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 30,000.93, critical value = 1,348.87, found 
a significant difference in the first and fifth years of follow-up (rank mean = 49,337.50 
and 19,336.57, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 
3,405.23, critical value = 593.72, found a significant difference in the second and third 
years of follow-up (rank mean = 33,752.49 and 30,347.26, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 6,922.55, critical value = 683.07, found a 
  153
significant difference in the second and fourth years of follow-up (rank mean = 33,752.49 
and 26,829.94, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 
14,415.92, critical value = 1,340.89, found a significant difference in the second and fifth 
years of follow-up (rank mean = 33,752.49 and 19,336.57, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 3,517.32, critical value = 721.99, found a 
significant difference in the third and fourth years of follow-up (rank mean = 30,347.26 
and 26,829.94, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 
11,010.69, critical value = 1,361.13, found a significant difference in the third and fifth 
years of follow-up (rank mean = 30,347.26 and 19,336.57, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 7,493.37, critical value = 1,402.41, found a 
significant difference in the fourth and fifth years of follow-up (rank mean = 26,829.94 
and 19,336.57, respectively, p<0.0025 (adjusted p-value)). 
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Multivariate Regression Results 
 
ACEI or ARB Monotherapy versus neither 
 
The following six tables present multivariate regression results for comparisons 
between ACEI or ARB monotherapy and neither therapy.  Table 23 shows the results for 
the logistic regression of ACEI monotherapy’s effect and ARB monotherapy’s effect, 
compared to neither therapy, on development of ESRD.  Several patient characteristics 
were simultaneously entered in the model to control for their effects. 
With robust standard errors we only have Pregibon’s Link Test and Hosmer and 
Lemeshow goodness-of-fit test for diagnostic tests of logistic regression. The Pregibon’s 
Link Test was nonsignificant (p=0.95) as was Hosmer and Lemeshow (p=0.53, 
χ²(8)=7.05). 
The interaction between ACEI and time (t+4), the interaction between ARB and 
time (t+4), pulmonary circulation disorders, AIDS, lymphoma, metastatic cancer, and 
rheumatoid arthritis/collagen vascular diseases were dropped because each of these 
variables have no observations with an ESRD value of one.  Time (t+2), annual income 
$18,000-34,999, CHF, diabetes complicated, fluid and electrolyte disorders, and 
deficiency anemias were associated with higher odds of ESRD development.  ACEI 
monotherapy, age, and LDL were associated with lower odds of ESRD (p<0.017 each).  
Focusing on ACEI monotherapy, with an odds ratio (OR)=0.43 (95% CI: 0.23-0.80), 
patients were associated with having 57% (20-77%) lower odds of ESRD development 
compared to patients receiving neither therapy.  Particular emphasis should be placed on 
diabetes complicated (OR=3.40, 2.39-4.84), fluid and electrolyte disorders (OR=4.19, 
2.44-7.19), and deficiency anemias (OR=4.25, 2.56-7.07).  Note although all conditions 
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have high point estimates, the confidence intervals for the latter two are wider, indicating 
fewer patients with these conditions compared to diabetes complicated.  The model was 
significant [Wald χ²(49) = 499.17, p<0.001] and explained 13.24% of the variance in 
ESRD development.  It also has a 0.82 probability of correctly classifying a randomly 
selected pair of cases from those developing and not developing ESRD based on the area 
under the receiver operating characteristic (ROC) curve. (Note this value varies from 0.5 
to 1.0, chance to perfect prediction, respectively). 
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Table 23: Logistic Regression, ACEI or ARB versus Neither, for Variables Predicting 
ESRD (N=72,153 person-years; N=35,475 patients) 
 
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 0.43 0.14 <0.01 0.23 0.80
ARBa 0.50 0.37 0.35 0.12 2.13
Time (t+1) b 1.00 0.28 0.99 0.57 1.74
Time (t+2) b 2.76 0.67 <0.001 1.71 4.45
Time (t+3) b 0.89 0.38 0.78 0.38 2.04
Time (t+4) b 2.28 1.86 0.31 0.46 11.28
ACEI*time (t+1) c 1.30 0.61 0.58 0.52 3.27
ACEI*time (t+2) c 0.84 0.36 0.69 0.36 1.96
ACEI*time (t+3) c 1.95 1.36 0.34 0.50 7.66
ARB*time (t+1) d 3.12 2.38 0.14 0.70 13.92
ARB*time (t+2) d 0.73 0.76 0.77 0.10 5.66
ARB*time (t+3) d 2.99 3.93 0.40 0.23 39.28
Age  0.97 0.01 <0.01 0.96 0.99
Annual income $6,000-
17,999e 1.63 0.42 0.06 0.98 2.71
Annual income $18,000-
34,999e 1.86 0.46 0.01 1.14 3.03
Annual income 
≥$35,000e 1.10 0.33 0.74 0.61 1.98
Income missinge 1.46 0.72 0.44 0.56 3.84
Urban/suburbanf 1.52 0.33 0.06 0.99 2.33
Never smokerg 0.46 0.81 0.04 0.22 0.96
Ever smokerg 0.66 0.30 0.04 0.45 0.97
HbA1c 0.89 0.07 0.11 0.77 1.03
LDL 0.99 0.00 <0.01 0.99 1.00
Triglycerides  1.00 0.00 0.17 1.00 1.00
CHFh 2.63 0.68 <0.001 1.59 4.35
Cardiac arrhythmiasi 1.38 0.49 0.37 0.69 2.76
Valvular diseasej 1.25 1.07 0.79 0.24 6.63
Peripheral vascular 
disordersk 2.01 0.58 0.02 1.14 3.54
Hypertensionl 1.32 0.27 0.17 0.89 1.97
Paralysism 1.51 1.60 0.70 0.19 12.12
Other neurological 
disordersn 0.52 0.52 0.52 0.07 3.72
Chronic pulmonary 
diseaseo 0.69 0.21 0.23 0.38 1.26
Hypothyroidismp 0.99 0.34 0.98 0.50 1.95
Diabetes complicatedq 3.40 0.61 <0.001 2.39 4.84
Liver diseaser 1.84 0.83 0.18 0.76 4.43
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Table 23 (cont.) 
 
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Peptic ulcer diseases 0.81 0.66 0.80 0.17 3.98
Solid tumor without 
metastasist 1.98 0.63 0.03 1.07 3.69
Coagulopathyu 1.68 1.08 0.42 0.48 5.89
Obesityv 0.57 0.16 0.04 0.33 0.98
Weight lossw 5.16 5.88 0.15 0.55 48.21
Fluid and electrolyte 
disordersx 4.19 1.15 <0.001 2.44 7.19
Blood loss anemiay 4.06 4.59 0.22 0.44 37.19
Deficiency anemiasz 4.25 1.10 <0.001 2.56 7.07
Alcohol abuseaa 1.22 0.55 0.66 0.50 2.97
Drug abusebb 0.67 0.47 0.57 0.17 2.68
Psychoses cc 0.96 0.33 0.91 0.49 1.88
Depression dd 1.32 0.32 0.25 0.82 2.12
Cohort 2004ee 0.82 0.30 0.58 0.40 1.67
Cohort 2005 ee 1.13 0.41 0.74 0.55 2.30
Cohort 2006 ee 0.69 0.29 0.38 0.30 1.57
 
McFadden’s Pseudo R² = 0.13 
Wald χ²(49) = 499.17, p<0.001, Log pseudolikelihood =  -1008.18 
Area under the ROC curve = 0.82 
 
a Reference category = neither, b Reference category = time (t),  c Reference category 
=ACEI* time (t), d Reference category = ARB*time (t), e Reference category = Annual 
income <$6,000, f Reference category = rural, g Reference category = Current smoker, h 
Reference category = No CHF, I Reference category = No cardiac arrhythmias,  j 
Reference category = No valvular disease, k Reference category = No peripheral vascular 
disorders, l Reference category = Normotension,  m Reference category = No paralysis,  n 
Reference category = No other neurological disorders,  o Reference category = No chronic 
pulmonary disease,  p Reference category = No hypothyroidism,  q Reference category = 
No diabetes complicated,  r Reference category = No liver disease,  s Reference category = 
No peptic ulcer disease, t Reference category = No solid tumor without metastasis,  u 
Reference category = No coagulopathy, v Reference category = No obesity, w Reference 
category = No weight loss, x Reference category = No fluid and electrolyte disorders,  y 
Reference category = No blood loss anemia,  z Reference category = No deficiency 
anemias, aa Reference category = No alcohol abuse,  bb Reference category = No drug 
abuse, cc Reference category = No psychoses,  dd Reference category =No depression,  ee 
Reference category =Cohort 2003 
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 Table 24 displays results of the logistic regression of ACEI monotherapy’s and 
ARB monotherapy’s effect, compared to neither, on having an IVDE.  Several patient 
characteristics were simultaneously entered in the model to quantify their effects.  
         After running the original model, diagnostic tests were checked; Pregibon’s Link 
test was significant (p=0.004), so another model was constructed by iteratively adding 
age squared; income divided by 100,000; the interactions between HbA1c and LDL, 
HbA1c and triglycerides, LDL and triglycerides, albuminuria and HbA1c, albuminuria 
and triglycerides, albuminuria and LDL, age and triglycerides, age and LDL, and age and 
HbA1c.  Only those variables that were significant at their time of entry and contributed 
to a larger p-value for the Pregibon’s Link Test were retained.  This model resulted in a 
significant Pregibon’s Link Test (p=0.01) and nonsignificant Hosmer and Lemeshow 
goodness-of-fit (χ²(8) = 10.10, p=0.26).  Accordingly, we conducted a Box-Tidwell 
estimation to determine if there were any other transformations of variables that we 
should include that we did not.  Box-Tidwell did not provide any meaningful 
transformations.  (For instance, it specified that dividing several dummy codes by a 
number and then multiplying them by a decimal would help with fit; however, this goes 
against common sense.)  Due to this, we kept the model with the significant iteratively 
added variables mentioned above. 
 The interaction between ARB and time (t+4) was dropped because no 
observations with that characteristic had an IVDE during the study period.  Age squared, 
never smoker, ever smoker, LDL, and the interaction between LDL and triglycerides 
were associated with lower odds while ACEI monotherapy, age, history of MI, history of 
stroke, CHF, peripheral vascular disorders, chronic pulmonary disease, fluid and 
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electrolyte disorders, and deficiency anemias were associated with higher odds of IVDE 
occurrence (p<0.017 each).  Particular attention should be paid to patients with history of 
MI or stroke (OR=1.98 (1.51-2.58) and OR=2.70 (1.96-3.71) as well as patients with 
fluid and electrolyte disorders (OR=1.99 (1.44-2.76) and peripheral vascular disorders 
(OR=2.93 (2.46-3.49).  The model was significant [Wald χ²(66) = 700.48, p<0.001] and 
explained 5.30% of the variance in IVDE occurrence.  It also has a 0.68 probability of 
correctly classifying a randomly selected pair of cases from those who did and did not 
experience an IVDE. 
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Table 24: Logistic Regression Analysis, ACEI or ARB versus Neither, for Variables 
Predicting IVDE (N=55,526 person-years; N=34,060 patients) 
 
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 1.54 0.12 <0.001 1.33 1.79
ARBa 1.35 0.22 0.07 0.98 1.86
Time (t+1) b 1.04 0.11 0.72 0.84 1.28
Time (t+2) b 1.17 0.15 0.22 0.91 1.50
Time (t+3) b 1.40 0.22 0.03 1.03 1.91
Time (t+4) b 1.38 0.58 0.45 0.60 3.16
ACEI*time (t+1) c 0.85 0.12 0.24 0.65 1.11
ACEI*time (t+2) c 0.95 0.15 0.73 0.69 1.29
ACEI*time (t+3) c 0.78 0.17 0.24 0.51 1.18
ACEI*time (t+4) c 0.73 0.81 0.77 0.08 6.36
ARB*time (t+1) d 1.29 0.32 0.31 0.79 2.10
ARB*time (t+2) d 1.01 0.32 0.98 0.54 1.89
ARB*time (t+3) d 0.68 0.35 0.45 0.25 1.86
Age 1.20 0.04 <0.001 1.12 1.28
Age squared 1.00 0.00 <0.001 1.00 1.00
Annual income $6,000-
17,999e 1.20 0.11 0.05 1.00 1.44
Annual income $18,000-
34,999e 1.17 0.11 0.08 0.98 1.40
Annual income ≥$35,000e 1.08 0.10 0.43 0.89 1.30
Income missinge 0.86 0.18 0.48 0.57 1.30
Urban/suburbanf 1.02 0.07 0.79 0.89 1.16
Never smokerg 0.47 0.30 <0.001 0.35 0.61
Ever smokerg 0.65 0.11 <0.001 0.56 0.75
Baseline 
microalbuminuriah 0.99 0.09 0.89 0.82 1.18
Microalbuminuria in 
follow-upi 0.65 0.14 0.04 0.43 0.98
Macroalbuminuria in 
follow-upi 0.54 0.22 0.13 0.24 1.20
HbA1c 0.92 0.06 0.19 0.81 1.00
Albuminuria*HbA1c 1.06 0.03 0.04 1.00 1.12
LDL 1.00 0.00 <0.001 0.99 1.00
Triglycerides 1.00 0.00 0.17 1.00 1.00
Albuminuria*triglycerides 1.00 0.00 0.09 1.00 1.00
LDL*triglycerides 1.00 0.00 <0.01 1.00 1.00
History of MIj 1.98 0.27 <0.001 1.51 2.58
History of strokek 2.70 0.44 <0.001 1.96 3.71
Family history of CVDl 1.65 0.43 0.06 0.98 2.75
CHFm 1.41 0.17 <0.01 1.12 1.79
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Table 24 (cont.) 
 
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Cardiac arrhythmiasn 1.32 0.17 0.03 1.03 1.70
Valvular diseaseo 1.70 0.52 0.08 0.94 3.10
Pulmonary circulation 
disordersp 2.70 1.17 0.02 1.15 6.31
Peripheral vascular 
disordersq 2.93 0.26 <0.001 2.46 3.49
Hypertensionr 1.10 0.08 0.19 0.95 1.27
Paralysiss 0.54 0.32 0.30 0.16 1.76
Other neurological 
disorderst 1.76 0.46 0.03 1.05 2.95
Chronic pulmonary 
diseaseu 1.27 0.12 0.01 1.05 1.52
Hypothyroidismv 1.06 0.15 0.68 0.80 1.41
Diabetes complicatedw 1.12 0.09 0.16 0.95 1.32
Liver diseasex 1.28 0.29 0.27 0.83 1.99
Peptic ulcer diseasey 0.88 0.27 0.67 0.48 1.61
AIDSz 1.46 1.06 0.61 0.35 6.03
Lymphomaaa 0.59 0.36 0.39 0.18 1.93
Metastatic cancerbb 1.68 1.48 0.56 0.30 9.40
Solid tumor without 
metastasiscc 0.95 0.12 0.65 0.74 1.20
Rheumatoid arthritis/ 
collagen vascular 
diseasesdd 1.34 0.36 0.28 0.79 2.28
Coagulopathyee 1.05 0.28 0.86 0.63 1.75
Obesityff 1.02 0.08 0.82 0.87 1.20
Weight lossgg 0.63 0.67 0.66 0.08 5.01
Fluid and electrolyte 
disordershh 1.99 0.33 <0.001 1.44 2.76
Blood loss anemiaii 1.40 1.01 0.64 0.34 5.79
Deficiency anemiasjj 1.50 0.21 <0.01 1.14 1.97
Alcohol abusekk 1.03 0.20 0.90 0.70 1.49
Drug abusell 1.09 0.31 0.77 0.63 1.89
Psychosesmm 1.05 0.16 0.75 0.78 1.40
Depressionnn 1.18 0.12 0.09 0.97 1.43
Cohort 2004oo 0.94 0.12 0.61 0.73 1.20
Cohort 2005oo 0.91 0.12 0.45 0.70 1.17
Cohort 2006oo 0.98 0.13 0.86 0.75 1.27
 
McFadden’s PseudoR² = 0.05 
Wald χ²(65) = 700.48, p<0.001, Log pseudolikelihood=-6753.45 
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Area under the ROC curve = 0.68 
 
a Reference category = neither, b Reference category = time (t),  c Reference category 
=ACEI* time (t), d Reference category = ARB*time (t), e Reference category = Annual 
income <$6,000, f Reference category = rural, g Reference category = Current smoker, h 
Reference category = Baseline macroalbuminuria, iReference category = 
Normoalbuminuria in follow-up, j Reference category = No history of MI, k Reference 
category = No history of stroke, l Reference category = No family history of CVD, m 
Reference category = No CHF, n Reference category = No cardiac arrhythmias, o 
Reference category = No valvular disease, p Reference category = No pulmonary 
circulation disorders, q Reference category = No peripheral vascular disorders, r  
Reference category = Normotension, s Reference category = No paralysis, t Reference 
category = No other neurological disorders, u Reference category = No chronic pulmonary 
disease, v Reference category = No hypothyroidism, w Reference category = No diabetes 
complicated, x Reference category = No liver disease, y Reference category = No peptic 
ulcer disease, z Reference category = No AIDS, aa Reference category = No Lymphoma bb 
Reference category = No metastatic cancer, cc Reference category = No solid tumor 
without metastasis, dd Reference category = No rheumatoid arthritis/collagen vascular 
diseases, ee Reference category = No coagulopathy, ff  Reference category = No obesity, gg 
Reference category = No weight loss, hh Reference category = No fluid and electrolyte 
disorders, ii Reference category = No blood loss anemia, jj Reference category = No 
deficiency anemias, kk Reference category = No alcohol abuse, ll Reference category = No 
drug abuse, mm Reference category = No psychoses, nn Reference category = No 
depression, oo Reference category = Cohort 2003 
 
 
 
 
 
 
 
 
  163
Table 25 displays the results of the logistic regression of ACEI monotherapy’s 
effect and ARB monotherapy’s effect, compared to neither’s effect, on all-cause 
mortality.  Several patient characteristics were simultaneously entered in the model to 
control for their effects. 
            After running the model, diagnostic tests were checked.  The model had a 
nonsignificant Pregibon’s Link Test (p = 0.45) as well as a nonsignificant Hosmer and 
Lemeshow goodness-of-fit [χ²(8) = 9.63, p = 0.29]. 
             The interaction between ACEI monotherapy and time (t+4), the interaction 
between ARB monotherapy and time (t+4), and blood loss anemia were dropped as none 
of their observations had a value of one for all-cause mortality.  ACEI monotherapy, 
ARB monotherapy, times (t+1) and (t+2), and income missing were associated with 
lower odds while the interaction between ACEI monotherapy and times (t+1), (t+2), and 
(t+3), age, urban/suburban living, HbA1c, CHF, peripheral vascular disorders, chronic 
pulmonary disease, metastatic cancer, coagulopathy, fluid and electrolyte disorders, and 
cohorts 2004, 2005, and 2006 were associated with higher odds of all-cause mortality 
(p<0.017 each).  (Note the large odds ratios and robust standard errors for cohorts 2004, 
2005, and 2006, something to be cautious of when interpreting results of a logistic 
regression.)  Worth pointing out, patients with chronic pulmonary disease were 
associated with a 107% (62-164%) higher odds of dying.  Because the Wald test for time 
(t+4) cannot be reported as it is dependent on the (robust) standard error for that variable 
and the Wald statistic for the model is dependent upon the Wald test for the variable, no 
Wald statistic (or associated p-value) is reported for the model.  The model explained 
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13.50% of the variance in all-cause mortality and has a 0.82 probability of correctly 
classifying a randomly selected pair of cases from those who did and did not die. 
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Table 25:  Logistic Regression Analysis, ACEI or ARB versus Neither, for Variables 
Predicting All-Cause Mortality (N=55,457 person-years; N=34,034 patients) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 0.16 0.03 <0.001 0.11 0.22
ARBa 0.11 0.06 <0.001 0.03 0.33
Time (t+1) b 0.43 0.08 <0.001 0.30 0.60
Time (t+2) b 0.59 0.12 <0.01 0.39 0.88
Time (t+3) b 0.85 0.23 0.55 0.49 1.45
Time (t+4) b 1.22 x 107 . . . .
ACEI*time (t+1) c 2.58 0.88 <0.01 1.32 5.05
ACEI*time (t+2) c 2.92 1.11 <0.01 1.38 6.14
ACEI*time (t+3) c 5.78 2.61 <0.001 2.39 14.00
ARB*time (t+1) d 1.97 2.32 0.56 0.20 19.77
ARB*time (t+2) d 6.14 5.78 0.05 0.97 38.84
ARB*time (t+3) d 8.48 10.22 0.08 0.80 89.88
Age  1.04 0.01 <0.001 1.03 1.05
Annual income 
$6,000-17,999e 1.34 0.20 0.05 1.00 1.79
Annual income 
$18,000-34,999e 1.35 0.20 0.04 1.01 1.79
Annual income 
≥$35,000e 1.10 0.17 0.55 0.81 1.47
Income missinge 0.16 0.12 0.01 0.04 0.67
Urban/suburbanf 1.32 0.16 <0.02 1.04 1.66
Never smokerg 0.55 0.22 0.13 0.25 1.19
Ever smokerg 0.98 0.15 0.88 0.73 1.31
Baseline 
microalbuminuriah 0.93 0.20 0.70 0.65 1.33
Microalbuminuria in 
follow-upi 1.44 0.27 0.05 1.00 2.08
Macroalbuminuria in 
follow-upi 1.63 0.42 0.05 0.99 2.69
HbA1c 1.02 0.00 <0.001 1.01 1.02
LDL 1.00 0.00 0.42 0.99 1.00
Triglycerides  1.00 0.00 0.14 1.00 1.00
History of MIj 1.62 0.40 0.05 0.99 2.63
History of strokek 1.77 0.55 0.07 0.96 3.27
Family history of 
CVDl 0.48 0.44 0.42 0.08 2.85
CHFm 2.46 0.39 <0.001 1.81 3.35
Cardiac arrhythmiasn 1.05 0.20 0.79 0.73 1.52
Valvular diseaseo 0.52 0.37 0.36 0.13 2.13
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Table 25 (cont.) 
 
 
Odds 
Ratio
Robust
Standard 
Error p
95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound
Pulmonary 
circulation disordersp 1.48 1.17 0.62 0.31 6.96
Peripheral vascular 
disordersq 1.51 0.24 0.01 1.10 2.06
Hypertensionr 0.86 0.09 0.15 0.70 1.06
Paralysiss 1.80 1.10 0.33 0.55 5.94
Other neurological 
disorderst 1.65 0.61 0.18 0.80 3.39
Chronic pulmonary 
diseaseu 2.07 0.26 <0.001 1.62 2.64
Hypothyroidismv 1.33 0.26 0.14 0.91 1.93
Diabetes 
complicatedw 1.08 0.15 0.55 0.83 1.42
Liver diseasex 1.54 0.51 0.19 0.80 2.96
Peptic ulcer diseasey 0.40 0.28 0.20 0.10 1.60
AIDSz 4.15 2.98 0.05 1.02 16.98
Lymphomaaa 2.68 1.18 0.03 1.13 6.36
Metastatic cancerbb 9.29 4.27 <0.001 3.77 22.87
Solid tumor without 
metastasiscc 1.30 0.21 0.10 0.95 1.78
Rheumatoid 
arthritis/collagen 
vascular diseasesdd 1.69 0.68 0.20 0.76 3.73
Coagulopathyee 2.33 0.69 <0.01 1.31 4.14
Obesityff 0.89 0.14 0.46 0.66 1.21
Weight lossgg 1.48 1.83 0.75 0.13 16.68
Fluid and electrolyte 
disordershh 2.00 0.52 <0.01 1.20 3.32
Deficiency anemiasii 1.15 0.25 0.51 0.76 1.75
Alcohol abusejj 1.92 0.53 0.02 1.11 3.30
Drug abusekk 1.45 0.61 0.38 0.63 3.30
Psychosesll 1.02 0.26 0.94 0.62 1.66
Depressionmm 1.37 0.22 0.05 1.00 1.87
Cohort 2004nn 3.00 x 107 3.03 x 107 <0.001 4.14 x 106 2.17 x 108
Cohort 2005nn 4.06 x 107 4.10 x 107 <0.001 5.61 x 106 2.94 x 108
Cohort 2006nn 3.57 x 107 3.61 x 107 <0.001 4.93 x 106 2.59 x 108
 
McFadden’s Pseudo R² = 0.14 
Wald χ²(58) and its p-value were not reported, Log pseudolikelihood = -2144.450 
Area under the ROC curve = 0.82                  
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a Reference category = neither, b Reference category = time (t),  c Reference category 
=ACEI* time (t), d Reference category = ARB*time (t), e Reference category = Annual 
income <$6,000, f Reference category = rural, g Reference category = Current smoker, h 
Reference category = Baseline macroalbuminuria, iReference category = 
Normoalbuminuria in follow-up, j Reference category = No history of MI, k Reference 
category = No history of stroke, l Reference category = No family history of CVD, m 
Reference category = No CHF, n Reference category = No cardiac arrhythmias, o 
Reference category = No valvular disease, p Reference category = No pulmonary 
circulation disorders, q Reference category = No peripheral vascular disorders, r  
Reference category = Normotension, s Reference category = No paralysis, t Reference 
category = No other neurological disorders, u Reference category = No chronic pulmonary 
disease, v Reference category = No hypothyroidism, w Reference category = No diabetes 
complicated, x Reference category = No liver disease, y Reference category = No peptic 
ulcer disease, z Reference category = No AIDS, aa Reference category = No Lymphoma bb 
Reference category = No metastatic cancer, cc Reference category = No solid tumor 
without metastisis, dd Reference category = No rheumatoid arthritis/collagen vascular 
diseases, ee Reference category = No coagulopathy, ff  Reference category = No obesity, gg 
Reference category = No weight loss, hh Reference category = No fluid and electrolyte 
disorders, ii Reference category = No deficiency anemias, jj Reference category = No 
alcohol abuse, kk Reference category = No drug abuse, ll Reference category = No 
psychoses, mm Reference category = No depression, nn Reference category = Cohort 2003 
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Table 26 presents the results of the negative binomial regression for variables 
predicting outpatient visits.  Times (t+1), (t+2), (t+3), and (t+4), age, annual income 
≥$35,000, income missing, never smoker, microalbuminuria in follow-up, LDL, 
hypertension, and cohorts 2005 and 2006 were associated with lower incidence rates of 
outpatient visits (p<0.017 each).  ACEI monotherapy, ARB monotherapy, the interaction 
between ACEI monotherapy and times (t+1), (t+2), and (t+3), the interaction between 
ARB monotherapy and time (t+3), annual income $6,000-17,999, annual income 
$18,000-34,999, urban/suburban living, history of stroke, CHF, cardiac arrhythmias, 
valvular disease, peripheral vascular disorders, paralysis, other neurological disorders, 
chronic pulmonary disease, diabetes complicated, liver disease, AIDS, lymphoma, 
metastatic cancer, solid tumor without metastasis, rheumatoid arthritis/collagen vascular 
diseases, coagulopathy, obesity, fluid and electrolyte disorders, blood loss anemia, 
deficiency anemias, alcohol abuse, drug abuse, psychoses, and depression were 
associated with higher incidence rates of outpatient visits (p<0.017 each).  Taking a 
closer look at ACEI monotherapy, with an incidence rate ratio (IRR)=1.19 (95%CI: 1.16-
1.21), we see that patients taking ACEI monotherapy were associated with 19% (16-21%) 
more outpatient visits than patients receiving neither therapy.  Special mention should be 
given to metastatic cancer (IRR=1.94, (1.59-2.36)), fluid and electrolyte disorders 
(IRR=1.32, (1.23-1.42)), drug abuse (IRR=1.69, (1.53-1.87)), and psychoses (IRR=1.54, 
(1.46-1.63)).  The model resulted in Wald χ2(62) = 8269.50, p<0.001, log 
pseudolikelihood = -192329.35.  Note for models involving robust standard errors, a p-
value is not reported in the regression output for the likelihood-ratio test of alpha.  Model 
fit diagnostic tests for all count variables are in Appendix F. 
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Table 26: Negative Binomial Regression Analysis, ACEI or ARB versus Neither, for 
Variables Predicting Outpatient Visits (N=55,530 person-years; N=34,060 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 1.19 1.01 <0.001 1.16 1.21 
ARBa 1.25 1.02 <0.001 1.20 1.30 
Time (t+1)b 0.80 1.02 <0.001 0.77 0.82 
Time (t+2)b 0.75 1.02 <0.001 0.72 0.77 
Time (t+3)b 0.61 1.03 <0.001 0.58 0.64 
Time (t+4)b 0.34 1.07 <0.001 0.30 0.39 
ACEI*time (t+1)c 1.05 1.02 0.01 1.01 1.09 
ACEI*time (t+2)c 1.08 1.02 <0.01 1.03 1.13 
ACEI*time (t+3)c 1.19 1.04 <0.001 1.11 1.27 
ACEI*time (t+4)c 1.05 1.20 0.80 0.73 1.50 
ARB*time (t+1)d 1.05 1.04 0.17 0.98 1.13 
ARB*time (t+2)d 1.17 1.07 0.03 1.02 1.34 
ARB*time (t+3)d 1.30 1.09 <0.01 1.10 1.53 
ARB*time (t+4)d 1.12 1.46 0.77 0.53 2.35 
Age 0.99 1.00 <0.001 0.99 0.99 
Annual income 
$6,000-17,999e 1.23 1.01 <0.001 1.20 1.26 
Annual income 
$18,000-34,999e 1.17 1.01 <0.001 1.14 1.20 
Annual income 
≥$35,000e 0.92 1.01 <0.001 0.89 0.94 
Income missinge 0.80 1.03 <0.001 0.76 0.84 
Urban/suburbanf 1.16 1.01 <0.001 1.14 1.18 
Never smokerg 0.86 1.01 <0.001 0.84 0.88 
Ever smokerg 1.05 1.03 0.08 0.99 1.11 
Baseline 
microalbuminuriah 1.02 1.02 0.27 0.99 1.05 
Microalbuminuria 
in follow-upi 0.93 1.01 <0.001 0.91 0.95 
Macroalbuminuria 
in follow-upi 1.03 1.02 0.08 1.00 1.08 
HbA1c 1.00 1.00 0.11 1.00 1.01 
LDL 1.00 1.00 <0.001 1.00 1.00 
Triglycerides 1.00 1.00 0.38 1.00 1.00 
History of MIj 0.97 1.03 0.22 0.92 1.02 
History of strokek 1.16 1.04 <0.001 1.07 1.25 
Family history of 
CVDl 1.08 1.05 0.11 0.98 1.20 
CHFm 1.13 1.02 <0.001 1.08 1.18 
 
  170
Table 26 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Cardiac 
arrhythmiasn 1.43 1.02 <0.001 1.37 1.49 
Valvular diseaseo 1.28 1.06 <0.001 1.14 1.45 
Pulmonary 
circulation 
disordersp 1.46 1.19 0.03 1.04 2.05 
Peripheral vascular 
disordersq 1.18 1.02 <0.001 1.13 1.22 
Hypertensionr 0.98 1.01 <0.02 0.96 1.00 
Paralysiss 1.67 1.09 <0.001 1.41 1.97 
Other neurological 
disorderst 1.30 1.05 <0.001 1.18 1.43 
Chronic pulmonary 
diseaseu 1.12 1.02 <0.001 1.09 1.16 
Hypothyroidismv 1.01 1.02 0.55 0.97 1.06 
Diabetes 
complicatedw 1.20 1.01 <0.001 1.17 1.23 
Liver diseasex 1.22 1.03 <0.001 1.14 1.30 
Peptic ulcer 
diseasey 0.99 1.05 0.88 0.91 1.09 
AIDSz 1.30 1.08 <0.001 1.13 1.49 
Lymphomaaa 1.29 1.07 <0.001 1.12 1.48 
Metastatic cancerbb 1.94 1.11 <0.001 1.59 2.36 
Solid tumor without 
metastasiscc 1.15 1.02 <0.001 1.10 1.19 
Rheumatoid 
arthritis / collagen 
vascular diseasesdd 1.19 1.05 <0.01 1.08 1.31 
Coagulopathyee 1.39 1.05 <0.001 1.26 1.53 
Obesityff 1.04 1.01 <0.01 1.02 1.07 
Weight lossgg 1.38 1.16 0.03 1.03 1.84 
Fluid and 
electrolyte 
disordershh 1.32 1.04 <0.001 1.23 1.42 
Blood loss anemiaii 1.52 1.17 <0.01 1.12 2.07 
Deficiency 
anemiasjj 1.26 1.03 <0.001 1.20 1.33 
Alcohol abusekk 1.18 1.03 <0.001 1.11 1.25 
Drug abusell 1.69 1.05 <0.001 1.53 1.87 
Psychosesmm 1.54 1.03 <0.001 1.46 1.62 
Depressionnn 1.25 1.02 <0.001 1.22 1.29 
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Table 26 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Cohort 2004oo 0.97 1.02 0.12 0.93 1.01 
Cohort 2005oo 0.94 1.02 <0.01 0.90 0.98 
Cohort 2006oo 0.93 1.02 <0.001 0.90 0.97 
        
/lnalpha -0.85 0.01  -0.86 -0.83 
      
alpha 0.43 0.004  0.42 0.44 
 
Wald χ2(62) = 8269.50, p<0.001, log pseudolikelihood = -192329.35 
 
a Reference category = neither, b Reference category = time (t),  c Reference category 
=ACEI* time (t), d Reference category = ARB*time (t), e Reference category = Annual 
income <$6,000, f Reference category = rural, g Reference category = Current smoker, h 
Reference category = Baseline macroalbuminuria, iReference category = 
Normoalbuminuria in follow-up, j Reference category = No history of MI, k Reference 
category = No history of stroke, l Reference category = No family history of CVD, m 
Reference category = No CHF, n Reference category = No cardiac arrhythmias, o 
Reference category = No valvular disease, p Reference category = No pulmonary 
circulation disorders, q Reference category = No peripheral vascular disorders, r  
Reference category = Normotension, s Reference category = No paralysis, t Reference 
category = No other neurological disorders, u Reference category = No chronic pulmonary 
disease, v Reference category = No hypothyroidism, w Reference category = No diabetes 
complicated, x Reference category = No liver disease, y Reference category = No peptic 
ulcer disease, z Reference category = No AIDS, aa Reference category = No Lymphoma bb 
Reference category = No metastatic cancer, cc Reference category = No solid tumor 
without metastisis, dd Reference category = No rheumatoid arthritis/collagen vascular 
diseases, ee Reference category = No coagulopathy, ff  Reference category = No obesity, gg 
Reference category = No weight loss, hh Reference category = No fluid and electrolyte 
disorders, ii Reference category = No blood loss anemia, jj Reference category = No 
deficiency anemias, kk Reference category = No alcohol abuse, ll Reference category = No 
drug abuse, mm Reference category = No psychoses, nn Reference category = No 
depression, oo Reference category = Cohort 2003 
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 Table 27 displays the results of the negative binomial regression for variables 
predicting ED visits.  Times (t+1), (t+2), and (t+3), the interaction between ARB 
monotherapy and time (t+4), age, annual income ≥$35,000, income missing, never 
smoker, and hypertension were associated with lower incidence rates of ED visits; ACEI 
monotherapy, annual income $6,000-17,999, annual income $18,000-34,999, 
urban/suburban living, ever smoker, HbA1c, CHF, cardiac arrhythmias, peripheral 
vascular disorders, paralysis, other neurological disorders, chronic pulmonary disease, 
diabetes complicated, liver disease, AIDS, metastatic cancer, solid tumor without 
metastasis, fluid and electrolyte disorders, blood loss anemia, deficiency anemias, drug 
abuse, psychoses, and depression were associated with significantly higher incidence 
rates of ED visits (p<0.017 each).  Of note, patients with fluid and electrolyte disorders 
were associated with 99% (70-133%) more ED visits, patients with deficiency anemias 
were associated with 59% (33-90%) more ED visits, and patients with drug abuse were 
associated with 81% (49-120%) more ED visits.  The model resulted in a Wald χ2(62) = 
2987.43, p<0.001, log pseudolikelihood = -27400.19. 
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Table 27: Negative Binomial Regression Analysis, ACEI or ARB versus Neither, for 
Variables Predicting ED Visits (N=55,530 person-years; N=34,060 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 1.16 1.04 <0.001 1.07 1.25
ARBa 1.18 1.10 0.08 0.98 1.41
Time (t+1)b 0.79 1.06 <0.001 0.70 0.88
Time (t+2)b 0.79 1.07 <0.01 0.68 0.90
Time (t+3)b 0.66 1.11 <0.001 0.54 0.82
Time (t+4)b 0.41 1.55 0.04 0.17 0.97
ACEI*time (t+1)c 0.99 1.08 0.89 0.85 1.15
ACEI*time (t+2)c 0.93 1.10 0.43 0.77 1.12
ACEI*time (t+3)c 0.95 1.16 0.74 0.72 1.27
ACEI*time (t+4)c 0.67 2.01 0.56 0.17 2.63
ARB*time (t+1)d 0.99 1.17 0.34 0.63 1.17
ARB*time (t+2)d 1.04 1.20 0.83 0.73 1.48
ARB*time (t+3)d 1.28 1.33 0.38 0.74 2.22
ARB*time (t+4)d 0.00 2.03 <0.001 0.00 0.00
Age 0.97 1.00 <0.001 0.96 0.97
Annual income 
$6,000-17,999e 1.46 1.05 <0.001 1.33 1.61
Annual income 
$18,000-34,999e 1.20 1.05 <0.001 1.09 1.32
Annual income 
≥$35,000e 0.66 1.06 <0.001 0.59 0.73
Income missinge 0.50 1.14 <0.001 0.39 0.65
Urban/suburbanf 1.48 1.04 <0.001 1.37 1.60
Never smokerg 0.75 1.04 <0.001 0.69 0.81
Ever smokerg 1.30 1.10 <0.01 1.09 1.56
Baseline 
microalbuminuriah 0.99 1.06 0.86 0.88 1.11
Microalbuminuria in 
follow-upi 0.89 1.05 0.02 0.81 0.98
Macroalbuminuria in 
follow-upi 0.99 1.07 0.90 0.87 1.13
HbA1c 1.04 1.01 <0.01 1.01 1.06
LDL 1.00 1.00 0.30 1.00 1.00
Triglycerides 1.00 1.00 0.13 1.00 1.00
History of MIj 1.17 1.10 0.08 0.98 1.40
History of strokek 1.28 1.15 0.08 0.97 1.70
Family history of 
CVDl 0.97 1.21 0.89 0.67 1.42
CHFm 1.37 1.08 <0.001 1.18 1.58
Cardiac arrhythmiasn 1.35 1.10 <0.01 1.13 1.61
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Table 27 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Valvular diseaseo 1.21 1.22 0.34 0.82 1.80
Pulmonary 
circulation disordersp 1.93 1.47 0.09 0.91 4.08
Peripheral vascular 
disordersq 1.38 1.07 <0.001 1.21 1.58
Hypertensionr 0.89 1.04 <0.01 0.83 0.96
Paralysiss 2.17 1.26 <0.01 1.38 3.41
Other neurological 
disorderst 1.96 1.18 <0.001 1.43 2.70
Chronic pulmonary 
diseaseu 1.52 1.06 <0.001 1.37 1.69
Hypothyroidismv 0.92 1.09 0.33 0.79 1.08
Diabetes 
complicatedw 1.27 1.04 <0.001 1.16 1.38
Liver diseasex 1.62 1.11 <0.001 1.31 1.99
Peptic ulcer diseasey 0.86 1.21 0.43 0.60 1.25
AIDSz 1.93 1.31 0.01 1.14 3.27
Lymphomaaa 1.90 1.32 0.02 1.10 3.26
Metastatic cancerbb 2.08 1.27 <0.01 1.30 3.33
Solid tumor without 
metastasiscc 1.34 1.07 <0.001 1.16 1.54
Rheumatoid arthritis / 
collagen vascular 
diseasesdd 1.31 1.18 0.11 0.94 1.82
Coagulopathyee 1.30 1.16 0.08 0.97 1.74
Obesityff 1.00 1.05 0.93 0.91 1.09
Weight lossgg 2.97 1.60 0.02 1.18 7.49
Fluid and electrolyte 
disordershh 1.99 1.09 <0.001 1.70 2.33
Blood loss anemiaii 2.94 1.34 <0.001 1.65 5.22
Deficiency anemiasjj 1.59 1.10 <0.001 1.33 1.90
Alcohol abusekk 1.21 1.08 0.02 1.03 1.42
Drug abusell 1.81 1.10 <0.001 1.49 2.20
Psychosesmm 1.42 1.08 <0.001 1.24 1.64
Depressionnn 1.20 1.06 <0.01 1.08 1.33
Cohort 2004oo 0.89 1.08 0.11 0.77 1.03
Cohort 2005oo 0.85 1.08 0.03 0.73 0.98
Cohort 2006oo 0.94 1.08 0.39 0.81 1.09
  
/lnalpha 1.63 0.03 1.58 1.69
alpha 5.11 0.15 4.83 5.40
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Wald χ2(62) = 2987.43, p<0.001, log pseudolikelihood = -27400.19 
a Reference category = neither, b Reference category = time (t),  c Reference category 
=ACEI* time (t), d Reference category = ARB*time (t), e Reference category = Annual 
income <$6,000, f Reference category = rural, g Reference category = Current smoker, h 
Reference category = Baseline macroalbuminuria, iReference category = 
Normoalbuminuria in follow-up, j Reference category = No history of MI, k Reference 
category = No history of stroke, l Reference category = No family history of CVD, m 
Reference category = No CHF, n Reference category = No cardiac arrhythmias, o 
Reference category = No valvular disease, p Reference category = No pulmonary 
circulation disorders, q Reference category = No peripheral vascular disorders, r  
Reference category = Normotension, s Reference category = No paralysis, t Reference 
category = No other neurological disorders, u Reference category = No chronic pulmonary 
disease, v Reference category = No hypothyroidism, w Reference category = No diabetes 
complicated, x Reference category = No liver disease, y Reference category = No peptic 
ulcer disease, z Reference category = No AIDS, aa Reference category = No Lymphoma bb 
Reference category = No metastatic cancer, cc Reference category = No solid tumor 
without metastisis, dd Reference category = No rheumatoid arthritis/collagen vascular 
diseases, ee Reference category = No coagulopathy, ff  Reference category = No obesity, gg 
Reference category = No weight loss, hh Reference category = No fluid and electrolyte 
disorders, ii Reference category = No blood loss anemia, jj Reference category = No 
deficiency anemias, kk Reference category = No alcohol abuse, ll Reference category = No 
drug abuse, mm Reference category = No psychoses, nn Reference category = No 
depression, oo Reference category = Cohort 2003 
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 The negative binomial regression for variables predicting hospitalization on the 
next page (Table 28) found times (t+1), (t+2), (t+3), and (t+4), the interaction between 
ACEI monotherapy and time (t+4), the interaction between ARB monotherapy and time 
(t+4), annual income ≥$35,000, income missing, never smoker, LDL, and hypertension 
were associated with lower incidence rates of hospitalization (p<0.017 each).  ACEI 
monotherapy, annual income $6,000-17,999, annual income $18,000-34,999, ever 
smoker, HbA1c, history of MI, history of stroke, family history of CVD, CHF, peripheral 
vascular disorders, paralysis, other neurological disorders, chronic pulmonary disease, 
diabetes complicated, liver disease, metastatic cancer, solid tumor without metastasis, 
coagulopathy, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency 
anemias, alcohol abuse, drug abuse, psychoses, and depression were associated with 
higher incidence rates of hospitalization (p<0.017 each).  Noteworthy conditions are 
peripheral vascular disorders (IRR=1.72, (1.52-1.95)), coagulopathy (IRR=2.20, (1.64-
2.96)), fluid and electrolyte disorders (IRR=2.97, (2.57-3.43)), and deficiency anemias 
(IRR=1.99, (1.69-2.34)).  The model resulted in a Wald χ2(62) = 7101.79, p<0.001, log 
pseudolikelihood = -21164.46. 
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Table 28: Negative Binomial Regression Analysis, ACEI or ARB versus Neither, for 
Variables Predicting Hospitalizations (N=55,530 person-years; N=34,060 patients) 
    
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 1.19 0.05 <0.001 1.08 1.30
ARBa 1.22 0.12 0.05 1.00 1.48
Time (t+1)b 0.77 0.06 <0.001 0.67 0.89
Time (t+2)b 0.79 0.06 <0.01 0.67 0.92
Time (t+3)b 0.59 0.07 <0.001 0.47 0.75
Time (t+4)b 0.11 0.06 <0.001 0.04 0.33
ACEI*time (t+1)c 1.11 0.10 0.25 0.93 1.33
ACEI*time (t+2)c 0.91 0.10 0.38 0.74 1.12
ACEI*time (t+3)c 1.05 0.18 0.77 0.75 1.47
ACEI*time (t+4)c 0.00 0.00 <0.001 0.00 0.00
ARB*time (t+1)d 0.97 0.17 0.86 0.68 1.37
ARB*time (t+2)d 0.86 0.19 0.48 0.55 1.32
ARB*time (t+3)d 0.92 0.32 0.81 0.46 1.83
ARB*time (t+4)d 0.00 0.00 <0.001 0.00 0.00
Age 0.98 0.00 <0.001 0.97 0.98
Annual income 
$6,000-17,999e 1.58 0.08 <0.001 1.43 1.74
Annual income 
$18,000-34,999e 1.39 0.08 <0.001 1.25 1.55
Annual income 
≥$35,000e 0.74 0.04 <0.001 0.65 0.83
Income missinge 0.53 0.08 <0.001 0.40 0.71
Urban/suburbanf 1.04 0.05 0.35 0.96 1.13
Never smokerg 0.56 0.03 <0.001 0.51 0.61
Ever smokerg 1.49 0.13 <0.001 1.24 1.77
Baseline 
microalbuminuriah 0.96 0.06 0.58 0.85 1.10
Microalbuminuria in 
follow-upi 0.92 0.06 0.16 0.81 1.04
Macroalbuminuria in 
follow-upi 1.05 0.09 0.58 0.89 1.23
HbA1c 1.02 0.01 <0.01 1.01 1.04
LDL 1.00 0.00 <0.001 1.00 1.00
Triglycerides 1.00 0.00 0.09 1.00 1.00
History of MIj 1.61 0.15 <0.001 1.35 1.94
History of strokek 1.75 0.23 <0.001 1.36 2.25
Family history of 
CVDl 1.67 0.29 <0.01 1.18 2.35
CHFm 1.70 0.12 <0.001 1.48 1.95
Cardiac arrhythmiasn 1.15 0.11 0.16 0.95 1.39
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Table 28 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Valvular diseaseo 0.89 0.22 0.65 0.54 1.46
Pulmonary 
circulation disordersp 1.24 0.38 0.47 0.69 2.25
Peripheral vascular 
disordersq 1.72 0.11 <0.001 1.52 1.95
Hypertensionr 0.81 0.03 <0.001 0.74 0.88
Paralysiss 2.95 0.55 <0.001 2.04 4.25
Other neurological 
disorderst 2.42 0.50 <0.001 1.61 3.63
Chronic pulmonary 
diseaseu 1.42 0.08 <0.001 1.27 1.57
Hypothyroidismv 1.03 0.09 0.72 0.87 1.22
Diabetes 
complicatedw 1.53 0.08 <0.001 1.39 1.68
Liver diseasex 1.80 0.19 <0.001 1.47 2.21
Peptic ulcer diseasey 1.01 0.18 0.95 0.71 1.43
AIDSz 1.61 0.48 0.11 0.90 2.88
Lymphomaaa 1.71 0.42 0.03 1.05 2.78
Metastatic cancerbb 3.79 1.13 <0.001 2.12 6.78
Solid tumor without 
metastasiscc 1.42 0.10 <0.001 1.24 1.63
Rheumatoid arthritis / 
collagen vascular 
diseasesdd 1.47 0.29 0.05 1.00 2.15
Coagulopathyee 2.20 0.33 <0.001 1.64 2.96
Obesityff 0.96 0.05 0.42 0.87 1.06
Weight lossgg 5.62 2.53 <0.001 2.33 13.59
Fluid and electrolyte 
disordershh 2.97 0.22 <0.001 2.57 3.43
Blood loss anemiaii 2.44 0.76 <0.01 1.32 4.50
Deficiency anemiasjj 1.99 0.17 <0.001 1.69 2.34
Alcohol abusekk 1.59 0.13 <0.001 1.35 1.87
Drug abusell 2.22 0.24 <0.001 1.79 2.75
Psychosesmm 1.50 0.11 <0.001 1.31 1.72
Depressionnn 1.30 0.07 <0.001 1.17 1.44
Cohort 2004oo 1.06 0.09 0.53 0.89 1.26
Cohort 2005oo 0.95 0.09 0.54 0.79 1.13
Cohort 2006oo 0.96 0.09 0.69 0.81 1.15
     
/lnalpha 1.66 0.04 1.59 1.73
alpha 5.28 0.19 4.91 5.67
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Waldχ2(62) = 7101.79, p<0.001, log pseudolikelihood = -21164.46  
 
a Reference category = neither, b Reference category = time (t),  c Reference category 
=ACEI* time (t), d Reference category = ARB*time (t), e Reference category = Annual 
income <$6,000, f Reference category = rural, g Reference category = Current smoker, h 
Reference category = Baseline macroalbuminuria, iReference category = 
Normoalbuminuria in follow-up, j Reference category = No history of MI, k Reference 
category = No history of stroke, l Reference category = No family history of CVD, m 
Reference category = No CHF, n Reference category = No cardiac arrhythmias, o 
Reference category = No valvular disease, p Reference category = No pulmonary 
circulation disorders, q Reference category = No peripheral vascular disorders, r  
Reference category = Normotension, s Reference category = No paralysis, t Reference 
category = No other neurological disorders, u Reference category = No chronic pulmonary 
disease, v Reference category = No hypothyroidism, w Reference category = No diabetes 
complicated, x Reference category = No liver disease, y Reference category = No peptic 
ulcer disease, z Reference category = No AIDS, aa Reference category = No Lymphoma bb 
Reference category = No metastatic cancer, cc Reference category = No solid tumor 
without metastisis, dd Reference category = No rheumatoid arthritis/collagen vascular 
diseases, ee Reference category = No coagulopathy, ff  Reference category = No obesity, gg 
Reference category = No weight loss, hh Reference category = No fluid and electrolyte 
disorders, ii Reference category = No blood loss anemia, jj Reference category = No 
deficiency anemias, kk Reference category = No alcohol abuse, ll Reference category = No 
drug abuse, mm Reference category = No psychoses, nn Reference category = No 
depression, oo Reference category = Cohort 2003 
 
 
 
 
 
 
 
 
 
 
  180
ACEI Monotherapy versus ARB Monotherapy 
 
The next section shows results of ACEI monotherapy compared to ARB 
monotherapy, a subgroup analysis of the overall sample.  As such, patients receiving 
neither therapy were excluded from the following analyses.  Table 29 displays the results 
of the logistic regression of ACEI monotherapy’s effect, compared to ARB monotherapy, 
on the development of ESRD.  Several patient characteristics were simultaneously 
entered in the model to control for their effects. 
The majority of diagnostic tests are not available because it is assumed that robust 
errors take care of problems related to leverage, influence, large residuals, normality, and 
heteroscedasticity.  The diagnostic tests for logistic regression are Pregibon’s Link Test 
and Hosmer and Lemeshow goodness-of-fit.  If each has a non-significant p-value it 
indicates a good model.  Pregibon’s Link Test tests for model misspecification.  A 
significant Pregibon’s Link Test indicates that there is at least one more predictor that 
would significantly contribute to the model.  This is usually an interaction variable.  The 
approach is to iteratively add interaction variables, keeping those that are significant and 
contribute to a higher p-value of the Pregibon’s Link Test.  Hosmer and Lemeshow is a 
Pearson chi-square derived from the observed and expected frequency contingency table; 
the closer the predicted and observed values the better the fit.  A non-significant p-value 
means that the predicted and observed values do not significantly differ.  In this model, 
the Pregibon’s Link Test was nonsignificant (p=0.88).  Similarly, the Hosmer and 
Lemeshow goodness-of-fit was nonsignificant (p=0.55; χ²(8) = 6.85). 
Time (t+4), valvular disease, pulmonary circulation disorders, other neurological 
disorders, peptic ulcer disease, AIDS, lymphoma, metastatic cancer, rheumatoid 
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arthritis/collagen vascular diseases, coagulopathy, weight loss, and blood loss anemia 
were all dropped because they predicted failure perfectly, meaning that all of their 
observations had a value of zero for ESRD (i.e., none of the patients with these 
characteristics developed ESRD).  The interaction between ACEI and time (t+4) was 
dropped due to multicollinearity. 
 LDL was associated with lower odds of ESRD development; time (t+2), diabetes 
complicated, liver disease, fluid and electrolyte disorders, and deficiency anemias were 
associated with higher odds of ESRD development (p<0.05 each).  Patients with diabetes 
complicated had 160% (51-347%) higher odds of developing ESRD.  The model resulted 
in Wald χ² (38) = 366.39, Log pseudolikelihood = -462.91, p<0.001 and explained 
15.76% of the variation in ESRD development.  The model also had a 0.83 probability of 
correctly classifying a randomly selected pair of cases from those who did and those who 
did not develop ESRD. 
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Table 29:  Logistic Regression Analysis, ACEI versus ARB, for Variables Predicting 
ESRD (N = 38,655 person-years; N= 18,451 patients) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 0.82 0.62 0.79 0.19 3.60
Time (t+1)b 3.47 2.45 0.08 0.87 13.87
Time (t+2)b 5.31 4.11 0.03 1.16 24.19
Time (t+3)b 1.94 1.61 0.43 0.38 9.90
ACEI*time (t+1)c 0.23 0.19 0.08 0.05 1.16
ACEI*time (t+2)c 0.24 0.22 0.11 0.04 1.38
ACEI*time (t+3)c 0.86 0.91 0.89 0.11 6.79
Age 0.99 0.02 0.32 0.96 1.01
Annual income 
$6,000-17,999d 1.42 0.51 0.32 0.71 2.85
Annual income 
$18,000-34,999d  1.47 0.51 0.27 0.74 2.90
Annual income 
≥$35,000d 0.70 0.31 0.42 0.29 1.69
Income missingd 0.47 0.53 0.50 0.05 4.27
Urban/suburbane 0.83 0.23 0.50 0.47 1.44
Never smokerf 0.47 1.24 0.20 0.15 1.47
Ever smokerf 0.80 0.37 0.43 0.45 1.41
HbA1c 0.91 0.09 0.30 0.75 1.09
LDL 0.99 0.00 <0.01 0.98 1.00
Triglycerides 1.00 0.00 0.82 1.00 1.00
CHFg 1.79 0.69 0.13 0.84 3.83
Cardiac arrhythmiash 1.48 0.88 0.51 0.46 4.72
Peripheral vascular 
disordersi 1.79 0.80 0.19 0.75 4.28
Hypertensionj 0.61 0.18 0.09 0.34 1.09
Paralysisk 4.91 4.93 0.11 0.69 35.16
Chronic pulmonary 
diseasel 0.78 0.33 0.55 0.34 1.77
Hypothyroidismm  0.80 0.45 0.69 0.27 2.38
Diabetes complicatedn 2.60 0.72 <0.01 1.51 4.47
Liver diseaseo 3.68 2.06 0.02 1.23 11.02
Solid tumor without 
metastasisp 1.59 0.68 0.28 0.69 3.69
Obesityq 0.49 0.21 0.09 0.22 1.13
Fluid and electrolyte 
disordersr 6.14 2.20 <0.001 3.04 12.41
Deficiency anemiass 5.79 2.21 <0.001 2.74 12.23
Alcohol abuset 1.43 0.79 0.52 0.48 4.22
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Table 29 (cont.) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Drug abuseu 0.72 0.78 0.76 0.09 6.03
Psychosesv 0.81 0.46 0.71 0.27 2.43
Depressionw 1.57 0.53 0.18 0.82 3.02
Cohort 2004x 0.57 0.26 0.23 0.23 1.41
Cohort 2005x 0.69 0.33 0.44 0.27 1.77
Cohort 2006x 0.44 0.24 0.14 0.15 1.30
 
McFadden’s Pseudo R2 = 0.16 
Wald χ² (38) = 366.39, Log pseudolikelihood = -462.91, p<0.001 
Area under the ROC curve = 0.83 
 
a Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*Time t, d Reference category = Annual income <$6000, e Reference category = 
rural , f Reference category = Current smoker, g Reference category = No CHF, h 
Reference category = No cardiac arrhythmias, i Reference category = No peripheral 
vascular disorders, j Reference category = Normotension, k Reference category = No 
paralysis, l Reference category = No chronic pulmonary disease, m Reference category = 
No hypothyroidism, n Reference category = No diabetes complicated, o Reference 
category = No liver disease, p Reference category = No solid tumor without metastasis, q 
Reference category = No obesity, r Reference category = No Fluid and electrolyte 
disorders, s Reference category = No deficiency anemias, t Reference category = No 
alcohol abuse, u Reference category = No drug abuse, v Reference category = No 
psychoses, w Reference category = No depression, x Reference category = Cohort 2003 
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The original model variables for logistic regression resulted in a significant 
Pregibon’s Link Test (p=0.005).  Age squared, income divided by 100,000, the 
interaction between HbA1c and LDL, the interaction between HbA1c and triglycerides, 
the interaction between LDL and triglycerides, the interaction between albuminuria and 
HbA1c, the interaction between albuminuria and triglycerides, the interaction between 
albuminuria and LDL, the interaction between age and triglycerides, the interaction 
between age and LDL, and the interaction between age and HbA1c were iteratively added 
to the model in an effort to have the model without a significant Pregibon’s Link Test.  
Of the variables sequentially added, only those that had a significant p-value when added 
to the model and those that resulted in a larger p-value for Pregibon’s Link Test were 
actually retained.  Since it still resulted in a significant Pregibon’s Link Test, indicating 
model misspecification, the Box-Tidwell transformation was attempted next.  Box-
Tidwell uses a maximum likelihood estimate to identify variable transformations to find 
better model fit.  As none of the transformations would be interpretable, this approach 
was discarded.  The final model is described on the next page. As previously mentioned, 
it still resulted in a significant Pregibon’s Link Test (p=0.01), but did have a 
nonsignificant Hosmer and Lemeshow (p = 0.43; χ²(8) = 8.09). A nonsignificant Hosmer 
and Lemeshow indicates lack of a systematic pattern of bias.   
Income missing was dropped due to multicollinearity.  Age squared, never 
smoker, and ever smoker were associated with lower odds of IVDE occurrence; age, 
history of MI, history of stroke, CHF, pulmonary circulation disorders, peripheral 
vascular disorders, chronic pulmonary disease, fluid and electrolyte disorders, and 
deficiency anemias were associated with higher odds of IVDE occurrence (p<0.05 each).  
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In particular, patients who never smoked were associated with 64% (50-74%) lower odds 
of suffering an IVDE, patients with history of stroke were associated with 219% (117-
368%) higher odds of an IVDE occurrence, patients with peripheral vascular disorders 
were associated with 197% (139-270%) higher odds of having an IVDE, and patients 
with fluid and electrolyte disorders were associated with 97% (31-197%) higher odds of 
acquiring an IVDE.  The model resulted in a Wald χ²(61) = 421.73, Log pseudolikelihood 
= -4028.29, p<0.001 and explained 5.88% of the variation in IVDE occurrence.  It also 
had a 0.68 probability of correctly classifying a randomly selected pair of cases from 
those who did and did not suffer an IVDE. 
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Table 30:  Logistic Regression Analysis, ACEI versus ARB, for Variables Predicting 
IVDE (N = 29,400 person-years; N = 17,753 patients) 
  
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 1.12 0.18 0.48 0.82 1.53
Time (t+1) b 1.07 0.19 0.72 0.75 1.52
Time (t+2) b 0.93 0.21 0.75 0.61 1.44
Time (t+3) b 1.00 0.26 0.99 0.61 1.65
Time (t+4) b 1.60 0.96 0.43 0.50 5.18
ACEI*time (t+1) c 0.76 0.16 0.19 0.51 1.14
ACEI*time (t+2) c 1.20 0.30 0.45 0.75 1.94
ACEI*time (t+3) c 0.89 0.28 0.71 0.48 1.66
Age 1.19 0.06 <0.001 1.08 1.31
Age squared 1.00 0.00 <0.01 1.00 1.00
Annual income $6,000-
17,999d 1.03 0.12 0.83 0.81 1.29
Annual income 
$18,000-34,999d 1.21 0.14 0.10 0.97 1.53
Annual income 
≥$35,000d 1.14 0.17 0.40 0.84 1.53
Annual 
income/100,000 0.84 0.08 0.08 0.69 1.02
Urban/suburbane 1.01 0.09 0.88 0.86 1.20
Never smokerf 0.36 0.46 <0.001 0.26 0.50
Ever smokerf 0.59 0.16 <0.001 0.49 0.70
Baseline 
microalbuminuriag 0.99 0.12 0.95 0.79 1.25
Microalbuminuria in 
follow-uph 0.61 0.18 0.09 0.35 1.07
Macroalbuminuria in 
follow-uph 0.51 0.29 0.23 0.17 1.53
HbA1c 0.87 0.07 0.09 0.74 1.02
Albuminuria*HbA1c 1.06 0.04 0.13 0.98 1.14
LDL 1.00 0.01 0.71 0.98 1.02
HbA1c*LDL 1.00 0.00 0.59 1.00 1.00
Triglycerides 1.00 0.00 0.41 1.00 1.00
LDL* triglycerides 1.00 0.00 0.06 1.00 1.00
Albuminuria* 
triglycerides 1.00 0.00 0.38 1.00 1.00
Age*LDL 1.00 0.00 0.22 1.00 1.00
History of MIi 2.30 0.38 <0.001 1.67 3.17
History of strokej 3.19 0.63 <0.001 2.17 4.68
Family history of 
CVDk 1.25 0.41 0.50 0.66 2.37
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Table 30 (cont.) 
 
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
CHFl 1.42 0.22 0.02 1.05 1.91
Cardiac arrhythmiasm 1.25 0.21 0.18 0.91 1.72
Valvular diseasen 1.56 0.65 0.29 0.69 3.52
Pulmonary circulation 
disorderso 3.57 1.89 0.02 1.26 10.07
Peripheral vascular 
disordersp 2.97 0.33 <0.001 2.39 3.70
Hypertensionq 1.03 0.10 0.80 0.84 1.25
Paralysisr 0.65 0.51 0.58 0.14 2.98
Other neurological 
disorderss 1.16 0.48 0.72 0.51 2.62
Chronic pulmonary 
diseaset 1.39 0.16 <0.01 1.11 1.74
Hypothyroidismu 1.04 0.21 0.86 0.70 1.53
Diabetes complicatedv 0.95 0.10 0.60 0.77 1.17
Liver diseasew 0.86 0.27 0.64 0.47 1.59
Peptic ulcer diseasex 0.65 0.29 0.33 0.27 1.55
AIDSy 2.28 2.17 0.39 0.35 14.77
Lymphomaz 0.82 0.62 0.79 0.19 3.58
Metastatic canceraa 0.70 0.79 0.75 0.08 6.46
Solid tumor without 
metastasisbb 0.96 0.15 0.79 0.71 1.30
Rheumatoid 
arthritis/collagen 
vascular diseasescc 1.05 0.40 0.90 0.50 2.21
Coagulopathydd 1.00 0.39 1.00 0.47 2.14
Obesityee 1.12 0.11 0.24 0.92 1.37
Fluid and electrolyte 
disordersff 1.97 0.41 <0.01 1.31 2.97
Blood loss anemiagg 1.80 1.31 0.42 0.43 7.51
Deficiency anemiashh 1.55 0.28 0.02 1.09 2.21
Alcohol abuseii 1.03 0.22 0.90 0.67 1.57
Drug abusejj 1.22 0.43 0.57 0.61 2.43
Psychoseskk 0.86 0.18 0.47 0.58 1.29
Depressionll 1.20 0.15 0.15 0.94 1.53
Cohort 2004mm 0.88 0.16 0.49 0.62 1.26
Cohort 2005mm 0.84 0.16 0.34 0.58 1.20
Cohort 2006mm 0.88 0.17 0.51 0.61 1.28
 
McFadden’s Pseudo R2 = 0.06 
Wald χ²(61) = 421.73, Log pseudolikelihood = -4028.29, p<0.001 
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Area under the ROC curve = 0.68 
 
a  Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*time t, d Reference category = Annual income <$6000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, h Reference category = Normoalbuminuria in follow-up, i Reference 
category No history of MI, j Reference category = No history of stroke, k Reference 
category = No family history of CVD, l Reference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t Reference 
category = No chronic pulmonary disease,  u Reference category = No hypothyroidism, v 
Reference category = No diabetes complicated, w Reference category = No liver disease, x 
Reference category = No peptic ulcer disease, y Reference category = No AIDS, z 
Reference category = No lymphoma, aa Reference category = No metastatic cancer, bb 
Reference category = No solid tumor without metastasis, cc Reference category = No 
rheumatoid arthritis/collagen vascular diseases, dd Reference category = No coagulopathy, 
ee Reference category = No obesity, ff Reference category = No fluid and electrolyte 
disorders, gg Reference category = No blood loss anemias, hh Reference category = No 
deficiency anemias, ii Reference category = No alcohol abuse, jj Reference category = No 
drug abuse, kk Reference category = No psychoses, ll Reference category = No depression, 
mm Reference category = Cohort 2003 
 
 
 
 
 
 
  189
Table 31 displays the results of the logistic regression of ACEI monotherapy’s 
effect, compared to ARB monotherapy on all-cause mortality.  Several patient 
characteristics were simultaneously entered in the model to quantify their effects. 
Again, because we have robust standard errors, there are limited available 
diagnostic tests.  The model resulted in a nonsignificant Pregibon’s Link Test (p=0.38).  
It also had a nonsignificant Hosmer and Lemeshow goodness-of-fit (p=0.08, χ²(8) =  
13.93). 
Never smoker, family history of CVD, valvular disease, pulmonary circulation 
disorders, paralysis, peptic ulcer disease, AIDS, metastatic cancer, rheumatoid 
arthritis/collagen vascular diseases, weight loss, and blood loss anemia were dropped 
from the model because observations with each of these characteristics did not experience 
all-cause mortality.  The interaction between ACEI and time (t+4) was dropped due to 
multicollinearity.  The interactions between ACEI monotherapy and times (t+1) and (t+2) 
were associated with lower odds of all-cause mortality (p<0.05 each).  Higher odds of all-
cause mortality were associated with times (t+1), (t+2), and (t+3), age, annual income 
$6,000-17,999, history of MI, CHF, peripheral vascular disorders, chronic pulmonary 
disease, lymphoma, and cohorts 2004, 2005, and 2006 (p<0.05 each). (Note the large 
odds ratios and robust standard errors for cohorts 2004, 2005, and 2006, a sort of warning 
to be heeded when interpreting results of a logistic regression.)   Worth mentioning, 
patients with peripheral vascular disorders had OR=2.15, (1.27-3.63) whereas patients 
with chronic pulmonary disease had OR=1.95, (1.22-3.11).  Because the Wald test for 
time (t+4) cannot be reported as it is dependent on the (robust) standard error for that 
variable and the Wald statistic for the model is dependent upon the Wald test for the 
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variable, there is no Wald statistic (or associated p-value) for the model.  However, the 
model did explain 8.76% of the variance in all-cause mortality. It also had a 0.77 
probability of correctly classifying a randomly selected pair of cases from those who did 
and did not die. 
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Table 31: Logistic Regression Analysis, ACEI versus ARB, for Variables Predicting All-
cause Mortality (N= 28,386 person-years; N=17,121 patients) 
  
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 1.50 0.92 0.51 0.45 4.99
Time (t+1) b 4.77 2.99 0.01 1.39 16.29
Time (t+2) b 7.30 4.68 <0.01 2.08 25.66
Time (t+3) b 8.38 6.06 <0.01 2.03 34.58
Time (t+4) b 7.35 x 107 . . . .
ACEI*time (t+1) c 0.22 0.16 0.03 0.06 0.88
ACEI*time (t+2) c 0.22 0.16 0.04 0.05 0.91
ACEI*time (t+3) c 0.41 0.34 0.28 0.08 2.10
Age  1.03 0.01 0.02 1.00 1.05
Annual income 
$6,000-17,999d 1.91 0.60 0.04 1.03 3.53
Annual income 
$18,000-34,999d 1.82 0.57 0.05 0.99 3.34
Annual income 
≥$35,000d 1.66 0.53 0.12 0.88 3.10
Income missingd 0.77 0.58 0.73 0.17 3.40
Urban/suburbane 1.29 0.27 0.22 0.85 1.95
Ever smokerf 0.89 0.29 0.65 0.54 1.47
Baseline 
microalbuminuriag 0.94 0.32 0.82 0.52 1.67
Microalbuminuria in 
follow-uph 1.22 0.33 0.46 0.72 2.06
Macroalbuminuria in 
follow-uph 1.27 0.48 0.53 0.60 2.65
HbA1c 1.00 0.01 0.76 0.97 1.02
LDL 1.00 0.00 0.98 0.99 1.01
Triglycerides  1.00 0.00 0.68 1.00 1.00
History of MIi 2.37 0.92 0.03 1.11 5.06
History of strokej 1.88 0.95 0.22 0.69 5.08
CHFk 2.09 0.65 0.02 1.13 3.84
Cardiac arrhythmiasl 1.78 0.54 0.06 0.98 3.23
Peripheral vascular 
disordersm 2.15 0.58 <0.01 1.27 3.63
Hypertensionn 0.67 0.14 0.06 0.44 1.02
Other neurological 
disorderso 0.95 0.97 0.96 0.13 7.01
Chronic pulmonary 
diseasep 1.95 0.47 <0.01 1.22 3.11
Hypothyroidismq  1.67 0.57 0.13 0.86 3.24
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Table 31 (cont.) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Diabetes 
complicatedr 1.03 0.26 0.90 0.63 1.69
Liver disease diseases 0.89 0.95 0.92 0.11 7.12
Lymphomat 6.52 5.19 0.02 1.37 31.02
Solid tumor without 
metastasisu 1.44 0.45 0.24 0.78 2.65
Coagulopathyv 0.61 0.61 0.62 0.09 4.30
Obesityw 1.13 0.28 0.62 0.70 1.83
Fluid and electrolyte 
disordersx 0.94 0.70 0.93 0.22 4.06
Deficiency anemiasy 0.86 0.46 0.78 0.30 2.48
Alcohol abusez 1.75 0.87 0.26 0.67 4.61
Drug abuseaa 0.73 0.76 0.76 0.10 5.56
Psychosesbb 0.81 0.44 0.70 0.28 2.34
Depressioncc 1.26 0.40 0.46 0.68 2.34
Cohort 2004dd 4.78x106 5.73x106 <0.001 4.57x105 5.01x107
Cohort 2005dd 5.89x106 6.98x106 <0.001 5.78x105 6.01x107
Cohort 2006dd 5.75x106 6.73x106 <0.001 5.79x105 5.70x107
 
McFadden’s Pseudo R2 = 0.09 
Wald χ² (and its p-value) not reported, Log pseudolikelihood = -697.75                  
Area under the ROC curve = 0.77 
 
a  Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*time t, d Reference category = Annual income <$6000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, h Reference category = Normoalbuminuria in follow-up, i Reference 
category No history of MI, j Reference category = No history of stroke, k Reference 
category = No CHF, l Reference category = No cardiac arrhythmias, m Reference category 
= No peripheral vascular disorders, n Reference category = Normotension, o Reference 
category = No other neurological disorders, p Reference category = No chronic 
pulmonary disease,  q Reference category = No hypothyroidism, r Reference category = 
No diabetes complicated, s Reference category = No liver disease, t Reference category = 
No lymphoma, u Reference category = No solid tumor without metastasis, v Reference 
category = No coagulopathy, w Reference category = No obesity, x Reference category = 
No fluid and electrolyte disorders, y Reference category = No deficiency anemias, z 
Reference category = No alcohol abuse, aa Reference category = No drug abuse, bb 
Reference category = No psychoses, cc Reference category = No depression, dd Reference 
category = Cohort 2003 
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The negative binomial regression on the next page resulted in the interaction 
between ACEI and time (t+4) being dropped due to multicollinearity.  Variables 
associated with lower incidence rates of outpatient visits were ACEI monotherapy, times 
(t+1), (t+2), (t+3), and (t+4), age, annual income ≥$35,000, income missing, never 
smoker, microalbuminuria in follow-up, LDL, and cohorts 2005 and 2006; variables 
associated with higher incidence rates of outpatient visits were the interaction between 
ACEI monotherapy and times (t+1), (t+2), and (t+3), annual income $6,000-17,999, 
annual income $18,000-34,999, urban/suburban living, ever smoker, triglycerides, history 
of stroke, CHF, cardiac arrhythmias, valvular disease, peripheral vascular disorders, 
paralysis, other neurological disorders, chronic pulmonary disease, diabetes complicated, 
liver disease, AIDS, lymphoma, metastatic cancer, solid tumor without metastasis, 
coagulopathy, obesity, fluid and electrolyte disorders, blood loss anemia, deficiency 
anemias, alcohol abuse, drug abuse, psychoses, and depression (p<0.05 each).  Closer 
inspection reveals patients with cardiac arrhythmias were associated with 45% (37-53%) 
more outpatient visits, patients with metastatic cancer were associated with 109% (60-
172%) more outpatient visits, and patients with drug abuse were associated with 54% 
(36-75%) more outpatient visits.  The model resulted in Wald χ2(56) = 4943.70, p<0.001, 
log pseudolikelihood = -106487.71. 
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Table 32: Negative Binomial Regression Analysis, ACEI versus ARB, for Variables 
Predicting Outpatient Visits (N=30,422 person-years; N=18,340 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 0.96 0.02 0.02 0.92 0.99
Time (t+1)b 0.65 0.02 <0.001 0.62 0.69
Time (t+2)b 0.64 0.03 <0.001 0.59 0.69
Time (t+3)b 0.49 0.02 <0.001 0.45 0.53
Time (t+4)b 0.20 0.02 <0.001 0.17 0.25
ACEI*time (t+1)c 1.28 0.04 <0.001 1.21 1.35
ACEI*time (t+2)c 1.25 0.05 <0.001 1.15 1.36
ACEI*time (t+3)c 1.46 0.08 <0.001 1.32 1.61
Age 0.99 0.00 <0.001 0.99 0.99
Annual income 
$6,000-17,999d 1.20 0.02 <0.001 1.16 1.24
Annual income 
$18,000-34,999d 1.14 0.02 <0.001 1.10 1.19
Annual income 
≥$35,000d 0.91 0.02 <0.001 0.88 0.94
Income missingd 0.77 0.02 <0.001 0.72 0.81
Urban/suburbane 1.18 0.02 <0.001 1.15 1.21
Never smokerf 0.88 0.01 <0.001 0.85 0.91
Ever smokerf 1.09 0.04 0.02 1.02 1.17
Baseline 
microalbuminuriag 0.99 0.02 0.56 0.95 1.03
Microalbuminuria in 
follow-uph 0.95 0.02 <0.01 0.92 0.98
Macroalbuminuria in 
follow-uph 0.97 0.02 0.22 0.93 1.02
HbA1c 1.00 0.00 0.06 1.00 1.01
LDL 1.00 0.00 <0.001 1.00 1.00
Triglycerides 1.00 0.00 0.05 1.00 1.00
History of MIi 0.99 0.03 0.65 0.92 1.05
History of strokej 1.15 0.05 <0.01 1.05 1.25
Family history of 
CVDk 1.16 0.08 0.03 1.02 1.32
CHFl 1.17 0.03 <0.001 1.12 1.23
Cardiac arrhythmiasm 1.45 0.04 <0.001 1.37 1.53
Valvular diseasen 1.31 0.09 <0.001 1.15 1.49
Pulmonary 
circulation disorderso 1.23 0.14 0.07 0.98 1.53
Peripheral vascular 
disorderp 1.18 0.03 <0.001 1.12 1.23
Hypertensionq 0.97 0.02 0.09 0.94 1.00
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Table 32 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Paralysisr 1.31 0.16 0.03 1.03 1.67
Other neurological 
disorderss 1.21 0.08 <0.01 1.06 1.38
Chronic pulmonary 
diseaset 1.11 0.02 <0.001 1.07 1.16
Hypothyroidismu 1.02 0.03 0.44 0.97 1.08
Diabetes 
complicatedv 1.20 0.02 <0.001 1.16 1.24
Liver diseasew 1.32 0.07 <0.001 1.20 1.47
Peptic ulcer diseasex 0.96 0.06 0.51 0.86 1.08
AIDSy 1.41 0.16 <0.01 1.13 1.75
Lymphomaz 1.27 0.13 0.02 1.03 1.55
Metastatic canceraa 2.09 0.28 <0.001 1.60 2.72
Solid tumor without 
metastasisbb 1.09 0.03 <0.001 1.04 1.14
Rheumatoid arthritis / 
collagen vascular 
diseasescc 1.12 0.08 0.12 0.97 1.29
Coagulopathydd 1.39 0.07 <0.001 1.26 1.54
Obesityee 1.04 0.02 0.02 1.01 1.07
Weight lossff 1.14 0.20 0.47 0.80 1.61
Fluid and electrolyte 
disordersgg 1.30 0.06 <0.001 1.20 1.42
Blood loss anemiahh 1.28 0.15 0.03 1.02 1.61
Deficiency anemiasii 1.21 0.04 <0.001 1.14 1.30
Alcohol abusejj 1.19 0.05 <0.001 1.10 1.28
Drug abusekk 1.54 0.10 <0.001 1.36 1.75
Psychosesll 1.51 0.05 <0.001 1.41 1.61
Depressionmm 1.24 0.02 <0.001 1.19 1.28
Cohort 2004nn 0.95 0.03 0.06 0.90 1.00
Cohort 2005nn 0.93 0.03 <0.01 0.88 0.98
Cohort 2006nn 0.92 0.03 <0.01 0.87 0.97
        
/lnalpha -0.91 0.01  -0.94 -0.88
        
alpha 0.40 0.01   0.39 0.41
 
Wald χ2(56) = 4943.70, p<0.001, log pseudolikelihood = -106487.71 
 
a  Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*time t, d Reference category = Annual income <$6000, e Reference category = 
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rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, h Reference category = Normoalbuminuria in follow-up, i Reference 
category No history of MI, j Reference category = No history of stroke, k Reference 
category = No family history of CVD, l Reference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t Reference 
category = No chronic pulmonary disease,  u Reference category = No hypothyroidism, v 
Reference category = No diabetes complicated, w Reference category = No liver disease, x 
Reference category = No peptic ulcer disease, y Reference category = No AIDS, z 
Reference category = No lymphoma, aa Reference category = No metastatic cancer, bb 
Reference category = No solid tumor without metastasis, cc Reference category = No 
rheumatoid arthritis/collagen vascular diseases, dd Reference category = No coagulopathy, 
ee Reference category = No obesity, ff Reference category = No weight loss, gg Reference 
category = No fluid and electrolyte disorders, hh Reference category = No blood loss 
anemias, ii Reference category = No deficiency anemias, jj Reference category = No 
alcohol abuse, kk Reference category = No drug abuse, ll Reference category = No 
psychoses, mm Reference category = No depression, nn Reference category = Cohort 2003 
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For the negative binomial regression model predicting ED visits (Table 33), times 
(t+1), (t+3), and (t+4), age, annual income ≥$35,000, income missing, never smoker, and 
hypertension were associated with lower incidence rates of ED visits (p<0.05 each).  
Annual income $6,000-17,999, urban/suburban living, ever smoker, history of MI, CHF, 
cardiac arrhythmias, peripheral vascular disorders, paralysis, other neurological disorders, 
chronic pulmonary disease, diabetes complicated, liver disease, metastatic cancer, solid 
tumor without metastasis, weight loss, fluid and electrolyte disorders, blood loss anemia, 
deficiency anemias, drug abuse, psychoses, and depression were associated with higher 
incidence rates of ED visits (p<0.05 each).  More specifically, patients with annual 
income ≥$35,000 were associated with 35% (26-44%) fewer ED visits whereas patients 
with CHF were associated with 60% (34-91%) more ED visits, patients with chronic 
pulmonary disease were associated with 55% (35-78%) more ED visits, and patients with 
fluid and electrolyte disorders were associated with 98% (58-148%) more ED visits.  The 
negative binomial regression for ED visits resulted in a Wald χ2(56) = 1191.52, p<0.001, 
log pseudolikelihood = -15420.78. 
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Table 33: Negative Binomial Regression Analysis, ACEI versus ARB, for Variables 
Predicting ED Visits (N=30,422 person-years; N=18,340 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 0.99 0.09 0.88 0.83 1.18
Time (t+1)b 0.67 0.08 <0.001 0.53 0.84
Time (t+2)b 0.82 0.10 0.09 0.64 1.03
Time (t+3)b 0.59 0.10 <0.01 0.43 0.80
Time (t+4)b 0.06 0.06 <0.01 0.01 0.48
ACEI*time (t+1)c 1.15 0.15 0.26 0.90 1.48
ACEI*time (t+2)c 0.89 0.12 0.39 0.68 1.16
ACEI*time (t+3)c 1.07 0.22 0.73 0.72 1.60
Age 0.97 0.00 <0.001 0.96 0.97
Annual income 
$6,000-17,999d 1.40 0.09 <0.001 1.24 1.59
Annual income 
$18,000-34,999d 1.11 0.07 0.12 0.97 1.25
Annual income 
≥$35,000d 0.65 0.05 <0.001 0.56 0.74
Income missingd 0.60 0.10 <0.01 0.44 0.82
Urban/suburbane 1.56 0.08 <0.001 1.41 1.72
Never smokerf 0.75 0.04 <0.001 0.68 0.83
Ever smokerf 1.36 0.16 0.01 1.07 1.72
Baseline 
microalbuminuriag 0.95 0.07 0.46 0.82 1.09
Microalbuminuria in 
follow-uph 0.96 0.06 0.53 0.85 1.09
Macroalbuminuria in 
follow-uph 1.05 0.09 0.59 0.88 1.24
HbA1c 1.02 0.01 0.10 1.00 1.03
LDL 1.00 0.00 0.64 1.00 1.00
Triglycerides 1.00 0.00 0.95 1.00 1.00
History of MIi 1.25 0.14 <0.05 1.00 1.56
History of strokej 1.27 0.19 0.12 0.94 1.69
Family history of 
CVDk 0.97 0.24 0.89 0.59 1.58
CHFl 1.60 0.15 <0.001 1.34 1.91
Cardiac arrhythmiasm 1.41 0.16 <0.01 1.13 1.75
Valvular diseasen 1.19 0.29 0.49 0.73 1.92
Pulmonary 
circulation disorderso 2.20 1.18 0.14 0.77 6.27
Peripheral vascular 
disorderp 1.31 0.11 <0.01 1.11 1.54
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Table 33 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Hypertensionq 0.88 0.05 0.02 0.79 0.98
Paralysisr 2.73 0.89 <0.01 1.44 5.19
Other neurological 
disorderss 1.65 0.39 0.03 1.04 2.63
Chronic pulmonary 
diseaset 1.55 0.11 <0.001 1.35 1.78
Hypothyroidismu 0.93 0.11 0.55 0.75 1.17
Diabetes 
complicatedv 1.27 0.07 <0.001 1.14 1.41
Liver diseasew 1.67 0.24 <0.001 1.26 2.22
Peptic ulcer diseasex 0.80 0.21 0.39 0.47 1.34
AIDSy 0.41 0.31 0.24 0.09 1.81
Lymphomaz 2.18 0.97 0.08 0.91 5.22
Metastatic canceraa 2.81 0.90 <0.01 1.51 5.26
Solid tumor without 
metastasisbb 1.38 0.14 <0.01 1.13 1.68
Rheumatoid arthritis / 
collagen vascular 
diseasescc 1.37 0.32 0.17 0.87 2.16
Coagulopathydd 1.08 0.22 0.70 0.73 1.60
Obesityee 1.00 0.05 0.98 0.90 1.11
Weight lossff 3.44 1.95 0.03 1.13 10.45
Fluid and electrolyte 
disordersgg 1.98 0.23 <0.001 1.58 2.48
Blood loss anemiahh 2.69 1.12 0.02 1.19 6.09
Deficiency anemiasii 1.47 0.17 <0.01 1.18 1.85
Alcohol abusejj 1.13 0.12 0.27 0.91 1.40
Drug abusekk 1.72 0.25 <0.001 1.30 2.27
Psychosesll 1.49 0.15 <0.001 1.23 1.81
Depressionmm 1.26 0.09 <0.01 1.10 1.44
Cohort 2004nn 0.81 0.09 0.06 0.65 1.01
Cohort 2005nn 0.80 0.09 0.05 0.64 1.00
Cohort 2006nn 0.85 0.10 0.16 0.68 1.07
       
/lnalpha 1.58 0.04  1.51 1.65
       
alpha 4.84 0.17   4.51 5.20
 
Wald χ2(56) = 1191.52, p<0.001, log pseudolikelihood = -15420.78 
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a  Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*time t, d Reference category = Annual income <$6000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, h Reference category = Normoalbuminuria in follow-up, i Reference 
category No history of MI, j Reference category = No history of stroke, k Reference 
category = No family history of CVD, l Reference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t Reference 
category = No chronic pulmonary disease,  u Reference category = No hypothyroidism, v 
Reference category = No diabetes complicated, w Reference category = No liver disease, x 
Reference category = No peptic ulcer disease, y Reference category = No AIDS, z 
Reference category = No lymphoma, aa Reference category = No metastatic cancer, bb 
Reference category = No solid tumor without metastasis, cc Reference category = No 
rheumatoid arthritis/collagen vascular diseases, dd Reference category = No coagulopathy, 
ee Reference category = No obesity, ff Reference category = No weight loss, gg Reference 
category = No fluid and electrolyte disorders, hh Reference category = No blood loss 
anemias, ii Reference category = No deficiency anemias, jj Reference category = No 
alcohol abuse, kk Reference category = No drug abuse, ll Reference category = No 
psychoses, mm Reference category = No depression, nn Reference category = Cohort 2003 
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For the negative binomial regression predicting hospitalizations (Table 34), lower 
incidence rates of hospitalization were associated with times (t+1), (t+3), and (t+4), 
annual income ≥$35,000, age, income missing, never smoker, LDL, hypertension, and 
cohort 2005 (p<0.05 each).  Higher incidence rates of hospitalization were associated 
with annual income $6,000-17,999, annual income $18,000-34,999, ever smoker, HbA1c, 
history of MI, history of stroke, family history of CVD, CHF, peripheral vascular 
disorders, paralysis, other neurological disorders, chronic pulmonary disease, diabetes 
complicated, liver disease, lymphoma, solid tumor without metastasis, rheumatoid 
arthritis/collagen vascular diseases, coagulopathy, weight loss, fluid and electrolyte 
disorders, deficiency anemias, alcohol abuse, drug abuse, psychoses, and depression 
(p<0.05 each).  Of note, patients with history of MI were associated with 88% (52-133%) 
more hospitalizations, patients with CHF were associated with 71% (44-103%) more 
hospitalizations, patients with peripheral vascular disorders were associated with 70% 
(43-102%) more hospitalizations, and patients with fluid and electrolyte disorders were 
associated with 170% (121-229%) more hospitalizations.  The negative binomial resulted 
in a Wald χ2(56)=1524.66, p<0.001, log pseudolikelihood = -12080.93. 
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Table 34: Negative Binomial Regression Model, ACEI versus ARB, for Variables 
Predicting Hospitalization (N = 30,422 person years; N= 18,340 patients) 
 
 Incidence 
Rate 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 0.97 0.09 0.75 0.81 1.17 
Time (t+1)b 0.74 0.09 0.01 0.58 0.94 
Time (t+2)b 0.78 0.10 0.06 0.59 1.01 
Time (t+3)b 0.48 0.09 <0.001 0.33 0.68 
Time (t+4)b 0.15 0.08 <0.001 0.05 0.45 
ACEI*time (t+1)c 1.12 0.16 0.43 0.85 1.47 
ACEI*time (t+2)c 0.91 0.15 0.54 0.66 1.24 
ACEI*time (t+3)c 1.00 0.24 0.99 0.63 1.58 
Age 0.98 0.00 <0.001 0.97 0.98 
Annual income 
$6,000-17,999d 1.56 0.10 <0.001 1.37 1.78 
Annual income 
$18,000-34,999d 1.34 0.09 <0.001 1.17 1.53 
Annual income 
≥$35,000d 0.76 0.06 <0.001 0.66 0.89 
Income missingd 0.60 0.12 <0.01 0.41 0.88 
Urban/suburbane 1.00 0.05 0.98 0.90 1.11 
Never smokerf 0.56 0.03 <0.001 0.50 0.62 
Ever smokerf 1.52 0.18 <0.001 1.20 1.91 
Baseline 
microalbuminuriag 0.93 0.08 0.42 0.79 1.10 
Microalbuminuria 
in follow-uph 0.99 0.07 0.87 0.85 1.14 
Macroalbuminuria 
in follow-uph 1.00 0.10 0.97 0.83 1.22 
HbA1c 1.02 0.01 0.02 1.00 1.03 
LDL 1.00 0.00 <0.001 0.99 1.00 
Triglycerides 1.00 0.00 0.75 1.00 1.00 
History of MIi 1.88 0.21 <0.001 1.52 2.33 
History of strokej 1.54 0.25 <0.01 1.12 2.12 
Family history of 
CVDk 1.83 0.39 <0.01 1.21 2.78 
CHFl 1.71 0.15 <0.001 1.44 2.03 
Cardiac 
arrhythmiasm 1.28 0.17 0.05 1.00 1.65 
Valvular diseasen 1.11 0.37 0.75 0.58 2.14 
Pulmonary 
circulation 
disorderso 1.11 0.34 0.74 0.61 2.00 
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Table 34 (cont.) 
 
 Incidence 
Rate 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Peripheral vascular 
disorderp 1.70 0.15 <0.001 1.43 2.02 
Hypertensionq 0.74 0.04 <0.001 0.67 0.83 
Paralysisr 2.04 0.61 0.02 1.13 3.68 
Other neurological 
disorderss 2.60 0.91 <0.01 1.31 5.15 
Chronic pulmonary 
diseaset 1.42 0.10 <0.001 1.24 1.62 
Hypothyroidismu 0.98 0.11 0.84 0.78 1.23 
Diabetes 
complicatedv 1.41 0.09 <0.001 1.26 1.59 
Liver diseasew 1.89 0.24 <0.001 1.46 2.43 
Peptic ulcer 
diseasex 0.96 0.24 0.86 0.59 1.56 
AIDSy 0.64 0.26 0.28 0.29 1.42 
Lymphomaz 2.55 0.87 <0.01 1.31 4.98 
Metastatic canceraa 2.37 1.13 0.07 0.93 6.04 
Solid tumor without 
metastasisbb 1.35 0.13 <0.01 1.12 1.63 
Rheumatoid 
arthritis / collagen 
vascular diseasescc 1.82 0.45 0.02 1.12 2.93 
Coagulopathydd 1.57 0.29 0.01 1.10 2.25 
Obesityee 1.03 0.06 0.65 0.92 1.15 
Weight lossff 3.05 0.89 <0.001 1.72 5.40 
Fluid and 
electrolyte 
disordersgg 2.70 0.27 <0.001 2.21 3.29 
Blood loss anemiahh 1.57 0.55 0.20 0.79 3.12 
Deficiency 
anemiasii 1.91 0.23 <0.001 1.51 2.42 
Alcohol abusejj 1.58 0.18 <0.001 1.27 1.96 
Drug abusekk 1.95 0.29 <0.001 1.45 2.61 
Psychosesll 1.47 0.14 <0.001 1.22 1.77 
Depressionmm 1.27 0.08 <0.001 1.12 1.44 
Cohort 2004nn 0.88 0.10 0.25 0.71 1.09 
Cohort 2005nn 0.78 0.09 0.03 0.62 0.97 
Cohort 2006nn 0.81 0.09 0.07 0.65 1.02 
        
/lnalpha 1.56 0.05  1.47 1.65 
alpha 4.76 0.23   4.34 5.23 
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Wald χ2(56)=1524.66, p<0.001, log pseudolikelihood = -12080.93 
a  Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*time t, d Reference category = Annual income <$6000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, h Reference category = Normoalbuminuria in follow-up, i Reference 
category No history of MI, j Reference category = No history of stroke, k Reference 
category = No family history of CVD, l Reference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t Reference 
category = No chronic pulmonary disease,  u Reference category = No hypothyroidism, v 
Reference category = No diabetes complicated, w Reference category = No liver disease, x 
Reference category = No peptic ulcer disease, y Reference category = No AIDS, z 
Reference category = No lymphoma, aa Reference category = No metastatic cancer, bb 
Reference category = No solid tumor without metastasis, cc Reference category = No 
rheumatoid arthritis/collagen vascular diseases, dd Reference category = No coagulopathy, 
ee Reference category = No obesity, ff Reference category = No weight loss, gg Reference 
category = No fluid and electrolyte disorders, hh Reference category = No blood loss 
anemias, ii Reference category = No deficiency anemias, jj Reference category = No 
alcohol abuse, kk Reference category = No drug abuse, ll Reference category = No 
psychoses, mm Reference category = No depression, nn Reference category = Cohort 2003 
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ACEI Monotherapy versus ARB Monotherapy, PSA 
 
The following Table shows the differences between groups before and after 
nearest-neighbor matching with propensity score obtained from the first-stage PSA along 
with percent reduction in bias achieved for ESRD, our primary question.  The bias “is 
defined as the difference of the mean values of the treatment group and the (not 
matched/matched) non treatment group, divided by the square root of the average sample 
variance in the treatment group and the not matched non treatment group.”200  As can be 
seen with the percent reduction in bias in Table 35, comparing the difference in means of 
each variable between drug therapies, fourteen between group differences were 
significant before matching with propensity scores that are not with nearest-neighbor 
matching, seven between group differences became less significant with nearest-neighbor 
matching, one between group difference became more significant with nearest-neighbor 
matching, and one between group difference that was not significant before nearest-
neighbor matching became significant with nearest-neighbor matching.  (Note this tests 
all matched individuals between ACEI and ARB monotherapies.)  Achieving balanced 
groups at baseline means we do not have a systematic mechanism to create error thus 
allowing our results to be interpreted as “causal” rather than “associated with.”  The 
subsequent table (Table 36) indicates the improved amount of explanation of treatment 
selection achieved with nearest-neighbor matching compared to not matching: about 2.5 
times more explanation occurred with matching than not. 
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Table 35: Between Group Differences of Baseline Characteristics Before and After 
Matching on Propensity Score 
 
Variable Sample Mean, 
Treated (ACEI) 
Control (ARB) 
% bias % 
reduction 
|bias| 
p 
Age Unmatched 63.41    
65.78 
-22.70  <0.001 
Matched 63.30    
65.47 
-20.80 8.30 <0.001 
      
Age squared Unmatched 4133.60   
4431.80 
-22.00  <0.001 
Matched 4117.70   
4392.20 
-20.30 7.90 <0.001 
      
Income/100,000 Unmatched 0.35 
0.39 
-5.20  <0.001 
Matched 0.37    
0.39 
-3.00 43.20 0.37 
      
Rural versus 
urban/ suburban 
Unmatched 0.70    
0.72 
-4.80  <0.01 
Matched 0.69    
0.73 
-10.60 -119.20 <0.001 
      
Never smoker Unmatched 0.03     
0.04 
-4.20  <0.01 
Matched 0.03    
0.04 
-2.60 36.40 0.70 
      
Ever smoker Unmatched 0.21    
0.15 
14.50  <0.001 
Matched 0.21    
0.16 
13.20 9.00 <0.001 
      
HbA1c Unmatched 7.35    
7.30 
1.10  0.41 
Matched 7.32    
7.14 
4.20 -280.00 <0.001 
      
LDL Unmatched 92.71    
88.73 
12.70  <0.001 
Matched 96.62    
92.47 
13.30 -4.10 <0.001 
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Table 35 (cont.) 
 
Variable Sample Mean, 
Treated (ACEI) 
Control (ARB) 
% bias % 
reduction 
|bias| 
p 
Triglycerides  Unmatched 191.75    
189.52 
1.30  0.40 
Matched 193.27    
191.07 
1.30 1.20 0.12 
      
History of MI Unmatched 0.03    
0.02 
3.40  0.02 
Matched 0.03    
0.02 
3.60 -6.60 0.07 
      
History of stroke Unmatched 0.01    
0.01 
6.00  <0.001 
Matched 0.01    
0.00 
6.60 -8.90 0.08 
      
Family history 
of CVD 
Unmatched 0.00    
0.02 
-7.50  <0.001 
Matched 0.00    
0.02 
-7.00 6.90 0.03 
      
CHF Unmatched 0.05    
0.08 
-11.40  <0.001 
Matched 0.06    
0.08 
-10.40 9.00 <0.001 
      
Cardiac 
arrhythmias 
Unmatched 0.05    
0.07 
-5.80  <0.001 
Matched 0.05    
0.06 
-4.30 27.00 0.16 
      
Valvular disease Unmatched 0.00    
0.01 
-4.70  <0.001 
Matched 0.00    
0.01 
-4.80 -1.20 0.02 
      
Pulmonary 
circulation 
disorders 
Unmatched 0.00    
0.00 
-1.40  0.26 
Matched 0.00    
0.00 
2.20 -54.00 0.32 
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Table 35 (cont.) 
 
Variable Sample Mean, 
Treated (ACEI) 
Control (ARB) 
% bias % 
reduction 
|bias| 
p 
Peripheral 
vascular 
disorders 
Unmatched 0.06   
0.07 
-5.10  <0.001 
Matched 0.06    
0.08 
-5.90 -16.80 0.02 
      
Hypertension  Unmatched 0.81    
0.83 
-6.80  <0.001 
Matched 0.81    
0.84 
-6.40 5.40 0.04 
      
Paralysis  Unmatched 0.00    
0.00 
2.30  0.13 
Matched 0.00     
0.00 
2.80 -24.60 0.16 
      
Other 
neurological 
disorders 
Unmatched 0.00    
0.00 
0.60  0.66 
Matched 0.00    
0.00 
0.20 62.40 0.82 
      
Chronic 
pulmonary 
disease 
Unmatched 0.01    
0.11 
-4.60  <0.01 
Matched 0.10     
0.10 
-2.30 51.20 0.34 
      
Hypothyroidism  Unmatched 0.04    
0.05 
-2.60  <0.05 
Matched 0.05    
0.05 
-0.20 92.40 0.41 
      
Diabetes 
complicated 
Unmatched 0.14    
0.14 
2.80  <0.05 
Matched 0.15    
0.15 
1.80 33.00 0.13 
      
Liver disease Unmatched 0.01    
0.01 
1.10  0.45 
Matched 0.01    
0.01 
0.30 69.80 0.75 
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Table 35 (cont.) 
 
Variable Sample Mean, 
Treated (ACEI) 
Control (ARB) 
% bias % 
reduction 
|bias| 
p 
Peptic ulcer 
disease 
Unmatched 0.01    
0.02 
-5.20  <0.001 
Matched 0.01    
0.02 
-6.50 -25.80 0.01 
      
Lymphoma  Unmatched 0.00    
0.00 
1.90  0.19 
Matched 0.00     
0.00 
-2.70 -37.90 0.44 
      
Metastatic 
cancer 
Unmatched 0.00    
0.00 
1.50  0.32 
Matched 0.00     
0.00 
2.30 -49.30 0.32 
      
Solid tumor 
without 
metastasis 
Unmatched 0.06    
0.07 
-3.60  <0.01 
Matched 0.07    
0.07 
-2.90 19.30 0.48 
      
Rheumatoid 
arthritis/collagen 
vascular 
diseases 
Unmatched 0.00    
0.00 
0.10  0.93 
Matched 0.00    
0.00 
-1.50 -1216.50 0.56 
      
Coagulopathy  Unmatched 0.01    
0.02 
-4.30  <0.01 
Matched 0.01    
0.01 
-1.00 76.70 0.72 
      
Obesity  Unmatched 0.18     
0.17 
3.30  0.02 
Matched 0.19    
0.18 
2.50 24.60 0.40 
      
Fluid and 
electrolyte 
disorders 
Unmatched 0.02     
0.02 
1.20  0.38 
Matched 0.02    
0.02 
1.60 -33.90 0.26 
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Table 35 (cont.) 
 
Variable Sample Mean, 
Treated (ACEI) 
Control (ARB) 
% bias % 
reduction 
|bias| 
p 
Blood loss 
anemia 
Unmatched 0.00   
0.00 
-1.60  0.20 
Matched 0.00     
0.00 
-4.40 -181.50 0.48 
      
Deficiency 
anemias 
Unmatched 0.03    
0.04 
-2.80  0.03 
Matched 0.03    
0.04 
-4.30 -52.70 <0.05 
      
Alcohol abuse Unmatched 0.03    
0.03 
2.00  0.16 
Matched 0.03    
0.02 
4.30 -118.30 0.90 
      
Drug abuse Unmatched 0.01    
0.01 
6.80  <0.001 
Matched 0.01    
0.01 
8.60 -26.00 0.06 
      
Psychoses  Unmatched 0.04    
0.03 
7.20  <0.001 
Matched 0.05    
0.03 
7.00 2.70 0.03 
      
Depression  Unmatched 0.10     
0.10 
1.20  0.38 
Matched 0.10    
0.10 
2.10 -76.90 0.47 
      
Allergic rhinitis Unmatched 0.00    
0.00 
-4.00  <0.01 
Matched 0.00    
0.00 
-1.90 51.60 0.82 
      
Cohort 2004 Unmatched 0.42    
0.43 
-2.10  0.12 
Matched 0.33   
0.33 
-0.10 97.30 0.70 
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Table 35 (cont.) 
 
Variable Sample Mean, 
Treated (ACEI) 
Control (ARB) 
% bias % 
reduction 
|bias| 
p 
Cohort 2005 Unmatched 0.31    
030 
1.20  0.40 
Matched 0.32    
0.32 
-0.10 95.20 0.73 
      
Cohort 2006 Unmatched 0.20    
0.21 
-1.50  0.27 
Matched 0.30    
0.31 
-0.80 46.40 0.74 
      
Hypertension* 
peripheral 
vascular 
disorders  
Unmatched 0.05    
0.06 
-3.20  0.02 
Matched 0.05    
0.06 
-2.90 6.90 0.17 
*p-value for t-test, comparing between group differences before or after matching 
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Table 36: Differences in Explanation of Treatment Assignment, Unmatched versus 
Nearest-Neighbor Matched 
    
Sample McFadden’s 
Pseudo R2 
LR χ2 p 
Unmatched 0.07 687.64 <0.001 
Matched 0.17 687.78 <0.001 
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As mentioned in the Methods, PSA is comprised of two stages.  The first stage is 
predicting treatment selection for each patient based on that patient’s characteristics 
observable to the provider.  Specifically, the first stage attempts to incorporate all things 
available to the provider at baseline in addition to the regular regression methods of 
including all variables that could impact the outcome.  The result of this first stage 
logistic regression of treatment selection is a weight (inverse of the propensity score) that 
can be applied to each matched patient in the second stage.   
The first stage is extremely flexible for model specification since predicting 
treatment selection is crucial to control it.  Recommendations exist to change models 
until characteristics are balanced within each stratum.  Accordingly, stratification 
informed us that additional variables (i.e., interactions and higher-order terms) were 
needed.  After adding the interaction between hypertension and peripheral vascular 
disorders, age squared, and income/100,000, the only thing we were not able to balance 
within each stratum between groups was site, for which seven sites were not balanced in 
one of fourteen strata each.  Without these additional variables, family history of 
cardiovascular disease was not balancing and we knew from univariate comparisons that 
those prescribed ARBs were more likely to have a family history of cardiovascular 
disease (Table 14).   Obviously, this iterative process with feedback applies a more 
stringent criterion for propensity score balance between groups than weighted regression.  
Please see Figure 7 for overlap in common support (i.e., percent of ACEI and ARB 
patients within each stratum who have similar propensity scores).  (Note Table 35 is 
different in that it shows if there was balance in each covariate across the sample as this 
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is the result of the first stage regression.  However, even assessing balance this way we 
find 21 variables were balanced better with PSA.) 
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Figure 7: Overlap in Propensity Scores of ACEI and ARB Patients Obtained with 
Stratification 
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 Table 37 found age, family history of CVD, CHF, peripheral vascular disorders, 
hypertension, and peptic ulcer disease had lower odds of explaining ACEI monotherapy 
selection (p<0.05 each). In other words, patients with these characteristics had 
significantly higher odds of receiving ARB monotherapy.  In contrast, ever smoker, 
HbA1c, LDL, history of stroke, and the interaction between hypertension and peripheral 
vascular disorders had higher odds of receiving ACEI monotherapy (p<0.05 each).   
Although results of Table 37 do not show each state and metropolitan area, these 
have been controlled for in analysis.  Unlike previous regression results, this model does 
not have robust standard errors or clusters because we are only looking at baseline 
information for each patient.  Despite this, STATA does not allow us to check for 
regression diagnostics, probably due to the fact that the literature recommends entering as 
many baseline observable characteristics as possible.  However, this does mean this is the 
only regression model with likelihood ratio chi-square instead of a Wald chi-square as the 
model is based on log likelihoods rather than log pseudolikelihoods. 
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Table 37: Logistic Regression Analysis, for Variables Predicting ACEI or ARB 
Treatment Selection, a.k.a. First Stage PSA to Explain Treatment Selection (N=15,194 
patients) 
 
 Coefficient Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Age -0.06 0.03 0.04 -0.12 -0.01
Age squared 0.00 0.00 0.10 0.00 0.00
Income/100,000 0.00 0.04 0.95 -0.08 0.08
Urban/suburbana -0.10 0.12 0.40 -0.33 0.13
Never smokerb 0.01 0.16 0.95 -0.30 0.33
Ever smokerb 0.29 0.08 <0.01 0.13 0.45
Baseline 
microalbuminuriac 0.14 0.07 0.06 -0.01 0.28
HbA1c 0.07 0.02 <0.01 0.02 0.12
LDL 0.00 0.00 <0.01 0.00 0.00
Triglycerides 0.00 0.00 0.47 0.00 0.00
History of MId 0.19 0.19 0.32 -0.18 0.57
History of strokee 0.84 0.35 0.02 0.15 1.53
Family history of 
CVDf -0.78 0.26 <0.01 -1.29 -0.26
CHFg -0.40 0.11 <0.001 -0.62 -0.18
Cardiac arrhythmiash 0.04 0.13 0.74 -0.20 0.29
Valvular diseasei -0.42 0.30 0.17 -1.01 0.17
Pulmonary 
circulation disordersj 1.07 1.05 0.30 -0.98 3.12
Peripheral vascular 
disordersk -0.64 0.24 <0.01 -1.10 -0.18
Hypertensionl -0.23 0.08 <0.01 -0.39 -0.07
Paralysism 0.67 0.74 0.37 -0.78 2.12
Other neurological 
disordersn 0.05 0.35 0.90 -0.63 0.72
Chronic pulmonary 
diseaseo -0.09 0.10 0.38 -0.28 0.11
Hypothyroidismp 0.01 0.14 0.93 -0.26 0.28
Diabetes 
complicatedq 0.08 0.09 0.34 -0.09 0.25
Liver diseaser -0.13 0.26 0.61 -0.65 0.38
Peptic ulcer diseases -0.64 0.25 0.01 -1.13 -0.15
Lymphomat -0.19 0.46 0.68 -1.09 0.71
Metastatic canceru 0.80 1.04 0.44 -1.24 2.84
Solid tumor without 
metastasisv 0.04 0.12 0.74 -0.19 0.26
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Table 37 (cont.) 
 
 Coefficient Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Rheumatoid arthritis/ 
collagen vascular 
diseasesw -0.16 0.32 0.62 -0.79 0.47
Coagulopathyx 0.09 0.29 0.76 -0.48 0.66
Obesityy -0.01 0.08 0.88 -0.16 0.14
Fluid and electrolyte 
disordersz 0.11 0.23 0.65 -0.35 0.56
Blood loss anemiaaa -0.80 0.69 0.25 -2.16 0.56
Deficiency anemiasbb -0.07 0.16 0.65 -0.38 0.24
Alcohol abusecc 0.00 0.20 1.00 -0.39 0.39
Drug abusedd 0.71 0.39 0.07 -0.05 1.46
Psychosesee 0.31 0.17 0.07 -0.02 0.63
Depressionff -0.06 0.10 0.55 -0.26 0.14
Allergic rhinitisgg -0.38 0.36 0.29 -1.08 0.32
Cohort 2004hh -0.05 0.16 0.74 -0.37 0.26
Cohort 2005hh -0.07 0.16 0.69 -0.38 0.25
Cohort 2006hh -0.10 0.16 0.55 -0.42 0.22
Hypertension* 
Peripheral vascular 
disorders 0.62 0.27 0.02 0.10 1.14
 
McFadden’s Pseudo R² = 0.08 
LR χ²(300) = 742.44, p<0.001, Log likelihood = -4,370.95 
 
a Reference category = rural, b Reference category = Current smoker, c Reference 
category = Baseline macroalbuminuria, d Reference category = No history of MI, e 
Reference category = No history of stroke, f Reference category = No family history of 
CVD, g Reference category = No CHF, h Reference category = No cardiac arrhythmias, i 
Reference category = No valvular disease, j Reference category = No pulmonary 
circulation disorders, k Reference category = No peripheral vascular disorders, l 
Reference category = Normotension, m Reference category = No paralysis,  n Reference 
category = No other neurological disorders, o Reference category = No chronic 
pulmonary disease, p Reference category = No hypothyroidism, q Reference category = 
No diabetes complicated, r Reference category = No liver disease, s Reference category = 
No peptic ulcer disease, t Reference category = No lymphoma, u Reference category = No 
metastatic cancer, v Reference category = No solid tumor without metastasis, w Reference 
category = No rheumatoid arthritis/collagen vascular diseases, x Reference category = No 
coagulopathy, y Reference category = No obesity, z Reference category = No fluid and 
electrolyte disorders,  aa Reference category = No blood loss anemia, bb Reference 
category = No deficiency anemias, cc Reference category = No alcohol abuse, dd 
Reference category = No drug abuse, ee Reference category = No Psychoses, ff Reference 
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category = No depression, gg Reference category = No allergic rhinitis, hh Reference 
category = Cohort 2003 
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The following section presents the second stage weighted regressions, where each 
regression equation was weighted by the inverse of the propensity score obtained from 
the first stage PSA (Table 38).  Second stage PSA balances observable patient 
characteristics at baseline by including those patients’ characteristics that allow for any 
combination of observables to be observed in both treatments; therefore, the second stage 
weighted regressions were run in the context of common support = 1.  There are 15,193 
patients contributing 46,494 person-years who meet the common support of = 1 
threshold.   
Table 38 displays results for the logistic regression analysis weighted by inverse 
propensity scores of ACEI monotherapy’s effect, compared to ARB monotherapy, on 
development of ESRD. Several patient characteristics were simultaneously entered in the 
model to control for their effects.  Comparing the number of ACEI and ARB patients 
who merged with zipcode data and the number of patients who had common support, 
72.77% of the sample matched. 
The only diagnostic test assessed after model analysis was the Pregibon’s Link 
Test, which was nonsignificant (p=0.59).  We were unable to conduct the Hosmer and 
Lemeshow goodness-of-fit because the model was weighted.  Similarly, we were unable 
to assess area under the ROC curve. 
Time (t+4), the interaction between ACEI monotherapy and time (t+3), valvular 
disease, pulmonary circulation disorders, other neurological disorders, peptic ulcer 
disease, AIDS, lymphoma, metastatic cancer, rheumatoid arthritis/collagen vascular 
diseases, coagulopathy, weight loss, blood loss anemia, and drug abuse were dropped 
because each variable did not have an observation with a value of one for ESRD.  The 
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interaction between ACEI monotherapy and time (t+4) was dropped due to 
multicollinearity.  No variables were identified as having significantly lower odds of 
ESRD development.  Times (t+1) and (t+2), diabetes complicated, liver disease, fluid and 
electrolyte disorders, and deficiency anemias had higher odds of ESRD development 
(p<0.05 each).  Of particular importance, diabetes complicated had OR=2.66, (1.42-
4.96).  The model was significant [Wald χ²(35) = 415.42, p<0.001] and explained 15.84% 
of the variance in ESRD development. 
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Table 38: Second Stage PSA: Logistic Regression Weighted by Inverse Propensity 
Scores, ACEI versus ARB, for Variables Predicting ESRD (N=30,732 person-years; 
N=14,230 patients) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 1.12 1.03 0.90 0.19 6.72
Time (t+1) b 2.16 0.82 0.04 1.03 4.53
Time (t+2) b 4.13 1.57 <0.001 1.97 8.69
Time (t+3) b 2.04 1.31 0.27 0.58 7.21
ACEI*time (t+1) c 1.10 1.18 0.93 0.13 8.98
ACEI*time (t+2) c 2.57 2.67 0.36 0.34 19.65
Age 0.98 0.02 0.23 0.95 1.01
Annual income $6,000-
17,999d 1.28 0.54 0.56 0.56 2.92
Annual income $18,000-
34,999d 1.60 0.63 0.24 0.74 3.46
Annual income 
≥$35,000d 0.60 0.33 0.36 0.20 1.78
Urban/suburbane 0.73 0.23 0.32 0.40 1.35
Never smokerf 0.45 1.50 0.23 0.12 1.64
Ever smokerf 1.02 0.32 0.94 0.54 1.96
HbA1c 0.93 0.11 0.51 0.74 1.16
LDL 0.99 0.00 0.13 0.98 1.00
Triglycerides 1.00 0.00 0.96 1.00 1.00
CHFg 1.54 0.76 0.38 0.59 4.03
Cardiac arrhythmiash 1.97 1.23 0.28 0.58 6.72
Peripheral vascular 
disordersi 2.48 1.21 0.06 0.95 6.48
Hypertensionj 0.69 0.24 0.29 0.34 1.37
Paralysisk 6.04 5.80 0.06 0.92 39.68
Chronic pulmonary 
diseasel 0.65 0.35 0.42 0.23 1.85
Hypothyroidismm 0.31 0.33 0.28 0.04 2.58
Diabetes complicatedn 2.66 0.85 <0.01 1.42 4.96
Liver diseaseo 7.40 3.53 <0.001 2.91 18.87
Solid tumor without 
metastasisp 1.97 1.06 0.21 0.69 5.64
Obesityq 0.54 0.25 0.19 0.22 1.35
Fluid and electrolyte 
disordersr 7.71 3.14 <0.001 3.46 17.15
Deficiency anemiass 5.81 2.63 <0.001 2.40 14.09
Alcohol abuset 1.51 0.99 0.53 0.42 5.44
Psychosesu 0.97 0.65 0.96 0.26 3.64
Depressionv 1.10 0.48 0.82 0.47 2.59
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Table 38 (cont.) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Cohort 2004w 0.91 0.60 0.88 0.25 3.28
Cohort 2005w 1.30 0.83 0.68 0.37 4.55
Cohort 2006w 0.95 0.67 0.94 0.24 3.75
 
McFadden’s Pseudo R2 = 0.16 
Wald χ²(35) = 415.42, p<0.001, Log pseudolikelihood = -337.18                 
 
a Reference category = ARB, b Reference category = Time (t), c Reference category = 
ACEI * time t, d Reference category = Annual income <$6,000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = No CHF, h 
Reference category = No cardiac arrhythmias, I Reference category = No peripheral 
vascular disorders,  j Reference category = Normotension, k Reference category = No 
paralysis, lReference category = No chronic pulmonary disease, m Reference category = 
No hypothyroidism, nReference category = No diabetes complicated, o Reference 
category = No liver disease,  p Reference category =  No solid tumor without metastasis, q 
Reference category = No obesity, r Reference category = No fluid and electrolyte 
disorders, s Reference category = No deficiency anemias, t  Reference category = No 
alcohol abuse, uReference category = No psychoses, v Reference category = No 
depression, wReference category = Cohort 2003 
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Table 39 presents the results for logistic regression of ACEI monotherapy’s 
effect, compared to ARB monotherapy, on occurrence of IVDEs.  Several patient 
characteristics were concurrently entered to quantify their effects.  The original model 
resulted in a nonsignificant Pregibon’s Link Test (p=0.83).  
Weight loss was dropped because none of its observations had a value of one for 
IVDE.  The interaction between ACEI and time (t+4) and income missing were dropped 
due to multicollinearity.  Never smoker, ever smoker, and LDL had lower odds of IVDE 
occurrence (p<0.05 each).  Age, history of MI, history of stroke, pulmonary circulation 
disorders, peripheral vascular disorders, chronic pulmonary disease, and fluid and 
electrolyte disorders had higher odds of IVDE occurrence (p<0.05 each).  In particular, 
patients who never smoked had 64% (49-75%) lower odds of having an IVDE occurrence 
whereas patients with history of MI had 133% (65-233%) higher odds of suffering an 
IVDE, patients with history of stroke had 232% (119-395%) higher odds of acquiring an 
IVDE, and patients with peripheral vascular disorders had 229% (159-317%) higher odds 
of having an IVDE occurrence.  The model was significant [Wald χ²(54) = 372.64, 
p<0.001] and explained 6.02% of IVDE occurrence. 
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Table 39: Second Stage PSA: Logistic Regression Weighted by Inverse Propensity 
Scores, for Variables Predicting IVDE (N=25,143 person-years; N=14,864 patients) 
 
 Odds 
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
ACEIa 1.01 0.20 0.97 0.68 1.49
Time (t+1) b 0.88 0.07 0.12 0.74 1.03
Time (t+2) b 1.10 0.11 0.37 0.90 1.35
Time (t+3) b 0.97 0.15 0.86 0.72 1.33
Time (t+4) b 1.55 1.12 0.55 0.37 6.43
ACEI*time (t+1) c 1.07 0.30 0.81 0.62 1.85
ACEI*time (t+2) c 0.77 0.35 0.57 0.32 1.88
ACEI*time (t+3) c 0.42 0.33 0.26 0.09 1.94
Age 1.01 0.00 0.04 1.00 1.02
Annual income $6,000-
17,999d 1.04 0.15 0.76 0.79 1.37
Annual income 
$18,000-34,999d 1.24 0.16 0.09 0.97 1.58
Annual income 
≥$35,000d 1.12 0.15 0.40 0.86 1.46
Urban/suburbane 0.98 0.09 0.79 0.82 1.17
Never smokerf 0.36 0.51 <0.001 0.25 0.51
Ever smokerf 0.58 0.19 <0.001 0.47 0.72
Baseline 
microalbuminuriag 1.01 0.12 0.93 0.80 1.28
Microalbuminuria in 
follow-uph 0.88 0.11 0.30 0.70 1.12
Macroalbuminuria in 
follow-uph 1.07 0.16 0.63 0.80 1.44
HbA1c 1.00 0.01 0.99 0.99 1.02
LDL 1.00 0.00 <0.001 0.99 1.00
Triglycerides 1.00 0.00 0.89 1.00 1.00
History of MIi 2.35 0.42 <0.001 1.65 3.33
History of strokej 3.30 0.68 <0.001 2.19 4.95
Family history of 
CVDk 1.18 0.40 0.62 0.61 2.30
CHFl 1.25 0.22 0.20 0.89 1.76
Cardiac arrhythmiasm 1.22 0.23 0.29 0.84 1.75
Valvular diseasen 1.26 0.61 0.63 0.49 3.26
Pulmonary circulation 
disorderso 5.76 3.11 <0.001 2.00 16.60
Peripheral vascular 
disordersp 3.29 0.40 <0.001 2.59 4.17
Hypertensionq 1.05 0.12 0.68 0.84 1.30
Paralysisr 0.73 0.58 0.69 0.15 3.47
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Table 39 (cont.) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Other neurological 
disorderss 1.32 0.59 0.54 0.54 3.19
Chronic pulmonary 
diseaset 1.39 0.18 0.01 1.08 1.78
Hypothyroidismu 1.03 0.22 0.90 0.68 1.55
Diabetes complicatedv 1.00 0.12 1.00 0.80 1.26
Liver diseasew 0.81 0.29 0.57 0.41 1.64
Peptic ulcer diseasex 0.79 0.36 0.61 0.32 1.93
AIDSy 2.78 2.57 0.27 0.45 17.04
Lymphomaz 1.06 0.80 0.94 0.24 4.69
Metastatic canceraa 0.63 0.75 0.70 0.06 6.56
Solid tumor without 
metastasisbb 0.82 0.15 0.29 0.58 1.18
Rheumatoid arthritis/ 
collagen vascular 
diseasescc 0.97 0.43 0.95 0.41 2.31
Coagulopathydd 0.91 0.34 0.80 0.44 1.88
Obesityee 1.15 0.14 0.24 0.91 1.45
Fluid and electrolyte 
disordersff 2.00 0.47 <0.001 1.27 3.17
Blood loss anemiagg 1.11 1.13 0.92 0.15 8.09
Deficiency anemiashh 1.41 0.29 0.10 0.94 2.12
Alcohol abuseii 1.30 0.47 0.46 0.64 2.64
Drug abusejj 1.12 0.44 0.77 0.52 2.44
Psychoseskk 1.05 0.32 0.86 0.58 1.90
Depressionll 1.05 0.16 0.73 0.78 1.42
Cohort 2004mm 0.89 0.18 0.57 0.60 1.32
Cohort 2005mm 0.82 0.17 0.33 0.55 1.22
Cohort 2006mm 0.86 0.18 0.46 0.58 1.28
 
McFadden’s Pseudo R2 = 0.06 
Wald χ²(54) = 372.64, p<0.001, Log pseudolikelihood = -3495.21 
 
a Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*Time t, d Reference category = Annual income <$6000, e Reference category = 
rural , f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, hReference category = Normoalbuminuria in follow-up, i Reference 
category = No history of MI, jReference category = No history of stroke, kReference 
category = No family history of CVD, lReference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
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peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t No chronic 
pulmonary disease, u Reference category = No hypothyroidism, v Reference category = 
No diabetes complicated, w Reference category = No liver disease, x Reference category = 
No peptic ulcer disease, y Reference category = No AIDS, z Reference category = No 
lymphoma, aa Reference category = No metastatic cancer, bb Reference category = No 
solid tumor without metastasis, cc Reference category = No rheumatoid arthritis/collagen 
vascular diseases, dd Reference category = No coagulopathy, ee Reference category = No 
obesity, ff Reference category = No fluid and electrolyte disorders, ggReference category = 
No blood loss anemia, hh Reference category = No deficiency anemias, ii Reference 
category = No alcohol abuse, jj Reference category = No drug abuse, kk Reference 
category = No psychoses, ll Reference category = No depression, mm Reference category = 
Cohort 2003 
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Table 40 displays the results of the logistic regression weighted by inverse 
propensity scores of ACEI monotherapy’s effects, compared to ARB monotherapy, on 
all-cause mortality for those individuals in the region of common support.  Several 
patient characteristics were concurrently entered to quantify their effects. 
Again, because of the use of weights in this model the Hosmer and Lemeshow 
goodness-of-fit test was unable to be performed.  The Pregibon’s Link Test was 
significant (p=0.001), which resulted in an attempt of construction of another model.  
Age squared, income divided by 100,000, the interaction between HbA1c and LDL, the 
interaction between HbA1c and triglycerides, the interaction between LDL and 
triglycerides, the interaction between albuminuria and HbA1c, the interaction between 
albuminuria and triglycerides, the interaction between albuminuria and LDL, the 
interaction between age and triglycerides, the interaction between age and LDL, and the 
interaction between age and HbA1c were iteratively added to the original model for 
possible inclusion into the new model.  Only the interaction between age and 
triglycerides was significant (p=0.01), but it did not increase the p-value for Pregibon’s 
Link Test so the original model was retained for parsimony. 
The interaction between ACEI monotherapy and time (t+3), never smoker, family 
history of CVD, valvular disease, pulmonary circulation disorders, paralysis, peptic ulcer 
disease, AIDS, metastatic cancer, rheumatoid arthritis/collagen vascular diseases, 
coagulopathy, weight loss, and blood loss anemia were dropped because none of the 
observations had a value of one for all-cause mortality.  The interaction between ACEI 
monotherapy and time (t+4) as well as income missing were dropped due to 
multicollinearity.  No variables were identified as having lower odds of all-cause 
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mortality.  Higher odds of all-cause mortality were found for times (t+1), (t+2), and (t+3), 
age, annual income $6,000-17,999, annual income $18,000-34,999, annual income 
≥$35,000, history of MI, CHF, peripheral vascular disorders, and cohorts 2004, 2005, and 
2006 (p<0.05 each). (Note the large odds ratios and robust standard errors for cohorts 
2004, 2005, and 2006, something to take into consideration of when interpreting results 
of a logistic regression.)  Also worth mentioning, patients with history of MI had 185% 
(26-546%) higher odds of all-cause mortality while patients with peripheral vascular 
disorders had 144% (36-337%) higher odds of all-cause mortality.  Because the Wald test 
for time (t+4) cannot be reported as it is dependent on the (robust) standard error for that 
variable and the Wald statistic for the model is dependent upon the Wald test for the 
variable, there is no Wald statistic (or associated p-value) for the model.  However, the 
model explained 8.69% of the variance in all-cause mortality. 
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Table 40:  Second Stage PSA: Logistic Regression Weighted by Inverse Propensity 
Scores, ACEI versus ARB, for Variables Predicting All-Cause Mortality (N=23,143 
person-years; N=13,734 patients) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper  
Bound 
  
ACEIa 0.86 0.56 0.81 0.24 3.07
Time (t+1) b 2.01 0.58 0.02 1.13 3.55
Time (t+2) b 3.71 1.18 <0.001 1.99 6.91
Time (t+3) b 7.44 3.13 <0.001 3.26 16.96
Time (t+4) b 1.06x108 . . . .
ACEI*time (t+1) c 0.47 0.57 0.53 0.04 4.99
ACEI*time (t+2) c 0.90 0.93 0.92 0.12 6.88
Age 1.04 0.01 <0.01 1.01 1.06
Annual income 
$6,000-17,999d 2.23 0.89 0.04 1.02 4.88
Annual income 
$18,000-34,999d 2.44 0.93 0.02 1.15 5.15
Annual income 
≥$35,000d 2.22 0.86 0.04 1.03 4.75
Urban/suburbane 1.28 0.30 0.30 0.80 2.04
Ever smokerf 0.81 0.37 0.49 0.45 1.47
Baseline 
microalbuminuriag 1.03 0.34 0.92 0.54 1.96
Microalbuminuria 
in follow-uph 1.60 0.57 0.19 0.79 3.21
Macroalbuminuria 
in follow-uph 1.89 0.85 0.15 0.79 4.56
HbA1c 1.01 0.01 0.09 1.00 1.02
LDL 1.00 0.00 0.51 1.00 1.01
Triglycerides 1.00 0.00 0.84 1.00 1.00
History of MIi 2.85 1.19 0.01 1.26 6.46
History of strokej 2.04 1.20 0.23 0.64 6.47
CHFk 2.19 0.79 0.03 1.08 4.45
Cardiac 
arrhythmiasl 1.47 0.55 0.30 0.71 3.05
Peripheral vascular 
disordersm 2.44 0.72 <0.01 1.36 4.37
Hypertensionn 0.72 0.18 0.20 0.44 1.19
Other neurological 
disorderso 1.65 1.66 0.62 0.23 11.85
Chronic pulmonary 
diseasep 1.64 0.48 0.09 0.92 2.93
Hypothyroidismq 1.48 0.61 0.34 0.66 3.31
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Table 40 (cont.) 
 
 Odds  
Ratio 
Robust 
Standard 
Error 
p 95% CI 
Lower 
Bound 
95% CI 
Upper 
Bound 
Diabetes 
complicatedr 0.92 0.27 0.79 0.52 1.63
Liver diseases 1.98 2.07 0.52 0.25 15.42
Lymphomat 2.20 2.40 0.47 0.26 18.60
Solid tumor without 
metastasisu 1.17 0.46 0.69 0.54 2.53
Obesityv 1.10 0.32 0.74 0.62 1.95
Fluid and 
electrolyte 
disordersw 0.64 0.66 0.66 0.08 4.86
Deficiency 
anemiasx 0.93 0.57 0.90 0.28 3.10
Alcohol abusey 1.01 0.63 0.99 0.29 3.46
Drug abusez 1.32 1.28 0.78 0.19 8.92
Psychosesaa 0.51 0.38 0.36 0.12 2.17
Depressionbb 1.48 0.50 0.25 0.76 2.87
Cohort 2004cc 5.09x106 5.87x106 <0.001 5.32x105 4.88x107
Cohort 2005 cc 7.14x106 7.92x106 <0.001 8.09x105 6.29x107
Cohort 2006 cc 8.44x106 9.57x106 <0.001 9.14x105 7.79x107
 
McFadden’s Pseudo R² = 0.09 
Wald χ²(42) and its p-value were not reported, Log pseudolikelihood = -530.83 
 
a Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*Time t, d Reference category = Annual income <$6000, e Reference category = 
rural , f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, hReference category = Normoalbuminuria in follow-up, i Reference 
category = No history of MI, jReference category = No history of stroke, kNo CHF, l 
Reference category = No cardiac arrhythmias, m Reference category = No peripheral 
vascular disorders, n Reference category = Normotension, o Reference category = No 
other neurological disorders, p No chronic pulmonary disease, q Reference category = No 
hypothyroidism, r Reference category = No diabetes complicated, s Reference category = 
No liver disease, t Reference category = No lymphoma, u Reference category = No solid 
tumor without metastasis, v Reference category = No obesity, w Reference category = No 
fluid and electrolyte disorders, x Reference category = No deficiency anemias, y Reference 
category = No alcohol abuse, z Reference category = No drug abuse, aa Reference 
category = No psychoses, bb Reference category = No depression, cc Reference category = 
Cohort 2003 
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 Table 41 shows negative binomial regression weighted by inverse propensity 
scores for variables predicting outpatient visits among matched individuals.  Lower 
incidence rates of outpatient visits were observed for times (t+1), (t+2), (t+3), and (t+4), 
age, annual income ≥$35,000, never smoker, microalbuminuria in follow-up, and LDL 
(p<0.05 each).  Higher incidence rates of outpatient visits were found for annual income 
$6,000-17,999, annual income $18,000-34,999, urban/suburban living, ever smoker, 
history of stroke, CHF, cardiac arrhythmias, valvular diseases, pulmonary circulation 
disorders, peripheral vascular disorders, paralysis, other neurological disorders, chronic 
pulmonary disease, diabetes complicated, liver disease, AIDS, lymphoma, metastatic 
cancer, solid tumor without metastasis, coagulopathy, obesity, fluid and electrolyte 
disorders, deficiency anemias, alcohol abuse, drug abuse, psychoses, and depression 
(p<0.05 each). In more detail, patients with cardiac arrthythmias had 45% (37-54%) more 
outpatient visits, patients with metastatic cancer had 139% (87-205%) more outpatient 
visits, patients with coagulopathy had 40% (25-55%) more outpatient visits, and patients 
with psychoses had 50% (39-62%) more outpatient visits.  The model resulted in a Wald 
χ2(55) = 3789.42, p<0.001, log pseudolikelihood = -855257.20. 
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Table 41: Second Stage PSA: Negative Binomial Regression Analysis Weighted by 
Inverse Propensity Scores, ACEI versus ARB, for Variables Predicting Outpatient Visits 
(N=25,160 person-years; N=14,871 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 1.02 0.02 0.33 0.98 1.07
Time (t+1)b 0.80 0.01 <0.001 0.78 0.82
Time (t+2)b 0.76 0.01 <0.001 0.73 0.78
Time (t+3)b 0.59 0.02 <0.001 0.56 0.62
Time (t+4)b 0.20 0.03 <0.001 0.16 0.26
ACEI*time (t+1)c 1.03 0.05 0.51 0.94 1.13
ACEI*time (t+2)c 1.12 0.17 0.45 0.83 1.51
ACEI*time (t+3)c 1.15 0.13 0.24 0.91 1.44
ACEI*time (t+4)c 1.23 0.25 0.32 0.82 1.83
Age 0.99 0.00 <0.001 0.99 0.99
Annual income 
$6,000-17,999d 
1.20 0.02 <0.001 1.16 1.25
Annual income 
$18,000-34,999d 
1.14 0.02 <0.001 1.10 1.19
Annual income 
≥$35,000d 
0.91 0.02 <0.001 0.88 0.94
Urban/suburbane 1.17 0.02 <0.001 1.14 1.21
Never smokerf 0.89 0.02 <0.001 0.86 0.92
Ever smokerf 1.11 0.04 <0.01 1.03 1.20
Baseline 
microalbuminuriag 
1.01 0.02 0.63 0.97 1.05
Microalbuminuria 
in follow-uph 
0.94 0.02 0.01 0.90 0.99
Macroalbuminuria 
in follow-uph 
0.99 0.03 0.72 0.94 1.05
HbA1c 1.01 0.00 0.06 1.00 1.01
LDL 1.00 0.00 <0.001 1.00 1.00
Triglycerides 1.00 0.00 0.09 1.00 1.00
History of MIi 0.97 0.04 0.49 0.91 1.05
History of strokej 1.16 0.06 <0.01 1.06 1.28
Family history of 
CVDk 
1.09 0.07 0.16 0.96 1.24
CHFl 1.18 0.03 <0.001 1.11 1.24
Cardiac 
arrhythmiasm 
1.45 0.04 <0.001 1.37 1.54
Valvular diseasen 1.33 0.10 <0.001 1.14 1.54
Pulmonary 
circulation 
disorderso 
1.35 0.19 0.03 1.03 1.77
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Table 41 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Peripheral vascular 
disorderp 
1.16 0.03 <0.001 1.10 1.23
Hypertensionq 0.97 0.02 0.12 0.94 1.01
Paralysisr 1.35 0.15 <0.01 1.09 1.68
Other neurological 
disorderss 
1.24 0.09 <0.01 1.07 1.43
Chronic pulmonary 
diseaset 
1.12 0.02 <0.001 1.07 1.17
Hypothyroidismu 1.01 0.03 0.82 0.95 1.07
Diabetes 
complicatedv 
1.19 0.02 <0.001 1.15 1.23
Liver diseasew 1.30 0.07 <0.001 1.16 1.46
Peptic ulcer 
diseasex 
1.01 0.08 0.85 0.87 1.18
AIDSy 1.35 0.19 0.03 1.03 1.78
Lymphomaz 1.38 0.16 <0.01 1.10 1.72
Metastatic canceraa 2.39 0.30 <0.001 1.87 3.05
Solid tumor without 
metastasisbb 
1.11 0.03 <0.001 1.05 1.17
Rheumatoid 
arthritis/ collagen 
vascular diseasescc 
1.05 0.09 0.56 0.89 1.23
Coagulopathydd 1.40 0.08 <0.001 1.25 1.55
Obesityee 1.03 0.02 <0.05 1.00 1.07
Weight lossff 1.17 0.23 0.42 0.80 1.72
Fluid and 
electrolyte 
disordersgg 
1.32 0.06 <0.001 1.20 1.45
Blood loss anemiahh 1.23 0.18 0.16 0.92 1.65
Deficiency 
anemiasii 
1.21 0.04 <0.001 1.12 1.30
Alcohol abusejj 1.19 0.05 <0.001 1.10 1.30
Drug abusekk 1.44 0.08 <0.001 1.29 1.62
Psychosesll 1.50 0.06 <0.001 1.39 1.62
Depressionmm 1.21 0.03 <0.001 1.16 1.26
Cohort 2004nn 0.96 0.03 0.23 0.90 1.02
Cohort 2005nn 0.94 0.03 0.05 0.88 1.00
Cohort 2006nn 0.94 0.03 0.06 0.88 1.00
           
/lnalpha -0.93 0.02   -0.96 -0.89
alpha 0.40 0.01   0.38 0.41
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Wald χ2(56) = 3789.42, p<0.001, log pseudolikelihood = -855257.20 
 
a Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*Time t, d Reference category = Annual income <$6000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, hReference category = Normoalbuminuria in follow-up, i Reference 
category = No history of MI, jReference category = No history of stroke, kReference 
category = No family history of CVD, lReference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t No chronic 
pulmonary disease, u Reference category = No hypothyroidism, v Reference category = 
No diabetes complicated, w Reference category = No liver disease, x Reference category = 
No peptic ulcer disease, y Reference category = No AIDS, z Reference category = No 
lymphoma, aa Reference category = No metastatic cancer, bb Reference category = No 
solid tumor without metastasis, cc Reference category = No rheumatoid arthritis/collagen 
vascular diseases, dd Reference category = No coagulopathy, ee Reference category = No 
obesity, ff Reference category = No weight loss, gg Reference category = Fluid and 
electrolyte disorders, hh Reference category = No blood loss anemia, ii Reference category 
= No deficiency anemias, jj Reference category = No alcohol abuse, kk Reference category 
= No drug abuse, ll Reference category = No psychoses, mm Reference category = No 
depression, nn Reference category = Cohort 2003 
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For the negative binomial regression weighted by inverse propensity scores 
among matched individuals predicting ED visits (Table 42), income missing was dropped 
due to multicolinearity.  Lower incidence rates of ED visits were found for times (t+1) 
and (t+4), the interaction between ACEI monotherapy and time (t+4), age, annual income 
≥$35,000 and never smoker while higher incidence rates of ED visits were found for 
annual income $6,000-17,999, annual income $18,000-34,999, urban/suburban living, 
CHF, cardiac arrhythmias, peripheral vascular disorders, paralysis, chronic pulmonary 
disease, diabetes complicated, liver disease, metastatic cancer, solid tumor without 
metastasis, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency 
anemias, drug abuse, psychoses, and depression (p<0.05 each).  Of note, patients with 
annual income $6,000-17,999 had 55% (36-78%) more ED visits, patients who lived in 
urban/suburban areas had 58% (41-77%) more ED visits, patients with chronic 
pulmonary disease had 52% (30-77%) more ED visits, and patients with fluid and 
electrolyte disorders had 111% (65-169%) more ED visits.  The model resulted in a Wald 
χ2(56) = 2246.68, p<0.001, log pseudolikelihood = -126635.08. 
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Table 42:  Second Stage PSA: Negative Binomial Regression Analysis Weighted by 
Inverse Propensity Scores, ACEI versus ARB, for Variables Predicting ED visits 
(N=25,160 person-years; N=14,871 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 1.08 0.14 0.55 0.84 1.40
Time (t+1)b 0.73 0.04 <0.001 0.65 0.81
Time (t+2)b 0.73 0.05 <0.001 0.64 0.83
Time (t+3)b 0.59 0.07 <0.001 0.47 0.74
Time (t+4)b 0.11 0.11 0.03 0.01 0.83
ACEI*time (t+1)c 0.82 0.19 0.39 0.53 1.28
ACEI*time (t+2)c 1.01 0.23 0.98 0.65 1.56
ACEI*time (t+3)c 2.04 0.87 0.09 0.89 4.71
ACEI*time (t+4)c 0.00 0.00 <0.001 0.00 0.00
Age 0.96 0.00 <0.001 0.96 0.97
Annual income 
$6,000-17,999d 1.55 0.11 <0.001 1.36 1.78
Annual income 
$18,000-34,999d 1.24 0.09 <0.01 1.07 1.43
Annual income 
≥$35,000d 0.71 0.05 <0.001 0.61 0.82
Urban/suburbane 1.58 0.09 <0.001 1.41 1.77
Never smokerf 0.73 0.05 <0.001 0.64 0.83
Ever smokerf 1.25 0.16 0.08 0.97 1.62
Baseline 
microalbuminuriag 0.98 0.08 0.81 0.83 1.15
Microalbuminuria 
in follow-uph 1.01 0.07 0.88 0.88 1.16
Macroalbuminuria 
in follow-uph 1.12 0.11 0.27 0.92 1.35
HbA1c 1.02 0.01 0.12 1.00 1.04
LDL 1.00 0.00 0.54 1.00 1.00
Triglycerides 1.00 0.00 0.87 1.00 1.00
History of MIi 1.12 0.14 0.39 0.87 1.43
History of strokej 1.15 0.20 0.42 0.82 1.61
Family history of 
CVDk 0.83 0.24 0.53 0.47 1.48
CHFl 1.52 0.16 <0.001 1.24 1.87
Cardiac 
arrhythmiasm 1.43 0.18 <0.01 1.12 1.83
Valvular diseasen 1.15 0.31 0.60 0.68 1.96
Pulmonary 
circulation 
disorderso 1.66 0.77 0.27 0.68 4.10
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Table 42 (cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Peripheral vascular 
disordersp 1.34 0.12 <0.01 1.12 1.60
Hypertensionq 0.91 0.06 0.11 0.81 1.02
Paralysisr 3.02 1.04 <0.01 1.54 5.92
Other neurological 
disorderss 1.74 0.45 0.03 1.05 2.90
Chronic pulmonary 
diseaset 1.52 0.12 <0.001 1.30 1.77
Hypothyroidismu 0.89 0.11 0.34 0.69 1.13
Diabetes 
complicatedv 1.24 0.08 <0.01 1.10 1.41
Liver diseasew 1.71 0.29 <0.01 1.23 2.40
Peptic ulcer 
diseasex 0.95 0.25 0.85 0.56 1.61
AIDSy 0.50 0.39 0.37 0.11 2.26
Lymphomaz 2.36 1.17 0.08 0.90 6.23
Metastatic canceraa 2.51 0.95 0.02 1.19 5.28
Solid tumor without 
metastasisbb 1.47 0.17 <0.01 1.18 1.83
Rheumatoid 
arthritis / collagen 
vascular diseasescc 1.04 0.24 0.88 0.66 1.62
Coagulopathydd 1.17 0.27 0.49 0.75 1.84
Obesityee 0.98 0.06 0.68 0.87 1.10
Weight lossff 3.49 1.94 0.03 1.17 10.39
Fluid and 
electrolyte 
disordersgg 2.11 0.26 <0.001 1.65 2.69
Blood loss anemiahh 2.32 0.98 <0.05 1.01 5.32
Deficiency 
anemiasii 1.54 0.19 <0.01 1.21 1.97
Alcohol abusejj 1.08 0.14 0.54 0.84 1.40
Drug abusekk 1.74 0.29 <0.01 1.25 2.41
Psychosesll 1.50 0.17 <0.001 1.21 1.87
Depressionmm 1.27 0.10 <0.01 1.09 1.49
Cohort 2004nn 0.87 0.11 0.29 0.67 1.12
Cohort 2005nn 0.84 0.11 0.19 0.65 1.09
Cohort 2006nn 0.94 0.12 0.64 0.73 1.22
       
/lnalpha 1.53 0.04  1.46 1.61
alpha 4.64 0.18  4.29 5.01
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Wald χ2(56) = 2246.68, p<0.001, log pseudolikelihood = -126635.08 
 
a Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*Time t, d Reference category = Annual income <$6000, e Reference category = 
rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, hReference category = Normoalbuminuria in follow-up, i Reference 
category = No history of MI, jReference category = No history of stroke, kReference 
category = No family history of CVD, lReference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t No chronic 
pulmonary disease, u Reference category = No hypothyroidism, v Reference category = 
No diabetes complicated, w Reference category = No liver disease, x Reference category = 
No peptic ulcer disease, y Reference category = No AIDS, z Reference category = No 
lymphoma, aa Reference category = No metastatic cancer, bb Reference category = No 
solid tumor without metastasis, cc Reference category = No rheumatoid arthritis/collagen 
vascular diseases, dd Reference category = No coagulopathy, ee Reference category = No 
obesity, ff Reference category = No weight loss, gg Reference category = Fluid and 
electrolyte disorders, hh Reference category = No blood loss anemia, ii Reference category 
= No deficiency anemias, jj Reference category = No alcohol abuse, kk Reference category 
= No drug abuse, ll Reference category = No psychoses, mm Reference category = No 
depression, nn Reference category = Cohort 2003 
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The negative binomial regression weighted by inverse propensity scores for 
variables predicting hospitalization among matched patients (Table 43), found times 
(t+1), (t+2), (t+3), and (t+4), age, annual income ≥$35,000, never smoker, LDL, and 
hypertension had significantly lower incidence rates of hospitalization (p<0.05 each).  On 
the other hand, annual income $6,000-17,999, annual income $18,000-34,999, ever 
smoker, HbA1c, history of MI, history of stroke, CHF, peripheral vascular disorders, 
paralysis, other neurological disorders, chronic pulmonary disease, diabetes complicated, 
liver disease, lymphoma, metastatic cancer, solid tumor without metastasis, 
coagulopathy, weight loss, fluid and electrolyte disorders, deficiency anemias, alcohol 
abuse, drug abuse, psychoses, and depression had higher incidence rates of 
hospitalization (p<0.05 each).  In particular, patients with weight loss had 151% (79-
251%) more hospitalizations, patients with fluid and electrolyte disorders had 172% 
(117-238%) more hospitalizations, and 93% (51-150%) more hospitalizations.  The 
model resulted in a Wald χ2(56) = 2895.33, p<0.001, log pseudolikelihood = -98569.52. 
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Table 43:  Second Stage PSA: Negative Binomial Regression Analysis Weighted by 
Inverse Propensity Scores, ACEI versus ARB, for Variables Predicting Hospitalizations 
(N= 25,160 person-years; N=14,871 patients) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
ACEIa 1.05 0.13 0.68 0.83 1.33
Time (t+1)b 0.78 0.05 <0.001 0.68 0.89
Time (t+2)b 0.73 0.06 <0.001 0.62 0.85
Time (t+3)b 0.43 0.06 <0.01 0.32 0.57
Time (t+4)b 0.14 0.11 0.02 0.03 0.69
ACEI*time (t+1)c 0.67 0.15 0.08 0.43 1.04
ACEI*time (t+2)c 0.94 0.31 0.86 0.50 1.79
ACEI*time (t+3)c 0.85 0.49 0.78 0.27 2.65
ACEI*time (t+4)c 0.00 0.00 <0.001 0.00 0.00
Age 0.98 0.00 <0.001 0.97 0.98
Annual income 
$6,000-17,999d 1.63 0.12 <0.001 1.41 1.89
Annual income 
$18,000-34,999d 1.36 0.10 <0.001 1.17 1.57
Annual income 
≥$35,000d 0.77 0.07 <0.01 0.65 0.91
Urban/suburbane 1.00 0.06 0.96 0.90 1.12
Never smokerf 0.58 0.04 <0.001 0.52 0.66
Ever smokerf 1.68 0.21 <0.001 1.31 2.16
Baseline 
microalbuminuriag 0.98 0.09 0.87 0.82 1.18
Microalbuminuria in 
follow-uph 0.99 0.08 0.89 0.84 1.16
Macroalbuminuria in 
follow-uph 1.06 0.12 0.60 0.85 1.32
HbA1c 1.02 0.01 0.02 1.00 1.04
LDL 1.00 0.00 <0.001 0.99 1.00
Triglycerides 1.00 0.00 0.79 1.00 1.00
History of MIi 1.84 0.23 <0.001 1.44 2.35
History of strokej 1.42 0.24 0.04 1.01 1.99
Family history of 
CVDk 1.33 0.28 0.18 0.88 2.00
CHFl 1.60 0.15 <0.001 1.33 1.92
Cardiac arrhythmiasm 1.25 0.18 0.13 0.94 1.67
Valvular diseasen 0.96 0.34 0.91 0.48 1.94
Pulmonary 
circulation disorderso 1.35 0.42 0.34 0.73 2.50
Peripheral vascular 
disorderp 1.77 0.16 <0.001 1.48 2.12
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Table 43(cont.) 
 
 Incidence Robust p 95% CI 95% CI 
 Rate 
Ratio 
Standard 
Error 
 Lower 
Bound 
Upper 
Bound 
Hypertensionq 0.76 0.05 <0.001 0.68 0.86
Paralysisr 2.36 0.75 <0.01 1.27 4.40
Other neurological 
disorderss 2.79 1.03 <0.01 1.35 5.76
Chronic pulmonary 
diseaset 1.44 0.11 <0.001 1.24 1.68
Hypothyroidismu 0.98 0.12 0.89 0.77 1.26
Diabetes 
complicatedv 1.37 0.09 <0.001 1.20 1.56
Liver diseasew 1.88 0.29 <0.001 1.39 2.54
Peptic ulcer diseasex 1.24 0.38 0.48 0.68 2.26
AIDSy 0.78 0.32 0.55 0.35 1.75
Lymphomaz 2.78 1.03 <0.01 1.34 5.75
Metastatic canceraa 2.72 1.32 0.04 1.05 7.03
Solid tumor without 
metastasisbb 1.41 0.15 <0.01 1.15 1.73
Rheumatoid arthritis / 
collagen vascular 
diseasescc 1.53 0.41 0.11 0.90 2.60
Coagulopathydd 1.56 0.32 0.03 1.05 2.32
Obesityee 1.02 0.07 0.71 0.90 1.17
Weight lossff 2.50 0.43 <0.001 1.79 3.51
Fluid and electrolyte 
disordersgg 2.71 0.31 <0.001 2.17 3.38
Blood loss anemiahh 1.47 0.60 0.34 0.66 3.25
Deficiency anemiasii 1.94 0.25 <0.001 1.51 2.50
Alcohol abusejj 1.65 0.24 <0.01 1.24 2.20
Drug abusekk 1.96 0.32 <0.001 1.41 2.70
Psychosesll 1.48 0.17 <0.01 1.18 1.86
Depressionmm 1.27 0.09 <0.01 1.10 1.46
Cohort 2004nn 0.97 0.12 0.80 0.76 1.23
Cohort 2005nn 0.83 0.10 0.12 0.65 1.05
Cohort 2006nn 0.90 0.11 0.42 0.71 1.16
       
/lnalpha 1.51 0.05  1.40 1.61
alpha 4.51 0.24  4.07 5.01
 
Wald χ2(56) = 2895.33, p<0.001, log pseudolikelihood = -98569.52 
 
a Reference category = ARB, b Reference category = Time t, c Reference category = 
ACEI*Time t, d Reference category = Annual income <$6000, e Reference category = 
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rural, f Reference category = Current smoker, g Reference category = Baseline 
macroalbuminuria, hReference category = Normoalbuminuria in follow-up, i Reference 
category = No history of MI, jReference category = No history of stroke, kReference 
category = No family history of CVD, lReference category = No CHF, m Reference 
category = No cardiac arrhythmias, n Reference category = No valvular diseases, o 
Reference category = No pulmonary circulation disorders, p Reference category = No 
peripheral vascular disorders, q Reference category = Normotension, r Reference category 
= No paralysis, s Reference category = No other neurological disorders, t No chronic 
pulmonary disease, u Reference category = No hypothyroidism, v Reference category = 
No diabetes complicated, w Reference category = No liver disease, x Reference category = 
No peptic ulcer disease, y Reference category = No AIDS, z Reference category = No 
lymphoma, aa Reference category = No metastatic cancer, bb Reference category = No 
solid tumor without metastasis, cc Reference category = No rheumatoid arthritis/collagen 
vascular diseases, dd Reference category = No coagulopathy, ee Reference category = No 
obesity, ff Reference category = No weight loss, gg Reference category = Fluid and 
electrolyte disorders, hh Reference category = No blood loss anemia, ii Reference category 
= No deficiency anemias, jj Reference category = No alcohol abuse, kk Reference category 
= No drug abuse, ll Reference category = No psychoses, mm -Reference category = No 
depression, nn Reference category = Cohort 2003 
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Comparisons of Non-PSA and PSA Regressions, ACEI Monotherapy versus ARB 
Monotherapy 
 
 As found in Table 37, variables were identified to be significant for selection of 
one monotherapy over another.  Without propensity score adjustment, the lack of balance 
between the ACEI and ARB groups in age, HbA1c, LDL, and the interaction between 
hypertension and peripheral vascular disease, along with proportion of patients with 
history of stroke, family history of CVD, CHF, peripheral vascular disorders, 
hypertension, peptic ulcer disease, and ever smokers would have biased the results.  This 
is demonstrated in the different results between the two models, in which change in 
direction of relationship of a covariate with outcome (i.e., protective factor became a risk 
factor after propensity score adjustment) occurred.  Also, variables identified as not 
significant emerged as being significant or vice versa.  Although many variables were 
common between the models, the differences mentioned above have important 
implications.  The next paragraph focuses on these differences by outcome. 
 The unweighted logistic regression found LDL had lower odds of ESRD 
development, but after PSA, this disappeared and time (t+2) emerged with as having 
higher odds. The unweighted logistic regression found CHF and deficiency anemias had 
higher odds of IVDE while they became nonsignificant after propensity score adjustment; 
instead, LDL emerged as having a lower odds of IVDE.  Despite the other outcomes 
being important, it is crucial to know what truly impacts all-cause mortality.  The 
unweighted model found the interactions between ACEI monotherapy and times (t+1) 
and (t+2) had lower odds of all-cause mortality; these variables no longer remained 
significant after propensity score adjustment.  Chronic pulmonary disease and lymphoma 
had higher odds of all-cause mortality, which also disappeared with the weighted model.  
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Lastly, although annual income $18,000-34,999 and annual income ≥$35,000 were not 
significant with the unweighted model, they emerged with higher odds of all-cause 
mortality in the second stage PSA.  The unweighted model of outpatient visits found 
ACEI monotherapy and cohorts 2005 and 2006 had lower incidence rates whereas the 
interactions between ACEI monotherapy and times (t+1), (t+2), and (t+3), triglycerides 
and blood loss anemia had higher incidence rates; all became nonsignificant after 
propensity score adjustment.  This adjustment also led to the discovery that pulmonary 
circulation disorders had a significantly higher incidence rate. In terms of ED visits, the 
unweighted model identified time (t+3) and hypertension as having lower incidence rates 
and ever smoker, history of MI, and other neurological disorders as having higher 
incidence rates; all disappeared in the weighted model.  Also, the weighted model found 
annual income $18,000-34,999 had a higher incidence rate of ED visits, while the 
interaction between ACEI monotherapy and time (t+4) had a lower incidence rate; neither 
was not found in the unweighted model.  Lastly, the unweighted model of 
hospitalizations identified time (t+2) and cohort 2005 as having lower incidence rates and 
family history of CVD and rheumatoid arthritis/collagen vascular diseases as having 
higher incidence rates; all three became nonsignificant after second stage PSA.  Also 
after second stage PSA, metastatic cancer materialized with a higher incidence rate 
although this was nonsignificant with the unweighted model. 
ATT Attained by PSA Techniques Other Than Weighted Regression 
 
 At first look, the average treatment effect on the treated (i.e., ACEI patients) bore 
the same results regardless of stratification or nearest-neighbor matching:  all ATTs bore 
nonsignificant t-statistics (Appendix F, Tables 23 and 24).  ESRD had similar ATT 
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values across methods.  We see similar point estimates but a protective tendency for 
ACEI monotherapy with stratification while we see a protective tendency with ARB 
monotherapy with nearest-neighbor matching for IVDE occurrence.  For all-cause 
mortality, point estimates were extremely similar across methods.  Outpatient visits 
reveal differences in point estimates between the two methods.  Although both show a 
nonsignificant protective effect with ACEI monotherapy, nearest-neighbor matching 
shows this effect to be about five-fold higher than that attained through stratification.  ED 
visits exhibit relatively similar point estimates with either ATT estimation technique.  
Hospitalizations show a nonsignificant protective effect with ACEI monotherapy for 
nearest-neighbor matching and a nonsignificant protective effect with ARB monotherapy 
from stratification. 
Validation of PSA:  Sensitivity Analyses 
 
 Nearest-neighbor matching allowed the researchers to perform sensitivity 
analyses.  Due to the fact that PSA can only balance observable characteristics, Mantel-
Haenszel bounds and Rosenbaum bounds were defined for dichotomous and count 
variables, respectively, to assess the robustness of our findings in case there is an 
exogenous variable differentially affecting odds of treatment assignment. (Note no test 
exists that an unobserved variable is doing this.)  The hypothetical situation of odds of 
differential treatment assignment is tested by changing gamma (the odds of differential 
treatment assignment) from one to two.172,201,202  All sensitivity analyses were conducted 
using a weighted average across strata instead of separately assessing each stratum. 
 Mantel-Haenszel bounds found nonsignificant differences for ESRD and all-cause 
mortality between ACEI and ARB monotherapies holds true to the point that if an 
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unobserved variable exists, it would have to increase the odds of treatment assignment by 
more than 200% to change this conclusion. (Please see Appendix F, Tables’ 25 and 27 p-
value columns.)  The nonsignificant between group differences for IVDE occurrence 
holds true in the potential presence of an unobserved variable until it increases the odds 
of treatment assignment by 115% to 120%. (Please see Appendix F, Table 26.)  
 Rosenbaum bounds reveal the nonsignificant differences in outpatient visits found 
by PSA only holds true in the presence of an unobserved variable if it affects odds of 
treatment assignment by between 105% and 110% (Please see Appendix F, Table 28).  
On the other hand, the PSA for ED visits showed patients receiving either monotherapy 
had similar ED visits, but this conclusion changes if an unobserved variable increased the 
odds of treatment assignment by less than 105% (Appendix F, Table 29).  Finally, the 
result of no differences between monotherapies for hospitalizations remains true if an 
unobserved variable changed the odds of treatment assignment between 115% and 120% 
(Appendix F, Table 30). 
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CHAPTER 5: DISCUSSION 
 
 
 This chapter starts by reviewing the research problem and putting the problem in 
context of the diabetes epidemic.  Then the chapter discusses the study results.  Next, we 
discuss answers and implications to the research questions specific to this study.  From 
there, the chapter delves into other issues pertinent to understanding the results of the 
study.  In particular, the topics address compliance, VA as a closed system, and internal 
and external validity.  Thereafter, we address limitations and close with a summary of 
conclusions and significance. 
 
Background 
 
 The prevalence of diabetes has increased by 80% in the last ten years,4 and 
projections estimate its prevalence to increase by more than 2.5 fold between the years 
2000 and 2050.5  The major modifiable contributor to this increase is obesity.  Diabetes is 
already the leading health condition contributing to incident ESRD cases,19 and the 
number of P2DM developing ESRD is expected only to increase as the number of P2DM 
increases despite a reduction in complications seen in the last decade as type 2 diabetes 
has such a steep rate of incidence.203,204  Each of these complications has a high morbidity 
and mortality rate. 
 As albuminuria and hypertension are predictors of ESRD and CVD and because 
ACEIs and ARBs have been shown to reduce both albuminuria and hypertension, this 
study was designed to evaluate the effectiveness of ACEI or ARB monotherapy in 
reducing ESRD or CVD.  Taking this one step further, it would be helpful for clinicians 
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to know the related complication all-cause mortality as well as be able to provide insight 
into differences in healthcare utilization between these monotherapies.  As more 
Americans develop type 2 diabetes, there will be increased healthcare burden; therefore, 
information about any factors that reduce or increase healthcare utilization would be 
extremely valuable. 
 
Current State of Diabetes in the VA Population 
 
 Our study provides insight regarding the current state of diabetes patients in the 
VA population.  This itself is an important contribution as the study spans several years, 
is longitudinal, and analyzes a large patient population.  We found that approximately 
71% of the VA population had normoalbuminuria at baseline, 23% had microalbuminuria 
at baseline, and 6% had macroalbuminuria at baseline.  This is comparable to a combined 
prevalence of microalbuminuria and macroalbuminuria of 26.5% in Americans with 
undiagnosed diabetes who are at least 40 years of age.37  Our study demonstrated a 70.6% 
prevalence of hypertension at baseline, which is comparable to rates in two previous 
studies: one in American P2DM, which showed 73% were hypertensive and one in 
veteran patients with diabetes, which showed 67% had hypertension.3,142   In terms of 
mean clinical parameters, patients in our study had a mean baseline HbA1c of 7.30% and 
mean baseline LDL of 94.56 mg/dL.  This was similar to VA registry data, among 
veterans with diabetes, who had mean HbA1c values in fy2000 and fy2001 were 7.61% 
and 7.37%, respectively.142  The same VA registry data showed veterans with diabetes 
had a mean LDL of 104 mg/dL in fy2000 and of 108 mg/dL in fy2001.142   
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Drug Therapy and Patient Characteristics 
 
As expected, there were fewer between group differences for ACEI and ARB 
patients than either monotherapy compared to those receiving neither therapy (Tables 13 
and 14).  It appears that the patients receiving neither therapy may have been healthier.  
Specifically, the ACEI and ARB groups had over 80% of patients who were hypertensive 
while those receiving neither therapy had a hypertensive rate of about 60% (Table 14).  
The 20% difference in hypertensive status between patients receiving either monotherapy 
and those receiving neither therapy suggests that VA prescribers preferentially prescribed 
an ACEI or ARB based on hypertensive, rather than albuminuric, status.  Nevertheless, 
the guidelines advise prescribing an ACEI or ARB to all P2DM with hypertension or all 
P2DM who have nephropathy (i.e., microalbuminuria or macroalbuminuria).54,142  
Alternately, it could suggest that patients with hypertension were more compliant to 
ACEI or ARB monotherapy compared to patients with normotension.  This notion is due 
to the classification of patients into treatment groups based upon medication they have 
on-hand; patients were considered to have received ACEI or ARB monotherapy if they 
had at least a one-half years supply.  Even though we were unable to assess this in our 
study, patients with normotension perhaps did not refill their prescription as frequently 
because of perceived lack of disease severity.  
ACEI patients had a higher history of stroke (Table 16) while ARB patients were 
the oldest, had the highest percentage of never smokers, and had the highest percentage 
of CHF (Tables 15 and 16).  (Notice these variables were all identified as factors 
influencing treatment selection of ACEI and ARB in the first stage PSA.)   
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Multivariate Analyses 
 
ACEI or ARB Monotherapy versus neither 
 
 Unlike the comparisons between ACEI and ARB monotherapies, these analyses 
were conducted only by using traditional multivariate logistic regression and negative 
binomial regression techniques, as appropriate.  The driving force behind this decision is 
the vast amount of published literature consistently showing benefit of ACEI or ARB 
monotherapy over neither therapy for nephropathy,45-49,116,120 to the point that clinical 
guidelines published by the American Diabetes Association and the VA advocate their 
use in this patient population.54,89,142  Still, it was believed that comparisons to patients 
receiving neither therapy were important for two main reasons.  First, there is less 
published literature about monotherapy benefits in P2DM for cardio- and cerebro- 
vascular disease events and all-cause mortality.  Second, many patients in our sample 
were found to have received less than 50% of a year’s supply of ACEI or ARB 
monotherapy in a given year.  Thus, not only should outcomes be compared across these 
three groups, but reasons for not adhering to the guidelines should also be discussed. 
ACEI versus ARB Monotherapy 
 
Propensity Score Analysis  
 
 The propensity score analysis (PSA) was successful for two main reasons.  The 
first was the fact that it fulfilled the goal of undergoing this type of analysis: to achieve 
balance between groups on observable characteristics.  The second goal was to have 
enough people on common support, meaning substantial overlap existed in propensity 
scores between patients on the two drug therapies. 
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 With respect to the first reason, meeting the goal is key in arguing that the study 
controlled for treatment selection by having similar information a provider would have at 
the time of prescribing therapy and entering this information into a model.  (Note we did 
not have information about blood pressure readings, race/ethnicity, antihypertensives, and 
antihyperlipidemics.)  As can be seen in this study, treatment selection bias existed in the 
VA for these patients because we identified variables in the first stage PSA that had 
higher odds of one monotherapy over the other. 
The first stage of PSA tries to balance each of the characteristics entered into the 
model across therapy groups.  The flexibility in this stage of specifying different models 
is what allows for better estimation of treatment selection.  Stratification balanced 
everything but seven sites in one of fourteen strata each.  This means that for other than 
site, both groups were comparable at baseline.  This is similar to the way patients are 
comparable at baseline in randomized clinical trials.  Even in randomized clinical trials, 
not all observable variables may be balanced (failure of randomization).205  If balance on 
observable variables cannot always be guaranteed through randomized clinical trials, the 
argument also exists that unobservable variables cannot always be balanced in 
randomized designs.  Similar to randomized trials, our study cannot guarantee balance on 
unobservable variables.  By achieving balanced groups at baseline in a similar way as 
randomized trials we can say we do not have a systematic mechanism to create error in 
our study.   
Taking it one step further, Seeger et al. (2007) and Joffe et al. (1999) claim that 
PSA creates a better balance at baseline than randomization.152,206  As a matter of 
statistical probability this is true.  In a randomized clinical trial, 5% of covariates may not 
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be balanced due to chance alone.  These variables would not generally be further 
adjusted.  Particular to this study, out of 57 covariates, about 3 may not be statistically 
similar due to chance alone. 
With respect to the second reason, common support refers to the overlap in those 
receiving ACEIs and those receiving ARBs who have similar propensity scores.  In other 
words, a high proportion of patients should be matched on propensity scores.  If there is 
not enough common support there is not enough information to generate accurate 
information about the counterfactual- what would have happened to a patient receiving 
one therapy if they instead received the other, based on their propensity score.  The other 
implication of lack of common support is loss of generalizability.  The current study was 
able to match 72.77% of patients 
Intention-to-Treat Analysis 
 
 Since we used ITT for the same reasons it is used in randomized clinical trials, 
i.e., to maintain comparable between group characteristics established at baseline, we 
needed to assess the percentage of patients within each drug therapy at baseline who 
remained on the same drug therapy.  The regression analyses comparing ACEI and ARB 
patients had substantially higher amounts of patients who stayed on the same therapy 
since neither patients were excluded:  99.14% and 99.73% of ACEI and ARB patients, 
respectively (data not shown). 
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Primary Constructs of Interest:  Renal and Cardio- and Cerebro- Vascular Diseases 
 
Relationship Between Drug Therapy and ESRD 
 
 In univariate analysis, we found that ACEI patients had a lower rate of ESRD 
development compared to ARB and neither patients (Table 17).  We further explored 
albuminuria over time and by drug therapy.  (See Appendix F, Tables 7-10).   
 Among those with baseline microalbuminuria, ACEI and ARB patients had 
similar improvement in albuminuria in years 1-5 despite a wider range of albuminuria 
values among ARB patients at year 1 (Appendix F, Tables 7 and 8).  Neither patients, 
after their initial improvement between years 1 and 2, experienced worsening 
albuminuria between years 2 and 3 and years 2 and 4 (Appendix F, Table 8).  These 
findings are important as about 78% of the sample had baseline microalbuminuria.  
Among patients with baseline macroalbuminuria, ACEI patients were the only group that 
not only had improving albuminuria at every year of follow-up compared to the first year, 
but also had better albuminuria in later years when compared to years two and three 
(Appendix F, Table 8).     
Differences in ESRD Development, ACEI or ARB Monotherapy versus neither  
 
 As shown in Table 23, our primary interest, effectiveness of ACEI and ARB 
monotherapies, compared to neither therapy, found ACEI patients were associated with 
lower odds of developing ESRD.  Age and LDL also were associated with lower odds of 
ESRD development (p<0.017 each; see Table 23).  Time (t+2), annual income $18,000-
34,999, CHF, diabetes complicated, fluid and electrolyte disorders, and deficiency 
anemias were associated with higher odds of ESRD development (p<0.017 each).   
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 To our knowledge, this is the first study comparing ACEI monotherapy to 
neither/placebo among P2DM for ESRD and only the second study comparing ARB 
monotherapy to neither/placebo patients among P2DM for ESRD.  It is the first 
comparing ARB monotherapy to neither/placebo for patients with majority baseline 
microalbuminuria.  Although ARB monotherapy was not even found to have statistically 
significantly lower odds of ESRD development, the point estimate of the odds ratio, 0.50, 
shows promise of benefit.  Based on the a priori power calculation for ESRD assuming 
equal size treatment groups, we were lower than the 80% power threshold as we had 
fewer patients in the ARB group than mentioned in Table 4.   
 Age makes sense as being associated with lower odds of ESRD development as it 
is associated with higher odds of all-cause mortality, a competing risk.  It is also intuitive 
that LDL is associated with lower odds of ESRD.  First, analysis of the RENAAL study 
found baseline LDL was not associated with development of ESRD.207  Obviously, this in 
itself, does not give the complete picture.  However, we captured LDL longitudinally and 
LDL levels can decrease as patients develop ESRD.208 
It is interesting that patients who have three years of follow-up were associated 
with 2.76 higher odds of developing ESRD given that the mean follow-up is 2.17 years 
and the median follow-up is 2.00 years.  In light of Brenner et al. finding significant 
beneficial effects of ARB monotherapy, compared to placebo, over 3.4 years in his 
baseline macroalbuminuric sample,49 we may have also found a significant benefit for 
ARB monotherapy if we had longer average follow-up.  We note annual income $18,000-
34,999 was associated with a higher odds of ESRD (all other income levels had higher 
point estimate than <$6,000); the USRDS found approximately 25% of incident ESRD 
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cases in the U.S. had Medicaid coverage between 2002 and 2006.209  CHF also makes 
sense as being associated with higher odds of ESRD development since renal and cardiac 
diseases are intricately woven together.  Likewise, diabetes complicated and fluid and 
electrolyte disorders have rationale to be indicative of ESRD development.  Diabetes 
complicated, defined by Elixhauser et al., includes any of the following:  diabetes with 
renal manifestations, diabetes with ophthalmic manifestations, diabetes with neurological 
manifestations, diabetes with peripheral circulatory disorders, and diabetes with 
unspecified complications.195  Similarly, fluid and electrolyte disorders is a collective of 
hypernatremia, hyponatremia, acidosis, alkalosis, volume depletion, fluid overload, 
hyperkalemia, hypokalemia, and fluid and electrolyte disorders not otherwise specified.  
Since fluid and electrolyte disorders can be a result of renal or cardiac dysfunction, 
perhaps the kidney already had some predisposition.210  It is reasonable to say someone 
who has more clinically evident complications of diabetes at baseline or who has a fluid 
and electrolyte disorder at baseline would have higher odds (OR = 3.40 and OR = 4.19, 
respectively) of developing ESRD than someone who has not.  Even if a patient has good 
glycemic control during the study, a patient may have had increasing levels of 
hyperglycermia over a long period of time, leading to diagnosis of type 2 diabetes.  
Deficiency anemias is intuitive as it encompasses iron deficiency anemias and anemia not 
otherwise specified, both of which have causes that are seemingly unrelated to ESRD or 
diabetes except for one:  long-term treatment with NSAIDs.211,212  This study did not 
capture the cause of deficiency anemias for each patient, but since other causes are 
cancer, esophageal varices, peptic ulcer disease, celiac disease, Crohn’s disease, gastric 
bypass surgery, and antacid therapy there is no way to know if deficiency anemias was, 
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in fact, caused by long-term NSAID use in this sample.  The researchers set out to look at 
this very covariate, but there were too many missing observations to retain the 
information. 
 When P2DM are newly-diagnosed healthcare providers should give ACEI or 
ARB therapy as recommended in treatment guidelines and encourage compliance with 
medication.  The other factors found to be significant were nonmodifiable.  Because this 
study showed ACEI monotherapy was associated with a lower odds of ESRD 
development at two years, albeit with limitations in using multivariate regression without 
propensity score adjustment, and found the three year time point to be a significant 
predictor, patients having longer treatment duration with at least 50% compliance would 
only be expected to reap larger benefits.  
Difference in ESRD Development, ACEI versus ARB Monotherapy  
 
 There were no significant differences in ACEI and ARB monotherapies for ESRD 
development (Table 38).  The only variable having lower odds of ESRD development 
was LDL, which was only found by unweighted logistic regression (Table 29).  Time 
(t+2), diabetes complicated, liver disease, fluid and electrolyte disorders and deficiency 
anemias had higher odds of ESRD development in both models (p<0.05 each).   
 Similar to ACEI or ARB monotherapy versus neither therapy results of variables 
predicting ESRD, time (t+2), diabetes complicated, fluid and electrolyte disorders, and 
deficiency anemias had higher odds of ESRD development.  Liver disease may have 
higher odds of ESRD development through two different mechanisms:  first, cirrhosis 
could lead to expanded fluid volume, which could lead to ESRD; second, liver disease 
may predispose patients to ESRD because hepatorenal syndrome is a complication.210,213 
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 This is the first study with comparable baseline characteristics between 
monotherapies to assess differences in ESRD development.  The study shows no trends 
or significant differences between ACEI and ARB monotherapies for effects on ESRD 
development.  Similarly, no trends or significant differences were seen for interactions 
between either monotherapy and time.  Since propensity score adjustment is viewed as 
achieving similar balances in baseline characteristics as randomization, this is fairly 
strong evidence, yet is only one study in one population.  Future research is needed to 
confirm results. 
 
Relationship Between Drug Therapy and IVDE 
 
 ACEI and ARB patients suffered an IVDE more frequently in years 1-4 compared 
with neither patients (Table 18).  Components analysis finds this pattern to be upheld the 
most for LVH, but is also seen for stroke and MI. 
Differences in IVDE Occurrence, ACEI or ARB Monotherapy versus neither  
 
 Our primary research interest, whether ACEI or ARB monotherapy was 
associated with reducing IVDE occurrence, did not hold true; in fact, the difference was 
found in the opposite direction (Table 24).  ACEI monotherapy, age, the interaction 
between LDL and triglycerides, history of MI, history of stroke, CHF, peripheral vascular 
disorders, chronic pulmonary disease, fluid and electrolyte disorders, and deficiency 
anemias were associated with higher odds of IVDE occurrence while age squared, never 
smoker, ever smoker, and LDL were associated with lower odds (p<0.017 each; Table 
24).   
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As mentioned previously, the substantially higher mortality rate seen in neither 
patients compared to ACEI or ARB patients likely obscured benefits of monotherapies’ 
other endpoints compared to neither patients assessed in this study.  This makes it 
plausible that patients with ACEI monotherapy were associated with 1.54 higher odds of 
suffering an IVDE:  more ACEI patients were alive to be at risk for having an IVDE.20,214  
Age, history of MI, history of stroke, CHF, peripheral vascular disorders, and fluid and 
electrolyte disorders are intuitively appealing to higher odds of IVDEs.  Chronic 
pulmonary disease and deficiency anemias have been previously identified as risk factors 
for cardiovascular events:  COPD may put patients at increased risk because of 
hypoxemia and inflammation215,216 whereas anemia worsens cardiac function while 
simultaneously affecting renal function.217  In fact, deficiency anemias was also 
associated with higher odds of ESRD development in the comparison of ACEI or ARB 
monotherapy to neither.  Never smoker, ever smoker, and the interaction between LDL 
and triglycerides odds ratios make sense as there is a vast array of evidence that smoking 
and increased lipids lead to cardio- and cerebro- vascular disease events.214  Age squared 
may be associated with a lower odds of IVDEs because death may be a competing risk of 
IVDEs. Similar to the mortality comment among neither patients, patients may die before 
suffering an IVDE.218 
 The modifiable factors are ACEI monotherapy, smoking, and lipid levels.  In the 
context of results from all-cause mortality (Table 25), clinicians should prescribe ACEI 
monotherapy, again realizing this statistical method does not provide evidence of 
causality.  This study adds evidence to already existing literature that healthcare 
professionals need to discourage smoking and encourage lower lipid levels. 
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Difference in IVDE Occurrence, ACEI versus ARB Monotherapy 
 
 No difference in effectiveness for reduction of IVDE was found between ACEI 
and ARB monotherapies (Table 39).  Both the unweighted (Table 30) and weighted 
logistic regression models found never smoker and ever smoker had lower odds while 
age, history of MI, history of stroke, pulmonary circulation disorders, peripheral vascular 
disorders, chronic pulmonary disease, and fluid and electrolyte disorders had higher odds 
of IVDE occurrence (p<0.05 each).  Also after propensity score adjustment, LDL had a 
lower odds of IVDE occurrence (p<0.05), despite it not being revealed in the unweighted 
model.  Also after propensity score adjustment, CHF and deficiency anemias became 
nonsignificant although they were each identified as being associated with higher odds of 
IVDE occurrence. 
We find it intuitively appealing that never smoker and ever smoker had lower 
odds of IVDE occurrence given the literature that smoking increases rates of MI and 
stroke.  Similarly, history of MI, history of stroke, and peripheral vascular disorders are 
intuitive to having higher odds of IVDEs as history of MI,20 history of stroke,20 and 
peripheral vascular disorders219 put patients at increased risk of MI and stroke.  
Pulmonary circulation disorders captures patients documented with chronic pulmonary 
heart disease, so this also makes sense. 
 Healthcare providers should prescribe ACEI or ARB monotherapy in P2DM as 
advocated in the guidelines54,89,142,144,145,220 as the findings show evidence of comparable 
effectiveness in IVDE occurrence.  Healthcare professionals should encourage prevention 
of MI, stroke, peripheral vascular disorders, chronic pulmonary disease, and fluid and 
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electrolyte disorders, so patients would be more likely to avoid downstream effects of 
increased IVDEs.  One risk factor of these conditions is smoking.  Cardio- and cerebro- 
vascular disease is cascading; previous research shows P2DM are at higher risk of cardio- 
and cerebro- vascular disease events than the general population.91  P2DM with history of 
CVD are twice as likely as P2DM without such a history to suffer a recurrent MI or 
stroke.20  Therefore, time needs to be spent educating and emphasizing to patients about 
these downstream effects, especially since approximately two-thirds of the diabetes 
population will die from cardio- or cerebro- vascular events. 
 
 
Other Constructs:  All-cause Mortality and Healthcare Utilization 
 
Relationship Between Drug Therapy and All-cause Mortality 
 
 Every year, patients receiving neither therapy were dying at a rate several fold 
higher than ACEI or ARB patients (p<0.001 each; Table 18).  In year 1, neither patients 
died at an 8-times higher rate than ACEI or ARB patients, which continued throughout 
follow-up (Table 18).  All-cause mortality was comparable between ACEI and ARB 
patients at every year. 
Differences in All-cause Mortality, ACEI or ARB Monotherapy versus neither  
 
 ACEI and ARB monotherapies were associated with 0.16 and 0.11 odds of all-
cause mortality compared to neither therapy, respectively (p<0.001 each; Table 25).  Also 
found, times (t+1) and (t+2), and income missing were associated with lower odds while 
the interaction between ACEI monotherapy and times (t+1), (t+2), and (t+3), age, 
urban/suburban living, HbA1c, CHF, peripheral vascular disorders, chronic pulmonary 
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disease, metastatic cancer, coagulopathy, fluid and electrolyte disorders, and cohorts 
2004, 2005, and 2006 were associated with higher odds of all-cause mortality (p<0.017 
each; Table 25).   
Although multivariate logistic regression holds all other variables entered into the 
regression equation constant, it still does not ensure balance in baseline observable 
characteristics, thus this analysis most likely overestimated the benefit of ACEI and ARB 
monotherapy over neither therapy for all-cause mortality.  Otherwise, with the mean and 
median follow-up of approximately 2 years in this study, it would be well-known 
publicly as well as found in previous studies, which it has not.  Times (t+1) and (t+2) 
were associated with lower odds of all-cause mortality compared to time (t) even though 
univariate comparisons found similar or higher mortality rates at times (t+1) and (t+2) 
than time (t) within each drug therapy, suggesting some control over covariates (Table 
19). 
 The interactions between ACEI monotherapy and times (t+1), (t+2), and (t+3) 
make sense because looking at the univariate comparisons we can see ACEI patients had 
a higher mortality rate at each of these timepoints compared to ACEI patients at time (t) 
(see Table 19).  Age and HbA1c intuitively make sense as being associated with higher 
odds of all-cause mortality because age and HbA1c have a lot of supporting evidence of 
higher frequency of death.  Also, Elixhauser et al. showed CHF, peripheral vascular 
disorders, chronic pulmonary disease, metastatic cancer, coagulopathy, and fluid and 
electrolyte disorders are associated with higher in-hospital mortality in the general 
population.195   
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 To understand why cohorts 2004, 2005, and 2006, compared to cohort 2003, were 
associated with higher odds of all-cause mortality, we have to closely examine the 
results.  Each of these variables has extremely large odds ratios and robust standard 
errors, signaling that there are a small number of patients with all-cause mortality in at 
least one cell of the 2x2 table for each of these cohorts compared to cohort 2003.  
Consequently, we have to use caution in interpreting the significance of these variables.  
Nevertheless, because of the associations of higher odds, additional post hoc analyses 
were conducted to further explore the relationship.   
 ANOVA followed by Tukey’s Honestly Significant Differences pairwise 
comparisons found cohorts 2005 and 2006 each had more comorbidities than cohorts 
2003 and 2004 (group means = 1.73, 1.75, 1.61, and 1.65, respectively).  It is apparent 
from these numbers that the cohorts still do not “look” that different in terms of numbers 
of comorbidities.  To shed a little more light on this perspective, Elixhauser et al. found 
1.89 times as many people with three comorbidities had an in-hospital death (their only 
measure of mortality) than people with two comorbidities.195  (Remember we excluded 
diabetes as a comorbidity since everyone in the sample has this condition whereas 
Elixhauser et al. studied the general population.)  This only provides part of the picture so 
age and each of the mean baseline clinical parameters were also assessed between 
cohorts.  However, age went in the opposite direction than expected and patients in 
cohort 2003 were significantly younger than cohorts 2004, 2005, and 2006 (adjusted p-
value<0.004 each).  None of the cohorts were significantly different than cohort 2003 for 
LDL or triglycerides while each cohort had higher mean baseline HbA1c than cohort 
2003 (adjusted p-value<0.004 each).  The only significant difference between cohorts, 
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when compared to cohort 2003, was for baseline albuminuria: cohort 2003 had fewer 
patients with macroalbuminuria than cohort 2004. 
 Modifiable significant factors were ACEI monotherapy, ARB monotherapy, and 
HbA1c.  Due to observed associations, providers should write prescriptions for and 
encourage compliance with ACEI or ARB monotherapy.  Providers should also educate 
patients about how to control HbA1c, prescribing medication when necessary and 
reinforcing compliance.  Looking more upstream, healthcare professionals should 
counsel on preventable behaviors of chronic pulmonary disease and metastatic cancer as 
these comorbidities had higher odds of all-cause mortality (OR = 2.07 and OR = 9.29, 
respectively). 
Difference in All-cause Mortality, ACEI versus ARB Monotherapy 
 
 No differences were found between monotherapies for all-cause mortality (Table 
40).  Lower odds of all-cause mortality were only found for the interactions between 
ACEI monotherapy and times (t+1) and (t+2); these variables were only found significant 
in the unweighted model.  Chronic pulmonary disease, and lymphoma were associated 
with higher odds of all-cause mortality in the unweighted model while the second stage 
PSA found higher odds for annual income $18,000-34,999 and annual income ≥$35,000 
(p<0.05 each).  Both models found times (t+2) and (t+3), age, annual income $6,000-
17,999, history of MI, CHF, peripheral vascular disorders, cohorts 2004, 2005, and 2006 
were the only variables having higher odds of all-cause mortality (p<0.05 each; Tables 31 
and 40).   
 Just as in the comparison of ACEI or ARB monotherapy to neither therapy for all-
cause mortality, extremely large odds ratios and robust standard errors are present for 
  265
each of the cohorts, meaning that in each of the cohorts, compared to cohort 2003, there 
is at least one cell in the 2x2 table where there are only a small number of deaths.  Still, 
we further explored the differences between cohorts to see if there are any other possible 
explanations.  All cohorts, compared to cohort 2003, had higher mean baseline HbA1c 
(adjusted p-value<0.004 each).  Also, cohorts 2005 and 2006 each had higher 
comorbidities compared to cohorts 2003 and 2004.  These two differences could explain 
why members of cohorts 2004, 2005, and 2006 had higher odds of all-cause mortality 
compared to cohort 2003.   
Times (t+1), (t+2), and (t+3) having higher odds of all-cause mortality make 
sense in relation to the univariate comparisons across time (Table 19).  Age also is 
intuitive as people in general tend to die when they are older.  It is extremely interesting 
that people with any income higher than the lowest of our categories are at higher odds of 
dying.  History of MI also is rational as people with this history are about twice as likely 
to have a cardio- or cerebro- vascular event,20 and we know that most P2DM die from 
these events.3  In fact, history of MI and peripheral vascular disorders also had higher 
odds of IVDE occurrence in our sample.  Additionally, CHF and peripheral vascular 
disorders are intuitive to having higher odds of all-cause mortality based on previous 
research by Elixhauser et al.195  
This study provides evidence that there is no difference in ACEI and ARB 
monotherapy for all-cause mortality.  Therefore, clinicians can view these medications as 
virtually identical for all-cause mortality.  Clinicians also need to focus on preventive 
efforts so that MI, CHF, or peripheral vascular disorders do not develop.   
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Relationship Between Drug Therapy and Healthcare Utilization 
 
 ACEI patients had more outpatient visits, ED visits, and hospitalizations than 
neither patients (Table 20).  Similarly, ARB patients had more outpatient visits and ED 
visits than neither patients (Table 20).  When these groups were compared to neither 
patients, ACEI and ARB patients had higher rates of outpatient visits, ED visits, and 
hospitalizations for years 1-4 (Table 21).  For healthcare utilization, we found only one 
significant difference between ACEI and ARB patients:  overall, ACEI patients had more 
outpatient visits than ARB patients (p<0.0083; Table 20).  When analyzed annually, no 
significant differences were seen between these two groups (Table 21).   
Differences in Outpatient Visits, ACEI or ARB Monotherapy versus neither 
 
ACEI and ARB monotherapies were associated with higher incidence rates of 
outpatient visits (1.19 and 1.25, respectively) compared to neither therapy (p<0.001 each; 
Table 26).  In addition, the interactions between ACEI monotherapy and times (t+1), 
(t+2), (t+3), the interaction between ARB monotherapy and time (t+3), annual income 
$6,000-17,999, annual income $18,000-34,999, urban/suburban living, history of stroke, 
CHF, cardiac arrhythmias, valvular disease, peripheral vascular disorders, paralysis, other 
neurological disorders, chronic pulmonary disease, diabetes complicated, liver disease, 
AIDS, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid 
arthritis/collagen vascular diseases, coagulopathy, obesity, fluid and electrolyte disorders, 
blood loss anemia, deficiency anemias, alcohol abuse, drug abuse, psychoses, and 
depression were associated with higher incidence rates of outpatient visits (p<0.017 
each).  Times (t+1), (t+2), (t+3), and (t+4), age, annual income ≥$35,000, income 
missing, never smoker, microalbuminuria in follow-up, LDL, hypertension, and cohorts 
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2005 and 2006 were associated with lower incidence rates of outpatient visits (p<0.017 
each).   
ACEI and ARB monotherapies could have been associated with higher incidence 
rates of outpatient visits because these patients could have been seeking help more 
frequently than patients receiving neither therapy because they are concerned with their 
health, and thus, are more compliant with their medications.  As already mentioned, 
because neither patients are dying at a substantially higher rate than ACEI or ARB 
patients this is probably the main contributor.  The interactions between ACEI 
monotherapy and times (t+1), (t+2), and (t+3) being associated with higher incidence 
rates of outpatient visits makes sense when taking Table 21 into consideration:  univariate 
comparisons found significant difference between ACEI and neither therapies at each of 
these timepoints (p<0.001 each).  Although not found statistically significant in 
univariate comparisons of ARB monotherapy and neither therapy at time (t+3), the mean 
number of outpatient visits is comparable to ACEI monotherapy, validating the finding of 
an association of higher incidence of outpatient visits for the interaction between ARB 
and time (t+3).  Annual income $6,000-17,999 and annual income $18,000-34,999 could  
have higher incidence rates of outpatient visits because veterans may be more likely to 
afford transportation, public or private, to have outpatient visits compared to those with 
income <$6,000.221  For a similar reason urban/suburban living may be associated with a 
higher incidence rate of outpatient visits:  patients who live in cities will be more likely to 
have affordable public transportation; they are also more likely to be closer to a VA 
facility to obtain care.222  The remaining significant predictors are comorbidities, so it is 
logical that patients with comorbidities, compared to patients without comorbidities, will 
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have more outpatient visits. This is especially true if patients with comorbidities are not 
dying earlier in the follow-up period, allowing more time for patients to attend outpatient 
clinics.  There is no association between higher odds of all-cause mortality and cardiac 
arrhythmias, valvular disease, paralysis, other neurological disorders, diabetes 
complicated, liver disease, solid tumor without metastasis, rheumatoid arthritis/collagen 
vascular diseases, obesity, blood loss anemia, deficiency anemias, or psychoses, making 
this argument easy for these comorbidities (Tables 25 and 40). However, there is a 
relationship between higher odds of mortality for CHF, peripheral vascular disorders, 
chronic pulmonary disease, AIDS, lymphoma, metastatic cancer, coagulopathy, fluid and 
electrolyte disorders, alcohol abuse, drug abuse, and depression.  Although it is outside 
the scope of this project to see when patients with each comorbidity die, making it unable 
to confirm this assumption, it does make sense.  Preliminary evidence could be contrived 
from Table 14 as the comorbidities with increased odds of all-cause mortality make up 
maximally 29.58% of the sample while comorbidities without comprise maximally 
50.27% of the sample. (Note the amount of overlap between comorbidities within the 
sample is unknown).  With about equal proportions, it does provide more evidence that 
patients with the comorbidities identified as predictors of outpatient visits are not, in 
general, dying at earlier points in follow-up, allowing for accumulation of healthcare 
utilization, including outpatient visits.  
Times (t+1), (t+2), (t+3), and (t+4) have face validity as univariate comparisons 
of outpatient visits over time displays fewer outpatient visits in each of these years from 
year 1 across all drug therapies. (Please see Table 22.)  Age and people in cohorts 2005 
and 2006 were probably associated with lower incidence rates of outpatient visits as they 
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were both associated with higher odds of all-cause mortality, a competing risk of 
outpatient visits (see Table 25).218  Annual income ≥$35,000 makes sense as being 
associated with lower incidence rate of outpatient visits because higher income is 
associated with better health and better health could lead to fewer outpatient visits.223,224  
Those with missing income may have the same reason.  The fact that never smokers had 
lower incidence rates of outpatient visits compared to current smokers is intuitively 
appealing because never smokers are believed to be generally healthier.  The finding that 
patients with microalbuminuria in follow-up were associated with lower incidence rates 
than patients with normoalbuminuria in follow-up perhaps is due to differences in health 
perceptions.  More specifically, patients with normoalbuminuria may attend outpatient 
clinics more often because they want to stay in good health.  As evidence exists that a 
higher proportion of patients taking ACEI or ARB monotherapy regress to 
normoalbuminuria than placebo, and in the context that we defined patients as receiving 
ACEI or ARB monotherapy based on at least a 50% coverage in days supply with 
medication in a year, this conjecture also makes sense as people who are more compliant 
tend to be more concerned about their health.  LDL could be protective if patients with 
higher LDL have higher LDL because they do not seek help as often as those with more 
controlled LDL. The same could be true for those with hypertension. 
 These findings should not be interpreted as evidence to not provide ACEI or ARB 
monotherapy, because, as mentioned above, it is probable that ACEI or ARB 
monotherapy was not associated with lower incidence rates of outpatient visits because 
patients receiving neither therapy were dying at a much faster rate in each year of follow-
up, thereby allowing time for patients receiving either monotherapy to have higher 
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incidence rates of outpatient clinics than neither patients.  Again, preventive medicine 
should be taking place before patients develop comorbidities.  If providers advocated, and 
patients listened to and followed, preventive measures against acquiring comorbidities, 
there would be less strain on healthcare resources. 
Difference in Outpatient Visits, ACEI versus ARB Monotherapy  
 
 ACEI and ARB monotherapies had similar incidence rates of outpatient visits in 
the weighted model (Table 41) although the unweighted model found ACEI monotherapy 
was associated with a lower incidence rate and the interactions between ACEI 
monotherapy and time (t+1), (t+2), and (t+3) were associated with higher incidence rates 
(Table 32).  Times (t+1), (t+2), (t+3), and (t+4), age, annual income ≥$35,000, never 
smoker, microalbuminuria in follow-up, and LDL had significantly lower incidence rates 
of outpatient visits in unweighted and weighted negative binomial regression analyses 
(p<0.05 each).  Higher incidence rates of outpatient visits were found for annual income 
$6,000-17,999, annual income $18,000-34,999, urban/suburban living, ever smoker, 
history of stroke, CHF, cardiac arrhythmias, valvular disease, peripheral vascular 
disorders, paralysis, other neurological disorders, chronic pulmonary disease, diabetes 
complicated, liver disease, AIDS, lymphoma, metastatic cancer, solid tumor without 
metastasis, coagulopathy, obesity, fluid and electrolyte disorders, deficiency anemias, 
alcohol abuse, drug abuse, psychoses, and depression across models (p<0.001 each).  
Pulmonary circulation disorders also emerged as having a higher incidence rate of 
outpatient visits after second stage PSA. 
 Insight into why times (t+1), (t+2), (t+3), and (t+4) were protective factors of 
outpatient visits can be identified through univariate analysis of ESRD and mortality 
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within ACEI and ARB monotherapy across time.  (Please see Table 20.)  Among ACEI 
patients we see increasing rates of ESRD at times (t+1) and (t+2) compared to time (t).  
We also see increasing mortality rates at times (t+1), (t+2), and (t+3) compared to time 
(t).  Turning to ARB patients we see an increasing trend in ESRD at time (t+3) compared 
to time (t) amounting to over a 12-fold difference.  Although there is no statistical 
difference between subsequent years of follow-up, people who died in the previous year 
cannot seek outpatient care.  The reason why ESRD is specifically addressed here is 
because there is literature that veterans with ESRD are more likely to receive care outside 
the VA.225  This may also be why we see increasing age is protective against outpatient 
visits:  people are Medicare-eligible so may be more likely to see providers outside the 
VA.  Patients with annual income ≥$35,000 may have been otherwise employed, 
meaning Medicare Advantage’s reduced payments could apply to these individuals; 
however, there were special enrollment periods for retired military personnel in which 
premiums were waived (although still had to pay copayments), which may nullify this 
reason.226 An alternate hypothesis is that patients in this income group are healthier; 
previous literature has found patients with higher income have better health.223,224  Never 
smoker seems reasonable to have a lower incidence rate of outpatient visits because, in 
theory, these patients are healthier than current smokers, reducing the need for outpatient 
visits.  Similar to an argument made for LDL’s lower incidence rate of hospitalization for 
ACEI or ARB monotherapy versus neither therapy, LDL and microalbuminuria in 
follow-up could have lower incidence rates of outpatient visits because they, in 
themselves, are probably not reasons for outpatient visits, but rather their complications. 
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 Revisiting the higher incidence rates seen in income, veterans with annual income 
$6,000-17,999 and annual income $18,000-34,999 could have an easier time getting to 
the doctors’ offices than those with annual income <$6,000 as those with the least 
amount of income probably could not afford a car and may even have a hard time paying 
for public transportation, if available.221  Similarly, urban/suburban living promotes 
higher access to care, where rural areas may not even have a healthcare facility.222  The 
remaining variables with significantly higher incidence rates of outpatient visits are 
comorbidities.  Only three of these twenty-two comorbidities had increased odds of all-
cause mortality (Tables 25 and 40), making the argument easy to make that patients with 
these comorbidities had the time to accumulate outpatient visits and that patients with 
comorbidities would be expected to have more outpatient visits than patients without 
comorbidities. 
Differences in ED Visits, ACEI or ARB Monotherapy versus neither  
 
 Our primary interest, whether ACEI or ARB monotherapy was associated with 
reducing ED visits compared to neither therapy, was again not proven.  Patients receiving 
ACEI monotherapy were associated with a significantly higher incidence rate of ED 
visits (1.16) compared to neither patients; ARB patients were associated with similar 
rates as neither patients (Table 27).  The analysis also revealed annual income $6,000-
17,999, annual income $18,000-34,999, urban/suburban living, ever smoker, HbA1c, 
CHF, cardiac arrhythmias, peripheral vascular disorders, paralysis, other neurological 
disorders, chronic pulmonary disease, diabetes complicated, liver disease, AIDS, 
metastatic cancer, solid tumor without metastasis, fluid and electrolyte disorders, blood 
loss anemia, deficiency anemias, drug abuse, psychoses, and depression were associated 
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with higher incidence rates of ED visits (p<0.001 each; Table 27).  Times (t+1), (t+2), 
and (t+3), the interaction between ARB monotherapy and time (t+4), age, annual income 
≥$35,000, income missing, never smoker, and hypertension were associated with lower 
incidence rates of ED visits (p<0.017 each).   
 As with outpatient visits, the fact that ACEI monotherapy was associated with a 
higher incidence rate of ED visits should not mean that providers conclude ACEI 
monotherapy is detrimental as it is associated with protection against all-cause mortality.  
Most variables identified as being associated with higher incidence rates of ED visits are 
nonmodifiable, but the fact that certain comorbidities associated with higher incidence 
rates of ED visits as well as outpatient visits (i.e., CHF, cardiac arrhythmias, peripheral 
vascular disorders, paralysis, chronic pulmonary disease, AIDS, metastatic cancer, fluid 
and electrolyte disorders, blood loss anemia, deficiency anemias, drug abuse, and 
psychoses) means special attention should be given to patients to try to make sure that 
they limit behaviors that could result in these comorbidities, thus decreasing the burden 
on the healthcare system. 
As found with outpatient visits, univariate analysis of ED visits across time 
decreased compared to time (t).  (Please see Table 22.)  This explains seeing incidence 
rate ratios less than one for times (t+1), (t+2), and (t+3).  Unlike outpatient visits, there 
was not a significant difference between time (t+4) and time (t), most likely because there 
were few observations at time (t+4) and because of the fewer ED visits experienced by 
study participants compared to outpatient visits.  The interaction between ARB 
monotherapy and time (t+4) being associated with a lower incidence rate of ED visits can 
be gleaned again from univariate comparisons seen in Tables 21 and 22.  Although not 
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significantly different, looking at the rates themselves we see zero ED visits for ARB 
patients at time (t+4), the only intersection of drug therapy and time with a rate of zero 
for ED visits.  Similar arguments can be made for age, annual income ≥$35,000, income 
missing, and never smoker as what was voiced for these associations with lower 
incidence rates of outpatient visits.  Similar statements made for outpatient visits can be 
applied to rationalizing why ACEI monotherapy, annual income $6,000-17,999, annual 
income $18,000-34,999, urban/suburban living, and ever smoker as well as the 
comorbidities being associated with higher incidence rates of ED visits. 
Difference in ED Visits, ACEI versus ARB Monotherapy 
 
 Patients receiving ACEI and ARB monotherapies had similar rates of ED visits 
(Table 42) although significantly lower incidence rates of ED visits were seen for age, 
times (t+1) and (t+4), annual income ≥$35,000, and never smoker across both models 
(p<0.001 each; Table 33).  Significantly higher incidence rates of ED visits were 
observed for annual income $6,000-17,999, urban/suburban living, CHF, cardiac 
arrhythmias, peripheral vascular disorders, chronic pulmonary disease, paralysis, diabetes 
complicated, liver disease, metastatic cancer, solid tumor without metastasis, weight loss, 
fluid and electrolyte disorders, blood loss anemia, deficiency anemias, drug abuse, 
psychoses, and depression across both models (p<0.05 each).  ACEI monotherapy and 
time (t+4) and annual income $18,000-34,999 emerged after propensity score adjustment 
as having a lower and a higher incidence rate, respectively.   
 Times (t+1) and (t+4) are rational to have lower incidence rates based on 
assessment of univariate analysis of ED visits over time.  As mentioned previously, age 
could have a lower incidence rate of ED visits since patients with advanced age were 
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dying at a higher frequency (there is evidence in the weighted logistic regression 
comparison between ACEI and ARB monotherapy for all-cause mortality).  Please see 
Table 40.  Patients with annual income ≥$35,000 could have a higher incidence rate for 
the same two reasons used in outpatient visits:  1. a possibility that these patients were 
more likely to seek care outside the VA and 2.  these patients may be healthier.  Again, it 
is rational that never smokers have lower incidence rates of ED visits because they are 
presumed to be healthier than current smokers.   
 Veterans with annual income $6,000-17,999 may have higher odds of ED visits 
compared to those with income <$6,000 for the same reasons as they have higher odds of 
outpatient visits:  these patients need a way to get to the ED and it costs a substantial 
amount of money to summon an ambulance.  Urban/suburban living most likely has a 
higher incidence rate of ED visits, again because of patients’ relative proximity to an 
ED.222  The remaining variables with significantly higher incidence rates are 
comorbidities.  Along the lines of previous arguments for patients with certain 
comorbidities having increased use of healthcare resources, patients with these 
comorbidities likely had higher incidence rates of ED visits than patients without these 
comorbidities as long as they were not at higher odds of all-cause mortality.  Even if they 
were, as long as patients were not dying earlier in follow-up veterans would have had 
higher incidence rates of ED visits.  Of the six comorbidities with higher incidence rates 
of ED visits, only CHF had a trend towards higher odds of all-cause mortality; none had a 
significantly higher odds of all-cause mortality. (Please see Table 40.) 
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 Again, the clinical implication is that there are no significant differences between 
ACEI and ARB monotherapy for ED visits.   Emphasis should be placed on prevention of 
comorbidities. 
Differences in Hospitalizations, ACEI or ARB Monotherapy versus neither  
 
 Looking at Table 28, patients receiving ACEI monotherapy were associated with 
higher incidence rate of hospitalization (IRR=1.19).  Other variables that were associated 
with higher incidence rates of hospitalization were annual income $6,000-17,999, annual 
income $18,000-34,999, ever smoker, HbA1c, history of MI, history of stroke, family 
history of CVD, CHF, peripheral vascular disorders, paralysis, other neurological 
disorders, chronic pulmonary disease, diabetes complicated, liver disease, metastatic 
cancer, solid tumor without metastasis, coagulopathy, weight loss, fluid and electrolyte 
disorders, blood loss anemia, deficiency anemias, alcohol abuse, drug abuse, psychoses, 
and depression (p<0.001 each).  Alternately, times (t+1), (t+2), (t+3), and (t+4), the 
interaction between ACEI monotherapy and time (t+4), the interaction between ARB 
monotherapy and time (t+4), annual income ≥$35,000, income missing, never smoker, 
LDL, and hypertension were associated with lower incidence rates of hospitalization 
(p<0.017 each).    
 Since ACEI monotherapy, annual income $6,000-17,999 and annual income 
$18,000-34,999 were associated with higher incidence rates of hospitalization as they 
were for outpatient visits and ED visits, similar comments can be made as to the 
justification of why they were associated with higher incidence rates of hospitalization.  
The finding that ever smokers were associated with higher incidence rates of 
hospitalization may be a spurious finding.  The remaining variables associated with 
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higher incidence rates of hospitalization were comorbidities.  Since all comorbidities 
associated with higher incidence rates of hospitalization were identified as being 
associated with higher incidence rates of outpatient and/or ED visits except weight loss, a 
similar argument can be made as in those outcomes:  as long as patients with these 
comorbidities are not dying earlier in follow-up, it is intuitively appealing that patients 
with these comorbidities would be hospitalized more frequently over the period of 
observation.  Again looking at Table 25, this does not appear likely. 
 Similar to comparisons across time for all drug therapies for outpatient visits and 
ED visits, univariate comparisons demonstrated lower hospitalization rate for times (t+1), 
(t+2), (t+3), and (t+4) compared to time (t).  (Please see Table 22).  The interaction 
between ACEI monotherapy and time (t+4) and the interaction between ARB 
monotherapy and time (t+4) were probably due to the lower rates of hospitalization seen 
at time (t+4) compared to time (t) within each respective therapy. (Note it is significant 
for ACEI monotherapy, but not ARB despite ARB patients having a hospitalization rate 
of zero at time (t+4).)   Age, annual income  ≥$35,000, income missing, and never 
smoker again appear as being inversely related to incidence rates as they did for 
outpatient visits and ED visits.  LDL, HbA1c, and hypertension may be associated with 
lower incidence rates due to the fact that not many hospitalizations are, in and of 
themselves, directly due to either of these conditions, but rather complications from these 
conditions.227   
 As mentioned for the previous two types of healthcare utilization, just because 
ACEI monotherapy was associated with a higher incidence rate of hospitalization does 
not mean clinicians should not prescribe and enforce compliance with ACEI 
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monotherapy as patients receiving ACEI monotherapy were associated with lower odds 
of all-cause mortality than patients receiving neither therapy.  Also as mentioned with 
outpatient visits and ED visits, the majority of variables associated with higher incidence 
rates of hospitalization are non-modifiable, making it imperative for healthcare providers 
to educate patients about the lifestyle choices that could lead to the comorbidities seen 
with increased hospitalization.  The overwhelming majority of comorbidities associated 
with higher odds of hospitalization were also associated with higher odds of outpatient 
visits and/or ED visits.  Lastly, we return to Elixhauser et al., who found all of the 
comorbidities identified in the present analysis as predicting hospitalization were found 
to increase length of stay (their marker of healthcare utilization) except for solid tumor 
without metastasis.195  
Difference in Hospitalizations, ACEI versus ARB Monotherapy 
 
 There was no difference in incidence rates of hospitalization for patients on ACEI 
and ARB monotherapies (Tables 34 and 43).  However, times (t+1), (t+3), and (t+4), age, 
annual income ≥$35,000, never smoker, LDL, and hypertension had significantly lower 
incidence rates while annual income $6,000-17,999, annual income $18,000-34,999, ever 
smoker, HbA1c, history of MI, history of stroke, CHF, peripheral vascular disorders, 
paralysis, other neurological disorders, chronic pulmonary disease, diabetes complicated, 
liver disease, lymphoma, solid tumor without metastasis, coagulopathy, weight loss, fluid 
and electrolyte disorders, deficiency anemias, alcohol abuse, drug abuse, psychoses, and 
depression had significantly higher incidence rates of hospitalization across unweighted 
and weighted negative binomial regression models (p<0.05 each).  Time (t+2) had a 
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lower incidence rate of hospitalization and metastatic cancer had a higher incidence rate 
only after propensity score adjustment. 
 Times (t+1), (t+2), and (t+4) had lower rate of hospitalization among ACEI 
patients compared to time (t) in univariate comparisons across time. (Please see Table 
22.)  Although no statistical difference was found for decreased hospitalization rate 
between the time (t+3) and time (t) among ACEI patients or any of these three time 
periods among ARB patients in univariate comparisons, looking at the rates at each year, 
we do see a pattern a decreasing rates.  For age, the same rationale applied to why age 
had a lower incidence rate of ED visits can be applied to hospitalizations:  there was a 
higher odds of all-cause mortality (Table 31).  Veterans with an annual income ≥$35,000 
could have a lower incidence rate of hospitalization since income is positively related to 
health.  Never smoker again emerged with a lower incidence rate of hospitalization, 
presumably because people who have never smoked are generally healthier than people 
who currently smoke.  LDL, HbA1c, and hypertension, as mentioned in the ACEI or 
ARB monotherapy comparison with neither therapy for hospitalization, likely had lower 
incidence rates  of hospitalization because they generally do not necessitate 
hospitalization; rather, their complications do.227   
 Veterans with annual income $6,000-17,999 and annual income $18,000-34,999 
may have higher incidence rates of hospitalization because they have more means to pay 
for it than patients with income <$6,000.  Ever smokers having higher incidence rates 
than current smokers is most likely due to a spurious finding.  There was a trend toward 
higher odds of all-cause mortality for only two of the nine comorbidities with higher odds 
of hospitalization:  CHF and peripheral vascular disorders, and none of the comorbidities 
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with higher incidence rates of hospitalization had significantly higher odds for all-cause 
mortality (Table 31).  Thus, support is provided that patients with these comorbidities had 
the opportunity to be hospitalized in the follow-up period. 
 The first clinical implication that can be drawn from this information is that there 
is no difference in ACEI or ARB monotherapy in terms of hospitalization. Second, as has 
been mentioned before, healthcare professionals need to educate the public on actions, 
behaviors, and other lifestyle choices that can predispose patients to comorbidities in an 
effort to reduce healthcare utilization, including hospitalizations.  In fact, numerous 
published articles exist across disease states documenting the benefits of such 
education;228-233 furthermore, preventive services are recommended in clinical practice 
guidelines234 and are now mandated to be reimbursed by private health plans.235 
Summary of ACEI or ARB Monotherapy versus neither  
 
 ACEI monotherapy was associated with lower odds of ESRD development, 
higher odds of IVDE occurrence, lower odds of all-cause mortality, and higher incidence 
rates of outpatient visits, ED visits, and hospitalizations.  The interaction between ACEI 
monotherapy and time (t+3) was associated with a higher odds of all-cause mortality and 
a higher incidence rate of outpatient visits while the interaction between ACEI 
monotherapy and time (t+4) was associated with a lower incidence rate of hospitalization.  
There were also associations between higher odds of all-cause mortality and higher 
incidence rates of outpatient visits for the interactions between ACEI monotherapy and 
times (t+1) and (t+2). 
 ARB monotherapy was associated with lower odds of all-cause mortality and a 
higher incidence rate of outpatient visits.  The interaction between ARB monotherapy 
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and time (t+3) was associated with a higher incidence rate of outpatient visits while the 
interaction between ARB monotherapy and time (t+4) was associated with lower 
incidence rates of ED visits and hospitalizations. 
 Again we note the substantially higher mortality rate seen among neither patients 
likely biased results of our comparisons.  There are plausible explanations of neither 
patients having a higher mortality rate while having fewer IVDEs, outpatient visits, ED 
visits, and hospitalizations compared to patients receiving either monotherapy despite, in 
general, appearing to be healthier.  First, since death is a competing risk of healthcare 
utilization and other clinical events (like ESRD), it could be deduced that patients died 
before having these.218  Second, even though death is a competing risk, patients receiving 
neither therapy and/or their providers could have been less vigilant about their health in 
general.  Neither patients may have been prescribed ACEI or ARB monotherapy, but 
requested refills less than one-half the time even if providers were following the 
guidelines that all microalbuminuric and macroalbuminuric P2DM should have ACEI or 
ARB monotherapy regardless of hypertension status.  Similarly, using another 
recommendation from the ADA and VA guidelines, that all patients should be tested 
annually for albuminuria, we found a higher percentage of missing data for patients 
receiving neither therapy than ACEI therapy; providers could be ordering these tests, but 
patients are not showing up at the lab.  Third, ACEI and ARB monotherapies could 
afford more protection to P2DM who are sicker than the samples studied in previous 
research.  Lastly, neither patients were more urban and had less income, indicating a 
possibility for worse living conditions.  Although more urban, patients receiving neither 
therapy still may not have had the same access to care (i.e., transportation) due to their 
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decreased income.221  In fact, previous nationwide research has shown that lower income 
is associated with poorer physical and mental health as well as less consumption of fruits 
and vegetables and less physical activity among patients with diabetes.223,224  A recently-
published study of veteran P2DM found increased physical activity was associated with 
lower risk of mortality.236  Environmental factors and lifestyle choices were not captured 
in the current study. 
 We were surprised to find almost one-half of newly-diagnosed P2DM were 
receiving neither therapy.  Three main reasons exist for not adhering to guideline 
recommendations for P2DM with microalbuminuria or macroalbuminuria:  poor quality 
of care, patient refusal of treatment, and presence of contraindication or adverse reaction 
to therapy. (Personal communication, G. Murata. December 16, 2010).  Assessing patient 
refusal of treatment and presence of contraindication or adverse reaction to therapy is 
beyond the scope of this project:  no data are available in the VA datasets to indicate 
treatment refusal and, although ICD-9-CM codes would document hyperkalemia or 
azotemia, these codes were not collected for the study.  However, we do have the ability 
to explore quality of care in the VA through post hoc analyses. 
 Since the guideline recommendation of annual albuminuria assessment54,89,145,220 
is most closely related to prescribing ACEI or ARB monotherapy to prevent albuminuria 
progression (i.e., both recommendations address the same clinical parameter), the 
percentage of missing albuminuria values were compared across the three treatment 
groups.  Although similar proportions of missing values were found for ACEI and ARB 
patients, those receiving neither therapy had significantly more missing albuminuria 
values (23.51%, 24.99%, and 39.08%, respectively; p<0.001 each).  We also assessed 
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differences in percentages of missing values for HbA1c, triglycerides, and LDL to further 
compare quality of care across drug therapies.  Neither patients were found to 
consistently have significantly more missing values for these clinical parameters as well 
(p<0.001 each).  It should also be noted that patients receiving neither therapy had 
HbA1c values between ACEI and ARB patients at year 1; HbA1c values at subsequent 
timepoints were comparable to ACEI and ARB groups for the rest of the study.  Although 
patients receiving neither therapy had triglyceride values between ACEI and ARB 
patients at the two timepoints for which they were significantly different from 
monotherapy values, they had the highest LDL at baseline and years 2-4 (p<0.0083 each; 
Table 13 and Appendix F, Table 5).  
 Comparing these findings to previous studies of VA process and outcome 
measures, there are more missing values of albuminuria in each drug therapy compared to 
a cohort study including diabetes patients from six states in 1998 and 1999.97  ACEI and 
ARB patients have similar frequencies of HbA1c testing as a random sample of diabetes 
patients from every VA in years 2004 and 2005.96  Likewise, annual triglyceride and 
LDL had similar frequencies of testing in this study compared to the cohort study.97  
Given that some proportion of veterans also receive care outside the VA, it is essential to 
ensure continuity of care across healthcare organizations.  In fact, this importance is now 
highlighted in a 2009 VHA Directive.237 
Summary of ACEI versus ARB Monotherapy 
 
  Our study found no difference in ACEI and ARB monotherapies for all endpoints 
studied.  The second stage PSA only found a difference between these monotherapies in 
terms of the interactions between ACEI monotherapy and time (t+4), in which a lower 
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incidence rate of ED visits was found.  With respect to focusing educational preventive 
efforts on development of diseases identified as comorbidities with higher odds for 
clinical endpoints, our study found diabetes complications, liver disease, fluid and 
electrolyte disorders, and deficiency anemias caused ESRD; history of MI, history of 
stroke, pulmonary circulation disorders, peripheral vascular disorders, chronic pulmonary 
disease, and fluid and electrolyte disorders caused IVDEs; and history of MI, CHF, and 
peripheral vascular disorders caused all-cause mortality.  Comorbidities causing 
consistently higher incidence rates of healthcare utilization were CHF, peripheral 
vascular disorders, paralysis, chronic pulmonary disease, diabetes complications, liver 
disease, metastatic cancer, solid tumor without metastasis, fluid and electrolyte disorders, 
deficiency anemias, drug abuse, psychoses, and depression.  Patients should also be 
encouraged to not smoke as it caused fewer IVDEs and less healthcare utilization. 
 The two other PSA techniques (i.e., stratification and nearest-neighbor matching) 
looked at the average treatment effect on the treated (ACEI patients), and found the same 
results as revealed with the second stage regression, lending credence to our findings.  
Also, the results of the sensitivity analyses confirmed robustness of our findings in case 
an unobserved variable exists that increases the odds of treatment selection for ESRD and 
all-cause mortality by up to 100%.  According to Aakvik (2001), “differing odds…by a 
factor of 2, or 100%, must be considered a very large number given that we have adjusted 
for many important characteristics.”238  Our findings are not as robust to possible 
unobserved variables affecting treatment selection for IVDE occurrence, outpatient visits, 
ED visits, and hospitalizations.   
Outcome Rates in the Sample Compared to Previous Studies 
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Studies Comparing ACEI or ARB Monotherapy to Placebo 
 
 There are some interesting findings that are revealed when comparing this study 
to previous studies analyzing effects of monotherapy versus placebo.  Again, none of the 
studies were conducted exclusively in the U.S.; in particular, four of seven studies 
included the continent of North America as part of their international studies.  Two of the 
studies had majority or exclusive normoalbuminuric patients upon enrollment.46,47  Two 
studies had healthier patients than ours as hypertensive or obese patients were excluded, 
limiting external validity.47,48  Interestingly, another study may have had sicker patients 
with 69% having a history of CVD, although about two-thirds of patients had baseline 
normoalbuminuria.46  Clearly, subjects in these previous studies are not representative of 
newly-diagnosed P2DM in the U.S.  In general, these studies make for easier 
comparisons to our study than studies of ACEI and ARB monotherapy comparisons as 
studies comparing monotherapies to placebo have endpoints of progression from one 
albuminuria category to another, CVD, or mortality.  There is one exception to this.47 
 Differences in patient characteristics between HOPE MICRO-HOPE and the 
current study explain the differences in event rates.  Specifically, the majority of patients 
with normoalbuminuria at baseline in the former study explains our higher rate of 
macroalbuminuria progression.46,71  An almost 8-fold higher amount of patients with 
history of CVD  in HOPE MICRO-HOPE, each about twice as likely to have another 
CVD event than those without,20 also contributed to the differences, especially in light of 
those with history of CVD having higher risks of MI than stroke.20 Also important is that 
our patients were more hypertensive and albuminuric, which is each associated with 
higher rates of stroke than MI.25,239  There is also evidence that gender, smoking status, 
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year, and racial/ethnic composition could affect rates of cardio- and cerebro- vascular 
events,203,204,240-242 all in the direction we have seen between the studies.  Taking into 
consideration the lower IVDE rate and shorter follow-up in the current study explains the 
lower mortality rate for ACEI patients with the current study, but this does not ring true 
for neither patients.  Instead, we observed a higher rate despite there being significantly 
fewer documented comorbidities than our ACEI patients (p<0.0083).  Perhaps this is due 
to more patients receiving neither therapy receiving non-VA care as well.  Although we 
do not know the number of patients in each drug therapy receiving non-VA care, if 
conditions do not affect or require patient care or treatment, they would not be coded so 
would not be captured in the VA datasets.243  Compared to Ahmad et al., univariate 
analysis of the current study patients who were microalbuminuric at baseline did not 
show as dramatic a difference between ACEI and neither patients as Ahmad’s ACEI and 
placebo patients.  Although the previous study had a higher HbA1c, they were less 
hypertensive, but we feel univariate analysis did not sufficiently control for covariates. 
 The current study had similar rates of macroalbuminuria progression for ARB 
patients as Parving’s lower dose of ARB therapy.45  The difference in hypertensive status 
among placebo and neither patients across studies explains the lower progression rate in 
the current study.  The fact that we had similar rates of progression for ARB and neither 
patients is due to the fact that univariate analyses did not control for difference in health 
status.  Hypertension, albuminuria, and HbA1c differences accounted for the higher 
ESRD, cardio- and cerebro- vascular disease, and mortality rates seen in the studies 
conducted by Brenner, Lewis, and Berl.49,53,109  Comparisons between studies, 
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unfortunately, have not allowed us to explain similar mortality rates observed between 
neither and placebo patients for this study and the study conducted by Lewis. 
Studies Comparing ACEI and ARB Monotherapy 
 
 As mentioned earlier, it is difficult to compare this study to previous studies 
looking at differences in effects between ACEI and ARB monotherapy in P2DM for the 
several reasons that make this study unique in its contribution to the field. The main 
reason behind this is the fact that all previous studies analyzed change in albuminuria as a 
continuous variable, and we did not.  In general, subjects in previous studies were 
healthier than the general population of P2DM due to their strict exclusion criteria 
prohibiting certain comorbidities.  Additionally, subjects behaved differently during 
follow-up than in the current study through two main reasons:  1.  patients in other 
studies were given dietary and/or exercise advice123,127,130,244 and 2.  patients had 
treatment duration maximum of one year except for one study.121   
 In terms of cardio- and cerebro- vascular disease events reported, we can compare 
the present study to Barnett et al.’s, in which they report in their adverse events section 
that 11.5% of ACEI patients and 17.5% of ARB patients suffered from fatal and nonfatal 
heart failure, MI, or stroke over their 5 year follow-up.121  The current study had an 
8.07% incidence in ACEI patients while there was an 8.76% incidence in ARB patients 
Table 22).  Our mean follow-up was 2.17 years; although we do not know the mean 
follow-up in the DETAIL study, we know 5 years of data were available for 67.2% of 
their patients resulting in longer follow-up than our study.  Due to implications of 
capturing incident CHF through ICD-9 codes, (G. Murata, Personal Communication, 
2007) different definitions of combining endpoints were used where the present study 
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excluded CHF and included LVH.  Another reason for the difference in incidence rates 
seen for cardio- and cerebro- vascular disease events is that 48.84% of patients in the 
DETAIL study had a history of CVD while 8.88% of patients in the present study had 
documented CVD at baseline.  (This was estimated by combining history of MI, history 
of stroke, and CHF in Table 16, but we are unaware of the amount of people who had 
documented LVH at baseline.)  We know from Haffner et al. that P2DM who have a 
history of CVD are approximately twice as likely to have another event compared to 
those without a history.20  Both studies had similar proportions of microalbuminuria and 
macroalbuminuria at baseline. The present study also had lower mean baseline HbA1c, 
LDL, and triglyceride values of 7.30%, 94.56mg/dL, and 189.96mg/dL compared to 
8.4%, 136mg/dL, and 202mg/dL, respectively.  We do not see as dramatic of a difference 
between treatment groups as the previous study. 
 In terms of all-cause mortality, the DETAIL study reported a 4.62% and 5.00% 
rate in ACEI and ARB groups, respectively.  Our study found 1.01% and 1.04% mortality 
rates in ACEI and ARB patients, respectively.  Similar arguments made for differences in 
cardio- and cerebro- vascular disease incidence rates between studies can be applied to 
the differences in mortality rates between studies.  Specifically, we have a shorter follow-
up period, fewer people with baseline CVD, and better mean values of clinical 
parameters at baseline.  Since approximately 2/3 of P2DM die from CVD events3 and 
patients in the current study had fewer CVD events, our study results make sense in light 
of Barnett et al.121 
 There are limited data that can be compared to previous studies due to the 
majority of these studies only assessing change in albuminuria, a surrogate endpoint.  
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However, our event rates appear reasonable for what can be compared.  We find our 
patients had lower rates of cardio- and cerebro- vascular disease events and mortality 
than Barnett’s due to 5.5 times as many patients having history of CVD in the previous 
study, higher HbA1c, LDL, and triglyceride values in the previous study, and a longer 
follow-up period in the previous study. 
 
Other Issues to Consider in Context of Study Results 
 
Compliance  
 
 The proportion of people who switched from ACEI or ARB monotherapy to 
neither therapy is a combination of two factors: prescribers not writing prescriptions and 
patients not refilling their prescriptions.  In our study a patient needed to have enough 
medication on-hand for a minimum of 50% of the year to be classified as receiving ACEI 
or ARB therapy in that year.  In fact, Table 12 shows good differentiation in days supply 
between ACEI or ARB therapy and neither therapy.  A patient needs to have the 
medication on-hand to be able to ingest it since this is what determines clinical 
effectiveness.245  Clearly, medications with longer half-lives will be more forgiving of a 
less compliant patient in terms of their effectiveness.  In the case of this study, because 
two therapeutic classes of medications are being combined for analysis, large variation in 
half-lives exists among the individual drugs.  For instance, captopril can be dosed three 
times daily while losartan can be dosed once daily.  
 Our definition of compliance may, at first, appear to be arbitrary.  We had the 
knowledge that 80% is the convention of determining adherence because it was the 
threshold that still demonstrated effectiveness in antihypertensives246 and the knowledge 
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that there is no standard for what defines adequate adherence247 in addition to the fact that 
as dosing regimen complexity increases (i.e., number of prescribed medications, 
frequency of administration), compliance decreases.248 As seen in Table 1, P2DM 
generally have many prescribed medications.  We note there is also evidence that 
compliance is lower with long-term therapy than short-term among P2DM in clinical 
practice and that compliance is lower in clinical practice than research studies.246,248-250  
We point to two previous studies of ARB and/or ACEI monotherapy in P2DM:  one had 
a 46.5% discontinuation rate of ARB monotherapy at 3.4 years while the other had a 
32.8% discontinuation rate for patients using ACEI or ARB monotherapy at 5 years.49,121 
Furthermore, the HOPE MICRO-HOPE study showed a treatment effect at a 65% 
adherence level46.  We also note that, among clinical trials of patients with chronic 
diseases, in which compliance is reported, it averages 43%-78%.251-253   
 It is important to assess the rate at which patients take medication to determine the 
effectiveness of these medications in clinical practice.245  Since HOPE MICRO-HOPE 
showed treatment effect at 65% adherence, and in this study, monotherapy was defined as 
having minimally 50% of medication on-hand in a year, it is reasonable to expect to see 
treatment effect in this setting.  Additionally, several VA cardiovascular disease or 
diabetes studies document lower adherence for non-White veterans compared to non-
Hispanic white veterans.254  Another finding from the investigation of racial disparities is 
that non-White veterans are less likely to receive care outside the VA.254  These two 
findings are highlighted because of the lack of published literature in non-White P2DM:  
increasing the adherence level would likely lead to differential selection of non-Hispanic 
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whites to the monotherapies, and since were unable to obtain information on non-VA 
care, more non-VA care would not be captured. 
 Due to the definition of compliance and how our data were set up, if a patient died 
before month 6 of a given year, that patients was considered as receiving neither therapy 
among ACEI/ARB versus neither comparisons, which would inherently contribute to a 
higher mortality rate among those receiving neither therapy.  Thus, a post hoc analysis 
was conducted in which all endpoints except mortality were re-run with multivariate 
regression excluding patients who died to see if results changed (see Appendix F, Table 
31).  Similar odds ratios and incidence rate ratios were obtained in this analysis as 
including all patients in our sample.  Having said this, there are three statistically 
significant differences.  First, ACEI monotherapy was previously associated with lower 
odds of ESRD compared to neither therapy, but no longer is.  Second, ARB monotherapy 
was previously nonsignificant and now is associated with higher odds of IVDE compared 
to neither therapy.  Third, ARB monotherapy was previously nonsignificant and now is 
associated with higher odds of ED visits compared to neither therapy.  A direct 
interpretation of these results across the analyses is that the data suggest that patients who 
died were more likely to have ESRD, less likely to have IVDE, and less likely to have 
ED visits since the majority of deaths occurred in the neither group.  Due to similar point 
estimates across both types of analysis, we can say there was no clinically significant 
difference in these analyses. 
The VA as a “Closed System” and VA-Medicare Dual Enrollees  
 
 As of July 9, 2001, veterans who were exposed to Agent Orange and/or other 
herbicides were allowed to receive compensation for type 2 diabetes because it was 
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added to the list of conditions associated with Agent Orange and herbicide exposure.255  
This means that these veterans with this exposure have no financial incentive to go 
outside the VA Healthcare System because they have no copayments associated with 
outpatient medications or visits.256  While all veterans are allowed to apply for 
compensation of VA healthcare benefits, those without a service-connected disability 
(including Agent Orange exposure) are placed on a sliding copayment scale based on 
income.256  Lastly, patients with an annual household income and/or net worth below the 
VA threshold are also exempt from copayments.257  Using Means Test data available and 
assuming all patients with missing data are above the threshold, we find 74.44% of our 
sample had no copays for all VA care and VA prescribed medications.  For those 
veterans who were fortunate enough to not fall into these categories, and thus have 
copayments, receiving VA healthcare benefits comes without having to pay premiums.  
For instance, a majority of our sample could have applied for Medicare Part D to receive 
medications with copayments before reaching “the donut hole”, but they also would have 
had to pay premiums to receive these medications, creating a financial disincentive. 
Furthermore, despite lack of a gold standard for assessing compliance, rates of 
prescription refills are accurate in a closed pharmacy system such as the VA as long they 
are followed longitudinally.193,247,258,259  In fact, recent evidence shows that VA 
cardiovascular disease patients who were “ideal recipients” for ACEIs were more likely 
to receive these medications upon discharge compared to non-VA patients.260 
 Despite these arguments for why a small amount of outcomes and healthcare 
utilization was not captured in VA datasets, we acknowledge that undoubtedly, some 
services were provided outside the VA Health Care System.  For instance, the 2001 
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National Survey of Veterans found that, among patients receiving VA care, roughly one-
third only used VA for medical care while two-thirds used a combination of VA and non-
VA care in the previous year.261 We note this utilization rate was obtained before type 2 
diabetes was declared to be associated with Agent Orange and herbicide exposure.256  In 
terms of study implications, we can definitively say in light of this limitation that findings 
for all-cause mortality are robust to this circumstance:  our method of capturing all-cause 
morality is independent of healthcare organization.262   
 In spite of this, expert opinion exists that patients use VA for certain conditions 
and non-VA for others before using VA for those conditions as well (Personal 
communication, G. Murata, December 16, 2010).  Possible implications of this 
circumstance include the higher rate of ESRD development seen in this study (0.79% 
over 2 years) compared to UKPDS 64 (0.80% over 10 years) and the baseline prevalence 
of macroalbuminuria (8.00% versus 0.70% in UKPDS)71 due to longer lead time than 
expected with newly-diagnosed diabetes patients.  Also because of the use of non-VA 
services for certain conditions, ESRD development could be due to acute conditions not 
documented in VA ICD-9-CM codes for which ACEIs or ARBs are not effective. 
(Personal communication, G. Murata, December 16, 2010).  Still, unless obtaining care 
outside the VA differentially affects the odds of selection of ACEI or ARB monotherapy 
beyond what is controlled with PSA, PSA findings should remain the same.  
Internal and External Validity 
 
 As mentioned above, our common support was excellent, meaning we have 
internal validity because there was enough overlap between monotherapy propensity 
score distributions to provide unbiased estimates of effect.  Additionally, the sensitivity 
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analyses of ESRD and all-cause mortality show even if an unobservable characteristic 
affects treatment selection, it would have to change the odds of choice by more than 
double, giving even more evidence of causality. 
Also because our common support had substantial overlap, were able to estimate 
ATT with good precision163 and to maintain generalizability to veteran P2DM because 
only approximately 27% of our patients were not able to be matched in PSA.  Also in 
terms of generalizability, all of the states in the United States are represented as well as 
the District of Columbia and Puerto Rico.  We would have a hard time extending this to 
women or younger individuals since these people were not included in the study.  As the 
VA has achieved the 90th percentile in diabetes measures for quality of care, it may be 
difficult to extend these results to patients receiving care outside the VA.  However, there 
are two alternate hypotheses.  The first is that patients who have worse LDL and HbA1c 
may be more likely to show a difference in monotherapies as there may be more 
complications since these are risk factors.  The second is that there may not be 
differences because of previous studies assessing patients with various blood pressure 
measurements, obesity, HbA1c, lipid profiles, and albuminuria status showed no 
difference in the surrogate marker in the short-term. 
 
Limitations 
 
Documentation 
 
As with any database analysis, the conclusions of this study rely on the accuracy 
of the data.  However, technical reports from the VA Health Economics Resource Center 
show agreement between electronic medical records and the national datasets to be about 
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99% for inpatient and outpatient records.263,264  Additionally, capturing all-cause 
mortality with our methods has been found to capture approximately 97% of deaths in 
VA patients in- and out- side of the VA Health Care System.262 
On that note, in an effort to control for history, inclusion of ICD-9 codes 
pertaining to history of MI or stroke were included.  Once again, data inaccuracy may 
have lead to misclassification, especially for smoking status, family history of CVD, and 
LVH as it is noted that this is rarely coded, at least locally (Personal communication, G. 
Murata, January 8, 2008).  In fact, “the very low rates for family history of CVD 
probably reflect the inadequacy of [the] data sources rather than the true genetic 
predisposition.  After all, diabetes and vascular disease have strong familial tendencies.” 
(Personal communication, G. Murata, December 16, 2010).  We believe this also may 
have happened for documentation of obesity, cardiac disease, and ischemic stroke.  
Specifically, our documented prevalence of obesity is lower than the 62.4% found among 
P2DM in the U.S. and there is evidence that doctors underdiagnose obesity 25-50% of the 
time.265-267  There is also evidence that cardiac disease can be under-reported in ICD-9 
codes although this finding was reported in a different disease state.268  Lastly, a study 
conducted at one VA medical center between 1995 and 1997 revealed 15-20% of 
inpatients with an ICD-9 code of stroke did not actually have one; this finding was 
mostly related to ICD-9-CM codes 433.X0 and 433.X1, which, of the patients with these 
codes, only 2% and 20%, respectively, had strokes.269  Although using ICD-9 codes 
makes rates comparable to other studies relying on ICD-9 codes, it biases overall rates of 
baseline conditions as well as outcomes.  Not only does use of ICD-9 codes probably 
miss some patients, but it also biases for disease severity. (Personal communication, G. 
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Murata, December 16, 2010).  In particular, researchers who compared patients identified 
through two different methods, HbA1c ≥6.5% and problem lists versus ICD-9 codes for 
hospitalization and visits, found the former method identified patients with less severe 
disease. (Personal communication, G. Murata, December 16, 2010). 
Also, we were not able to capture diagnoses at other healthcare organizations, and 
there is evidence that VA-Medicare dual enrollees seek care outside the VA.  This may 
have influenced true prevalence rates of baseline characteristics and incidence rates of 
outcomes.  However, because we do not expect misclassification to be different between 
ACEI and ARB patients, we can treat this data as missing completely at random.270  
Furthermore, unless care outside the VA differentially affects odds of treatment selection 
beyond what was found to be controlled with PSA, it should not impact PSA findings.  
Lastly, medications within each therapeutic class are assumed to have the same effects on 
progressive nephropathy, cardio- and cerebro- vascular disease events, and all-cause 
mortality. Having said this, no studies have been identified showing a difference between 
medications within the same therapeutic class, within diabetes or any other 
cardiovascular disease patients.   
Limited Blood Pressure Information 
 
 In the VA administrative datasets we were only able to capture diagnosis of 
hypertension through ICD-9-CM codes, limiting blood pressure information to a 
dichotomous, rather than continuous, variable.  Although the UKPDS 38 found no 
significant difference in renal failure or all-cause mortality for a 10 point difference in 
systolic blood pressure and a 5 point difference in diastolic blood pressure, the study 
revealed a 34% difference for their composite vascular disease endpoint (p=0.019).25  
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Additionally, JNC-7 states that for each 20 mmHg increase in systolic blood pressure or 
10 mmHg increase in diastolic blood pressure there is a doubling of risk of cardiovascular 
disease.70 
Lack of Race/Ethnicity Data 
 
 Although we previously discussed the important disparities in terms of acquiring 
complications from type 2 diabetes and the differing risk of developing more severe 
complications in many races and ethnicities, we unfortunately had a lot of missing data 
for this variable which would result in a substantially reduced sample size.  As found in 
the U.S. population, African American veterans are more likely to have renal disease and 
lower limb amputations.254,271  Among cardiovascular disease studies, mixed results were 
found regarding racial disparities, including survival differences, between African 
Americans and non-Hispanic whites in the VA:  3 studies found African Americans had 
similar or less all-cause mortality while 2 other studies found African Americans had 
higher all-cause mortality.254  Diabetes studies in the VA also had conflicting findings for 
racial disparities, but testing frequency as well as blood pressure, glycemia, and lipid 
control were generally worse for non-Whites than non-Hispanic whites.254  Because the 
U.S. and VA populations are becoming more diverse we elected to keep individuals with 
missing data for analysis, especially in light of previous studies with majority non-
Hispanic whites.   
 The current study still was able to obtain information pointing to higher risks in 
these races/ethnicities.  For instance, African Americans, Mexican Americans, American 
Indians, and Native Hawaiians have higher risk of heart disease than Caucasians, mostly 
due to their higher rates of obesity and diabetes.272  Similarly, African Americans have 
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higher risk of stroke than Caucasians, mostly because of higher rates of hypertension, 
diabetes, and obesity.272  We were able to capture diagnosis of hypertension, diabetes, 
and obesity, hopefully accounting for most of these discrepancies although we note we 
were unable to extract the severity of hypertension and believe obesity was not reported 
as frequently as it should have been based on other estimates of obesity among P2DM.265 
Lack of Lifestyle Information 
 
 Controllable risk factors for atherosclerosis include LDL, tobacco, hypertension, 
diabetes, obesity, and physical inactivity.272  We captured LDL, previous and current 
tobacco use, hypertension, obesity, and diabetes information.  Problems relating to 
hypertension and obesity information have already been described above.  In this section 
we are focusing on physical activity and mentioning dietary consumption since it is 
related to LDL, hypertension, and obesity.  Obviously, obesity and hypertension are also 
related to physical inactivity, especially in P2DM.  Inappropriate nutrition and lack of 
physical activity increase the likelihood of acquiring long-term diabetes complications, in 
particular, heart disease.273 
High cholesterol is a major risk factor for coronary artery disease, MI, and stroke 
due to atherosclerosis.272  As LDL and platelets are deposited in the arterial walls leading 
to the heart and brain, an embolus becomes more likely.272  If the embolus blocks a blood 
vessel leading to the heart, an MI results.272 Alternately, if it blocks a blood vessel 
leading to the brain, a stroke can occur. 
 In a survey of veteran P2DM who were seen at a VA in Washington state between 
2005 and 2006, 22% self-reported eating no fruits or vegetables per day in the last week, 
64% reported eating between 1 and 4 fruits or vegetables per day in the last week, 42% 
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reported eating a diet rich in fats, and 33% admitted to not following their diabetic meal 
plan.274  This same study found 9% did not engage in any physical activity while another 
33% reported only light physical activity in the last week.274 
 Although we did not capture dietary consumption we do have LDL and 
triglyceride levels that are related to food choices.  In fact, incorporation of food choices 
may have actually led to that information ultimately being dropped out of the regression 
models due to multicollinearity.  Years ago there was hope that a better definition of diet 
for P2DMs would lead to better health outcomes.  This included caloric restriction and 
percentage of types of foods consumed (i.e., carbohydrates versus proteins).  There has 
been no consensus about what type of diet leads to better outcomes.  For instance, the 
amount of protein consumed has not been found to be related to ESRD development or 
progressive renal impairment.89 
Lack of Control over Unobservable Variables 
 
 Although every attempt was made to control for selection bias, PSA is not a 
perfect technique as it only controls observable variables.  In theory, these observable 
patient characteristics are exactly what the provider would know when faced with the 
decision of which monotherapy to prescribe in these newly-diagnosed veteran P2DM.  
However; we did lose information on race and ethnicity; did not have information about 
lifestyle choices; were not aware of NSAID, antihypertensive, or antihyperlipidemic 
usage; did not have the exact blood pressure measurements; and were unable to capture 
care received outside the VA.  Despite inability to control for unobservables, the 
sensitivity analyses revealed that we can be fairly confident in our results for ESRD and 
all-cause mortality.  This means this study’s estimates of effect for these clinical 
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outcomes are “causal” in nature.  We cannot be as confident in the results pertaining to 
IVDE occurrence and healthcare utilization. The researchers remind the readers that those 
outcomes would only change if an exogenous variable exists that is changing odds of 
treatment assignment 
 
Summary of Conclusions and Significance 
 
Contribution to the Literature 
 
 Of the sixteen previously-published studies comparing ACEI and ARB 
monotherapies, only three controlled for albuminuria in their analyses.121-123  Two of 
these three studies assessed the change in geometric mean albuminuria excretion rate 
while the third advised their patients to follow a special diet.  This pattern was seen for 
the other studies as well.  Looking at the sixteen studies as a whole, except for a safety 
endpoint in one study, the only outcome that has been assessed in ACEI and ARB 
monotherapy is related to change in albuminuria.  This means that before this study there 
was a lack of information pertaining to clinical outcomes as albuminuria was a surrogate 
endpoint.  This study is also the first to provide information about healthcare utilization 
when ACEI and ARB monotherapies are used in P2DM.  Second, the previous studies 
had small sample sizes of relatively healthy individuals:  80% excluded patients with 
severe hypertension or enrolled patients who had a mean systolic blood pressure 
<140mmHg, 60% excluded patients with recent CVD or stroke, and 60% excluded 
patients with cancer.  Third, no previous study has been conducted in the U.S., and there 
is extensive literature reporting the differences in complications and severity of type 2 
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diabetes across race/ethnicity groups.  The U.S. population is generally more diverse than 
countries represented from previous studies; the VA also has a diverse population.   
Additionally, as there are different rates of cardio- and cerebro- vascular disease 
across countries20 as well as different patterns of healthcare utilization across 
countries,275,276 this study is the most directly applicable to the U.S. population.  Fourth, 
this is only the second study with treatment and/or follow-up lasting more than one 
year.121  Fifth, this is only the second study that enrolled subjects diagnosed with type 2 
diabetes within the year.244  The previous study enrolled patients with baseline 
normoalbuminuria who were advised to follow a special diet and exercise; these people 
were not representative of newly-diagnosed P2DM as roughly one-quarter have 
microalbuminuria or macroalbuminuria upon diagnosis, and although P2DM may be 
counseled on a special diet or exercise, this is not communicated systematically in 
clinical practice.  Furthermore, patients are more likely to adhere to instructions when 
being watched more closely (i.e., in a trial) according to the Hawthorne Effect.  So, not 
only does this study supplement the published literature by providing the first 
comparisons of several clinically important outcomes, but this study is also most 
applicable to P2DM in the VA and U.S., populations that have been previously ignored, 
in terms of patient comorbidities, composition, and habits.  
 Particularly important findings relate to ACEI monotherapy being effective at 
reducing all-cause mortality compared to neither therapy.  This could be added, at a lower 
grade of evidence, to the HOPE findings of ramipril reducing risk of all-cause mortality 
compared to placebo.  Even more important, because of comparable baseline 
characteristics between treatment groups, are the head-to-head comparisons of ACEI and 
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ARB monotherapy, for which no significant differences were found for all endpoints.  
Until this study, it has just been assumed in clinical practice that these two therapeutic 
classes achieved comparable effects.  However, previous notions in clinical practice have 
been subsequently dispelled by research,277-279 which provided the impetus for this study.  
Thus, this study provides the first support for evidence-based medicine that can be 
practiced in P2DM; it also has particular focus on the U.S. population.  Also of interest 
were comorbidities identified with increasing odds of clinical outcomes and/or incidence 
rates of healthcare utilization.  Further research is needed in other populations to see if 
comorbidity findings hold true in other healthcare organizations.   
Clinical Practice Guideline Implications 
 
 Due to the study contributions just cited, current guidelines should be updated, 
keeping in mind that PSA is a statistical technique used to mimic randomization.  The 
first guideline, the ADA’s Standards of Medical Care in Diabetes—2011, should update 
the section entitled, “Nephropathy Screening and Treatment,” which states, “there are no 
adequate head-to-head comparisons of ACEIs and ARBs.”220  Our study findings for 
ESRD development using PSA can be added as Level of Evidence B (supportive 
evidence from well-conducted cohort studies).  Later, these guidelines mention ACEIs 
reduce MI, stroke, and death in patients with diabetes, giving support for this medication 
class in microalbuminuric patients.220  This study’s findings of head-to-head comparisons 
using PSA relating to IVDE and all-cause mortality should be added, again with Level of 
Evidence B to further support ARBs’ effects on these outcomes.   
 Turning to VA guidelines, VA/DoD Clinical Practice Guideline for Management 
of Diabetes Mellitus 2010 recommends use of an ACEI or ARB with kidney disease 
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(Strength of Recommendation A refers to preferential use of these therapeutic classes 
over other medication classes).145  Similar to the ADA proposed update, we can say there 
are no differences in effectiveness between ACEIs and ARBs; this study provides Quality 
of Evidence II-2 (well-designed cohort), which provides moderate grade evidence 
directly linked to health outcomes for which no previous evidence exists for these head-
to-head comparisons.  This can also be incorporated into VA/DoD Clinical Practice 
Guideline for Management of Chronic Kidney Disease in Primary Care 2007 
recommendations of using ACEIs or ARBs to slow nephropathy progression in diabetes 
patients with microalbuminuria or macroalbuminuria.89  In its section entitled, “Summary 
of Supporting Studies of ACEI/ARB Treatment,” study findings of the head-to-head 
therapies with PSA can be added in terms of nephropathy progression; IVDEs, all-cause 
mortality, and healthcare utilization can be added as well.  Cardiovascular disease and 
mortality risk are mentioned earlier in these guidelines for patients with chronic kidney 
disease, allowing this information to be relevant to the guideline.  The VA/DoD Clinical 
Practice Guideline for Diagnosis and Management of Hypertension in the Primary Care 
Setting 2004 states, “ARBs appear to have similar short-term effects as ACEIs in patients 
with diabetes and nephropathy with fewer side effects.  However there are no long-term 
outcome trials comparing an ACEI to an ARB to determine if these agents provide 
similar long-term benefits in patients with diabetes.”144  Our findings address this 
literature gap. 
 Focusing on identified comorbidities, the VA/DoD Clinical Practice Guideline for 
Management of Diabetes Mellitus 2010’s145 Screening Module S allows the opportunity 
for clinicians, while screening for diabetes based on its risk factors, to counsel on 
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interventions to prevent comorbidities that were found to increase odds ratios and/or 
incidence rate ratios in our study sample while simultaneously counseling on prevention 
of diabetes.  Our study similarly affects the VA/DoD Clinical Practice Guideline for 
Diagnosis and Management of Hypertension in the Primary Care Setting 2004.144  Since 
clinicians are advised to educate hypertensive patients about lifestyle modification in 
relation to other cardiovascular risk factors, communication regarding the significance of 
preventing some comorbidities identified as having increased odds of IVDE is already 
occurring.  The remaining comorbidities identified as having increased healthcare 
utilization in this study should also be mentioned at this time since hypertension is a risk 
factor for diabetes.  Obviously, these comorbidities would peak patient interest if 
implications on quality of life were stressed more than healthcare utilization. 
Contribution to Public Policy  
 
The federal government recognized the need for reducing nephropathy in patients 
with diabetes by declaring two objectives in Healthy People 2010.10  This study provided 
information relating to Objective 4-7, which pertains to reducing the number of patients 
with incident cases of ESRD by 31%.  In particular, ACEI monotherapy, compared to 
neither therapy, had a lower odds of ESRD development (p<0.01).  Furthermore, patients 
with the comorbidities liver disease, fluid and electrolyte disorders, and deficiency 
anemias have 7.40, 7.71, and 5.81 higher odds of ESRD development, emphasizing the 
need for preventive measures of these comorbidities.  According to Objective 4-8, there 
is a recognized need to increase the proportion of patients with diabetes and proteinuria 
who receive medical therapy to attenuate progression to chronic renal insufficiency.  This 
study provides additional evidence of the importance of ACEI monotherapy and 
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simultaneously shows a substantial amount of patients not receiving ACEI or ARB 
monotherapy.  Although it can be argued that patients not receiving therapy may be, in 
fact, receiving prescriptions at other healthcare organizations, this is unlikely given the 
high mortality rate in these patients and that minimally three-fourths of our sample would 
receive medications for free in the VA.   
 Healthy People 2010 also calls for a 10% reduction in CVD-related deaths and a 
43% reduction in all-cause mortality.10  As this is the only study comparing ACEI and 
ARB monotherapy for CVD endpoints and assessed treatment differences in all-cause 
mortality, this study provides evidence of a significant reduction in all-cause mortality for 
ACEI and ARB monotherapies compared to neither therapy (p<0.001 each) while also 
finding a nonsignificant difference between ACEI and ARB monotherapies.  We also 
found a higher odds of IVDE occurrence for ACEI patients compared to neither patients 
while also finding no difference between ACEI and ARB monotherapies.  Lastly, we 
found history of MI, history of stroke, pulmonary circulation disorders, peripheral 
vascular disorders, chronic pulmonary disease, and fluid and electrolyte disorders had 
higher odds of IVDE whereas history of MI, CHF, and peripheral vascular disorders had 
higher odds of all-cause mortality.  This study provides the best evidence to date in 
addressing these endpoints for ACEI and ARB monotherapies in the U.S. population. 
Contribution to the VA 
 
 Almost one-half of our sample received neither therapy meaning that it is 
essential for clinicians to prescribe, educate, and counsel patients on the importance of 
adhering to ACEI or ARB monotherapy.  Findings of a recent study of cardiovascular 
patients who were “ideal candidates” for ACEIs were more likely to receive these in VA 
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than non-VA settings, underlining the importance of these activities.  Since a proportion 
of the sample receives a combination of VA and non-VA care, continuity of care across 
healthcare organizations is a priority and must be ensured.  This is emphasized in the 
2011 ADA guidelines:  “there is persistent variation in quality of diabetes care across 
practice settings…that indicates the potential for further improvements in diabetes 
care.”220 
 The current study results are directly applicable to the VA as patients from all 
states plus the District of Columbia and Puerto Rico are represented.  Additionally, for 
patients receiving ACEI or ARB monotherapy, about three-fourths were matched with 
PSA.  This finding indicates clinicians have clinical equipoise for the majority of P2DM, 
making the results generalizable to veteran P2DM.  Identification of lower odds of ESRD 
development associated with ACEI monotherapy compared to neither therapy (p<0.01) 
can confer a cost savings to the VA if prescribing of and counseling on implications of 
compliance with ACEI monotherapy was systematically increased.  However, since 
ACEI and ARB monotherapies were associated with reduced all-cause mortality 
compared to neither therapy, our results also show ACEI or ARB monotherapy were 
associated with higher incidence rates of outpatient visits, ED visits, and hospitalizations 
compared to neither therapy.  This means a higher burden on healthcare resources could 
ensue.  Alternately, it could mean those who are more compliant with their medication 
are, in general, more vigilant about their health, so they are going to the doctor more 
often than those who are less vigilant, which could lead to less healthcare strain in the 
long run.  Specific to comparisons of ACEI and ARB monotherapies, clinicians should 
prescribe what is on formulary, and if patients are intolerant to an ACEI, should not 
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hesitate to change patients over to an ARB.  In fact, this is exactly what the VA 
guidelines advocate.89,144,145 
 Obviously, it is unethical to hold treatment that would otherwise help patients; 
because of this, healthcare providers are required to uphold the Hippocratic Oath.  An 
appropriate way to offset healthcare resources would be on measures aimed at preventing 
comorbidities identified with higher odds of clinical outcomes and/or higher incidence 
rates of healthcare utilization.  CHF, chronic pulmonary disease, diabetes complications, 
liver disease, solid tumor without metastasis, fluid and electrolyte disorders, deficiency 
anemias, drug abuse, psychoses, and depression had higher incidence rates of outpatient 
visits, ED visits, and hospitalizations.  Although these comorbidities stem from several 
causes, each has at least one modifiable risk factor.  For instance, smoking contributes to 
CHF, chronic pulmonary disease, and solid tumor without metastasis; exercise is 
associated with lower likelihood of diabetes complicated, drug abuse, and depression; 
and tattoos and intravenous drug use contribute to liver disease and psychoses.  Of 
course, the veteran population is more at risk for drug abuse, psychoses, and depression 
purely due to exposure to combat situations when these patients were on active duty.  
Also, Agent Orange exposure can contribute to CHF, liver disease, and solid tumor 
without metastasis.280  Exactly because these patients are already at higher risk 
emphasizes the importance of counseling on reducing and avoiding behaviors and 
attitudes that place these patients at higher risk of developing these comorbidities.  VA 
guidelines already address preventing a substantial proportion of these comorbidities by 
advising clinicians to recommend lifestyle modification of risk factors contributing to 
these comorbidities in veterans at high risk for developing type 2 diabetes.  This study 
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provides supplemental information by giving clinicians specific disease states in which to 
emphasize patient education efforts. 
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Human Research Review Committee MSC 08 4560 BMSB Room B71  
1 University of New Mexico~Albuquerque, NM 87131-0001  
(505) 272-1129 Facsimile (505) 272-0803 
http://hsc.unm.edu/som/research/hrrc/  
04-Apr-2008  
Khan, Nasreen 
Pharmacy Practice 
 
SUBJECT: HRRC Approval of New VA Research Protocol HRRC#: 08-094 Study 
Title: Comparison of Monotherapy with Angiotensin-Converting Enzyme Inhibitors or 
Angiotensin II Receptor Blocckers in Improving Health Outcomes among Veteran 
Patients with Type 2 Diabetes Type of Review: Expedited Review Approval Date: 01-
Apr-2008 Expiration Date: 31-Mar-2009  
Dear Dr. Khan:  
The Human Research Review Committee (HRRC) has reviewed and approved* the 
above-mentioned research protocol including the following:  
1. HRRC Application received 031908  
2. Protocol received 031908  
 
It is the responsibility of the Principal Investigator to ensure that all requirements of 
the VA are met and that documented VA approval has been obtained prior to study 
initiation (i.e., subject enrollment and/or data collection).  
Consent decision: Waived the requirement for informed consent HIPAA Authorization 
Addendum waived  
Medical Records are not to be flagged.  
This study is approved to enroll only the number of subjects listed in the application, 
protocol and consent form(s). If the PI wants to enroll additional subjects, it is the 
responsibility of the PI to submit an Amendment/Change to the HRRC before the 
approved number of enrolled subjects is exceeded. If increased enrollment is requested, 
the application, protocol and/or consent form(s) must also be amended to include the 
new target.  
Sincerely, Mark Holdsworth, Pharm.D., BCOP Executive Chair Human Research 
Review Committee 
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TABLE OF IDENTIFIED STUDIES COMPARING ACEI OR ARB MONOTHERAPY TO PLACEBO IN P2DM* 
 
Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference; Notes 
ACEI 
(Ramipril 
10mg daily); 
Placebo 
Double-blind 
RCT for 4.5y. 
Study 
conducted in 
S. America, 
Europe, UK, 
N. America. 
N=3,577.  
ACEI, 
N=1,808. 
Placebo, 
N=1,769. 
Normo or micro 
(micro=32%). Type 
2DM=97.5%. Mean 
age=65.4y. Mean 
BMI=28.8kg/m2. 
Mean 
BP=142/80mmHg. 
Mean duration with 
diabetes=11.4y. 
Current 
smoker=15%. Hx 
of CVD=69.0%. 
Macro, 
severe renal 
dx, CHF, 
ejection 
fraction<0.4
, 
uncontrolled 
HTN, MI or 
stroke 
within 4wk 
 8.4% of pts in placebo developed 
macro compared to 6.5% of pts in 
ACEI at 4.5y (p=0.027). 
 NS diff for dialysis 
 Sig diff for combined endpt of 
developing macro, dialysis, or laser 
therapy for retinopathy (17.6% for 
placebo vs. 15.1% for ACEI, 
p=0.036). 
 The combined outcome of MI, 
stroke, or cardiovascular death was 
reached in 19.8% of placebo pts 
compared to 15.3% of ACEI pts at 
4.5y (p=0.0004). 
 Sig diffs:              
                  Placebo  ACEI    p-value 
         MI            12.9%    10.2%   0.01 
         Stroke       6.1%     4.2%    0.0074 
         CV death   9.7%     6.2%    0.0001 
 Total mortality was reached by 
14.0% of placebo pts vs. 10.8% 
of ACEI pts (p=0.004). 
 NS diffs for unstable angina, heart 
failure, worsening angina 
 Sig diffs: 
              Placebo   ACEI   p-value 
Gerstein (HOPE)46. 
Stopped 6 mo early 
b/c found famipril 
was beneficial. 
Adherence 
rate=65% for 
ramipril (NR for 
placebo). 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference; Notes 
     Revasc.   16.4%     14.0%   0.031 
     TIA          5.9%        4.4%   0.04 
ACEI 
(Enalapril 
10mg daily); 
 Placebo 
Double-blind 
RCT for 6 y. 
Study 
conducted in 
Israel. N=156. 
ACEI, N=77. 
Placebo, 
N=79. 
Normo. Mean 
age=54.9y. Mean 
duration of 
diabetes=5.8y. 
Mean 
BMI=24.7kg/m2. 
Current 
smokers=15%. 
Mean BP NR. 
Mean HbA1c=9.2%
HTN; CA; 
autoimmune
, hepatic, 
cardiovascul
ar, or renal 
dx; 
BMI≥30kg/
m2. 
At 6 y, mean UAER was 26.5mg/24h in 
placebo group and 15.8mg/24h in ACEI 
group (p=0.001) 
Ravid47 
In sample size 
calculation 
assumed 15% of 
normotensive 
normoalbuminurics 
will develop 
microalbuminuria 
in 6y. 
ACEI 
(Enalapril 
(dosing 
NR)); 
Placebo 
Single-blind 
RCT. Study 
conducted in 
India. N=103. 
ACEI, N=52. 
Placebo, 
N=51. 
Micro. Mean 
duration of 
diabetes=9.3y. Age 
range=43-55y. 
Mean 
HbA1c=8.0%. 
Mean BP=132/81 
mmHg. 
Obesity; hx 
or evidence 
of 
nondiabetic 
renal, 
systemic, 
cardiac, or 
hepatic dxs; 
GFR<90mL
/min 
 At 5 y, 23.5% of placebo pts and 
7.7% of ACEI pts developed macro 
(p<0.001) 
 Annually, albuminuria decreased at a 
mean rate of 16.7% in the ACEI 
group while it increased at a mean 
rate of 12.3% in the Placebo group. 
Ahmad48 
ARB 
(Irbesartan 
150mg 
daily);  
ARB 
(Irbesartan 
300mg 
Double-blind 
RCT for 2y. 
Study 
conducted in 
Europe, 
Australia, 
Canada, UK. 
Micro. Mean 
BP=153/90mmHg. 
Mean age=58.0y. 
Mean BMI=30.1 
kg/m2. Mean 
duration with 
diabetes=9.7y.  
Nondiabetic 
kidney dx, 
CA 
14.9% of pts in the placebo group 
reached macro at 2y, compared to 9.7% 
for ARB 150mg (p=0.08) and 5.2% for 
ARB 300mg (p<0.001). 
Parving45. At end of 
study, 56% of those 
in placebo group 
were taking 
antihypertensives.  
Adherence 
rate=81% for ARB 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference; Notes 
daily); 
Placebo 
N=590. ARB 
150mg, 
N=195. ARB 
300mg, 
N=194. 
Placebo, 
N=201. 
Mean HbA1c= 
7.1%. Hx of 
CVD=26.6%. Mean 
CrCl=109mL/min/1
.73m2. Mean 
TG=183.1mg/dL. 
Mean 
LDL=140.0mg/dL. 
150mg and 89% for 
ARB 300mg (NR 
for Placebo). 
ARB negated 
nephropathy 
progression. 
ARB 
(Losartan 50-
100mg 
daily); 
Placebo 
Double-blind 
RCT for 3.4y. 
Study 
conducted in 
Asia, Europe, 
Central 
America, N. 
America, S. 
America. 
N=1,513. 
ARB, N=751. 
Placebo, 
N=762. 
Macro. Mean 
BP=153/82mmHg. 
Mean age=60y. 
Mean BMI=19.4 
kg/m2. Mean 
HbA1c= 8.4%. 
Current smokers= 
18.3%. Mean 
LDL=142 mg/dL. 
Mean TG=219 
mg/dL. Hx of 
MI=11.2% 
Nondiabetic 
renal dx, MI 
or CABG 
within 4 wk, 
CVA or 
PTCA 
within 6mo, 
TIA within 
1y, hx of 
heart failure 
 25.5% of pts in Placebo group 
reached ESRD at 3.4y, compared to 
19.6% for ARB (p=0.002).  
 ARB had 35% reduction in mean 
albuminuria vs. placebo’s 20% 
increase (p<0.001). 
Brenner 
(RENAAL)49. 
Planned to have 
mean f/u of 4.5y, 
but stopped early 
b/c of new evidence 
that ACEIs may 
benefit pts with 
renal impairment in 
terms of CVD 
events (ACEIs were 
excluded in this 
study). 
ARB 
(Irbesartan 
300mg 
daily);  
CCB 
(Amlodipine 
10mg daily); 
Plabebo 
Double-blind 
RCT for 2.6y. 
Study 
conducted in 
N. America, 
S. America, 
Europe, Asia, 
Middle East, 
Macro. Mean 
age=58.9y. Mean 
BMI=30.8kg/m2. 
Mean 
BP=159/87mmHg. 
Insulin use=58.0%. 
Hx of CVD=28.7%. 
Mean HbA1c=8.2%
Normotensi
on 
 For the combined endpt of doubling 
SCr, development of ESRD, or 
death, 39.0% of placebo pts, 41.1% 
of CCB pts, and 32.6% of ARB pts 
reached this endpt. Compared to 
ARB pts, a sig higher proportion of 
placebo and CCB pts reached this 
endpt (p-values=0.02 and 0.006, 
Lewis (IDNT 
(renal))53 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference; Notes 
Australia. 
N=1,715. 
ARB, N=579. 
CCB, N=567. 
Placebo, 
N=569. 
resp). 
 14.2% of the ARB group, 18.3% of 
the CCB groups, and 17.8% of the 
placebo group developed ESRD (p-
value>0.05) 
 NS diffs for death (incidence rates 
much closer than ESRD) 
 NS diffs for combined endpt of death 
from CVD, nonfatal MI, hosp for 
heart failure, permanent neurological 
defect from a cerebrovascular event, 
or lower limb amputation above the 
ankle 
ARB 
(Irbesartan 
300mg 
daily);  
CCB 
(Amlodipine 
10mg daily); 
Placebo 
Double-blind 
RCT for 2.6y. 
Study 
conducted in 
N. America, 
S. America, 
Europe, Asia, 
Middle East, 
Australia. 
N=1,715. 
ARB, N=579. 
CCB, N=567. 
Placebo, 
N=569. 
Macro. Mean 
age=58.9y. Mean 
BMI=30.8kg/m2. 
Mean 
BP=159/87mmHg. 
Insulin use=58.0%. 
Hx of CVD=28.7%. 
Mean HbA1c=8.2%
Normotensi
on 
 Having a CVD event before renal 
failure, death, or censorship occurred 
in 32.5% of placebo pts, 28.3% of 
CCB pts, and 29.7% of ARB pts 
(p>0.2 for each comparison) 
   Developing CHF occurred in 
13.8% of the ARB group, 19.9% 
of the placebo group, and 25.9% 
of the CCB group. Compared to 
the ARB group, the other groups 
had a sig higher rate (p=0.048 and 
p=0.004, resp) 
Berl (IDNT 
(CVD))109 
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*= 100% of subjects have type 2 diabetes unless otherwise stated;  ACEI= angiotensin-converting enzyme inhibitor; ARB= 
angiotensin II type 1 receptor blocker; BMI= body mass index; btwn= between; BP= blood pressure;  CA= cancer; CABG= coronary 
artery bypass graft;  CCB= calcium channel blocker;  CHF= congestive heart failure;  CrCl= creatinine clearance; CVA= 
cerebrovascular accident;  CVD= cardiovascular disease; d= days; dx= days; endpt= endpoint; ESRD= end-stage renal disease; f/u= 
follow-up; h= hours; HbA1c= glycosylated hemoglobin;  HTN= hypertension; hx= history; LDL= low-density lipoprotein;  macro= 
macroalbuminuria;  mo= month;  normo= normoalbuminuria; NR= not reported; NS= nonsignificant; PTCA= Percutaneous 
transluminal coronary angiography; pts= patients;  RCT= randomized controlled trial;  revasc.= revascularization;  SCr= serum 
creatinine;  sig= significant;  TG= triglycerides; TIA= transient ischemic attack; UAER= urinary albumin excretion rate; wk= weeks; 
y= years 
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TABLE OF IDENTIFIED STUDIES COMPARING ACEI OR ARB MONOTHERAPY TO ACTIVE CONTROLS IN P2DM 
Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference, Notes 
ACEI 
(Captopril 
50mg twice 
daily);  
BB  
(Atenolol 50-
100mg daily) 
Double-blind 
RCT for 9y. 
Study 
conducted in 
UK. N=758. 
ACEI, 
N=400. BB, 
N=358. 
Normo 
(75.6%)/Micro 
(17.9%)/Macro 
(6.5%). Mean 
age=56.2y. 
Mean BMI=159/ 
94mmHg. 
Receiving HTN 
drugs=35.5%. 
Current 
smokers=22.9%. 
Mean 
HbA1c=6.9%. 
Normotension  For albuminuria progression, 31% of 
ACEI group & 26% of BB group had 
micro at 9y (p=0.31) while 5% of 
ACEI group & 10% of BB group had 
macro at 9y (p=0.09). 
 Of 21 clinical endpts related to 
diabetes, none were sig btwn groups. 
Clinical endpts capture micro- & 
macro- vascular complications as well 
as death. 
 
UKPDS 39110 
Adherence=80% for 
ACEI & 74% for 
BB. 
ACEI 
(Fosinopril 
20mg daily); 
CCB 
(Amlodipine 
10mg daily) 
Open-label 
RCT for 2.5y. 
Study 
conducted in 
Italy. N=380. 
ACEI, 
N=189. CCB, 
N=191. 
Normo. Mean 
age=63.1y. 
Mean duration 
with diabetes 
=10.6y. Current 
smokers=5.8%. 
Mean BMI= 
30.6kg/m2. 
Mean BP= 
171/94mmHg. 
Mean HbA1c= 
7.0%. Mean 
TG=156mg/dL. 
Normotension
; hx of CVD, 
stroke, or 
other 
condition 
with a poor 
prognosis 
 ACEI was sig better for: 
 Any major vascular event (2.6% 
vs. 5.0%, p=0.030) 
 Any major vascular event or any 
procedure (2.6% vs. 5.0%, 
p=0.030) 
 Any death, vascular event, or 
procedure (3.6% vs. 6.3%, 
p=0.036) 
Tatti (FACET)119 
To control BP, 
amlodipine was 
given to 30.7% of 
fosinopril pts while 
fosinopril was given 
to 26.2% of 
amlodipine pts. 
ACEI Double-blind Normo Normotension  Among those with BL normo or Chan116 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference, Notes 
(Enalapril 
10-40mg 
daily); 
CCB 
(Nifedipine 
20-40mg 
twice daily) 
RCT for 1y. 
Study 
conducted in 
Europe. 
N=335. 
ACEI, 
N=168. CCB, 
N=167. 
(42.2%)/Micro 
(33.3%)/Macro 
(24.5%). Mean 
age=58.0y. 
Mean BMI= 
24.9kg/m2. 
Mean 
BP=169/93 
mmHg. Mean 
HbA1c=7.5%. 
Mean TG=1.99 
mmol/L. Mean 
LDL=3.62mmol
/L. 
, hx of CVD macro there were no between group 
diffs for progression of albuminuria 
(p=0.46 and p=0.086, resp) 
 Among those with BL micro, those on 
CCB were more likely to progress to 
macro than those on ACEI (p=0.046) 
ACEI 
(Cilaprazil 
2.5mg daily); 
CCB 
(Amlodipine 
5mg daily) 
Double-blind 
RCT of 3y. 
Study 
conducted in 
Italy. N=44. 
ACEI, N=22. 
CCB, N=22. 
Normo 
(59%)/Micro 
(41%). Mean 
age=54.3y. 
Mean duration 
with HTN=3.2y. 
Mean duration 
with diabetes= 
5.4y. Mean 
TG=2.1mmol/L. 
Mean BMI= 
29.9kg/m2. 
Endocrine 
HTN; heart 
failure class 
III or IV; hx 
of MI, LVH, 
or AV 
blockage of 
2nd or 3rd 
degree; 
HbA1c>10% 
with 
variations>30
% in past 
6mo; BMI> 
35kg/m2 
 NS diffs btwn groups at 3y for 
reduction in UAER 
 BL Normo (ACEI=33.0% vs. 
CCB=25.0%, p>0.05) 
 BL Micro (ACEI=30.8% vs. 
CCB=26.5%, p>0.05) 
Velussi111 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference, Notes 
within last 
6mo. 
ACEI 
(Lisinopril 
10-20mg 
daily);  
CCB 
(Nifedipine 
20-40mg 
twice daily) 
Double-blind 
RCT for 1y. 
Study 
conducted in 
Europe. 
N=335. 
ACEI, 
N=168. CCB, 
N=167. 
Micro. Mean 
age=58.5y. 
Mean BP= 
163/98mmHg. 
Normotension
; autonomic 
neuropathy; 
renal artery 
stenosis; 
hematuria; 
malignant 
HTN; 
aortic/mitral 
valve 
obstruction; 
sig hepatic, 
hemapoietic, 
or endocrine 
dysfx; MI, 
unstable 
angina, TIA, 
or stroke 
within 3mo; 
CA; 
Psychiatric 
disorder; 
EtOH or drug 
abuse  
 Median difference of UAER btwn 
groups at 6mo=20µg/min (p=0.0002) 
at 12mo=20µg/min (p=0.0006), 
favoring ACEI 
 NS diffs in BP reduction 
Agardh120 
ACEI 
(Enalapril 5-
20mg daily); 
Double-blind 
RCT for 98d 
followed by 
Micro with mild 
HTN and 
diabetic 
Nondiabetic 
renal dx, 
heart failure 
 Short-term study: 
 ACEI group was better at 
controlling albuminuria change 
Ruggenenti112 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference, Notes 
CCB 
(Nitrendipine 
10-40mg 
daily) 
single-blind 
RCT for 1y. 
Study 
conducted in 
Italy. 
Double-blind: 
N=16. ACEI, 
N=8. CCB, 
N=8. Single-
blind: N=14. 
ACEI, N=6. 
CCB, N=8. 
glomerulopathy. 
Mean age= 
52.5y. Mean 
BMI=29.5kg/m2. 
Mean duration 
of HTN=3.6y. 
Mean duration 
of diabetes= 
9.3y. Mean 
BP=156/97mmH
g. Mean HbA1c 
=7.4%. 
class III or 
IV, AV 
blockage of 
2nd or 3rd 
degree, 
symptomatic 
coronary 
ischemic dx, 
liver or 
hematologic 
dx, CA, 
collagen 
vascular dx 
(28.8 vs. 70.3, p<0.05) 
 Long-term study: 
 NS diffs for albuminuria change 
(p>0.05) 
ACEI 
(Lisinopril 
10-20mg 
daily);  
BB  
(Atenolol 50-
100mg daily) 
Double-blind 
RCT for 
12mo 
followed by 
single-blind 
RCT through 
3.5y. Study 
conducted in 
Denmark. 
N=43. ACEI, 
N=21. BB, 
N=22. 
Macro. Mean 
age=60.5y. 
Mean BMI= 
33.1kg/m2. 
Mean duration 
of diabetes= 
9.5y. Current 
smokers=54.5% 
Mean 
HbA1c=8.6%. 
Mean LDL= 
3.7mmol/L. 
Mean TG= 
2.1mmol/L 
Nondiabetic 
renal dx 
 ACEI was sig better for percent 
reduction in albuminuria than BB 
(55% vs. 15%, p=0.01) at 3.5y 
Nielsen113 
ACEI 
(Lisinopril 
Blinding NR. 
Randomized 
Macro. Mean 
age=62.1y. 
Heart failure, 
poor diabetes 
 ACEI was sig better for reduction in 
albuminuria than BB ((-1.65g/d vs. –
Bakris114 
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Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Results Reference, Notes 
(dosing 
NR));  
CCB 
(Verapamil 
or Diltiazem 
(dosing 
NR));  
BB  
(Atenolol 
(dosing NR)) 
trial for 6y. 
Study 
conducted in 
USA N=52. 
ACEI, N=18. 
CCB, N=18. 
BB, N=16. 
Mean duration 
of diabetes= 
13.7y. Mean 
duration of 
HTN=15.0y. 
Mean HbA1c= 
10.7%. Mean 
BP=157/98mmH
g. 
or HTN 
control, CAD, 
severe 
claudication, 
orthostatic 
hypotension, 
psychiatric 
disorders, 
blindness 
0.5g/d, p<0.01) 
 NS diffs btwn groups for reduction in 
albuminuria, ACEI vs. CCB (-1.65g/d 
vs. –1.95g/d, p>0.99) 
ACEI 
(Ramipril 
5mg daily); 
CCB 
(Nitrendipine 
10mg twice 
daily) 
Blinding NR. 
Randomized 
trial for 2y. 
Study 
conducted in 
Italy. N=107. 
ACEI, N=54. 
CCB, N=53. 
Macro. Mean 
age=56.3y. 
Mean duration 
with 
diabetes=8.3y. 
Mean 
weight=73.9kg. 
Mean 
BP=166/102mm
/Hg. Mean 
HbA1c=7.1% 
Cardiac or 
hepatic dysfx, 
ankle edema, 
albuminuria>
2g/d. 
 NS diffs btwn groups for percentage 
change in UAER at 2y (-32.3% vs. –
19.5%, p>0.05) 
Fogari115 
Men only. 
Low protein, low 
sodium diet. 
56 pts dropped out 
(NS diffs btwn 
groups). 
UAER decreased 
sig at 3mo for 
ACEI; took 1y for 
CCB. 
Changes in UAER 
not correlated with 
DBP, HbA1c, 
CrCL, or SCr 
changes. 
ACEI 
(Enalapril 
(dosing 
Double-blind 
RCT for 5.5y. 
Study 
Stage of 
albuminuria NR. 
Mean 
Normotension
. MI or CVA 
within 6mo, 
 ACEI was sig better for: 
 Nonfatal MI (2.1% vs. 9.4%, 
p=0.001) 
Estacio (ABCD trial 
subanalysis of 
hypertensive pts)118. 
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NR));  
CCB 
(Nisoldipine 
(dosing NR)) 
conducted in 
USA. N=470. 
ACEI, 
N=235. CCB, 
N=235. 
age=57.4y. 
Family hx of 
CAD=47%. 
Mean duration 
with diabetes= 
8.6y. Mean 
HbA1c=11.6% 
Mean duration 
with HTN= 
156/98mmHg. 
Current or 
former smokers 
=62%. Mean 
LDL=129mg/dL
. Mean TG=291 
mg/dL. Mean 
BMI=31.6kg/m2.
CABG within 
3mo, unstable 
angina within 
6mo, class III 
or IV CHF 
 Nonfatal & fatal MI (2.1% vs. 
10.6%, p=0.001) 
 NS diffs for: 
 CVA (4.7% vs. 3.0%, p>0.05) 
 CHF (2.5% vs. 2.1%, p>0.05) 
 CVD death (4.3% vs. 2.1%, 
p>0.05) 
 All cause mortality (7.2% vs. 
5.5%, p>0.05) 
DSMB stopped trial 
early due to sig 
better rate in CVD 
events in ACEI 
group for 
hypertensives. 
Annual rate of 1 
MI/y in ACEI group 
vs. 5 MIs/y in CCB 
group. 
ARB 
(Valsartan 
80-160mg 
daily);  
CCB 
(Amlodipine 
5-10mg 
daily) 
Double-blind 
RCT for 6mo. 
Study 
conducted in 
UK. N=332. 
ARB, N=169. 
CCB, N=163. 
Micro. Normo- 
(35.0%) or 
hyper- (65.0%) 
tensive. Mean 
age=58.0y. 
Mean BMI=30.8 
kg/m2. Mean 
BP=147/85mm 
Hg. 
Hx of MI, 
PTCA, or 
CVA within 
3mo; severe 
neuropathy; 
hx of 
hypertensive 
encephalopat
hy; hepatic dx
 ARB was sig better for: 
 Reversal to normo (29.9% vs. 
14.5%, p=0.001) 
 Decrease in UAER (44% vs 8%, 
p<0.001) 
Viberti 
(MARVAL)117 
Study length set 
because max effect 
of RAAS inhibition 
is 6mo. 
Similar reduction in 
UAER for normo- 
and hyper- tensives. 
ARB 
(Irbesartan 
300mg 
Double-blind 
RCT for 2.6y. 
Study 
Macro. Mean 
age=58.9y. 
Mean 
Normotension  For the combined endpt of doubling 
SCr, development of ESRD, or death, 
39.0% of placebo pts, 41.1% of CCB 
Lewis (IDNT 
(renal))53 
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daily);  
CCB 
(Amlodipine 
10mg daily); 
Plabebo 
conducted in 
N. America, 
S. America, 
Europe, Asia, 
Middle East, 
Australia. 
N=1,715. 
ARB, N=579. 
CCB, N=567. 
Placebo, 
N=569. 
BMI=30.8kg/m2. 
Mean 
BP=159/87mmH
g. Insulin 
use=58.0%. Hx 
of CVD=28.7%. 
Mean 
HbA1c=8.2% 
pts, and 32.6% of ARB pts reached 
this endpt. Compared to ARB pts, a 
sig higher proportion of placebo and 
CCB pts reached this endpt (p-
values=0.02 and 0.006, resp). 
 14.2% of the ARB group, 18.3% of 
the CCB groups, and 17.8% of the 
placebo group developed ESRD (p-
value>0.05) 
 NS diffs for death (incidence rates 
much closer than ESRD) 
 NS diffs for combined endpt of death 
from CVD, nonfatal MI, hosp for 
heart failure, permanent neurological 
defect from a cerebrovascular event, 
or lower limb amputation above the 
ankle 
ARB 
(Irbesartan 
300mg 
daily);  
CCB 
(Amlodipine 
10mg daily); 
Placebo 
Double-blind 
RCT for 2.6y. 
Study 
conducted in 
N. America, 
S. America, 
Europe, Asia, 
Middle East, 
Australia. 
N=1,715. 
ARB, N=579. 
Macro. Mean 
age=58.9y. 
Mean 
BMI=30.8kg/m2. 
Mean 
BP=159/87mmH
g. Insulin 
use=58.0%. Hx 
of CVD=28.7%. 
Mean 
HbA1c=8.2% 
Normotension  Having a CVD event before renal 
failure, death, or censorship occurred 
in 32.5% of placebo pts, 28.3% of 
CCB pts, and 29.7% of ARB pts 
(p>0.2 for each comparison) 
   Developing CHF occurred in 
13.8% of the ARB group, 19.9% of 
the placebo group, and 25.9% of 
the CCB group. Compared to the 
ARB group, the other groups had a 
sig higher rate (p=0.048 and 
Berl (IDNT 
(CVD))109 
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CCB, N=567. 
Placebo, 
N=569. 
p=0.004, resp) 
ARB 
(Losartan 
(dosing 
NR));  
BB  
(Atenolol 
(dosing NR) 
Double-blind 
RCT for 4.7y. 
Study 
conducted in 
Europe, UK, 
USA. 
N=1,195. 
ARB, N=586. 
BB, N=609. 
Stage of 
albuminuria NR. 
Mean 
age=67.4y. 
Mean 
BP=177/96mmH
g. Mean 
BMI=30.0kg/m2. 
Current 
smokers=13.6%. 
Any vascular 
event=35%. 
Normotension
, no signs of 
LVH 
 ARB was sig better for: 
 CVD mortality, stroke, or MI 
(39.2% vs. 53.6%, p=0.017) 
 CVD mortality (13.6% vs. 21.8%, 
p=0.019) 
 All cause mortality (22.5% vs. 
37.2%, p=0.001) 
 Hosp admission for heart failure 
(11.8% vs. 20.7%, p=0.013) 
 NS diffs for: 
 Stroke (19.0% vs. 24.5%, 
p=0.190) 
 MI (15.2% vs. 18.7%, p=0.318) 
 Hosp admission for angina (11.1% 
vs. 11.1%, p=0.989) 
 Revasc (23.5% vs. 26.6%, 
p=0.470) 
Lindholm (LIFE)50 
 
ACEI= angiotensin-converting enzyme inhibitor; ARB= angiotensin II receptor type 1 blocker;  AV= atrioventricular blockage; BL= 
baseline;  BMI= body mass index; BB= beta-blocker;  BP= blood pressure; btwn= between; CA= cancer; CAD= coronary artery 
disease;  CCB= calcium channel blocker;  CHF= congestive heart failure;  CrCl= creatinine clearance; CVA= cerebrovascular 
accident; CVD=  cardiovascular disease; DBP= diastolic blood pressure;  DSMB= data and safety monitoring board;  dx= disease; 
endpts= endpoints;  ESRD= end-stage renal disease; EtOH= alcohol; hosp= hospitalization;  HTN=  hypertension;  hx= history; 
LDL= low density lipoprotein; LVH= left ventricular hypertrophy; macro= macroalbuminuria; MI= myocardial infarction; micro=  
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microalbuminuria;  mo=  months; normo= normoalbuminuria; NR= not reported; NS= nonsignificant; PTCA= percutaneous 
transluminal coronary angioplasty; pts= patients; RAAS= renin angiotensin aldosterone system; RCT= randomized controlled trial; 
revasc.= revascularization; SCr= serum creatinine; sig= significant; TG= triglycerides; TIA= transient ischemic attack; UAER= 
urinary albumin excretion rate; y= years  
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TABLE OF IDENTIFIED STUDIES COMPARING ACEI AND ARB MONOTHERAPY IN P2DM 
 
Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Endpoint, 
baseline  
Endpoint, 
results 
Reference, Notes 
ACEI 
(Enalapril 
5mg daily); 
ARB 
(Losartan 
50mg daily).  
RCT of 12 mo 
treatment 
duration 
(blinding NR) 
in Turkey. 
Comparisons 
between 
enalapril 
monotherapy, 
losaratan 
monotherapy, 
and combo tx. 
N=34: 
N=12 ACEI, 
N=12 ARB, 
N=10 combo 
tx. 
Micro. 
Mean age=55.6. 
CAD: 8.8%. 
Mean 
HbA1c=7.63%. 
Mean BP=124/77. 
Present or former 
smoking status.  
Mean BMI=29.0. 
Mean duration of 
DM=7.6y. 
Alcoholism, 
thyroid 
disease, 
renal 
insufficienc
y not related 
to DM, 
chronic liver 
disease, 
insulin use, 
overt 
cancer, 
noncomplia
nce 
Mean (SD) 
UAER (mg/d) 
 ACEI 
85.02 (31.25) 
 ARB 
101.66 (41.19) 
 Combo 
102.03 (32.77) 
Mean (SD) 
UAER (mg/d) 
 ACEI 
35.41 (19.59) 
 ARB 
41.33 (21.08) 
 Combo 
40.70 (29.52) 
% ∆ 
 ACEI: 58 
 ARB: 59 
 Combo: 60 
Tutuncu51. Sig decreases in 
albuminuria within each 
group (p<.0001, .0002, 
.0003, resp.). NS differences 
between groups. ARB group 
had 19.57% higher mean 
baseline UAER than ACEI, 
which was not controlled for 
in analyses. 
No drug-related AEs. Mean 
UAER for each group 
decreased throughout the 
study.  Some patients in ea 
group reverted to 
normoalbuminuria. 
At first, ACEI 
(Enalapril 
5mg daily); 
ARB 
(Losartan 
50mg daily). 
At wk 4, if 
sitting 
diastolic 
BP>85, 
Double-blind 
RCT of 12 mo 
treatment 
duration in 
Canada. 
N=103.  
ACEI, N=51 
ARB, N=52 at 
start of study. 
N=49 in each 
Micro. & macro. 
(9.7% macro). 
Mean age=58.5. 
Mean duration of 
DM=11.15y. 
96.1% NHW. 
Mean sitting 
BP=160/96.  
UTI, CVA 
or MI 
within the 
year, current 
TIAs, 
unstable 
angina, 
history of 
heart 
failure, 
Geometric 
mean UAER 
(mg/d, 
converted) 
 ACEI 
106.4 
 ARB 
92.3 
 
Geometric 
mean UAER 
(mg/d, 
converted) 
 ACEI 
12wk: 73.0 
28wk: 56.7 
52wk: 48.2 
 ARB 
12wk: 79.3 
Lacourciere128. Sig mean diff 
in UAER by wk 12, which 
was maintained for study 
duration. No sig diff btwn 
groups for ∆ from baseline in 
log UAER after 12 & 28 wk. 
Also true for wk 52 after sig 
treatment*center interaction 
added.  Fairly flat slope in 
UAER between wk 28 & 52. 
  330
Therapeutic 
strategies 
Design; N Patient 
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Endpoint, 
baseline  
Endpoint, 
results 
Reference, Notes 
enalapril 
doubled. At 
wk 8, if sitting 
diastolic 
BP>85 in 
either group, 
dose doubled. 
At wk 12, if 
sitting 
diastolic 
BP>85, 
HCTZ 12.5 
titrated to 25. 
Thereafter, 
agents other 
than ACEI, 
ARB, CCB 
added for BP 
control. 
group for ITT 
analysis.  
drug/EtOH 
abuse, 
treatment 
with 
antiHTNs 
except ß-
blockers or 
nitrates for 
treating 
stable 
angina, 
SBP>210 
28wk: 53.0 
52wk: 59.8 
Mean(SD) dose of losartan= 
86.3(22.5)mg. Mean (SD) 
dose of enalapril= 
16.0(6.2)mg. Despite the 
baseline mean UAER to be 
15.3% higher for ACEI than 
ARB, no statistical 
adjustment for this (ANOVA 
instead of ANCOVA). Sig 
diff @ baseline: sitting 
diastolic BP higher in 
losartan group, longer 
duration of diabetes in 
losartan group. As for 
UAER, no adjustment for 
these differences. Sig more 
cough in ACEI group (14% 
vs. 0%, p=.006), but no diffs 
btwn groups when all AEs 
combined. No deaths or 
CVD events.   
ACEI 
(Captopril 
25mg TID); 
ARB 
(Valsartan 
80mg daily; 
valsartan 
160mg daily); 
Double-blind 
RCT of 12 mo 
treatment 
duration in 
Canada. 
N=122. 
ACEI, N=29 
Each ARB 
Micro & macro. 
Mean age=56.0. 
89.1% NHW. 
38.5% use 
antiHTNs. Mean 
sitting 
BP=136/83.  
Noncomplia
nce, sitting 
DBP>95, 
sitting 
SBP>160. 
Geometric 
mean UAER 
(mg/d, 
converted) 
 ACEI 
58.8 
 ARB 80mg 
86.4 
Geometric 
mean UAER 
(mg/d, 
converted) 
 ACEI 
43.3 
 ARB 80mg 
62.4 
Muirhead129. NS baseline 
diffs in geometric mean 
UAER despite ARB 80 
group was 46.9% higher and 
ARB 160 group was 42.3% 
higher than ACEI group. No 
adjustments for diffs. 
Analysis of ratio of 
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Endpoint, 
baseline  
Endpoint, 
results 
Reference, Notes 
placebo. dosage, N=31 
Placebo, 
N=31 at start 
of study. 
N=27 for 
ARB 80, 
N=31 for 
ARB 160, 
N=29 for 
ACEI, N=28 
for ITT 
analysis. 
 ARB 160mg 
83.7 
 Placebo 
91.15 
 
 
 
 
 ARB 160mg 
66.0 
 Placebo 
107.7 
geometric mean at study end 
to baseline found ACEI and 
ARB 80 (but not 160) sig 
reduced UAER compared to 
placebo. The same analysis 
revealed NS differences in 
UAER reduction btwn ACEI 
and ARB 80 or 160. 
AEs: More incidence of 
cough and dizziness in ACEI 
group. No drug-related SAEs 
or deaths. 
ACEI 
(Lisinopril 
20mg daily); 
ARB 
(Candesartan 
16mg daily). 
Double-blind 
RCT for first 
12 wk; for wk 
12-24, the 
same patients 
received 
ACEI 
monotx, ARB 
monotx, or 
combo tx. 
Study 
conducted in 
Denmark, 
Finland, 
Israel, 
Australia. 
N=197. First 
Micro. DBP 90-
110 after 2-4 wk 
of placebo. Mean 
age=59.8. Mean 
BMI=30.3.  Mean 
duration of 
HTN=8.6. Mean 
duration of 
DM=9.1. Mean 
BP = 1623/96. 
Mean 
HbA1c=7.6%. 
Mean SCr=85.4 
umol/L. Mean 
CrCl=99.6ml/min 
BMI≥40, 
systolic 
BP>200, 
CVD event 
in past 6 
mo, 
SCr≥130 in 
women or 
150 in men 
for 6 days, 
HbA1c>10
% 
Geometric 
mean albumin: 
creatinine ratio 
(mg/mmol) 
 ACEI 
6.6 
 ARB 
5.9 
Wk 12: 
Adjusted mean 
reduction in 
geometric 
mean albumin: 
creatinine ratio 
(%, (CI)) from 
baseline 
 ACEI 
46 (35-56), 
p<0.001 
 ARB 
 30 (15-42), 
p<0.001 
 Wk 12: 
Adjusted mean 
Mogensen (CALM)122. NS 
diff in baseline 
characteristics. Adjusted 
means in previous 
column=adjusted based on 
center, treatment, baseline 
value, weight, ∆ in diastolic 
BP. The difference between 
treatments is the relative 
reduction, which has a trend 
favoring ACEI.  
Wk 24, compared to 
baseline: combo treatment 
had sig lower reduction in 
adjusted mean geometric 
albumin:creatinine ratio 
compared to ARB (34 (3-
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Endpoint, 
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Reference, Notes 
12 wk: ACEI, 
N=98, ARB, 
N=99. Wk 12-
24: ACEI, 
N=64, ARB, 
N=66, combo, 
N=67. 
difference 
between 
treatments (%, 
(CI)) 
 30 (1-70), 
p=0.058 
Wk 24: 
Adjusted mean 
reduction in 
geometric 
mean albumin: 
creatinine ratio 
(%, (CI)) from 
baseline 
 ACEI 
39 (20-54), 
p<0.001 
 ARB 
 24 (0-43), 
p=0.05 
  
55)), p=0.04 but NS 
compared to ACEI (18(-20-
44)), p>0.20. There were no 
statistical analyses between 
ACEI and ARB comparing 
wk 24 to baseline for 
reduction n adjusted mean 
geometric albumin:creatinine 
ratio. AEs: 14 of 197 (7.1%) 
stopped treatment due to 
AEs. 5 due to dizziness or 
weakness (2 ACEI, 2 ARB, 1 
combo tx). 3 due to cough 
(all on ACEI). NS ∆s in lab 
values, including HbA1c, 
throughout study period. 
ACEI 
(Enalapril 
10mg daily); 
ARB 
(Telmisartan 
40mg daily). 
Double-blind 
RCT of 5 
years 
treatment 
duration in 
Europe. 
N=250. 
Micro & macro. 
Mean age=60.6. 
98.4% NHW. 
Mean BMI=30.7. 
Mean BP=152/86. 
Median duration 
of HTN=6.7. 
Other than 
CVD, a 
condition 
that would 
lead to 
premature 
death 
No mention of 
raw numbers at 
baseline 
No mention of 
raw numbers 
at study end. 
 
Geometric 
mean UAER 
ratio 
Barnett (DETAIL)121. NS 
diff between baseline and 
study end not a surprise as 
patients were on ACEI ≥3 
mo before enrollment. These 
are 2° outcomes; study may 
not be powered to detect a 
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Endpoint, 
baseline  
Endpoint, 
results 
Reference, Notes 
ACEI, 
N=130. ARB, 
N=120. 
Patients on 
ACEI≥3 mo. 
before 
enrollment. 
Median duration 
of DM=8.0. 
48.8% have hx of 
CVD. Mean 
LDL=137mg/dL. 
Mean 
HDL=48mg/dL. 
Mean 
TG=206mg/dL. 
Mean 
HbA1c=8.3%. 
Mean SCr=1.00 
mg/dL. Mean 
GFR=92.9ml/min
/1.73m2. 
(end/baseline): 
 ACEI .99 
 ARB 1.03 
Geometric 
mean UAER 
ratio between 
groups 
(ARB/ACEI) 
(CI) 
1.04 (.71-1.51) 
difference. Adjusted for 
differences in baseline mean 
(ANCOVA) when compared 
geometric mean reductions 
between baseline and study 
end. Last observation carried 
forward: 35 of 115 (30.4%) 
in ARB, 42 of 125 (33.6%) 
in ACEI. NS diffs in BP but 
ARB reduced BP 6.9 from 
baseline while ACEI reduced 
BP 2.9 from baseline 
(baseline had 1mmHg diff 
btwn groups). Also, BP not 
adjusted for in ANCOVA. 
Over 5 y, micro  macro in 
17% of subjects not lost to 
f/u. 
AEs: 16.7% dropped out in 
ARB due to AEs; 23.1% 
dropped out in ACEI due to 
AEs. No statistical analysis 
performed for diffs in AEs 
btwn groups. CHF occurred 
in 7.5% of ARB & 5.4% of 
ACEI subjects. Combining 
fatal & nonfatal heart failure, 
MI & stroke, 17.5% of ARB 
and 11.5% of ACEI subjects 
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Endpoint, 
results 
Reference, Notes 
had these AEs. 
ACEI 
(Enalapril 
10mg daily); 
ARB 
(Losartan 
50mg daily); 
ACEI 
(Enalapril 
20mg); ARB 
(Losartan 
100mg daily); 
ACEI + ARB 
(Enalapril 
10mg daily, 
Losartan 
50mg daily). 
Randomized 
crossover 
study 
(blindness 
NR) in 
Turkey. Each 
tx period = 
3mo. Study 
had 6mo tx 
duration in 
total. N=22.  
11 were 
randomized 
each to ACEI 
or ARB 
monotx in 
first 3mo. In 
mo 3-6, 5 in 
each group 
went to 
combo tx; the 
remaining 6 in 
each group 
stayed with 
monotx, but 
had their 
dosages 
doubled. 
Macro. Mean 
age=54.7. Mean 
BP=151/93. Mean 
HbA1c=6.9%. At 
study start, 
advised to limit 
Na intake & BMI. 
Mean CrCl=65.3 
ml/min/1.73m2. 
At study start, 
advised to limit 
Na, AA, and 
caloric intake 
None 
reported 
Mean (SD) 
UAER (mg/d, 
converted) 
 ACEI 
4790 (1280) 
 ARB 
4840 (990) 
Wk 12: Mean 
(SD) 
UAER (mg/d, 
converted) 
 ACEI 
    3170 (690) 
 ARB 
3210 (710) 
Cetinkaya130. Other than 
UAER, no mention of 
baseline characteristics per 
group or diffs in baseline 
characteristics btwn groups. 
No statistical adjustment for 
any differences btwn groups 
(t-test). At wk 12, 33.8% 
reduction in UAER for ACEI 
compared to baseline 
(p<0.05) & 33.7% reduction 
in UAER for ARB compared 
to baseline (p<0.05). NS diff 
btwn groups. At wk 24, 51% 
reduction in UAER for 
combo tx compared to 
baseline (p<0.05) and 37% 
reduction in UAER when 
mono tx doubled dosage 
compared to 
baseline(p<0.05). 
AEs:  NR. 
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Endpoint, 
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Endpoint, 
results 
Reference, Notes 
ACEI 
(Perindopril 
8mg daily); 
ARB 
(Irbesartan 
300mg daily); 
ACEI + ARB 
(Perindopril 
8mg daily, 
Irbesartan 
300mg daily). 
Randomized, 
open-label 
crossover 
study in 
Brazil. 3 
treatment 
phases, 
each=16 wk. 
Subjects 
received 
ACEI mono, 
ARB mono, 
or combo tx 
in random 
order. Initial 
ACEI or ARB 
dosages 
titrated during 
first 2 wk. 
N=20. 
Macro. Median 
age=54. 50% 
white, 40% black, 
10% other. 
Median duration 
of HTN=10. 
Median duration 
of DM=11. 
Median BMI=30. 
50% use insulin. 
45% use oral 
hypoglycemics. 
All subjects 
received 
diuretics; 
hydralazine & 
clonidine 
sequentially 
added for BP 
control. At study 
start, advised to 
limit Na intake & 
eat 50%CHO, 
30%fat, 20%AA. 
5.3% smokers. 
Malignant 
HTN, any 
condition 
other than 
diabetes 
leading to 
renal 
involvement
, 
HbA1c≥9.0
%, recurrent 
UTI, severe 
PVD, 
stroke/MI in 
6 mo, 
noncomplia
nce 
Geometric 
mean (95%CI) 
UAER (mg/d) 
 ACEI 
829  
(537-1280) 
 ARB 
996  
(686-1445) 
 Combo 
966        
(681-1369) 
 
Geometric 
mean (95%CI) 
UAER (mg/d) 
 ACEI 
545  
(288-1029) 
 ARB 
773      
(478-1248) 
 Combo 
644      
(393-1085) 
Matos131. Other than UAER, 
no mention of baseline 
characteristics per group or 
diffs in baseline 
characteristics btwn groups. 
No statistical adjustment for 
any differences btwn groups 
(t-test). Baseline mean 
UAER was 20.1% higher for 
ARB group vs. ACEI. Sig 
reduction in mean UAER for 
ACEI: 34% (53%-9%), 
p<0.05. 
NS reduction in mean UAER 
for ARB: 22% (45%-9% 
increase), p=0.17. 
Sig reduction in mean UAER 
for combo: 33% (49%-12%), 
p<0.02. 
NS diffs btwn groups: ACEI 
vs. ARB v. combo tx. 
Compliance: 95%-96% 
across txs 
AEs: no mention of deaths. 2 
excluded b/c of PVD 
requiring hospitalization that 
led to missed visits. Sig 
reduction in hematocrit  and 
sig increase in serum K for 
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combo tx. 1 pt receiving 
ARB & another receiving 
combo tx dropped out for 
hyperkalemia. All 
hyperkalemic patients had 
GFR<60. 1 pt had increased 
BUN with ACEI. Uricemia 
decreased only during combo 
tx (5.9 5.3mg/dL, p<0.05). 
ARB and combo had similar 
increase in plasma rennin 
elevation; ACEI didn’t. 
Aldosterone only decreased 
in combo tx (36% (53%-
12%, p<0.02)). 
ACEI 
(Ramipril 
10mg daily); 
ARB 
(Candesartan 
16mg daily); 
ACEI + ARB 
(Ramipril 
5mg daily, 
Candesartan 
8mg daily). 
Double-blind 
crossover 
study in 
Korea. N=21. 
3 treatment 
periods, 
each=16 wk. 
ACEI or ARB 
titrated 
biweekly.  
Macro. Mean 
age=49y. 100% 
Korean. Mean 
BMI=21.0. Mean 
duration of 
diabetes=8y. 
Mean BP=134/80. 
Mean duration of 
ACEI or ARB 
before study= 
11mo. Mean 
HbA1c=7.4%. 
Patients already 
on ≥5mg ACEI or 
Absence of 
retinopathy, 
presence of 
nondiabetic 
renal dx, 
uncontrolled 
diabetes, 
morbid 
cardiac or 
vascular 
diseases, 
morbid 
malignancy 
Mean (SD) 
UAER (mg/d, 
converted) 
 4100 (1900) 
 
Mean (SD) 
UAER (mg/d, 
converted) 
 ACEI 
3500 (1800) 
 ARB 
3300 (2000) 
 Combo 
2900 (1400) 
Song132. Including UAER, 
no mention of baseline 
characteristics per group or 
diffs in baseline 
characteristics btwn groups. 
ACEI, ARB, or combo tx led 
to sig reduction in UAER 
compared to baseline. 
Combo tx also led to sig 
reduction compared to each 
mono tx (p<0.05). No 
adjustments for diffs made 
(t-test btwn baseline & end). 
UAER sig correlated with 
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≥8mg ARB. duration of diabetes (r2=.887) 
and systolic BP (r2=.617) at 
baseline, but NS after tx. % 
∆ in UAER not sig correlated 
with mean systolic or 
diastolic BP, plasma 
creatinine, or CrCl. 
AEs: No stats done for diffs 
btwn groups. No mention of 
deaths or CVD. 1 (4.8%) and 
2 (9.5%) in ARB and combo 
txs, resp, had hypotension. 1 
(4.8%) in ARB had malaise/ 
fatigue. 1 (4.8%) and 2 
(9.5%) had K>6.0mEq/L in 
ACEI and combo tx, resp. 1 
pt (4.8%) in ACEI had ∆ in 
SCr>30% (reversible w/d/c). 
1 pt (4.8%) in ACEI had 
cough. 
ACEI 
(Lisinopril 
20mg daily); 
ARB 
(Telmisartan 
80mg daily); 
ACEI + ARB 
(Lisinopril 
20mg daily, 
Randomized 
open-label 
crossover 
study of 52 
wk duration in 
Turkey. First 
24 wk, 
lisinopril vs. 
telmisartan. 
Micro. Previously 
diagnosed with 
HTN. On ACEI 
monotherapy ≥ 6 
mo. Patients 
advised to follow 
normocaloric diet 
(30kcal/kg) w/Na 
content 
>65 y, 
BMI≥ 40 
kg/m2, 2° 
diabetes, 
alcoholism, 
thyroid 
disease, 
SBP>200, 
any 
Week 0: 
Median (range) 
UAER (mg/d) 
 ACEI 264 
(150-300) 
 ARB 256 
(140-300) 
 
Week 24: 
Mean (range) 
adjusted 
absolute 
reduction 
UAER (mg/d) 
 ACEI 98 
(80-124) 
 ARB 80 
(74-105) 
Sengul123. Mean adjusted 
reductions in previous 
column take treatment, 
baseline value, weight & ∆ in 
DBP into account. Sig mean 
adjusted reductions in UAER 
within each group, wk 24 to 
baseline, p<0.001. Adjusted 
mean diffs btwn txs=18 
  338
Therapeutic 
strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Endpoint, 
baseline  
Endpoint, 
results 
Reference, Notes 
Telmisartan 
80mg daily). 
Wk 24-52, 
same patients 
randomized to 
continue each 
mono tx or to 
be on combo 
tx. 
Throughout 
the study 
12.5mg 
HCTZ QD 
added for BP 
control in 
some subjects. 
N=219. 
~150mmol/d & 
protein content 
~1.2g/kg. Mean 
age=56.6 y. Mean 
BMI=30.4kg/m2. 
Mean duration of 
DM=11.8 y. 
36.6% smokers. 
Mean BP=151/89. 
Mean Scr=85.5. 
Mean CrCl=96.8 
ml/min. Mean 
HbA1c=7.8%. 
Mean 
LDL=3.5mmol/L. 
Mean TG=2.1 
mmol/L. 
nondiabetic 
cause of 2° 
HTN (incl. 
Bilateral 
renal artery 
stenosis), 
UTI, 
persistent 
hematuria, 
chronic liver 
disease, 
overt 
cancer, 
CVD event 
in 6 mo, 
SCr≥ 
150mmol/L, 
serum K 
≥5.5mmol/L 
Median (range) 
UAER (mg/d) 
 ACEI 166 
(90-220) 
 ARB 176 
(80-220) 
 Combo 175 
(77-208) 
 
No 
comparison, 
week 24 to 
week 52 
(95%CI:0-37, p=0.12). No 
breakout of AEs except for 
increased cough noted in 
ACEI group. 
ACEI 
(Lisinopril 
10mg daily); 
ARB 
(Losartan 
50mg daily); 
ACEI + ARB 
(Lisinopril 
10mg daily, 
Losartan 
Randomized 
trial of 12 mo 
tx duration in 
Turkey 
(blinding 
NR). N=34 @ 
start; N=26 @ 
end. ACEI, 
N=9. ARB, 
N=9. Combo, 
Micro. 
Normotensive. 
Protein intake 
≤0.8g/kg/d. Mean 
age=55.1y. Mean 
time since DM 
diagnosis=7.5y. 
Mean 
HbA1c=6.1%. 
Mean BP=120/78. 
2° diabetes, 
chronic 
renal or 
hepatic 
failure, 
CHF, 
history of 
HTN 
(cannot be 
controlled 
Mean (SD) 
UAER(mg/d) 
 ACEI 70.2 
(32.9) 
 ARB 70.1 
(16.2) 
 Combo 70.1 
(31.9) 
 
Mean (SD) 
UAER(mg/d) 
 ACEI  
3mo:38.2 
(18.7) 
6mo: 24.0 
(12.5) 
9mo: 21.5 
(5.8) 
12mo: 21.9 
Atmaca127 . NS diffs btwn 
groups @ baseline, incl. 
UAER. Also only 0.1 
absolute diff in UAER @ 
baseline. UAER sig reduced 
in ea group from baseline 
(p=0.001), but NS diffs btwn 
groups (p=0.587). Reversion 
to normo. in ea group for 
majority of subjects. 67.6%, 
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50mg daily). N=8. Mean BMI=27.8 
kg/m². Mean 
TG=272mg/dL. 
Mean chol=249 
mg/dL. 
with 
antiHTNs), 
cancer, UTI, 
smoking 
history, 
HbA1c>7% 
(13.8) 
 ARB  
3mo: 45.3 
(18.0) 
6mo: 28.9 
(9.1) 
9mo: 27.3 
(9.5) 
12mo: 27.8 
(14.8) 
 Combo  
3mo: 48.1 
(29.5) 
6mo: 33.6 
(24.2) 
9mo: 37.7 
(32.6) 
12mo: 29.6 
(24.3) 
 
61.3% & 58.7% reduction in 
UAER for ACEI, ARB, 
combo, resp. Slope fairly flat 
after 6 mo (NS diff in 
reduction btwn 6 & 12 mo, 
p=1.000). Sig reduction in 
BP & BMI btwn baseline & 
study end w/in ea group but 
NS diffs btwn groups. 
AEs: 2 pts lost to f/u due to 
AEs (not told which group 
they were in). Although 
mentioned lost 4 pts to f/u in 
total, that would lead to 
N=30 
ACEI 
(Quinapril 
20mg daily); 
ARB 
(Losartan 
50mg daily). 
Randomized, 
single-blind 
(investigators 
blinded) 
crossover 
study in 
China. N=41. 
Ea tx 
period=4 wk. 
Micro & macro. 
61% Chinese, 
34% Malays, 5% 
Indians. Mean 
age=52y. Mean 
duration of 
DM=8y. 73% 
were not on 
antiHTNs. Mean 
SBP>180, 
DBP>105, 
TG>5mM, 
total 
chol>8mM, 
CAD, PVD, 
other 
serious 
chronic 
Mean (SD) 
UAER(mg/g 
Cr) 
 ACEI 
550 (170) 
 ARB 
471 (153) 
Mean (SD) 
UAER(mg/g 
Cr) 
 ACEI 
501 (146) 
 ARB 
378 (124) 
Lim125. NS diff of 16.8% in 
UAER btwn groups at 
baseline. ARB sig reduced 
albumin:creatinine ratio 
compared to ACEI (p=.025). 
ARB reduction:93mg/g, 
ACEI reduction:49mg/g; 
ARB sig reduced 
albumin:creatinine ratio from 
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BP=135/84. 
Patients were 
naïve to ACEI or 
ARB. 
illness 
needing 
medication 
baseline (p<.01) while ACEI 
had NS reduction. No 
statistical adjustments for 
covariates despite NS 
baseline diffs. 
AEs: sig increase in serum K 
(4.24.4mM, p=0.01) for 
ACEI. 
ACEI 
(Perindopril 
4mg daily); 
ARB 
(Candesartan 
16mg daily).  
Double-blind 
RCT in Italy. 
N=96. Tx 
period=4mo. 
Normo. “Mildly 
hypertensive” 
(defined as  
105<DBP>90). 
Dietary advice 
(50% CHO, 30% 
AA, 20% fat) and 
encouraged to 
exercise ≥30min 
X3-4 days/wk.  
Mean age=54y, 
Mean diabetes 
duration=3.5mo, 
mean BMI=27.0.  
2° HTN, 
malignant 
HTN, 
unstable 
angina, MI 
in last 6 mo, 
liver or 
kidney 
abnormalitie
s  
Mean (SD) 
UAER(mg/24h) 
 ACEI 
17 (10) 
 ARB 
18 (11) 
Mean (SD) 
UAER(mg/24h
) 
 ACEI 
6mo: 10.2 
(7.4) 
12mo: 9 (6.4) 
 ARB 
6mo: 11.8 
(7.2) 
12mo: 10 (6.9) 
 
Derosa244. NS diffs @ 
baseline. For reduction in 
albuminuria, no stat sig ∆ in 
either group btwn baseline & 
6 mo, but difference btwn 
baseline and 12 mo (p<0.05). 
NS diffs btwn groups for 
reduction in albuminuria. Sig 
diffs btwn groups for DBP, 
FPG, FPI, total chol, HDL, 
LDL. No statistical 
adjustments for covariates.  
No AEs were so severe for a 
subject to d/c therapy.  
ACEI 
(Fosinopril 
10mg daily); 
ARB 
(Losartan 
50mg daily). 
Open-label 
RCT in 
Turkey. 
N=33. Tx 
period=6mo. 
Normo (54.5%) 
& micro (45.5%). 
Median age = 
52.9y, median 
duration of 
diabetes =3y, 
15% treated with 
Macro, 
CrCl<100m
L/min, 
previously 
on ACEIs or 
ARBs 
Median (range) 
UAER(mg/24h) 
 ACEI 
154 (44-300) 
 ARB 
121 (32-264.5) 
Median (SD) 
UAER(mg/24h
) 
 ACEI 
14 (10.6-46) 
 ARB 
54.8 (8.6-
Kavgaci248. Unclear if sig 
diffs btwn groups in UAER 
@ baseline. Sig diffs btwn 
baseline & 6 mo for each tx, 
but NS diffs btwn trx for 
reduction in albuminuria. No 
statistical adjustments for 
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insulin, SBP 140-
180mmHg  
261.0) 
 
covariates.  Subgroup 
analysis:  In micro group, 
ARBs  had NS increase in 
albuminuria from mo. 1 
while ACEIs had continuous 
reduction in albuminuria. 
(Author notes similar to 
CALM, btwn wks 12 & 24 
and to Parving’s 150mg 
irbesartan group.) NS change 
in albuminuria from baseline 
for each therapy in normo 
group. Other metabolic 
parameters: stat sig 
reduction in FPG, TG for 
ARB group; stat sig 
reduction in total chol, TG 
for ACEI group.AEs: sig 
increase in transaminase for 
ACEI group.  
ACEI 
(Lisinopril 
10mg daily); 
ARB 
(Candesartan 
8mg daily). 
Double-blind 
RCT in the 
Netherlands. 
N=60. Tx 
period=12mo. 
Normo, micro & 
macro. HTN. 
100% NHW. 
Age=61 y, 
BP=150/93, 
BMI=28.9mg/k2, 
19.6% smoke, 
total 
chol=5.3±1.0mm
UAER≥100
mg/24h, 
age>70y, hx 
of MI, 
angina 
pectoris, 
CABG, 
angioplasty, 
stroke, 
Mean or median 
(range) 
UAER(mg/24h) 
 ACEI 
13.2 (7.3-32.0) 
 ARB 
12.3 (7.7-20.5) 
Mean (SD) 
UAER(mg/24h
) 
No mention of 
raw numbers 
for each tx. 
 
Schram249. UAER was 2° 
endpoint. Authors note lack 
of power. NS baseline diffs 
for all characteristics, incl. 
reduction in albuminuria. 
Authors do not note whether 
baseline values are mean or 
median (may even be 
something else). NS diffs 
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ol/L, 
LDL=3.2±0.9mm
ol/L, 
HDL=1.3mmol/L, 
TG=1.6mmol/L, 
CrCl=98mL/min,  
CHF, 
cancer, 
SCr>140m
mol/L, 
BMI>35kg/
m2, EtOH 
&/or drug 
abuse 
btwn groups for reduction in 
albuminuria (no p-value 
reported).Stat sig diffs for ea 
tx compared to baseline 
(p<.05).  Authors note 
difference in UAER was30% 
dependent on the decrease in 
SBP (70% for ARB, 5% for 
ACEI).  The study was a 
2X2 factorial, so have effects 
of intensive vs. regular BP 
control interfering with 
albuminuria. 
AEs: NR. 
ACEI 
(Enalapril 
10mg daily); 
ARB 
(Valsartan 
160mg daily 
(mean 
dosage=6.3m
g and 
109.1mg, 
resp.: only 
25% and 
36.4% 
achieved 
target dosage, 
RCT 
(blinding NR) 
in Hong 
Kong. N=42. 
Tx period =12 
mo. 
(I inferred) 
normo, micro, 
macro. 100% 
Chinese. Mean 
age=61.0y, Mean 
duration of 
diabetes=9.6y, 
mean BMI=25.3 
kg/m2, mean BP= 
143/77, mean 
FPG=8.5mmol/L, 
mean 
HbA1c=7.6%,   
HTN>200/1
15mmHg, 
hx of MI, 
CVA, or 
uncontrolled 
CHF within 
previous 6 
mo., plasma 
creatinine≥1
50mmol/L 
Mean (SD) 
albumin: 
creatinine ratio 
 ACEI 
7.1 (6.7) 
 ARB 
3.7 (6.5) 
Mean (SD) 
UAER 
 ACEI 
114.0 (7.6) 
 ARB 
40.1(7.0) 
Mean (SD) 
albumin: 
creatinine ratio 
 ACEI 
Wk 12: 123.7 
(534.1) 
Wk 24: 95.5 
(320.9)  
 ARB 
Wk 12: 69.5 
(200.7) 
Wk 24: 51.6 
(139.8) 
Mean (SD) 
UAER 
Ko281. No control for 
baseline diffs in albuminuria 
even through huge diffs btwn 
tx groups @ baseline. 
P=0.073 for ACEI compared 
to ARB in terms of keeping 
patients @ normo, micro, or 
macro @ baseline within 
their respective albuminuric 
states. When stratified by ea 
albuminuric state, NS diffs 
btwn groups in terms of 
keeping patients within their 
respective albuminuric 
states. Investigators consider 
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resp.))   ACEI 
Wk 12: 47.9  
(154.6) 
Wk 24: 58.3 
(195.3) 
 ARB 
Wk 12: 53.4 
(198.8) 
Wk 24: 33.9 
(92.6) 
 
clinically relevant reduction 
in albuminuria = 10mg/day. 
AEs: 35% of subjects on 
ACEI complained of cough 
vs. none on ARB (p=.003). 
ACEI 
(Enalapril 
10mg daily); 
ARB 
(Candesartan 
8mg daily). 
Double-blind 
RCT in Italy. 
N=118. Tx 
period=24 wk. 
Micro. Mild 
HTN. Mean age= 
58.4y, 4.7% 
retinopathy, 
10.8% heart 
disease 
Arrhythmia, 
hemodynam
ically 
relevant 
valvular dx, 
AV blocks 
grade II & 
III, CHF, 
MI, stroke, 
coronary 
artery 
surgery or 
TIA in 
previous 3 
mo., angina 
pectoris due 
to CAD 
Mean (SD) 
albumin: 
creatinine ratio 
 ACEI 
40.4 (88.3) 
 ARB 
112.4 (451.7) 
Mean (SD) 
UAER (mg/day, 
converted) 
 ACEI 
39.6 (86.0) 
 ARB 
147.0 (697.2) 
 
Mean (SD) 
albumin: 
creatinine ratio 
 ACEI 
12.8 (7.4) 
 ARB 
4.6 (6.6) 
Mean (SD) 
UAER 
(mg/day, 
converted) 
 ACEI 
120.8 (13.5) 
 ARB 
56.6 (9.5) 
 
Rosei124. Albuminuria not 
mentioned as an endpoint: 
assume it is post hoc 
analysis.  Baseline diffs in 
UAER btwn groups not 
controlled and are huge.  
“The comparison between 
groups, esp. when using non-
parametric tests (Mann-
Whitney test), showed stat 
sig diffs in favor of 
candesartan.”  I think this is 
hogwash: never an endpoint 
to begin with, did many tests 
to try to show a sig diff, and 
didn’t control for baseline 
diffs in UEAR.  
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needing tx 
other than 
nitrates, 
sympotomat
ic 
autonomic 
neuropathy, 
trophic 
lesions of 
lower limbs, 
proliferative 
retinopathy, 
renal artery 
stenosis, 
kidney 
transplant, 
SCr>1.6mg/
dL, severe 
liver dysfx, 
serum 
Na≤130mm
ol/L, serum 
K≤3.6 or 
≥5.5 
mmol/L, 
past or 
current 
EtOH or 
drug abuse 
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Δ= change; 2°= secondary; AA= protein; AEs= adverse events; antiHTNs= antihypertensives; BMI= body mass index; BP= blood 
pressure; btwn= between; CABG= coronary artery bypass graft; CAD= coronary artery disease; CCB= calcium channel blocker; 
CHF= congestive heart failure; CHO=carbohydrates; Chol= cholesterol; CI= confidence interval; Combo.= combination therapy; 
CrCl= creatinine clearance; CVA=  cerebrovascular accident; DBP= diastolic blood pressure; diff= different or differently; diffs= 
differences; DM= diabetes mellitus; dx= disease; ea= each; EtOH= alcohol; FPG= fasting plasma glucose; FPI= fasting plasma 
insulin; f/u= follow-up; GFR= glomerular filtration rate; HCTZ= hydrocholorothiazide; HDL= high-density lipoprotein; HTN= 
hypertension; hx= history (of); incl= including; ITT= intention-to-treat analysis; K= potassium; LDL= low-density lipoprotein 
cholesterol; Macro.= macroalbuminuria; Micro.= microalbuminuria; mo= month(s); Na= sodium; NHW= non-Hispanic White; 
Normo.= normoalbuminuria; NormoHTN= normotensive; NR= not reported; NS= nonsignificant; PVD= peripheral vascular disease; 
RCT= randomized clinical trial; resp.= respectively; SCr= serum creatinine; SD= standard deviation; sig= significant or 
significantly; SBP= systolic blood pressure; TG= triglycerides; TIA=  transient ischemic attack; TID= three times daily; tx= 
treatment; UAER= urinary albumin excretion rate; UTI= urinary tract infection; vs.= versus; wk= week(s); y= year(s) 
 
Geometric means reported when UAER was antilogged.  Logged because of skewness in data. “Converted” when I converted the units 
to mg/d (multiply microgram/min to mg/day by multiplying by 1.44).
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strategies 
Design; N Patient 
characteristics 
Exclusion 
criteria 
Endpoint, 
baseline 
Endpoint, 
results 
Reference, Notes 
ACEI 
(Lisinopril 
20mg daily); 
ARB 
(candesartan 
16mg daily); 
ACEI + ARB 
Double-blind 
RCT for first 
12 wk; for wk 
12-24, the 
same patients 
received 
either ACEI 
alone, ARB 
alone, or 
combo. Study 
conducted in 
Denmark, 
Finland, 
Israel, 
Australia. 
N=197. First 
12 wk: ACEI, 
N=98, ARB, 
N=99. Wk 12-
24: ACEI, 
N=64, ARB, 
N=66, combo, 
N=67. 
Micro. DBP 90-
110 after 2-4 wk 
of placebo. Mean 
age=59.8. Mean 
BMI=30.3.  Mean 
duration of 
HTN=8.6. Mean 
duration of 
DM=9.1. Mean 
BP = 162/96. 
Mean 
HbA1c=7.6%. 
Mean SCr=85.4 
umol/L. Mean 
CrCl=99.6ml/min 
BMI≥40, 
systolic 
BP>200, 
CVD event 
in past 6 
mo, 
SCr≥130 in 
women or 
150 in men 
for 6 days, 
HbA1c>10
% 
Geometric 
mean 
albumin: 
creatinine 
ratio 
(mg/mmol) 
 ACEI 
6.6 
 ARB 
5.9 
Wk 12: 
Adjusted 
mean 
reduction in 
geometric 
mean 
albumin: 
creatinine 
ratio (%, 
(CI)) from 
baseline 
 ACEI 
46 (35-
56), 
p<.001 
 ARB 
 30 (15-
42), 
p<.001 
 Wk 12: 
Adjusted 
mean 
difference 
between 
treatments 
(%, (CI)) 
Mogensen (CALM)122. NS diff 
in baseline characteristics. 
Adjusted means in previous 
column=adjusted based on 
center, treatment, baseline 
value, weight, ∆ in diastolic BP. 
The difference between 
treatments is the relative 
reduction, which has a trend 
favoring ACEI.  
Wk 24, compared to baseline: 
combo treatment had sig lower 
reduction in adjusted mean 
geometric albumin:creatinine 
ratio compared to ARB (34 (3-
55)), p=0.04 but NS compared 
to ACEI (18(-20-44)), p>0.20. 
There were no statistical 
analyses between ACEI and 
ARB comparing wk 24 to 
baseline for reduction n 
adjusted mean geometric 
albumin:creatinine ratio. AEs: 
14 of 197 (7.1%) stopped 
treatment due to AEs. 5 due to 
dizziness or weakness (2 ACEI, 
2 ARB, 1 combo tx). 3 due to 
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 30 (1-70), 
p=.058 
Wk 24: 
Adjusted 
mean 
reduction in 
geometric 
mean 
albumin: 
creatinine 
ratio (%, 
(CI)) from 
baseline 
 ACEI 
39 (20-
54), 
p<.001 
 ARB 
 24 (0-43), 
p=.05 
  
cough (all on ACEI). NS ∆s in 
lab values, including HbA1c, 
throughout study period. 
ACEI 
(Enalapril 
5mg daily); 
ARB 
(Losartan 
50mg daily); 
ACEI + ARB 
RCT of 12 mo 
treatment 
duration 
(blinding NR) 
in Turkey. 
Comparisons 
between 
Micro. 
Mean age=55.6. 
CAD: 8.8%. 
Mean 
HbA1c=7.63%. 
Mean BP=124/77. 
Present or former 
Alcoholism, 
thyroid 
disease, 
renal 
insufficienc
y not related 
to DM, 
Mean (SD) 
UAER (mg/d) 
 ACEI: 
85.02 (31.25) 
 ARB: 
101.66 
(41.19) 
Mean (SD) 
UAER 
(mg/d) 
 ACEI: 
35.41 
(19.59) 
 ARB: 
Tutuncu51. Sig decreases in 
albuminuria within each group 
(p<.0001, .0002, .0003, resp.). 
NS differences between groups. 
ARB group had 19.57% higher 
mean baseline UAER than 
ACEI, which was not controlled 
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baseline 
Endpoint, 
results 
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enalapril 
monotherapy, 
losaratan 
monotherapy, 
and combo tx. 
N=34: 
N=12 ACEI, 
N=12 ARB, 
N=10 combo 
tx. 
smoking status.  
Mean BMI=29.0. 
Mean duration of 
DM=7.6y. 
chronic liver 
disease, 
insulin use, 
overt 
cancer, 
noncomplia
nce 
 ACEI + 
ARB: 
102.03 
(32.77) 
41.33 
(21.08) 
 ACEI + 
ARB: 
40.70 
(29.52) 
% ∆ 
 ACEI: 58 
 ARB: 59 
 ACEI + 
ARB: 60 
for in analyses. 
No drug-related AEs. Mean 
UAER for each group decreased 
throughout the study.  Some 
patients in ea group reverted to 
normoalbuminuria. 
ACEI 
(Lisinopril 
20mg daily); 
ARB 
(Telmisartan 
80mg daily); 
ARB + ACEI 
(Telmisartan 
80mg daily, 
(Lisinopril 
20mg daily); 
ACEI + ARB 
(Lisinopril 
20mg daily, 
Telmisartan 
80mg daily). 
Randomized 
open-label 
crossover 
study of 52 
week duration 
in Turkey. 
First 24 wk, 
lisinopril vs. 
telmisartan. 
Wk 24-52, 
same patients 
randomized to 
continue each 
monotx or to 
be on combo 
tx. 
Throughout 
Micro. Previously 
diagnosed with 
HTN on ACEI 
monotherapy ≥ 6 
mo. Patients 
advised to follow 
normocaloric diet 
(30kcal/kg) w/Na 
content 
~150mmol/d & 
protein content 
~1.2g/kg. Mean 
age=56.6 y. Mean 
BMI=30.4kg/m2. 
Mean duration of 
DM=11.8 y. 
36.6% smokers. 
>65 y, 
BMI≥ 40 
kg/m2, 2° 
diabetes, 
alcoholism, 
thyroid 
disease, 
SBP>200, 
any 
nondiabetic 
cause of 2° 
HTN (incl. 
Bilateral 
renal artery 
stenosis), 
UTI, 
persistent 
Week 24: 
Median 
(range) 
UAER (mg/d) 
 ACEI 166 
(90-220) 
 ARB 176 
(80-220) 
 ACEI + 
ARB:  175 
(77-208) 
Unadjusted 
mean (95% 
CI) 
reduction in 
UAER from 
baseline to 
52 weeks: 
 ACEI: 
107 (34-
148) 
 ARB: 92 
(42-124) 
 ARB + 
ACEI: 
136 (24-
172) 
 ACEI + 
Sengul123. Mean adjusted 
reductions in previous column 
take treatment, baseline value, 
weight & ∆ in DBP into 
account. Sig mean adjusted 
reductions in UAER within 
each group, wk 24 to wk 52, 
p<0.001. “From baseline to 
week 52, percentage reductions 
in AER with telmisartan, 
lisinopril, telmisartan plus 
lisinopril, and lisinopril plus 
telmisartan were 36.0, 40.5, 
52.7, and 53.6%, respectively… 
“Subsequent treatment with 
lisinopril plus telmisartan for 28 
weeks resulted in further 
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the study 
12.5mg 
HCTZ QD 
added for BP 
control in 
some subjects. 
N=219. 
Mean BP=151/89. 
Mean Scr=85.5. 
Mean CrCl=96.8 
ml/min. Mean 
HbA1c=7.8%. 
Mean 
LDL=3.5mmol/L. 
Mean TG=2.1 
mmol/L. 
hematuria, 
chronic liver 
disease, 
overt 
cancer, 
CVD event 
in 6 mo, 
SCr≥ 
150mmol/L, 
serum K 
≥5.5mmol/L 
ARB: 
139 (23-
181) 
 
significant reductions (P<0.001) 
in SBP, DBP, and AER.” No 
breakout of AEs except for 
increased cough noted in ACEI 
group. 
ACEI 
(Imidapril 
10mg daily); 
ARB 
(Candesartan 
8mg daily); 
ACEI + ARB 
(Imidapril 
5mg, 
Candesartan 
4mg daily). 
Open-label 
before-and-
after study of 
27 Japanese 
P2DM + HTN 
already 
receiving 
imidapril or 
candesartan at 
baseline for 
>3mo. 3 mo 
f/u on 
ACEI+ARB. 
Combo 
therapy 
achieved with 
giving half the 
dose of ACEI 
Micro., Macro. 
Mean age=62.4y. 
Mean baseline BP 
= 140/84mmHg, 
mean baseline 
HbA1c = 7.7%. 
Mean years since 
DM diagnosis= 
14.0. 
Other 
kidney 
disease, 
hepatic 
cirrhosis, 
malignancy, 
severe lung 
disease, 
inflammator
y or 
infectious 
disease, 
≥1000mg/g 
Cr, serum 
creatinine 
≥1.5mg/dL 
Geometric 
mean (range) 
albumin:creati
nine ratio 
(mg/g), 
 ACEI or 
ARB: 79.4 
(27.4-230) 
 
Geometric 
mean 
(range) 
albumin:cre
atinine ratio 
(mg/g), 
 ACEI + 
ARB: 
52.5 
(17.1-
161) 
 
Fujisawa.136 Combination 
therapy associated with a sig 
34% mean reduction (95% CI = 
14-49%) compared to each 
monotherapy.  BP similar at 
baseline and after. Combination 
therapy found to be more 
effective at reducing 
albuminuria independent of BP 
or albuminuria at baseline. 
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or ARB seen 
in monotx. 
ACEI 
(Enalapril 
20mg daily, 
Lisinopril 
20mg daily, 
or Captopril 
100mg daily) 
+ placebo; 
ACEI + ARB 
(Enalapril 
20mg daily, 
Lisinopril 
20mg daily, 
or Captopril 
100mg daily, 
Candesartan 
8mg daily). 
Double-blind 
randomized 
crossover of 
18 P2DM + 
HTN + 
diabetic 
retinopathy 
already 
receiving 
recommended 
doses of 
ACEI in 
Denmark. 
Each 
treatment 
period=2mo. 
Macro. Mean 
baseline BP NR; 
mean BP, ACEI + 
placebo = 
148/74mmHg; 
mean BP, ACEI + 
ARB = 
138/71mmHg; 
mean HbA1c at 
end of second FU 
= 8.6%; NHW 
NR.  Mean 
BMI=32.0 kg/m2. 
Mean age=58y. 
Mean duration 
since DM 
diagnosed=13y. 
Serum K > 
4.6mmol/L, 
age >70y, 
EtOH or 
medicine 
abuse, 
systolic BP 
<100mmHg, 
GFR 
<25ml/min, 
pregnancy 
N/A Geometric 
mean (95% 
CI) 
albuminuria 
(mg/24h) 
 ACEI + 
Placebo: 
1764 
(1225-
2540) 
 ACEI + 
ARB:  
1334 
(890-
1998) 
Rossing.138 Combo tx led to a 
sig 24% mean reduction (2-
58%, p=0.036) compared to 
ACEI + placebo. Large 
interindividual variability: 3 
patients had no Δ in 
albuminuria. 
ACEI 
(Enalapril 
40mg daily, 
Lisinopril 
40mg daily, 
or Captopril 
150mg daily) 
Double-blind 
randomized 
crossover of 
20 P2DM + 
HTN already 
receiving 
maximum 
Macro. Mean 
age=62y. Mean 
duration since 
DM diagnosed: 
15y. Median # of 
antiHTNs in 
addition to those 
Nondiabetic 
kidney or 
kidney tract 
disease, 
plasma K > 
4.6mmol/L, 
GFR<25ml/
N/A Geometric 
mean (IQR) 
albuminuria 
(mg/24h) 
 ACEI + 
Placebo: 
706 (349-
Rossing.139 Combo tx led to a 
28% reduction (95% CI: 17-
38%, p<0.001) compared to 
ACEI + placebo. Large 
interindividual variability; no 
significant changes in BP. Mean 
BP, ACEI + placebo = 
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+ placebo; 
ACEI + ARB 
(Enalapril 
40mg daily, 
Lisinopril 
40mg daily, 
or Captopril 
150mg daily 
with 
Candesartan 
16mg daily). 
dosages of 
ACEI  2 mo 
in Denmark.  
Tx period=2 
mo. 
provided by 
study: 3. Mean 
baseline BP NR; 
100% NHW. 
Mean 
BMI=31kg/m2. 
min 1219) 
 ACEI + 
ARB: 
508 (228-
909) 
138/72mmHg; mean BP, ACEI 
+ ARB = 135/70mmHg. No 
relationship btwn albuminuria 
change and 24h diastolic ABP 
or renin changes. 
CCB 
(Amlodipine 
5mg daily); 
ACEI 
(Temocapril 
2mg daily); 
CCB + ARB 
(Amlodipine 
5mg daily, 
Candesartan 
4mg daily); 
ACEI + ARB 
(Temocapril 
2mg daily , 
Candesartan 
4mg daily). 
RCT 
(blinding NR) 
of 17 P2DM + 
HTN in 
Japan. Two tx 
periods = 12 
wk each. First 
12 wk: CCB 
or ACEI. 
Second 12 
wk: CCB + 
ARB or ACEI 
+ ARB. 
Macro. Mean 
age=52.7y. Mean 
BMI=23.2kg/m2. 
Mean HbA1c = 
7.7%. Mean 
baseline BP= 
152.8/90.9mmHg, 
%NHW NR.  
Mean duration 
since DM 
diagnosed NR. 
Serious 
diabetic 
complicatio
ns, insulin 
use 
Mean ±SD 
proteinuria 
(g/day)  
 CCB = 
4.1±1.9 
 ACEI = 
3.5±1.7 
 
Mean ±SD 
proteinuria 
(g/day)  
 CCB + 
ARB= 
3.5±1.5 
 ACEI + 
ARB=2.6
±1.3 
Kuriyama.140 Compared to each 
monotherapy, addition of an 
ARB led to a sig reduction in 
proteinuria (p<0.05 and p<0.01 
for CCB and ACEI, 
respectively). Analyses reported 
in terms of % Δ: 
 Compared to baseline, mean 
changes in daily proteinuria: 
 CCB:  + 11% 
 ACEI:  - 20% 
 CCB + ARB:  -10% 
 ACEI + ARB: -43% 
(Combo tx with ACEI 
and ARB had an 
additional 23% 
reduction in daily 
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proteinuria compared to 
ACEI monotherapy.)  
Maintained restricted caloric, 
salt, and protein intake. 
ACEI 
(Ramipril 5-
7.5mg daily); 
ACEI + 
placebo 
(Ramipril 5-
7.5mg daily); 
ACEI + ARB 
(Ramipril 5-
7.5mg daily, 
Candesartan 
4-8mg daily). 
Double-blind 
randomized 
crossover 
study 
including a 
subset of 18 
P2DM 
without HTN 
in Korea.  
8wk. run-in 
with ramipril, 
then two 16 
wk. tx periods 
of candesartan 
or placebo.  
Macro. Pts 
received ramipril 
 6mo. before 
study.  Mean age 
= 42 y. % NHW 
NR. Mean 
baseline arterial 
pressure 
=92.3mmHg, 
mean baseline 
HbA1c NR. Mean 
BMI NR. Mean 
duration since 
DM diagnosed 
NR. 
Vascular 
disease, 
cardiac 
disease, 
uncontrolled 
diabetes, 
malignancy 
N/A Mean 
(range) 
UAER 
(g/day) 
 ACEI: 
4.1 (0.3) 
 ACEI + 
placebo: 
 4.2 (0.3) 
 ACEI + 
ARB: 4.0 
(0.2) 
Song.137  Results in adjacent 
column are in P2DM only. 
ACEI+ARB did not 
significantly reduce albuminuria  
compared to ACEI. 
ACEI 
(Ramipril 
10mg daily); 
ARB 
(Candesartan 
16mg daily); 
Double-blind  
randomized 
crossver study 
of 21 P2DM 
without HTN 
in Korea.  8 
Macro. Pts 
received ACEI or 
ARB before. 
Mean age=49y. 
Mean 
BMI=21.9kg/m2. 
Age <18y; 
serum K 
>5.5mmol/L
;nondiabetic 
renal 
disease; 
N/A Mean (SD) 
albuminuria 
(g/day) 
 ACEI: 
3.5 (1.8) 
 ARB:  
Song.132 The authors found a 
significant correlation btwn 
albuminuria, duration of 
diabetes, and systolic BP. 
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ACEI +ARB 
(Ramipril 
5mg daily, 
Candesartan 
8mg daily). 
wk run-in 
with ramipril 
or 
candesartan, 
then three 16 
wk tx periods 
(ea. monotx 
then combo). 
8 wk washout 
btwn tx 
periods. 
Mean 
BP=134/70mmHg
. Mean 
HbA1c=7.4%. 
Mean duration 
since DM 
diagnosed=8y. 
renal artery 
stenosis; 
type IV 
renal tubular 
acidosis; 
morbid 
cardiac, 
vascular 
disease or 
malignancy; 
uncontrolled 
diabetes; 
absence of 
retinopathy 
3.3 (2.0) 
 ACEI + 
ARB: 2.9 
(1.4) 
[p<0.05 
compared 
to ea 
monotx] 
ACEI 
(Enalapril 
10mg daily); 
ARB 
(Losartan 
50mg daily); 
ACEI + ARB 
(Enalapril 
10mg daily, 
Losartan 
50mg daily). 
Randomized 
crossover 
study 
(blinding NR) 
of 22 Turkish 
P2DM. Ea tx 
period lasted 
12 wk. 
Macro. Mean 
age=54.7y. Mean 
weight=68.2kg. 
Mean 
CrCl=65.3ml/min
/1.73m2. Mean 
BP=151/93mmHg
. Mean 
HbA1c=6.9%. 
Mean duration 
since DM 
diagnosed NR. 
NR N/A Mean 
reduction in 
albuminuria 
(g/day) 
 ACEI: 
1.62 
 ARB: 
1.63 
 ACEI + 
ARB: 
2.36 
[p<0.05 
vs. ea 
monotx] 
Cetinkaya.130  Restriction of Na, 
protein, and calories. ACEI + 
ARB, compared to double the 
dose of either monotx (enalapril 
20mg daily or losartan 50mg 
daily) resulted in a 51% 
reduction in albuminuria 
compared to a 37% reduction in 
albuminuria (p<0.05). 
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ACEI 
(Perindopril 
8mg daily); 
ARB 
(Irbesartan 
300mg daily); 
ACEI + ARB 
Randomized 
open-label 
crossover 
study of 20 
P2DM in 
Brazil; Ea tx 
period=16 wk. 
Macro. Mean 
age=54y. 50% 
NHW. Duration 
since DM 
diagnosis: 11 y. 
50% insulin 
users. Mean 
HbA1c=6.7%. 
Age<40y, 
Malignant 
HTN, 
SBP≤140m
mHg, 
HbA1c≥9%, 
severe 
peripheral 
vascular dx, 
stroke or MI 
within 6 mo, 
recurrent 
UTI, 
CrCl<40ml/
min/1.72m2, 
serum 
K≥5.0mEq/
L, 
nondiabetic 
renal dx 
Geometric 
mean 
(95%CI) 
UAER (mg/d) 
 ACEI 
829  
(537-1280) 
 ARB 
996  
(686-1445) 
 Combo 
966        
(681-1369) 
 
Geometric 
mean 
(95%CI) 
UAER 
(mg/d) 
 ACEI 
545  
(288-
1029) 
 ARB 
773      
(478-
1248) 
 Combo 
644      
(393-
1085) 
Matos.131 Other than UAER, no 
mention of baseline 
characteristics per group or diffs 
in baseline characteristics btwn 
groups. No statistical 
adjustment for any differences 
btwn groups (t-test). Baseline 
mean UAER was 20.1% higher 
for ARB group vs. ACEI. Sig 
reduction in mean UAER for 
ACEI: 34% (53%-9%), p<0.05. 
NS reduction in mean UAER 
for ARB: 22% (45%-9% 
increase), p=0.17. 
Sig reduction in mean UAER 
for combo: 33% (49%-12%), 
p<0.02. 
NS diffs btwn groups: ACEI vs. 
ARB v. combo tx. 
Compliance: 95%-96% across 
txs 
AEs: no mention of deaths. 2 
excluded b/c of PVD requiring 
hospitalization that led to 
missed visits. Sig reduction in 
hematocrit  and sig increase in 
serum K for combo tx. 1 pt 
receiving ARB & another 
receiving combo tx dropped out 
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for hyperkalemia. All 
hyperkalemic patients had 
GFR<60. 1 pt had increased 
BUN with ACEI. Uricemia 
decreased only during combo tx 
(5.9 5.3mg/dL, p<0.05). ARB 
and combo had similar increase 
in plasma rennin elevation; 
ACEI didn’t. Aldosterone only 
decreased in combo tx (36% 
(53%-12%, p<0.02)). 
 
Δ= change; ABP= arterial blood pressure; AER= albumin excretion rate, to be used interchangeably with UAER; AEs= adverse 
events; antiHTNs= antihypertensives; BMI= body mass index; BP= blood pressure; btwn= between; CAD= coronary artery disease; 
CCB= calcium channel blocker; CHF= congestive heart failure; CHO=carbohydrates; Chol= cholesterol; CI= confidence interval; 
Combo= combination therapy; CrCl= creatinine clearance; DBP= diastolic blood pressure; diff= different or differently; diffs= 
differences; DM= diabetes mellitus; dx= disease; ea= each; EtOH= alcohol; f/u= follow-up; GFR= glomerular filtration rate; 
HCTZ= hydrocholorothiazide; HDL= high-density lipoprotein; HTN= hypertension; hx= history (of); IQR= interquartile range; K= 
potassium; LDL= low-density lipoprotein cholesterol; Macro.= macroalbuminuria; Micro.= microalbuminuria; mo= month(s); 
monotx= monotherapy; N/A= not applicable; NHW= non-Hispanic White; NR= not reported; NS= nonsignificant; pts= patients; 
RCT= randomized clinical trial; resp.= respectively; SBP= systolic blood pressure; SCr= serum creatinine; SD= standard deviation; 
sig= significant or significantly; TG= triglycerides; tx= treatment; UAER= urinary albumin excretion rate, to be used interchangeably 
with AER; vs.= versus; wk= week(s); y= year(s) 
 
Geometric means reported when UAER was antilogged.  Logged because of skewness in data. “Converted” when I converted the units 
to mg/d (multiply microgram/min to mg/day by multiplying by 1.44). 
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 Tables 1-4 detail how ICD-9-CM codes, DRGs, CPT-4 codes, and other data 
were incorporated in coding comorbidities, other covariates, original variables 
thought to affect treatment selection, and dependent variables.  These tables also 
show once status of each of these variables were determined, how each of the 
variables were coded in the dataset.
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Table 1.  ICD-9-CM Codes and DRGs Denoting Elixhauser Comorbidities of Interest, Data Coding 
 
Comorbidity* 
 
ICD-9-CM Codesa DRGsb Code in Dataset as: 
Congestive heart failure 398.91, 402.11, 402.91, 404.11, 
404.13, 404.91, 404.93, 428.0-9 
103-108, 110-112, 115-118, 
120-127, 129, 132-133, 135-
143 
1 if fit criteria in footnote; 
else 0 
    
Cardiac arrhythmias 426.10, 426.11, 426.13, 426.2-
426.53, 426.6-426.89, 427.0, 
427.2, 427.31, 427.60, 427.9, 
785.0, V53.3 
103-108, 110-112, 115-118, 
120-127, 129, 132-133, 135-
143 
1 if fit criteria in 
footnote; else 0 
    
Valvular disease 093.20-093.24, 394.0-397.1, 
424.0-424.91, 746.3-746.6, 
V42.2, V43.3 
103-108, 110-112, 115-118, 
120-127, 129, 132-133, 135-
143 
1 if fit criteria in 
footnote; else 0 
    
Pulmonary circulation 
disorders 
416.0-416.9, 417.9 88, 103-108, 110-112, 115-
118, 120-127, 129, 132-133, 
135-143 
1 if fit criteria in 
footnote; else 0 
    
Peripheral vascular 
disorders 
440.0-440.9, 441.2, 441.4, 441.7, 
441.9, 443.1-443.9, 447.1, 557.1, 
557.9, V43.4 
130-131 1 if fit criteria in 
footnote; else 0 
    
Hypertension, 
uncomplicated 
401.1, 401.9 134 1 if fit criteria in 
footnote; else 0 
    
Hypertension, 
complicated 
402.10, 402.90, 404.10, 404.90, 
405.11, 405.19, 405.91, 405.99 
103-108, 110-112, 115-118, 
120-127, 129, 132-133-143, 
302-305, 315-333 
1 if fit criteria in 
footnote; else 0 
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 Table 1 (cont.) 
 
Comorbidity* 
 
ICD-9-CM Codesa DRGsb Code in Dataset as: 
Paralysis 342.0-342.12, 342.9-344.9 5, 14-17 1 if fit criteria in 
footnote; else 0 
    
Other neurological 
disorders 
 
331.9, 332.0, 333.4, 333.5, 334.0-
335.9, 340.XX, 341.1-.9, 345.00-
.11, 345.40-.51, 345.80-.91, 
348.1, 348.3, 780.3, 784.3 
1-34 or 35 1 if fit criteria in 
footnote; else 0 
    
Chronic pulmonary 
disease 
490-492.8, 493.00-.91, 494.XX, 
495.0-505.XX, 506.4 
88 or 96-98 1 if fit criteria in 
footnote; else 0 
    
Hypothyroidism 243.XX-244.2, 244.8, 244.9 290 or 300-301 
 
1 if fit criteria in 
footnote; else 0 
    
Diabetes, complicated 250.40-.73, 250.90-.93 294 or 295 1 if fit criteria in 
footnote; else 0 
    
Renal failure 403.11, 403.91, 404.12, 404.92, 
585.XX, 586.XX, V42.0, V45.1, 
V56.0, V56.8 
302 or 316-317 1 if fit criteria in 
footnote; else 0 
    
Liver disease 070.32, 070.33, 070.54, 456.0, 
456.1, 456.20, 456.21, 571.0, 
571.2, 571.3, 571.40-.49, 571.5, 
571.6, 571.8, 571.9, 572.3, 572.8, 
V42.7 
199-202 or 205-208 
 
1 if fit criteria in 
footnote; else 0 
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 Table 1 (cont.) 
 
Comorbidity* 
 
ICD-9-CM Codesa DRGsb Code in Dataset as: 
Peptic ulcer disease 531.70, 531.90, 532.70, 532.90, 
533.70, 533.90, 534.70, 534.90, 
V12.71 
174-177 or 178 1 if fit criteria in 
footnote; else 0 
    
AIDS 042.XX-044.9 488, 489, or 490 1 if fit criteria in 
footnote; else 0 
    
Lymphoma 200.XX-202.38, 202.50-203.01, 
203.8-.81, 238.6, 273.3, V10.71, 
V10.72, V10.79 
400-414, 473, or 492 
 
1 if fit criteria in 
footnote; else 0 
    
Metastatic cancer 196.XX-199.1 10, 11, 64, 82, 172, 173, 199, 
203, 239, 257-260, 274, 275, 
303, 318, 319, 338, 344, 346, 
347, 354, 355, 357, 363, 366, 
367, or 406-414 
 
1 if fit criteria in 
footnote; else 0 
    
Solid tumor without 
metastasis 
140.XX-172.9, 174.XX-175.9, 
179.XX-195.8, V10.00-.9 
10, 11, 64, 82, 172, 173, 199, 
203, 239, 257-260, 274, 275, 
303, 318, 319, 338, 344, 346, 
347, 354, 355, 357, 363, 366, 
367, or 406-414 
 
1 if fit criteria in 
footnote; else 0 
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 Table 1 (cont.) 
 
Comorbidity* 
 
ICD-9-CM Codesa DRGsb Code in Dataset as: 
Rheumatoid 
arthritis/collagen 
vascular diseases 
701.0, 710.0-.9, 714.0-.9, 720.0-
.9, 725.XX 
240 or 241 1 if fit criteria in 
footnote; else 0 
    
Coagulopathy 286.0-.9, 287.1, 287.3-.5 397 1 if fit criteria in 
footnote; else 0 
    
Obesity 278.0 288 or 296-298 1 if fit criteria in 
footnote; else 0 
    
Weight loss 260.XX-263.9 296, 297, or 298 1 if fit criteria in 
footnote; else 0 
    
Fluid and electrolyte 
disorders 
276.0-.9 296, 297, or 298 1 if fit criteria in 
footnote; else 0 
    
Blood loss anemia 280.0 395 or 396 1 if fit criteria in 
footnote; else 0 
    
Deficiency anemias 280.1-.9, 285.9 395 or 396 1 if fit criteria in 
footnote; else 0 
    
Alcohol abuse 291.1, 291.2, 291.5, 291.8, 291.9, 
303.90-.93, 305.00-.03, V113 
433-436 or 437 1 if fit criteria in 
footnote; else 0 
    
Drug abuse 292.0, 292.82-.89, 292.9, 304.00-
.93, 305.20-.93 
433-436 or 437 1 if fit criteria in 
footnote; else 0 
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 Table 1 (cont.) 
 
Comorbidity* 
 
ICD-9-CM Codesa DRGsb Code in Dataset as: 
Psychoses 295.00-298.9, 299.10-.11 430 1 if fit criteria in 
footnote; else 0 
    
Depression 300.4, 301.12, 309.0, 309.1, 
311.XX 
426 1 if fit criteria in 
footnote; else 0 
*This table is modified from Elixhauser et al.195 
a  ICD-9-CM codes had implied decimal points across VA datasets. 
 
B The Elixhauser method, developed using only inpatient files, provides a DRG for inpatient files, meaning that the presence of 
any ICD-9 code without the presence of a DRG related to that indication defines that the condition as a comorbidity.  Personal 
communication with Anne Elixhauser gave guidance to use her method in outpatient files, which means DRGs could not be 
used as a screen.  Rather, ICD-9-CM codes were solely relied upon in determining comorbidities in outpatient files.  For the 
dissertation, we went back three months from first date of health care utilization to examine inpatient and outpatient records for 
these ICD-9s and DRGs. 
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Table 2.  ICD-9-CM Codes, CPT-4 Codes, Miscellaneous Data for Covariates of Interest, Data Coding 
 
Covariate ICD-9-CM Code(s)* CPT-4 Code(s) Miscellaneous Data Code in Dataset as: 
Age at baseline   Calculated from date 
of birth 
Continuously: age in 
years 
     
Gender   Gender 1=male, 0=female 
     
Race/ethnicity   Value carried over 
from race/ethnicity 
information 
1=Hispanic white, 
2=Hispanic Black, 
3=American Indian, 
4=African American, 
5=Asian, 
6=White 
7=Unknown 
Other=Missing 
     
Income   Value carried over 
from INCOME, if 
ever documented 
Continuously: annual 
household income in 
dollars 
     
Means test   If ever documented, 
from MEANS 
A=Below means test and 
no pharmacy copay 
I=Below means test with 
partial pharmacy copay 
C=Above means test 
threshold 
U=Means test required, 
but unknown result 
N=Means test no 
required 
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 Table 2 (cont.) 
 
Covariate ICD-9-CM Code(s)* CPT-4 Code(s) Miscellaneous Data Code in Dataset as: 
Smoking 305.1 (current tobacco 
dependence), 491.0 
(smoker’s cough), 
V15.82 (history of 
tobacco use), 989.84 
(toxic effect of tobacco) 
  3= If ICD-9 code 305.1 
or 989.84 was ever 
documented 
2=If ICD-9 code 491.0 
was ever documented 
1=If V15.82 was ever 
coded 
0=None of these ICD=9 
codes were ever 
documented 
     
Family history 
of 
cardiovascular 
disease 
V17.1, V17.3, V17.4   1=If any of the ICD-9 
codes to the left were 
ever documented, else=0 
     
History of 
stroke 
438, V12.59   1=Either ICD-9 code 
documented at baseline 
(within 3 months of 
initial date of health care 
utilization), else=0 
     
History of 
myocardial 
infarction 
412.XX, 429.7X   1=Either ICD-9 code 
documented at baseline 
(within 3 months of 
initial date of health care 
utilization), else=0 
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 Table 2 (cont.) 
 
Covariate ICD-9-CM Code(s)* CPT-4 Code(s) Miscellaneous Data Code in Dataset as: 
New user of 
ACEI or ARB 
  Prescription 
information for dates 
of ACEI or ARB 
1=If no prescription 
filled for ACEI or ARB 
within 6 months of initial 
date of health care 
utilization, else=0 
     
Newly-
diagnosed 
  Documented type 2 
diabeets previous to 
first date of health 
care utilization for 
type 2 diabetes in 
study period 
1=If type 2 diabetes not 
documented in the year 
previous to the first date 
of health care utilization 
for type 2 diabetes, 
else=0 
     
Cohort   Based on year within 
study period in 
which first date of 
health care 
utilization for type 2 
diabetes occurred 
Cohort 2003=If first date 
occurred in FY 2003 
Cohort 2004=If first date 
occurred in FY 2004 
Cohort 2005=If first date 
occurred in FY 2005 
Cohort 2006=If first date 
occurred in FY 2006 
     
Time   Each year for which 
information on 
health care 
utilization was 
available after the 
index date 
Time t = Year 1 
Time (t+1) = Year 2 
Time (t+2) = Year 3 
Time (t+3) = Year 4 
Time (t+4) = Year 5 
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 Table 2 (cont.) 
 
Covariate ICD-9-CM Code(s)* CPT-4 Code(s) Miscellaneous Data Code in Dataset as: 
Urban/suburban 
versus rural 
living 
  Zip codes were 
converted to Rural 
Urban Commuting 
Area codes, 
categorization C 
1=urban/suburban 
0=rural 
     
HbA1c   Value is obtained 
from RESULT field 
for test number 0017 
from Lab Results 
files 
Value was retained in 
natural units of % 
     
LDL   Value is obtained 
from RESULT field 
for test number 0017 
from Lab Results 
files 
Value was retained in 
natural units of mg/dL 
     
Triglycerides   Value is obtained 
from RESULT field 
for test number 0030 
from Lab Results 
files 
Value was retained in 
natural units of mg/dL 
     
NSAID use   NSAID prescription 
dates and days 
supply 
Proportion of months in a 
year with an NSAID 
0=no prescription for an 
NSAID within the year 
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 *ICD-9-CM codes had implied decimal points across VA datasets
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Table 3.  ICD-9-CM Codes, CPT-4 Codes, Miscellaneous Data for Variables Used for Control of Selection Bias, Data Coding 
 
Variable ICD-9-CM Code(s)* CPT-4 Code(s) Miscellaneous Data Code in Dataset as: 
Propensity Scores Analysis (variables indicating likelihood to cough) 
Allergic rhinitis 477.XX   If ICD-9 code is 
documented during the 
same visit an ACEI or 
ARB is first 
prescribed=1, else=0 
     
GERD 530.11, 530.81   If ICD-9 code is 
documented during the 
same visit an ACEI or 
ARB is first 
prescribed=1, else=0 
     
Postnasal drip 784.91   If ICD-9 code is 
documented during the 
same visit an ACEI or 
ARB is first 
prescribed=1, else=0 
     
Treatment started 
in winter 
  Date the first 
prescription for an 
ACEI or ARB was 
written 
If date of first 
prescription is during  
winter months=1, else=0 
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 Table 3 (cont.) 
 
Variable ICD-9-CM Code(s)* CPT-4 Code(s) Miscellaneous Data Code in Dataset as: 
Smoking 305.1, 491.0, V15.82, 
989.84 
  If smoking was ever 
documented, converted 
from categorical data 1-3 
when used as covariate to 
1. Is 0 if smoking was 
never documented, as 
was the case when 
smoking was used as a 
covariate. 
     
Asthma, COPD, 
chronic bronchitis 
   1=If documented having 
chronic pulmonary 
disease in Elixhauser, 
else=0 
 *ICD-9-CM codes had implied decimal points across VA datasets.
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Table 4.  ICD-9-CM Codes, CPT-4 Codes, Miscellaneous Data for Dependent Variables of Interest, Data Coding 
 
Variable ICD-9-CM 
Code(s)* 
CPT-4 Code(s) Miscellaneous 
Data 
Code in Dataset as: 
ESRD 585.6, V45.1, or 
V56.0, V56.8 
36800, 36810, 36815, 
90935, 90937, 90947, 
90989, 90993; 50300, 
50340, 50360, 50365, 
90920, 90921, 90924, 
90925, 90945, 90997, 
90999 
 1 if fit criteria to left, else 0 
     
Albuminuria; 
albumin:creatinine ratio 
  Value is obtained 
from RESULT 
field for test 
numbers 0032 
and 0056, 
respectively, from 
Lab Results files 
1. Value was retained in 
natural units of mg/dl and 
mg/g, respectively 
2. Value was converted into 
categorical values denoting 
microalbuminuria, 
macroalbuminuria 
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 Table 4 (cont.) 
 
Variable ICD-9-CM 
Code(s)* 
CPT-4 Code(s) Miscellaneous 
Data 
Code in Dataset as: 
Occurrence of incident 
MI 
410.00-.02, 
410.10-.12, 
410.20-.22, 
410.30-.32, 
410.40-.42, 
410.50-.52, 
410.60-.62, 
410.70-.72, 
410.80-.82, 
410.90-.92  
  1. Documented from any of 
the ICD-9 codes as the 
principal diagnosis in a 
year, else=0 
2. Used as part of the 
composite endpoint of 
vascular disease. If this 
occurred ≥1 time in a 
year=1, else=0. 
     
Left ventricular 
hypertrophy 
429.3   1. 1 if fit criteria to left, else 0. 
Left ventricular hypertrophy 
happens once in a person’s 
life, so once documented, all 
subsequent years=1. 
2. Used as part of the 
composite endpoint of 
vascular disease. 1 if fit 
criteria to left, else 0. 
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 Table 4 (cont.) 
 
Variable ICD-9-CM 
Code(s)* 
CPT-4 Code(s) Miscellaneous 
Data 
Code in Dataset as: 
Occurrence of incident 
ischemic stroke 
(lacunar, carotid 
circulation obstruction, 
vertebrobasilar 
occlusion) in a year 
433, 433.0, 
433.1, 433.2, 
433.3, 434, 
434.0, 434.1, 
434.9, 434.91 
  1. Documented from any of 
the ICD-9 codes as the 
principal diagnosis in a 
year, else=0 
2. Used as part of the 
composite endpoint of 
vascular disease. 
If this occurred ≥1 time in a 
year=1, else=0. 
     
All-cause mortality   Date of death 1=If date of death documented, 
else=0 
     
Number of 
hospitalizations 
   Number of times a patient was 
hospitalized in a given year. 
0=if no documented inpatient 
data. 
     
Number of ED visits  99281-8 in the 
outpatient visit data 
 Number of times a patient went 
to the ED in a given year. 0=if 
no documented ED visit data. 
     
 
 
 
  374
 Table 4 (cont.) 
 
Variable ICD-9-CM 
Code(s)* 
CPT-4 Code(s) Miscellaneous 
Data 
Code in Dataset as: 
Number of outpatient 
visits 
 All visits in the 
outpatient visit data 
that do not have 
99281-8 
 Number of times a patient was 
seen on an outpatient basis, but 
was not seen in the ED. 0=if no 
outpatient visit data 
documented without ED CPT-4 
codes. 
 *ICD-9-CM codes had implied decimal point 
  375
 Table 5 shows comparisons across drug therapies at each time point for 
continuous clinical parameters.  Using results from the ANOVA and Kruskal-Wallis test 
we find ACEI patients had a higher mean value of HbA1c than ARB or neither patients at 
Year 1.  During Year 2 each drug therapy had comparable HbA1c levels.  ACEI patients 
had a comparable mean HbA1c as neither patients, but had a higher HbA1c value than 
ARB patients in Year 3.  Years 4 and 5 showed no between group differences. 
Drug therapy comparisons for LDL within each time period show those receiving 
neither therapy had the highest mean values of LDL while ARB patients had the lowest 
mean values and ACEI patients had values between the neither and ARB groups over 
Years 1, 2, and 3.  At Year 4, ACEI and ARB had comparable LDL values, but each 
group had lower mean LDL than those in the neither group.  Statistically, there were no 
differences in the fifth year of follow-up. 
Triglyceride level comparisons between drug therapies show similar values in 
each group during Year 1.  In Year 2, ACEI or ARB monotherapies each have higher 
values compared to neither patients.  ACEI patients had a higher mean triglyceride value 
than those patients receiving neither therapy in Year 3; the mean triglyceride level for 
ARB patients was comparable to ACEI and neither patients.  There were no differences 
in drug therapies for Years 4 and 5. 
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Table 5: Continuous Clinical Parameters by Drug Therapy and Time Since Identification, 
Comparisons by Drug Therapy 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
HbA1c  7.32*** 
(1.82) 
7.28 
(4.13)
7.28†
(3.50)
7.24 
(1.63)
7.01 
(1.15) 
7.30 
(3.04)
       
LDL  96.19‡‡‡ 
(32.64) 
91.02║║║
(30.87) 
89.60§§§
(30.59) 
88.06 
(28.49) 
82.09 
(30.04) 
92.77 
(31.59) 
       
Triglycerides  197.70 
(169.70) 
189.60
(165.50) 
186.90
(177.50) 
174.60 
(122.90) 
173.80 
(112.40) 
191.60 
(167.20) 
       
ARB       
HbA1c  7.21 
(3.24) 
7.45 
(7.00)
7.17 
(3.81)
7.13 
(1.34)
7.31 
(1.71) 
7.27 
(4.754
       
LDL  91.66 
(30.32) 
88.16
(31.10) 
86.52 
(30.46) 
84.72¶¶¶ 
(27.05) 
96.13 
(23.15) 
89.01 
(30.44) 
       
Triglycerides  198.00$ 
(182.50) 
184.60&&
& 
(154.60)
177.90 
(121.30) 
176.20 
(153.20) 
178.90 
(115.40) 
188.20 
(161.10) 
       
Neither       
HbA1c  7.27 
(1.66) 
7.27 
(3.45)
7.39
(4.33) 
7.36 
(4.32)
7.06 
(1.29) 
7.30 
(3.14)
       
LDL  100.2 
(34.79) 
96.51
(33.84) 
94.01
(34.05) 
91.89 
(42.33) 
88.78 
(32.80) 
97.00 
(35.37) 
       
Triglycerides  193.00 
(179.50) 
187.30 
(209.80) 
183.00^
^^ 
(160.10)
184.60 
(222.40) 
175.00 
(139.60) 
188.50 
(189.60) 
Notes: mean (standard deviation) 
 
*** p<0.001, drug therapy group comparisons for Kruskal-Wallis test. Pairwise 
comparisons find two differences in rank means.  Rank Mean difference = 1,265.91, 
critical value = 649.98, finds a significant difference between ACEI and ARB groups 
(rank mean = 19,256.85 and 17,990.94, respectively, p<0.001 at an adjusted p-value 
indicating significance = 0.0083).  Rank Mean difference = 887.25, critical value = 
274.29, finds a significant difference between ACEI and neither groups (rank mean = 
19,256.85 and 18,369.60, respectively, p<0.0083 (adjusted p-value)).  
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†p<0.05, drug therapy group comparisons for Kruskal-Wallis test.  Pairwise comparisons 
find one difference in rank means.  Rank Mean difference = 421.43, critical value = 
407.64, finds a significant difference between ACEI and ARB groups (rank mean = 
8,203.52 and 7,782.10, respectively, p<0.0083 (adjusted p-value)). 
‡‡‡ p<0.001, drug therapy group comparisons for Kruskal-Wallis test within time t.  
Pairwise comparisons find three differences in rank means. Rank Mean difference = 
1,469.30, critical value = 602.72, finds a significant difference between ACEI and ARB 
groups (rank mean = 16,507.80 and 15,038.49, respectively, p<0.0083 (adjusted p-
value)). Rank Mean difference = 2,549.73, critical value = 604.37, finds a significant 
difference between ARB and neither groups (rank mean = 15,038.49 and 17,588.22, 
respectively, p<0.0083 (adjusted p-value)). Rank Mean difference = 1,080.42, critical 
value = 260.95, finds a significant difference between ACEI and neither groups (rank 
mean = 16,507.80 and 17,588.22, respectively, p<0.0083 (adjusted p-value)). 
║║║p<0.001, drug therapy group comparisons for Kruskal-Wallis test within time (t+1).  
Pairwise comparisons find three differences in rank means.  Rank Mean difference = 
772.99, critical value = 486.33, finds a significant difference between ACEI and ARB 
groups (rank mean = 11,490.06 and 10,717.07, respectively, p<0.0083 (adjusted p-
value)).  Rank Mean difference = 1,895.53, critical value = 489.66, finds a significant 
difference between ARB and neither groups (rank mean = 10,717.07 and 12,612.59, 
respectively, p<0.0083 (adjusted p-value)).  Rank Mean difference = 1,122.53, critical 
value = 220.06, finds a significant difference between ACEI and neither groups (rank 
mean = 11,490.06 and 12,612.59, respectively, p<0.0083 (adjusted p-value)). 
§§§ p<0.001, drug therapy group comparisons for Kruskal-Wallis test within time (t+2).  
Pairwise comparisons find three differences in rank means. Rank Mean difference = 
534.20, critical value = 383.12, finds a significant difference between ACEI and ARB 
groups (rank mean = 7,307.62 and 6,773.42, respectively, p<0.0083 (adjusted p-value)). 
Rank Mean difference = 1,099.01, critical value = 383.85, finds a significant difference 
between ARB and neither groups (rank mean = 6,773.42 and 7,872.43, respectively, 
p<0.0083 (adjusted p-value)).  Rank Mean difference = 564.81, critical value = 174.60, 
finds a significant difference between ACEI and neither groups (rank mean = 7,307.62 
and 7,872.43, respectively, p<0.0083 (adjusted p-value)).  
¶¶¶ p<0.001, drug therapy group comparisons for Kruskal-Wallis test within time (t+3).  
Pairwise comparisons find two differences in rank means.  Rank Mean difference = 
457.82, critical value = 282.95, finds a significant difference between ARB and neither 
groups (rank mean = 3,066.46 and 3,524.28, respectively, p<0.0083 (adjusted p-value)).  
Rank Mean difference = 211.86, critical value = 119.47, finds a significant difference 
between ACEI and neither groups (rank mean = 3,312.41 and 3,524.28, respectively, 
p<0.0083 (adjusted p-value)).  
$ p<0.05, drug therapy group comparisons for ANOVA within time t.  Tukey’s Honestly 
Significant Difference finds no comparison is greater than the studentized range critical 
value (0.05, 3, 36793) = 3.32.  
&&& p<0.001, drug therapy group comparisons for Kruskal-Wallis test within time (t+1).  
Pairwise comparisons find two differences in rank means.  Rank Mean difference = 
542.40, critical value = 509.40, finds a significant difference between ARB and neither 
groups (rank mean = 13,006.81 and 12,464.41, respectively, p<0.0083 (adjusted p-
value)).  Rank Mean difference = 668.42, critical value =  227.94, finds a significant 
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difference between ACEI and neither groups (rank mean = 13,132.83 and 12,464.41, 
respectively, p<0.0083 (adjusted p-value)). 
^^^ p<0.001, drug therapy group comparisons for Kruskal-Wallis test within time (t+2).  
Pairwise comparisons find one differences in rank means.  Rank Mean difference = 
348.45, critical value =  178.89, finds a significant difference between ACEI and neither 
groups (rank mean = 8,095.72 and 7,747.28, respectively, p<0.0083 (adjusted p-value)). 
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      Table 6 shows comparisons across time within each drug therapy for continuous 
clinical parameters.  Among ACEI patients HbA1c values stayed constant over follow-
up.  In stark contrast, LDL values progressively decreased across years of follow-up.  
Triglyceride levels almost perfectly mirrored what was seen with LDL values:  there was 
a constant decrease across years of follow-up until the fifth year.   
Relating to ARB patients, we again saw similar values in HbA1c across time.  
Although the overall value for LDL showed change across time, no pairwise comparisons 
were significant.  We also see comparable values in triglyceride across time within ARB 
patients. 
For patients receiving neither therapy we saw a dip in HbA1c values in Year 2 
that then returned and maintained at Year 1 values.  Similar to what happened in ACEI 
patients, LDL values progressively decreased across years of follow-up.  Triglyceride 
levels were comparable until the fifth year of follow-up, at which point they were lower 
than the first year.   
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Table 6: Continuous Clinical Parameters by Drug Therapy and Time Since Identification, 
Comparisons by Time Period  
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
HbA1c  7.32 
(1.82) 
7.28 
(4.13)
7.28 
(3.50)
7.24 
(1.63)
7.01 
(1.15) 
7.30 
(3.04)
       
LDL***  96.19 
(32.64) 
91.02
(30.87) 
89.60
(30.59) 
88.06 
(28.49) 
82.09 
(30.04) 
92.77 
(31.59) 
       
Triglycerides†††  197.70 
(169.70) 
189.60
(165.50) 
186.90
(177.50) 
174.60 
(122.90) 
173.80 
(112.40) 
191.60 
(167.20) 
       
ARB       
HbA1c  7.21 
(3.24) 
7.45 
(7.00)
7.17 
(3.81)
7.13 
(1.34)
7.31 
(1.71) 
7.27 
(4.75)
       
LDL‡‡‡  91.66 
(30.32) 
88.16
(31.10) 
86.52 
(30.46) 
84.72 
(27.05) 
96.13 
(23.15) 
89.01 
(30.44) 
       
Triglycerides║  198.00 
(182.50) 
184.60 
(154.60)
177.90 
(121.30)
176.20 
(153.20)
178.90 
(115.40) 
188.20 
(161.10)
       
Neither       
HbA1c§§§  7.27 
(1.66) 
7.27 
(3.45) 
7.39i
(4.33) 
7.36 
(4.32) 
7.06 
(1.29) 
7.30 
(3.14) 
       
LDL¶¶¶  100.2 
(34.79) 
96.51
(33.84) 
94.01
(34.05) 
91.89 
(42.33)
88.78 
(32.80) 
97.00 
(35.37)
       
Triglycerides$$$  193.00 
(179.50) 
187.30 
(209.80) 
183.00 
(160.10) 
184.60 
(222.40) 
175.00 
(139.60) 
188.50 
(189.60) 
*** p<0.001, time comparisons for Kruskal-Wallis test within ACEI therapy.  Pairwise 
comparisons find six differences in rank means.  Rank Mean difference = 2,091.39, 
critical value = 373.91, finds a significant difference between first and second years of 
follow-up (rank mean = 20,656.75 and 18,565.36, respectively, p<0.0025 (adjusted p-
value)). Rank Mean difference = 2,657.85, critical value = 439.76, finds a significant 
difference between first and third years of follow-up (rank mean = 20,656.75 and 
17,998.90, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 3,175.73, 
critical value = 658.43, finds a significant difference between first and fourth years of 
follow-up (rank mean = 20,656.75 and 17,481.02, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 5,531.87, critical value = 4,381.98, finds a significant 
difference between first and fifth years of follow-up (rank mean = 20,656.75 and 
15,124.88, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 566.46, 
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critical value = 464.12, finds a significant difference between second and third years of 
follow-up (rank mean = 18,565.36 and 17,998.90, respectively, p<0.0025 (adjusted p-
value)).  Rank Mean difference = 1,084.34, critical value = 674.94, finds a significant 
difference between second and fourth years of follow-up (rank mean = 18,565.36 and 
17,481.02, respectively, p<0.0025 (adjusted p-value)).   
††† p<0.001, time comparisons for Kruskal-Wallis test within ACEI therapy.  Pairwise 
comparisons find five significant differences in rank means.  Rank Mean difference = 
686.28, critical value = 384.85, finds a significant difference between first and second 
years of follow-up (rank mean = 21,087.10 and 20,400.82, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 1,047.81, critical value = 456.21, finds a 
significant difference between first and third years of follow-up (rank mean = 21,087.10 
and 20,039.29, respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 
1,940.73, critical value = 686.71, finds a significant difference between first and fourth 
years of follow-up (rank mean = 21,087.10 and 19,146.37, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 1,254.44, critical value = 703.70, finds a 
significant difference between second and fourth years of follow-up (rank mean = 
20,400.82 and 19,146.37, respectively, p<0.0025 (adjusted p-value)).  Rank Mean 
difference = 892.92, critical value = 745.13, finds a significant difference between third 
and fourth years of follow-up (rank mean = 20,039.29 and 19,146.37, respectively, 
p<0.0025 (adjusted p-value)). 
‡‡p<0.01, time comparisons for ANOVA.  Tukey’s Honestly Significant Difference finds 
no comparisons that are greater than the studentized range critical value (0.05, 5, 4057) = 
3.859.  
║p<0.05, time comparisons for Kruskal-Wallis test within ARB therapy.  Pairwise 
comparisons find no significant difference in rank means. 
§§§ p<0.001, time comparisons for Kruskal-Wallis test within neither therapy.  Pairwise 
comparisons find three significant differences in rank means.  Rank Mean difference = 
429.41, critical value = 406.56, finds a significant difference between first and second 
years of follow-up (rank mean = 21,216.60 and 20,787.19, respectively, p<0.0025 
(adjusted p-value)).  Rank Mean difference = 581.76, critical value = 503.51, finds a 
significant difference between second and third years of follow-up (rank mean = 
20,787.19 and 21,368.96, respectively, p<0.0025 (adjusted p-value)).  Rank Mean 
difference = 803.82, critical value = 606.04, finds a significant difference between second 
and fourth years of follow-up (rank mean = 20,787.19 and 21,591.01, respectively, 
p<0.0025 (adjusted p-value)). 
¶¶¶ p<0.001, time comparisons for Kruskal-Wallis test.  Pairwise comparisons find nine 
significant differences in rank means.  Rank Mean difference = 1,300.33, critical value 
383.83, finds a significant difference between first and second years of follow-up (rank 
mean = 19,907.05 and 18,606.73, respectively, p<0.0025 (adjusted p-value)).  Rank 
Mean difference = 2,142.27, critical value = 438.14, finds a significant difference 
between first and third years of follow-up (rank mean = 19,907.05 and 17,764.78, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 2,838.67, critical 
value = 543.07, finds a significant difference between first and fourth years of follow-up 
(rank mean = 19,907.05 and 17,068.38, respectively, p<0.0025 (adjusted p-value)).  Rank 
Mean difference = 3,955.18, critical value = 1,418.73, finds a significant difference 
between first and fifth years of follow-up (rank mean = 19,907.05 and 15,951.87, 
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respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 841.95, critical 
value = 469.66, finds a significant difference between second and third years of follow-
up (rank mean = 18,606.73 and 17,764.78, respectively, p<0.0025 (adjusted p-value)).  
Rank Mean difference = 1,538.35, critical value = 568.80, finds a significant difference 
between second and fourth years of follow-up (rank mean = 18,606.73 and 17,068.38, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 2,654.85, critical 
value = 1,428.78, finds a significant difference between second and fifth years of follow-
up (rank mean = 18,606.73 and 15,951.87, respectively, p<0.0025 (adjusted p-value)).  
Rank Mean difference = 696.40, critical value = 606.77, finds a significant difference 
between third and fourth years of follow-up (rank mean = 17,764.78 and 17,068.38, 
respectively, p<0.0025 (adjusted p-value)).  Rank Mean difference = 1,812.91, critical 
value = 1,444.32, finds a significant difference between third and fifth years of follow-up 
(rank mean = 17,764.78 and 15,951.87, respectively, p<0.0025 (adjusted p-value)). 
$$$ p<0.001, time comparisons for ANOVA.  Tukey’s Honestly Significant Difference 
finds one comparison that is greater than the studentized range critical value (0.05, 5, 
40636) = 3.86. Triglycerides were lower at the fifth year of observation than the first 
(HSD test statistic = 4.23). 
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 The next four tables show change in albuminuria over follow-up for a more direct 
comparison to previous studies based on patients’ baseline albuminuria status.  The first 
two show for those with microalbuminuria at baseline while the last two show for those 
with macroalbuminuria at baseline.  At the first year of follow-up we see significant 
differences between all three treatment groups with those receiving neither therapy 
having the highest albuminuria.  Also at this time we see a larger proportion of ARB 
patients across the spectrum of albuminuria than ACEI patients.  The drug therapy groups 
have comparable values in Years 2 and 5.  Those receiving neither therapy have higher 
albuminuria values than ACEI patients in Years 3 and 4.  During years three and four we 
see significantly better albuminuria among ACEI patients compared to neither patients.  
There are significant changes across time in albuminuria for all three treatment groups 
through year four of observation.   
For patients with macroalbuminuria at baseline, At Year 1, neither patients had 
higher levels of albuminuria than patients on ACEI or ARB monotherapies.  Neither 
patients or ACEI patients have higher levels of albuminuria in Year 2 than ARB patients.  
Albuminuria levels for years three, four, and five are not significantly different between 
ACEI, ARB, and neither patients.  In all groups we see regression to normoalbuminuria 
from baseline macroalbuminuria.  Note there are few observations seen after year three 
within each treatment group. 
  384
Table 7: Albuminuria Changes for Baseline Microalbuminuric Patients by Drug Therapy 
and Time Since Identification, Comparisons by Drug Therapy 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
Normoalbuminuria  0.07a  0.32 0.34 0.36 0.23  0.19 
Microalbuminuria  0.92  0.59  0.55 0.49  0.59  0.76 
Macroalbuminuria  0.02  0.01  0.13  0.15  0.18  0.06 
ARB       
Normoalbuminuria  0.07b  0.28 0.36  0.35  0.67  0.19 
Microalbuminuria  0.90  0.62 0.52  0.54  0.33  0.75 
Macroalbuminuria  0.03  0.10  0.12  0.11  0.00  0.07 
Neither       
Normoalbuminuria  0.05c  0.31 0.31  0.32  0.28  0.16 
Microalbuminuria  0.93  0.59 0.56  0.55  0.60  0.78 
Macroalbuminuria  0.02  0.10 0.13d  0.13e  0.13  0.06 
Notes:  values represent proportions 
a p<0.05, ACEI versus ARB, for chi-square test. Χ²(2) = 7.04. 
b p<0.001, ARB versus neither, for chi-square test. Χ²(2) = 20.41. 
c p<0.001, ACEI versus neither, for chi-square test. Χ²(2) = 24.51. 
d p<0.01, ACEI versus neither, for chi-square test. Χ²(2) = 10.44. 
e p<0.01, ACEI versus neither, for chi-square test. Χ²(2) = 10.77.
  385
Table 8: Albuminuria Changes for Baseline Microalbuminuric Patients by Drug Therapy 
and Time Since Identification, Comparisons by Time 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
Normoalbuminuria  0.07a,b,c,
d 
0.32e,f 0.34g 0.36 0.23  0.19
Microalbuminuria  0.92  0.59  0.55 0.49  0.59  0.76 
Macroalbuminuria  0.02  0.10  0.12  0.15  0.18  0.06 
ARB       
Normoalbuminuria  0.07h,i,j,k 0.28 l 0.36  0.35  0.67  0.19 
Microalbuminuria  0.90  0.62 0.52  0.54  0.33  0.75 
Macroalbuminuria  0.03  0.10  0.12  0.11  0.00  0.07
Neither       
Normoalbuminuria  0.05m,n,o
,p 
0.31q,r 0.31  0.32  0.28  0.16 
Microalbuminuria  0.93  0.59 0.56  0.55  0.60  0.78 
Macroalbuminuria  0.02  0.10 0.13  0.13  0.13  0.06
Notes:  values represent proportions 
a p<0.001, albuminuria, time t and time (t+1) within ACEI for chi-square test. Χ²(2) = 
3.10 x 10³. 
b p<0.001, albuminuria, time t and time (t+2) within ACEI for chi-square test. Χ²(2) = 
2.90 x 10³. 
c p<0.001, albuminuria, time t and time (t+3) within ACEI for chi-square test. Χ²(2) = 
2.10 x 10³. 
d p<0.001, albuminuria, time t and time (t+4) within ACEI for chi-square test. Χ²(2) = 
40.30. 
e p<0.001, albuminuria, time (t+1) and time (t+2) within ACEI for chi-square test. Χ²(2) 
= 16.62. 
f p<0.001, albuminuria, time (t+1) and time (t+3) within ACEI for chi-square test. Χ²(2) = 
55.19. 
g p<0.001, albuminuria, time (t+2) and time (t+3) within ACEI for chi-square test. Χ²(2) 
= 17.86. 
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h p<0.001, albuminuria, time t and time (t+1) within ARB for chi-square test. Χ²(2) = 
237.17. 
I p<0.001, albuminuria, time t and time (t+2) within ARB for chi-square test. Χ²(2) = 
303.74. 
j p<0.001, albuminuria, time t and time (t+3) within ARB for chi-square test. Χ²(2) = 
146.95. 
k p<0.001, albuminuria, time t and time (t+4) within ARB for chi-square test. Χ²(2) = 
15.98. 
l p<0.01, albuminuria, time (t+1) and time (t+2) within ARB for chi-square test. Χ²(2) = 
10.43. 
m p<0.001, albuminuria, time t and time (t+1) within neither for chi-square test. Χ²(2) = 
3.50 x 10³. 
n p<0.001, albuminuria, time t and time (t+2) within neither for chi-square test. Χ²(2) = 
3.10 x 10³. 
o p<0.001, albuminuria, time t and time (t+3) within neither for chi-square test. Χ²(2) = 
2.40 x 10³. 
p p<0.001, albuminuria, time t and time (t+4) within neither for chi-square test. Χ²(2) = 
334.78. 
q p<0.001, albuminuria, time (t+1) and time (t+2) within neither for chi-square test. Χ²(2) 
= 18.24. 
r p<0.001, albuminuria, time (t+1) and time (t+3) within neither for chi-square test. Χ²(2) 
= 14.64. 
  387
Table 9: Albuminuria Changes for Baseline Macroalbuminuric Patients by Drug Therapy 
and Time Since Identification, Comparisons by Drug Therapy 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
Normoalbuminuria  0.01  0.08a 0.10 0.15 0.00  0.05 
Microalbuminuria  0.07  0.35  0.36 0.36  0.60  0.19 
Macroalbuminuria  0.91  0.58  0.54  0.49  0.40  0.76 
ARB       
Normoalbuminuria  0.01b  0.14c 0.13  0.13  0.00  0.07 
Microalbuminuria  0.09  0.36 0.34  0.36  0.00  0.20 
Macroalbuminuria  0.90  0.50  0.53  0.51  1.00  0.73 
Neither       
Normoalbuminuria  0.01d  0.07 0.11  0.14  0.15  0.05 
Microalbuminuria  0.06  0.34 0.33  0.36  0.42  0.17 
Macroalbuminuria  0.94  0.58 0.57  0.50  0.44  0.78 
Notes:  values represent proportions 
a p<0.01, ACEI versus ARB within time (t+1), for chi-square test.  Χ²(2) = 10.41. 
b p<0.05, ARB versus neither within time t, for chi-square test.  Χ²(2) = 7.20. 
c p<0.01, ARB versus neither within time (t+1), for chi-square test.  Χ²(2) = 10.62. 
d p<0.01, ACEI versus neither within time t, for chi-square test.  Χ²(2) = 14.96. 
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Table 10: Albuminuria Changes for Baseline Macroalbuminuric Patients by Drug 
Therapy and Time Since Identification, Comparisons by Time 
 
Variable  Time t  Time 
(t+1)
Time 
(t+2)
Time 
(t+3)
Time 
(t+4) 
Total  
ACEI       
Normoalbuminuria  0.01a,b,c,
d 
0.08e,f 0.10g 0.15 0.00  0.05 
Microalbuminuria  0.07  0.35  0.36 0.36  0.60  0.19 
Macroalbuminuria  0.91  0.58  0.54  0.49  0.40  0.76 
ARB       
Normoalbuminuria  0.01h,i,j 0.14 0.13  0.13  0.00  0.07 
Microalbuminuria  0.09  0.36 0.34  0.36  0.00  0.20 
Macroalbuminuria  0.90  0.50  0.53  0.51  1.00  0.73 
Neither       
Normoalbuminuria  0.01k,l,m,
n 
0.07o 0.11  0.14  0.15  0.05 
Microalbuminuria  0.06  0.34 0.33  0.36  0.42  0.17 
Macroalbuminuria  0.94  0.58 0.57  0.50  0.44  0.78 
Notes:  values represent proportions 
a p<0.001, albuminuria, time t and time (t+1) within ACEI for chi-square test. Χ²(2) = 
953.12. 
b p<0.001, albuminuria, time t and time (t+2) within ACEI for chi-square test. Χ²(2) = 
858.93. 
c p<0.001, albuminuria, time t and time (t+3) within ACEI for chi-square test. Χ²(2) = 
588.10. 
d p<0.001, albuminuria, time t and time (t+4) within ACEI for chi-square test. Χ²(2) = 
39.68. 
e p<0.05, albuminuria, time (t+1) and time (t+2) within ACEI for chi-square test. Χ²(2) = 
6.18. 
f p<0.001, albuminuria, time (t+1) and time (t+3) within ACEI for chi-square test. Χ²(2) = 
24.06. 
g p<0.05, albuminuria, time (t+2) and time (t+3) within ACEI for chi-square test. Χ²(2) = 
7.95. 
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h p<0.001, albuminuria, time t and time (t+1) within ARB for chi-square test. Χ²(2) = 
127.07. 
I p<0.001, albuminuria, time t and time (t+2) within ARB for chi-square test. Χ²(2) = 
87.59. 
j p<0.001, albuminuria, time t and time (t+3) within ARB for chi-square test. Χ²(2) = 
62.62. 
k p<0.001, albuminuria, time t and time (t+1) within neither for chi-square test. Χ²(2) = 
937.91. 
l p<0.001, albuminuria, time t and time (t+2) within neither for chi-square test. Χ²(2) = 
814.74. 
m p<0.001, albuminuria, time t and time (t+3) within neither for chi-square test. Χ²(2) = 
800.24. 
n p<0.001, albuminuria, time t and time (t+4) within neither for chi-square test. Χ²(2) = 
193.50. 
o p<0.001, albuminuria, time (t+1) and time (t+3) within neither for chi-square test. Χ²(2) 
= 19.72. 
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Outpatient values have a mean of 10.52 and a standard deviation of 13.37, 
indicating overdispersion. With 14,962 of 124,296 patient-years (12.04%) without 
outpatient visits it is not abundantly clear that we have more zeroes than expected by 
chance. 
Table 11 displays the diagnostic tests of the count variable regression models.  
The Poisson regression model resulted in a significant Hosmer and Lemeshow goodness-
of-fit and Pregibon’s Link Test (p<0.001 each). The next step was to run a negative 
binomial regression model which resulted in a significant Pregibon’s Link Test (p<0.001) 
and overdispersion test (likelihood-ratio test of α=0:  chibar2(1) = 2.6e+05 Prob≥chibar2 
< 0.001).  A zero-inflated Poisson regression model was then run, which did not 
converge.  The last model constructed was the zero-inflated negative binomial regression 
model.  Looking at the results from the diagnostic tests of the Poisson, negative binomial, 
and zero-inflated negative binomial regressions, and knowing that the model with the 
lowest Akaike Information Criterion (AIC) is the best choice, we had another reason than 
the failed overdispersion test to rule out the Poisson model.  This left the negative 
binomial and zero-inflated negative binomial regressions for comparison.  Negative 
binomial regression had the best model fit because it had similar log pseudolikelihood 
and Bayesian Information Criterion (BIC) as the zero-inflated negative binomial, but it 
had fewer degrees of freedom. 
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Table 11:  Model Fit Diagnostic Tests for Assessment of Count Dependent Variable 
Models for Outpatient Visits, ACEI or ARB versus Neither 
 
Analytic 
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer and 
Lemeshow 
(p) 
411,404.40 
(<0.001) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
Pregibon’s 
Link Test (p) 
-0.09 
(<0.001) 
-0.08 
 (<0.001) 
Not applicable 
(model did not 
converge) 
Not available  
     
Pearson’s 
Correlation 
(p) 
552,673.30 
(<0.001)  
Not available Not applicable 
(model did not 
converge) 
Not available 
     
LL (null)d Not  
applicable 
-199,681.50 Not applicable 
(model did not 
converge) 
-199,681.50 
     
LL (model)e -320,534.80 -192,329.40 Not applicable 
(model did not 
converge) 
-192,402.90 
     
dff 63 64 Not applicable 
(model did not 
converge) 
103 
     
AICg 641,195.60 384,786.70 Not applicable 
(model did not 
converge) 
385,011.80 
     
BICh 641,757.90 385,357.90 Not applicable 
(model did not 
converge) 
385,931.00 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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The values of ED visits indicate overdispersion (mean = 0.18, standard deviation 
= 0.71).  Additionally, 111,867 of 124,296 (90.00%) person-years indicate no record of 
an ED visit. 
Table 12 presents the diagnostic tests for the count dependent variable regression 
models.  We first ran a Poisson regression model which resulted in a nonsignificant 
Hosmer and Lemeshow goodness-of-fit and Pregibon’s Link Test (p<0.001 each). As a 
next step we ran a negative binomial regression model which led to a significant 
Pregibon’s Link Test (p<0.001) and overdispersion test (likelihood-ratio test of α = 0:  
chibar2(1) = 1.1e+04 Prob≥chibar2 < 0.001.  We then ran a zero-inflated Poisson 
regression model which did not converge. The last step was construction of the zero-
inflated negative binomial regression model.  As can be seen, the Poisson model had 
higher log pseudolikelihood, AIC, and BIC than the negative binomial or zero-inflated 
negative binomial.  The negative binomial model has the best fit due to the similar AICs 
and BICs between it and the zero-inflated negative binomial and its fewer degrees of 
freedom. 
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Table 12:  Model Fit Diagnostic Tests for Assessment of Count Dependent Variable 
Models for ED Visits, ACEI or ARB versus Neither 
 
Analytic 
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer and 
Lemeshow (p) 
49,945.00 
(1.000) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
Pregibon’s 
Link Test (p) 
-0.09 
(<0.001) 
-0.14 
(<0.001) 
Not applicable 
(model did not 
converge) 
Not available 
     
Pearson’s 
Correlation (p) 
131,640.50 
(<0.001) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
LL(null)d Not 
applicable 
-28,694.64 Not applicable 
(model did not 
converge) 
-27,607.16 
     
LL (model)e -32,914.75 -27,400.19 Not applicable 
(model did not 
converge) 
-27,208.56 
     
dff 63 64 Not applicable 
(model did not 
converge) 
103 
     
AICg 65,955.50 54,928.38 Not applicable 
(model did not 
converge) 
54,623.12 
     
BICh 66,517.76 55,499.56 Not applicable 
(model did not 
converge) 
55,542.36 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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           Hospitalizations show overdispersion with a mean of 0.13 and standard deviation 
of 0.55.  That, provided with 115,036 of 124,296 person-years (92.55%) showing no 
record of hospitalization, indicates we may need to look at a zero-inflated negative 
binomial regression model.  
Table 13 presents the results for the diagnostic tests for the count dependent 
variable regression models.  As has been the pattern, a Poisson regression model was first 
constructed, which resulted in a nonsignificant Hosmer and Lemeshow goodness-of-fit 
(p=1.00) and a significant Pregibon’s Link Test (p<0.001).  A negative binomial 
regression analysis was conducted, which resulted in a significant Pregibon’s Link Test 
(p<0.001) and overdispersion test (likelihood-ratio test of α = 0:  chibar2(1) = 6525.74 
Prob≥chibar2 < 0.001).  As a next step, we ran a zero-inflated Poisson regression model 
which did not converge.  Lastly, we ran a zero-inflated negative binomial regression.  
Lower log pseudolikelihood, AIC, and BIC are seen with the negative binomial compared 
to the Poisson model.  Although all are also slightly lower with the zero-inflated negative 
binomial model than the negative binomial, the fewer degrees of freedom in the negative 
binomial model make this the model with the best fit.  
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Table 13:  Model Fit Diagnostic Tests for Assessment of Count Dependent Variable 
Models for Hospitalizations, ACEI or ARB versus Neither 
 
Analytic 
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer and 
Lemeshow (p) 
37,198.10 
(1.00) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
Pregibon’s 
Link Test (p) 
-0.08 
(<0.001) 
-0.10 
(<0.001) 
Not applicable 
(model did not 
converge) 
Not available 
     
Pearson’s 
Correlation (p) 
112,285.90 
(<0.001) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
LL (null)d Not  
applicable 
-22,581.48  Not applicable 
(model did not 
converge) 
-21,167.19 
     
LL (model)e -24,457.16 -21,164.46 Not applicable 
(model did not 
converge) 
-20,823.50 
     
dff 63 64 Not applicable 
(model did not 
converge) 
103 
     
AICg 49,040.32 42,456.91 Not applicable 
(model did not 
converge) 
41,852.99 
     
BICh 49,602.58 43,028.09 Not applicable 
(model did not 
converge) 
42,772.24 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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Outpatient visits have a mean of 10.52 and a standard deviation of 13.37 (range 0 
to 358), indicating overdispersion.  During the observation period there were 14,962 
person-years (12.04%) without an office visit, which is more than due to chance, so we 
run a zero-inflated negative binomial regression. (Note: we have information for these 
individuals because of at least one hospitalization and/or ED visit). 
Table 14 displays results of the diagnostic tests for each of the count variable 
regression models of ACEI monotherapy’s effects, compared to ARB monotherapy’s, on 
outpatient visits.  First, the Poisson regression model was run, which resulted in a 
significant Hosmer and Lemeshow goodness-of-fit and Pregibon’s Link Test (p<0.001 
each). Thus, a negative binomial regression model was constructed, which also resulted 
in significant Pregibon’s Link Test (p<0.001) as well as a significant overdispersion test 
(likelihood-ratio test of α = 0:  chibar2(1) = 2.6e+05 Prob ≥ chibar2 < 0.001).  The 
significant Pregibon’s Link Test is indicative that we still have model misspecification.  
The significant overdispersion test tells us that the dispersion factor, α, is significantly 
different from zero, meaning the Poisson regression may not be a good choice since the 
Poisson is only equal to the negative binomial regression when α = 0.  We then tried a 
zero-inflated Poisson (for comparison’s sake), but the model did not converge.  Lastly, a 
zero-inflated negative binomial regression was performed.  As the findings in the table 
show, the best model fit was for the negative binomial regression as it had lower AIC, 
BIC, and log pseudolikelihood compared to Poisson and it had similar AIC, BIC, and log 
pseudolikelihood compared to the zero-inflated binomial model, but fewer degrees of 
freedom. 
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Table 14:  Model Fit Diagnostic Tests for Assessment of Count Dependent Variable 
Models for Outpatient Visits, ACEI versus ARB 
 
Analytic  
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer and 
Lemeshow 
(p) 
219,389.30 
(<0.001) 
Not 
available 
Not applicable 
(model did not 
converge) 
Not available 
     
Pregibon’s 
Link Test (p) 
-0.10 
(<0.001) 
-0.09 
(<0.001) 
Not applicable 
(model did not 
converge) 
Not available 
     
Pearson’s 
Correlation 
(p) 
288,848.70 
(<0.001) 
Not 
available 
Not applicable 
(model did not 
converge) 
Not available 
     
LL (null)d Not 
applicable 
-110,468.30 Not applicable 
(model did not 
converge) 
-110,468.30 
     
LL (model)e -173,722.40 -106,487.70 Not applicable 
(model did not 
converge) 
-106,487.70 
     
dff 57 58 Not applicable 
(model did not 
converge) 
98 
     
AICg 347,558.90 213,091.40 Not applicable 
(model did not 
converge) 
213,171.40 
     
BICh 348,033.30 213,574.10  Not applicable 
(model did not 
converge) 
213,987.10 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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For ED visits, we again see overdispersion with a mean of 0.18 and a standard 
deviation of 0.71 (range=0-32). Since we have 111,867 person-years (90.00%) of our 
sample without a visit to the ED, we needed to consider the zero-inflated negative 
binomial model.  
Table 15 displays results of the diagnostic tests for each of the count variable 
regression models of ACEI monotherapy’s effects, compared to ARB monotherapy’s, on 
ED visits.  First, a Poisson regression model was constructed, which resulted in a 
nonsignificant goodness-of-fit test, but significant Pregibon’s Link Test (p<0.001).  The 
next step involved a negative binomial regression model which resulted in a significant 
Pregibon’s Link Test (p<0.001) and overdispersion test (likelihood-ratio test of α = 0:  
chibar2(1) = 1.1e+04 Prob≥chibar2 < 0.001). Then a zero-inflated Poisson regression 
model was constructed and finally a zero-inflated negative binomial regression model 
was constructed.  As Table 27 indicates, the Poisson model was quickly ruled out for 
good fit because it has the highest log pseudolikelihood, AIC, and BIC of the four 
models.  The zero-inflated Poisson was next ruled out because, of the three remaining 
models, it had the highest log pseudolikelihood, AIC, and BIC, with more degrees of 
freedom than the negative binomial.  This again left the negative binomial compared to 
the zero-inflated negative binomial.  Although the zero-inflated model has lower log 
pseudolikelihood and AIC, it does have higher BIC and more degrees of freedom than the 
negative binomial, leaving the negative binomial with the best fit. 
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Table 15:  Model Fit Diagnostic Tests for Assessment of Count Dependent Variable 
Models for ED Visits, ACEI versus ARB 
 
Analytic  
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer and 
Lemeshow (p) 
27,774.46 
(1.00) 
Not available Not available Not available 
     
Pregibon’s 
Link Test (p) 
-0.08 
(<0.001) 
-0.14 (<0.001) Not available Not available 
     
Pearson’s 
Correlation (p) 
68,951.36 
(<0.001) 
Not available  Not available Not available 
     
LL (null)d Not 
applicable 
-16,155.13 -16,041.63 -15,555.29 
     
LL (model)e -18,402.72 -15,420.78 -15,756.25 -15,304.59 
     
dff 57 58 97 98 
     
AICg 36,919.45 30,957.57 31,706.5 30,805.19 
     
BICh 37,393.85 31,440.30 31,620.83 31,620.83 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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 Hospitalization exhibits overdispersion with a mean of 0.13 and a standard 
deviation of 0.55 (range=0-16).  It also has many zero values: 115,036 person-years 
(92.55%) do not have a hospitalization recorded. 
Table 16 displays results of the diagnostic tests for each of the count variable 
regression models of ACEI monotherapy’s effects, compared to ARB monotherapy’s, on 
hospitalizations.  A Poisson regression model was first run, which resulted in a 
nonsignificant Hosmer and Lemeshow goodness-of-fit, but significant Pregibon’s Link 
Test (p<0.001 each) so we then ran a negative binomial regression model which resulted 
in a significant Pregibon’s Link Test (p<0.001) and overdispersion test (likelihood ratio 
test of α = 0:chibar2(1)=6532.85, prob≥chibar2 < 0.001). Systematically, a zero-inflated 
Poisson regression and zero-inflated negative binomial regression were performed next.  
Table 29 provides more evidence that the Poisson model had a poor fit; in fact, it had the 
poorest of the four models based on that it had the highest log pseudolikelihood, AIC, 
and BIC.  The zero-inflated Poisson had higher AIC and BIC than the negative binomial 
whereas the negative binomial had higher log pseudolikelihood and lower degrees of 
freedom; therefore, the zero-inflated Poisson also had poor model fit.  The zero-inflated 
negative binomial had lower log pseudolikelihood and AIC and higher BIC with more 
degrees of freedom, meaning the negative binomial model had the best fit. 
 
 
 
 
 
 
 
 
  401
Table 16:  Model Fit Diagnostic Tests for Assessment of Count Dependent Variable 
Models for Hospitalizations, ACEI versus ARB 
 
Analytic  
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer and 
Lemeshow (p) 
37,211.70 
(1.000) 
Not available Not available Not available 
     
Pregibon’s 
Link Test (p) 
-0.08 
(<0.001) 
-0.10 
(<0.001) 
Not available Not available 
     
Pearson’s 
Correlation (p) 
112,096.00 
(<0.001) 
Not available  Not available Not available 
     
LL (null)d Not 
applicable 
-12,862.65 -12,259.19 -12,098.96 
     
LL (model)e -13,763.78 -12,080.93 -12,040.23 -11,889.12 
     
dff 57 58 97 98 
     
AICg 27,641.56 24,277.85 24,274.46 23,974.24 
     
BICh 28,115.96 24,760.58  25,081.78 24,789.88 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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Since diagnostic tests for multivariate unweighted regression comparing ACEI 
versus ARB monotherapy for each count variable was complete, the next step was to set 
up the data for propensity score analyses (PSA).  The following tables show results of 
data setup for preparation of the first stage.  First, we excluded patients who received 
neither therapy at baseline. Then, using zip code as a proxy for facility formulary and 
prescriber preference, we merged state and metropolitan area with our sample.  Those 
individuals missing zip codes and their annual observations dropped out of future 
analysis giving us 20,876 patients with 120,900 person-years of observation (Tables 17 
and 18).  Table 19 shows the geographic diversity in the sample: patients in all states are 
represented as well as the District of Columbia and Puerto Rico.  First-stage PSA 
includes those on- and off- support. 
We verified two assumptions of the first-stage PSA were true for our study:  1) all 
propensity scores were between 0 and 1, and 2) we achieved enough overlap in our study, 
matching one ARB patient with one ACEI patient by obtaining a common support of 0.4 
to 1.0 for each patient.  This means ARB patients had similar propensities for treatment 
as ACEI patients.  Lack of overlap would indicate lack of between group balance on 
observable characteristics at baseline.  
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Table 17: Merge Tabulation for Census and VA Zip Code 
 
 Frequency Percent 
From VA data 3,396 2.35 
   
From Census data 20,517 14.17 
   
Both VA and Census data 120,900 83.49 
   
Total 144,813 100.00 
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Table 18:  Sample size on ACEI or ARB Monotherapy at Baseline after Zip Code Merge 
 
Treatment        Frequency Percent 
ARB 1,929 9.24 
   
ACEI 18,947 90.76 
   
Total 20,876 100.00 
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Table 19: State and Territory Representation in Sample (N=63,808 person-years) 
State/Territory Frequency Percent 
   
Alabama 1,208 1.89 
Alaska 67 0.11 
Arizona 840 1.32 
Arkansas 715 1.12 
California 2,470 3.87 
Colorado 440 0.69 
Connecticut 286 0.45 
Delaware 8 0.01 
District of Columbia 14 0.02 
Florida 3,990 6.25 
Georgia 2,744 4.30 
Hawaii 292 0.46 
Idaho 357 0.56 
Illinois 2,742 4.30 
Indiana 2,003 3.14 
Iowa 647 1.01 
Kansas 1,112 1.74 
Kentucky 1,311 2.05 
Louisiana 805 1.26 
Maine 378 0.59 
Maryland 497 0.78 
Massachusetts 524 0.82 
Michigan 2,499 3.92 
Minnesota 1,202 1.88 
Mississippi 1,047 1.64 
Missouri 2,746 4.30 
Montana 228 0.36 
Nebraska 322 0.50 
Nevada 15 0.02 
New Hampshire 357 0.56 
New Jersey 455 0.71 
New Mexico 228 0.36 
New York 2,113 3.31 
North Carolina 2,046 3.21 
North Dakota 36 0.06 
Ohio 3,356 5.26 
Oklahoma 2,391 3.75 
Oregon 630 0.99 
Pennsylvania 3,897 6.11 
Puerto Rico 78 0.12 
Rhode Island 218 0.34 
South Carolina 4,038 6.33 
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Table 19 (cont.) 
 
State/Territory Frequency Percent 
South Dakota 95 0.15 
Tennessee 3,251 5.09 
Texas 3,767 5.90 
Utah 282 0.44 
Vermont 137 0.21 
Virginia 429 0.67 
Washington 988 1.55 
West Virginia 405 0.63 
Wisconsin 1,240 1.94 
Wyoming 164 0.26 
Missing 1,698 2.66 
   
Total 63,808 100.00 
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The values for outpatient visits show overdispersion is present with a mean of 
11.84 and standard deviation of 13.56 (range = 0-358).  Values of zero look like they 
have the possibility to not be more than due to chance with a frequency of 3,821 of 
46,494 patient-years with common support = 1 (8.22%).  We first ran a Poisson 
regression, which resulted in a significant Pregibon’s Link Test (p<0.001), so we then ran 
a negative binomial regression which also had a significant Pregibon’s Link Test 
(p<0.001).  The next step was the zero-inflated Poisson regression, which did not 
converge, so we then ran a zero-inflated negative binomial regression. 
 Table 20 shows the results of the diagnostic tests for each of the regression 
models.  The same patient characteristics were entered in one step into each of the 
models.  Again, the Poisson model was found to have the worst fit with substantially 
higher log pseudolikelihood, AIC, and BIC than the other models.  The zero-inflated 
negative binomial had a slightly lower log pseudolikelihood, AIC, and BIC than the 
negative binomial, but we didn’t feel this was worth the 44 degrees of freedom. 
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Table 20:  Diagnostic Model Fit for Outpatient Visits, PSA ACEI versus ARB 
 
Analytic 
Model 
Poisson Nbrega ZIPb ZINBc 
Hosmer-
Lemeshow (p) 
1,755,631.00 
(<0.001) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
Pregibon’s 
Link Test (p) 
-0.90 (<0.001) -0.92 (<0.001) Not applicable 
(model did not 
converge) 
Not available 
     
Pearson (p) 2,387,487.00 
(<0.001) 
Not available Not applicable 
(model did not 
converge) 
Not available 
     
LL (null)d Not applicable -884,944.70 Not applicable 
(model did not 
converge) 
-884,944.70 
     
LL (model)e -11,392,757.00 -854,280.80 Not applicable 
(model did not 
converge) 
-853,881.00 
     
dff 56 57 Not applicable 
(model did not 
converge) 
101 
     
AICg 5,785,625.00 1,708,676.00 Not applicable 
(model did not 
converge) 
1,707,964.00 
     
BICh 2,786,081.00 1,709,139.00 Not applicable 
(model did not 
converge) 
1,708,785.00 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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As is expected, we have overdispersion with ED visits (mean = 0.19, standard 
deviation = 0.71.  Much of this is due to the large numbers of person-years without a 
recorded ED visit:  we have 41,424 of 46,494 person-years (89.10%) that do not show an 
ED visit.  Poisson regression resulted in a significant goodness-of-fit (p<0.001) and a 
significant Pregibon’s Link Test (p<0.001), so we then ran a negative binomial regression 
model which resulted in a significant Pregibon’s Link Test (p<0.001).  As a next step, we 
then ran a zero-inflated Poisson regression model since the Pregibon’s Link Test for 
Poisson regression had a higher p-value than for the negative binomial regression. Table 
21 shows the results of the diagnostic tests for each of the regression models.  The 
Poisson and zero-inflated Poisson models had the highest and second-highest log 
pseudolikelihood, AIC, and BIC of the four models, respectively.  The zero-inflated 
negative binomial had the lowest log pseudolikelihood, AIC, and BIC, but these seemed 
to be similar to the negative binomial model, which had fewer degrees of freedom. 
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Table 21:  Model Fit Diagnostic Tests for ED Visits, PSA ACEI versus ARB 
 
Analytic Model Poisson Nbrega ZIPb ZINBc 
Hosmer-
Lemeshow (p) 
227,339.00 
(<0.001) 
Not 
available 
Not available Not available 
     
Pregibon’s 
Link Test (p) 
-0.09 
(<0.001) 
-0.12 
(<0.001) 
Not available  Not available 
     
Pearson (p) 548,203.20 
(<0.001) 
Not 
available 
Not available Not available 
     
LL (null)d Not 
applicable 
-133,045.40 -132,018.60 -127,954.70 
     
LL (model)e -151,183.50 -126,677.00 -129,485.30 -125,679.90 
     
dff 56 57 100 101 
     
AICg 302,479.10 253,468.00 259,170.70 251,561.90 
     
BICh 302,934.50 253,931.60 259,984.00 252,383.30 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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  Similar to ED visits, we have overdispersion (mean = 0.14, standard deviation = 
0.56).  We also have many values for which hospitalization is zero: 42,576 of 46,494 
person-years (91.57%).  Poisson regression model was first performed, which resulted in 
a significant goodness-of-fit test and Pregibon’s Link Test (p<0.001 each). The next step 
was to perform a negative binomial regression analysis, which resulted in a significant 
Pregibon’s Link Test (p<0.001).  Thereafter, the researchers performed a zero-inflated 
Poisson regression.  The last step was to run a zero-inflated negative binomial regression 
model, which did not converge.  Table 22 shows results of the diagnostic tests for each of 
the regression models.  As Table 22 reveals, the Poisson model had the highest log 
pseudolikelihood, AIC, and BIC, so it provided the worst model fit of the three models.  
The zero-inflated Poisson had lower log pseudolikelihood, AIC, and BIC than the 
negative binomial, but the values appear to be similar.  As we did not want to waste 43 
degrees of freedom, the negative binomial regression had the best fit. 
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Table 22:  Model Fit Diagnostic Tests for Hospitalizations, PSA ACEI versus ARB 
 
Analytic Model Poisson Nbrega ZIPb ZINBc 
Hosmer-
Lemeshow (p) 
167676.30 
(<0.001) 
Not 
available 
Not available Not applicable 
(model did not 
converge) 
     
Pregibon’s 
Link Test (p) 
-0.07 
(<0.001) 
-0.09 
 (<0.001) 
Not available  Not applicable 
(model did not 
converge) 
     
Pearson (p) 472029.30 
(<0.001) 
Not 
available 
Not available Not applicable 
(model did not 
converge) 
     
LL (null)d Not 
applicable 
-105031.80 -100230.70 Not applicable 
(model did not 
converge) 
     
LL (model)e -111760.90 -98578.89 -985175.05 Not applicable 
(model did not 
converge) 
     
dff 56 57 100 Not applicable 
(model did not 
converge) 
     
AICg 223633.80 197271.80 196550.10 Not applicable 
(model did not 
converge) 
     
BICh 224089.20 197735.40 197363.40 Not applicable 
(model did not 
converge) 
 
a Nbreg stands for negative binomial regression, b ZIP stands for zero-inflated Poisson, c 
ZINB stands for zero-inflated negative binomial, d LL (null) stands for log 
(pseudo)likelihood of the null model, e LL (model) stands for log (pseudo)likelihood of 
the full model, f df stands for degrees of freedom, g AIC stands for Akaike Information 
Criterion, h BIC stands for Bayesian Information Criterion 
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This section shows the results of average treatment effect on the treated (ATT) for 
each dependent variable.  Please see Tables 23 and 24 for ATT for each outcome through 
matching with propensity score in each stratum (i.e., stratification) and then through 
nearest-neighbor matching.  
 
 
 
 
 
 
 
  414
Table 23:  Average Treatment Effect on the Treated Patients in Our Sample, for Effect of 
ACEI Compared to ARB for Each Outcome, Stratification 
 
 ACEI 
Patients 
(N) 
ARB 
Patients 
(N) 
ATT Standard 
Error 
T-
statistic 
ESRD 13,691 1,432 -0.00 0.001 -0.05 
      
IVDE 13,691 1,432 -0.01 0.01 -0.87 
      
All-cause 
mortality 
13,691 1,432 0.001 0.001 0.61 
      
Outpatient 
visits 
13,691 1,432 -0.09 0.46 -0.19 
      
ED visits 13,691 1,432 0.01 0.03 0.47 
      
Hospitalizations 13,691 1,432 0.01 0.02 0.29 
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Table 24:  Average Treatment Effect on the Treated Patients in Our Sample, for Effect of 
ACEI Compared to ARB for Each Outcome, Nearest-Neighbor Matching 
 
 Sample Treated 
(ACEI) 
Controls 
(ARB) 
Difference Standard 
Error 
T-statistic 
ESRD Unmatched 7.99 x 
10-4 
1.40 x 
10-3 
-5.98 x 10-
4 
8.12 x  
10-4 
-0.74 
ATT 6.99 x 
10-4 
1.40 x 
10-3 
-6.99 x 10-
4 
12.10 x 
10-4 
-0.58 
       
IVDE Unmatched 0.03 0.03 6.79 x 10-4 0.01 0.13 
ATT 0.04 0.03 7.69 x 10-3 0.01 1.08 
       
All-Cause 
Mortality 
Unmatched 0.002 0.002 0.000 0.001 0.10 
ATT 0.003 0.002 0.001 0.002 0.38 
       
Outpatient 
visits 
Unmatched 16.42 16.53 -0.10 0.38 -0.27 
ATT 16.06 16.53 -0.47 0.52 -0.89 
       
ED visits Unmatched 0.27 0.23 0.04 0.02 1.58 
ATT 0.26 0.23 0.03 0.03 1.12 
       
Hospital-
izations 
Unmatched 0.19 0.18 0.01 0.02 0.62 
ATT 0.16 0.18 -0.01 0.02 -0.60 
 
Note: S.E. for ATT does not take into account that the propensity score is estimated. 
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There is no direct test of the presence or absence of hidden bias from 
unobservable variables, but since PSA only includes observable variables, the sensitivity 
analysis that can be performed after nearest-neighbor matching gives a sense of 
robustness (or lack thereof) in determining true treatment effect for each dependent 
variable.  All dependent variables assessed sensitivity of results to hidden bias by using a 
weighted average across all strata rather than assessing each stratum separately.  The 
sensitivity analyses performed after nearest-neighbor matching yielded findings of 
interest in terms of robustness of this study’s findings.  Mantel-Haenszel bounds were 
conducted for dichotomous variables while Rosenbaum bounds were conducted for count 
dependent variables.  Since it has been recommended to test gamma, the odds of 
differential treatment assignment, from one to two, these values defined our range. 
Mantel-Haenszel bounds found nonsignificant differences for ESRD or all-cause 
mortality between ACEI and ARB monotherapies, as found in PSA results of this study, 
held true to the point that if an unobserved variable exists, it would have to increase the 
odds of treatment assignment by more than 200% to change the conclusion. (This can be 
seen by looking at the p-value columns.)  Mantel-Haenszel bounds reveal that the 
nonsignificant between group differences of ATT for IVDE, based on nearest-neighbor 
matching, holds true in the potential presence of an unobserved variable until such 
variable increases the odds of treatment assignment by 115% to 120%. 
Rosenbaum bounds reveal the nonsignificant differences in outpatient visits found 
by PSA only hold true if there is an unobserved variable affecting odds of treatment 
assignment by between 105% and 110%.  Even more sensitive to possible unobservalbes 
affecting ttreatment assignment, the PSA for ED visits shows patients with ACEI or ARB 
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monotherapy had comparable ED visits only at gamma=1 (p-value=0.05), so this would 
only be certain if an unobserved variable increased the odds of treatment assignment by 
between 100% and 105%.  Lastly, the PSA finding of no difference between ACEI and 
ARB monotherapies on hospitalizations would remain true if an unobserved variable 
existed and changed the odds of treatment assignment between 115% and 120% 
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Table 25: Sensitivity Analysis Determining Affect of Potential Hidden Bias from 
Unobservable Characteristics on Treatment Effect for ESRD, Nearest-Neighbor 
Matching 
 
Gamma QMH+ QMH- p-value + p-value - 
1 0.00 0.00 0.50 0.50 
1.05 0.04 -0.04 0.48 0.52 
1.1 0.08 -0.08 0.47 0.53 
1.15 0.12 -0.12 0.45 0.55 
1.2 0.16 -0.16 0.44 0.56 
1.25 0.19 -0.19 0.42 0.58 
1.3 0.23 -0.23 0.41 0.59 
1.35 0.26 -0.26 0.40 0.60 
1.4 0.29 -0.29 0.39 0.62 
1.45 0.32 -0.32 0.37 0.63 
1.5 0.35 -0.35 0.36 0.64 
1.55 0.38 -0.38 0.35 0.65 
1.6 0.41 -0.41 0.34 0.66 
1.65 0.44 -0.44 0.33 0.67 
1.7 0.47 -0.47 0.32 0.68 
1.75 0.49 -0.49 0.31 0.69 
1.8 0.52 -0.52 0.30 0.70 
1.85 0.54 -0.54 0.29 0.71 
1.9 0.57 -0.57 0.29 0.71 
1.95 0.59 -0.59 0.28 0.72 
2 0.61 -0.61 0.27 0.73 
 
Gamma : odds of differential assignment due to unobserved factors 
QMH+ : Mantel-Haenszel statistic (assumption: overestimation of treatment effect) 
QMH- : Mantel-Haenszel statistic (assumption: underestimation of treatment effect) 
p-value + : significance level (assumption: overestimation of treatment effect) 
p-value - : significance level (assumption: underestimation of treatment effect) 
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Table 26: Sensitivity Analysis Determining Affect of Potential Hidden Bias from 
Unobservable Characteristics on Treatment Effect for IVDE, Nearest-Neighbor Matching 
 
Gamma QMH+ QMH- p-value + p-value - 
1 0.99 0.99 0.16 0.16 
1.05 0.74 1.23 0.23 0.11 
1.1 0.50 1.47 0.31 0.07 
1.15 0.28 1.70 0.39 0.05 
1.2 0.06 1.92 0.48 0.03 
1.25 -0.06 2.13 0.52 0.02 
1.3 0.14 2.33 0.44 0.01 
1.35 0.33 2.52 0.37 <0.01 
1.4 0.52 2.71 0.30 <0.01 
1.45 0.70 2.90 0.24 <0.01 
1.5 0.87 3.07 0.19 0.001 
1.55 1.03 3.25 0.15 0.001 
1.6 1.19 3.41 0.12 <0.001 
1.65 1.35 3.58 0.09 <0.001 
1.7 1.50 3.74 0.07 <0.001 
1.75 1.65 3.89 0.05 <0.001 
1.8 1.79 4.05 0.04 <0.001 
1.85 1.93 4.19 0.03 <0.001 
1.9 2.07 4.34 0.02 <0.001 
1.95 2.20 4.48 0.01 <0.001 
2 2.33 4.62 0.01 <0.001 
 
Gamma : odds of differential assignment due to unobserved factors 
QMH+ : Mantel-Haenszel statistic (assumption: overestimation of treatment effect) 
QMH- : Mantel-Haenszel statistic (assumption: underestimation of treatment effect) 
p-value + : significance level (assumption: overestimation of treatment effect) 
p-value - : significance level (assumption: underestimation of treatment effect) 
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Table 27: Sensitivity Analysis Determining Affect of Potential Hidden Bias from 
Unobservable Characteristics on Treatment Effect for All-Cause Mortality, Nearest-
Neighbor Matching 
 
Gamma QMH+ QMH- p-value + p-value - 
1 0.00 0.00 0.50 0.50 
1.05 -0.06 0.06 0.53 0.47 
1.1 -0.13 0.13 0.55 0.45 
1.15 -0.19 0.19 0.57 0.43 
1.2 -0.24 0.24 0.60 0.41 
1.25 -0.30 0.30 0.62 0.38 
1.3 -0.35 0.35 0.64 0.36 
1.35 -0.37 0.40 0.64 0.35 
1.4 -0.32 0.45 0.63 0.33 
1.45 -0.28 0.50 0.61 0.31 
1.5 -0.23 0.54 0.59 0.30 
1.55 -0.19 0.58 0.58 0.28 
1.6 -0.15 0.63 0.56 0.27 
1.65 -0.11 0.67 0.55 0.25 
1.7 -0.07 0.71 0.53 0.24 
1.75 -0.04 0.75 0.52 0.23 
1.8 -0.002 0.79 0.50 0.22 
1.85 0.03 0.83 0.49 0.21 
1.9 0.07 0.86 0.47 0.19 
1.95 0.10 0.90 0.46 0.18 
2 0.13 0.93 0.45 0.18 
 
Gamma : odds of differential assignment due to unobserved factors 
QMH+ : Mantel-Haenszel statistic (assumption: overestimation of treatment effect) 
QMH- : Mantel-Haenszel statistic (assumption: underestimation of treatment effect) 
p-value + : significance level (assumption: overestimation of treatment effect) 
p-value - : significance level (assumption: underestimation of treatment effect) 
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Table 28: Sensitivity Analysis Determining Affect of Potential Hidden Bias from 
Unobservable Characteristics on Treatment Effect for Outpatient Visits, Nearest-
Neighbor Matching 
 
Gamma sig+ sig- t-hat+ t-hat- CI+ CI- 
1 0.27 0.27 -1.30 x 10-6 -1.30 x 10-6 -1.00 0.50 
1.05 0.08 0.57 -0.50 4.40 x 10-7 -1.50 1.00 
1.1 0.02 0.83 -1.00 0.50 -1.50 1.00 
1.15 0.002 0.95 -1.00 0.50 -2.00 1.50 
1.2 <0.001 0.99 -1.50 1.00 -2.00 1.50 
1.25 <0.001 1.00 -1.50 1.00 -2.50 2.00 
1.3 <0.001 1.00 -2.00 1.50 -2.50 2.00 
1.35 <0.001 1.00 -2.00 1.50 -3.00 2.50 
1.4 <0.001 1.00 -2.50 2.00 -3.00 2.50 
1.45 <0.001 1.00 -2.50 2.00 -3.50 3.00 
1.5 <0.001 1.00 -3.00 2.50 -3.50 3.00 
1.55 <0.001 1.00 -3.00 2.50 -4.00 3.50 
1.6 <0.001 1.00 -3.00 3.00 -4.00 3.50 
1.65 <0.001 1.00 -3.50 3.00 -4.00 4.00 
1.7 <0.001 1.00 -3.50 3.00 -4.50 4.00 
1.75 <0.001 1.00 -4.00 3.50 -4.50 4.00 
1.8 <0.001 1.00 -4.00 3.50 -5.00 4.50 
1.85 <0.001 1.00 -4.00 3.50 -5.00 4.50 
1.9 <0.001 1.00 -4.50 4.00 -5.00 4.50 
1.95 <0.001 1.00 -4.50 4.00 -5.50 5.00 
2 <0.001 1.00 -4.50 4.00 -5.50 5.00 
 
  gamma  - log odds of differential assignment due to unobserved factors 
  sig+   - upper bound significance level 
  sig-   - lower bound significance level 
  t-hat+ - upper bound Hodges-Lehmann point estimate 
  t-hat- - lower bound Hodges-Lehmann point estimate 
  CI+    - upper bound confidence interval (alpha = 0.95) 
  CI-    - lower bound confidence interval (alpha = 0.95) 
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Table 29: Sensitivity Analysis Determining Affect of Potential Hidden Bias from 
Unobservable Characteristics on Treatment Effect for ED Visits, Nearest-Neighbor 
Matching 
 
Gamma sig+ sig- t-hat+ t-hat- CI+ CI- 
1 0.05 0.05 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.05 0.11 0.02 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.1 0.22 <0.01 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.15 0.36 0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.2 0.51 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.25 0.66 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.3 0.78 
 
<0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.35 0.87 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.4 0.93 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.45 0.96 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.5 0.98 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.55 0.99 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.6 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.65 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.7 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.75 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.8 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.85 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
1.9 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
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Table 29 (cont.) 
 
Gamma sig+ sig- t-hat+ t-hat- CI+ CI- 
1.95 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
2 1.00 <0.001 -2.60 x 10-7 -2.60 x 
10-7 
-2.60 x 
10-7 
-2.60 x 
10-7 
 
* gamma  - log odds of differential assignment due to unobserved factors 
  sig+   - upper bound significance level 
  sig-   - lower bound significance level 
  t-hat+ - upper bound Hodges-Lehmann point estimate 
  t-hat- - lower bound Hodges-Lehmann point estimate 
  CI+    - upper bound confidence interval (alpha = 0.95) 
CI- - lower bound confidence interval (alpha = 0.95) 
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Table 30: Sensitivity Analysis Determining Affect of Potential Hidden Bias from 
Unobservable Characteristics on Treatment Effect for Hospitalizations, Nearest-Neighbor 
Matching 
 
Gamma Sig+ sig- t-hat+ t-hat- CI+ CI- 
1 0.40 0.40 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.05 0.26 0.56 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.1 0.15 0.70 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.15 0.08 0.81 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.2 0.04 0.89 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.25 0.02 0.94 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.3 0.01 0.97 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.35 <0.01 0.99 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.4 0.001 0.99 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.45 0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.5 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.55 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.6 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.65 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.7 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.75 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.8 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.85 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
1.9 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
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Table 30 (cont.) 
 
Gamma Sig+ sig- t-hat+ t-hat- CI+ CI- 
1.95 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
2 <0.001 1.00 -4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
-4.30 x 
10-7 
 
  gamma  - log odds of differential assignment due to unobserved factors 
  sig+   - upper bound significance level 
  sig-   - lower bound significance level 
  t-hat+ - upper bound Hodges-Lehmann point estimate 
  t-hat- - lower bound Hodges-Lehmann point estimate 
  CI+    - upper bound confidence interval (alpha = 0.95) 
CII- - lower bound confidence interval (alpha = 0.95) 
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Table 31: Post hoc Multivariate Regression, ACEI or ARB versus Neither, for Variables 
Predicting ESRD, IVDE, Outpatient Visits, ED Visits, and Hospitalizations 
 
 ACEI ARB 
 ORa RSEb 95% CIc OR RSE 95% CI 
ESRD 0.51 0.19 0.25-1.04 0.36 0.37 0.05-2.64 
       
IVDE 1.63 0.13 1.38-1.91 1.53 0.26 1.09-2.13 
       
 IRRd RSE 95% CI IRR RSE 95% CI 
Outpatient 
visits 
1.18 0.01 1.16-1.20 1.24 0.03 1.18-1.29 
       
ED visits 1.19 0.05 1.09-1.30 1.22 0.12 1.01-1.47 
       
Hospitalizations 1.32 0.07 1.20-1.46 1.41 0.15 1.14-1.74 
 
aOR stands for odds ratio, bRSE stands for robust standard error, c95%CI stands for 95% 
confidence interval, dIRR stands for incidence rate ratio
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